Original source Substance pref_name parent_chembl_id molregno mw_freebase type value source_unit Molar_value pMolar_value assay_chembl_id activity_id description activity_comment comments source_description pubmed_id doc_title ABACAVIR ABACAVIR CHEMBL1380 321707 286.34 Normal/therapeutic blood-plasma concentration 3.9 mg/L 1.3620171823706085e-05 4.86581741359675 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ABACAVIR CHEMBL1380 321707 286.34 Cmax 3.4300000000000006 ug.mL-1 1.197876650136202e-05 4.9215879005804775 CHEMBL1661927 5154216.0 Cmax in HIV infected male patient at 600 mg QD by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 1.5900000000000003 ug.mL-1 5.552839281972482e-06 5.2554848963027965 CHEMBL1661924 5154217.0 Cmax in HIV infected male patient at 300 mg BID by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 2.0900000000000003 ug.mL-1 7.299015156806595e-06 5.136735734512194 CHEMBL1661071 5154218.0 Ratio of weight normalized Cmax in HIV infected patient at 600 mg QD to weight normalized Cmax in HIV infected patient at 300 mg BID by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 2.0900000000000003 ug.mL-1 7.299015156806595e-06 5.136735734512194 CHEMBL1660921 5154219.0 Ratio of Cmax in HIV infected patient at 600 mg QD to Cmax in HIV infected patient at 300 mg BID by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 1.8399999999999996 ug.mL-1 6.425927219389536e-06 5.192064197613712 CHEMBL1660927 5154221.0 Weight normalized Cmax in HIV infected patient at 300 mg BID by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 3.85 ug.mL-1 1.3445554236222674e-05 4.871421291114748 CHEMBL1660929 5154222.0 Cmax in HIV infected patient at 600 mg QD by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 1.8399999999999996 ug.mL-1 6.425927219389536e-06 5.192064197613712 CHEMBL1660934 5154223.0 Cmax in HIV infected patient at 300 mg BID by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 1.6600000000000001 ug.mL-1 5.797303904449257e-06 5.236773932583193 CHEMBL1661930 5154287.0 Weight normalized Cmax in HIV infected male patient at 300 mg BID by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 3.579999999999999 ug.mL-1 1.250261926381225e-05 4.9029989939793746 CHEMBL1661933 5154288.0 Weight normalized Cmax in HIV infected male patient at 600 mg QD by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 4.830000000000001 ug.mL-1 1.686805895089754e-05 4.7729348898717365 CHEMBL1661939 5154289.0 Cmax in HIV infected female patient at 600 mg QD by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 2.249999999999999 ug.mL-1 7.857791436753506e-06 5.104699502511886 CHEMBL1661942 5154290.0 Weight normalized Cmax in HIV infected female patient at 300 mg BID by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 4.39 ug.mL-1 1.5331424181043517e-05 4.814417500381127 CHEMBL1661945 5154291.0 Weight normalized Cmax in HIV infected female patient at 600 mg QD by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ABACAVIR CHEMBL1380 321707 286.34 Cmax 3.83 ug.mL-1 1.337570720122931e-05 4.873683246654625 CHEMBL1660924 5154220.0 Weight normalized Cmax in HIV infected patient at 600 mg QD by HPLC/MS/MS analysis Scientific Literature 19188387.0 Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. ACAMPROSATE ACAMPROSATE CHEMBL1201293 675244 181.21 Normal/therapeutic blood-plasma concentration 0.7 mg/L 3.862921472324927e-06 5.413084120351841 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ACEBUTOLOL ACEBUTOLOL CHEMBL642 27347 336.43 Normal/therapeutic blood-plasma concentration 2.0 mg/L 5.9447730582885e-06 5.225864719920689 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ACENOCOUMAROL ACENOCOUMAROL CHEMBL397420 394206 353.33 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.4151076896951858e-06 5.849210509072009 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ACETAMINOPHEN CHEMBL112 16450 151.16 Cmax 17.699999999999996 ug.mL-1 0.0001170944694363588 3.9314636168831703 CHEMBL3788526 16534895.0 Cmax in Japanese healthy volunteer (5 volunteers) at 1000 mg, po by HPLC method Scientific Literature 17202677.0 Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. PARACETAMOL ACETAMINOPHEN CHEMBL112 16450 151.16 Normal/therapeutic blood-plasma concentration 25.0 mg/L 0.00016538766869542208 3.781496874572939 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ACETAMINOPHEN CHEMBL112 16450 151.16 Cmax 4.2 ug.mL-1 2.7785128340830912e-05 4.556187592847077 CHEMBL3889380 17805888.0 Evalaution of pharmacokinetic parameters of Acetaminophen following single oral co-administration of 325 mg Acetaminophen tablets with 37.5 mg Tramadol. corrected from ChEMBL Curated Drug Pharmacokinetic Data DailyMed|setid=39945812-f776-4b13-8199-e846e37aa101 | TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN - tramadol hydrochloride and acetaminophen tablet, film coated|Cadila Healthcare Limited ACETAZOLAMIDE ACETAZOLAMIDE CHEMBL20 1125 222.25 Normal/therapeutic blood-plasma concentration 20.0 mg/L 8.998875140607424e-05 4.04581177397827 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ACETOHEXAMIDE ACETOHEXAMIDE CHEMBL1589 454070 324.4 Normal/therapeutic blood-plasma concentration 70.0 mg/L 0.00021578298397040695 3.6659828055248616 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ACITRETIN ACITRETIN CHEMBL1131 169652 326.44 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.531675039823551e-07 6.814833364847876 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ACRIVASTINE ACRIVASTINE CHEMBL1224 226880 348.45 Normal/therapeutic blood-plasma concentration 0.07 mg/L 2.0088965418280963e-07 6.69704242884166 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ACYCLOVIR CHEMBL184 365538 225.21 Cmax 42000.0 nM 4.2000000000000004e-05 4.376750709602099 CHEMBL1266395 3481892.0 Cmax in human systemic circulation with normal renal function at 2000 mg, po every 6 hrs measured after fifth dose by radioimmunoassay Scientific Literature 20038622.0 Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. ACYCLOVIR ACYCLOVIR CHEMBL184 365538 225.21 Normal/therapeutic blood-plasma concentration 15.0 mg/L 6.660450246436658e-05 4.176496411530366 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ADALIMUMAB ADALIMUMAB CHEMBL1201580 675482 Normal/therapeutic blood-plasma concentration 9.0 mg/L 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AGOMELATINE AGOMELATINE CHEMBL10878 8209 243.31 Normal/therapeutic blood-plasma concentration 0.3 mg/L 1.2329949447207265e-06 5.909038704007994 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ALBENDAZOLE ALBENDAZOLE CHEMBL1483 406787 265.34 Normal/therapeutic blood-plasma concentration 1.5 mg/L 5.653124293359464e-06 5.247711465746899 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SALBUTAMOL ALBUTEROL CHEMBL714 34094 239.31 Normal/therapeutic blood-plasma concentration 0.02 mg/L 8.357360745476579e-08 7.077930851106911 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ALCURONIUM ALCURONIUM CHEMBL1180293 654243 666.91 Normal/therapeutic blood-plasma concentration 3.0 mg/L 4.498358099293758e-06 5.346945974788147 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ALENDRONATE ALENDRONIC ACID CHEMBL870 70674 249.1 Normal/therapeutic blood-plasma concentration 0.265 mg/L 1.0638297872340427e-06 5.973127853599698 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ALFENTANIL ALFENTANIL CHEMBL634 27190 416.53 Normal/therapeutic blood-plasma concentration 0.6 mg/L 1.4404724749717906e-06 5.841495035948007 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ALFUZOSINE ALFUZOSIN CHEMBL709 33667 389.46 Normal/therapeutic blood-plasma concentration 0.06 mg/L 1.5405946695424436e-07 6.8123116091311235 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ALFUZOSIN CHEMBL709 33667 389.46 Cmax 0.0136 ug.mL-1 3.4920145842962055e-08 7.4569239511445495 CHEMBL3889424 17806150.0 Evaluation of pharmacokinetic parameters for Alfuzosin hydrochloride following multiple oral or intravenous administration of Alfuzosin hydrochloride. Curated Drug Pharmacokinetic Data DailyMed|setid=1c5502c7-7731-4d3e-b4fe-7fd44dd5908b | UROXATRAL - alfuzosin hydrochloride tablet, extended release|Physicians Total Care, Inc. ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.025999999999999992 ug.mL-1 4.7121083059970626e-08 7.326784736014606 CHEMBL3509387 15443484.0 Cmax of SPP100 following single oral dose of SPP100 75 mg capsule studied in healthy human OUTCOME = Cmax would increase 2.6 fold when doubling the dose of aliskiren, indicating a deviation from true dose-proportionality across the 8-fold range of 75 to 600 mg. Inter-subject variability was high for Cmax (59-117%) FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.07199999999999998 ug.mL-1 1.3048915308914945e-07 6.884425587554155 CHEMBL3509388 15443485.0 Cmax of SPP100 following single oral dose of SPP100 150 mg capsule studied in healthy human OUTCOME = Cmax would increase 2.6 fold when doubling the dose of aliskiren, indicating a deviation from true dose-proportionality across the 8-fold range of 75 to 600 mg. Inter-subject variability was high for Cmax (59-117%) FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.202 ug.mL-1 3.660945683890027e-07 6.4364067145387995 CHEMBL3509389 15443486.0 Cmax of SPP100 following single oral dose of SPP100 300 mg capsule studied in healthy human OUTCOME = Cmax would increase 2.6 fold when doubling the dose of aliskiren, indicating a deviation from true dose-proportionality across the 8-fold range of 75 to 600 mg. Inter-subject variability was high for Cmax (59-117%) FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.42000000000000004 ug.mL-1 7.61186726353372e-07 6.118508793587523 CHEMBL3509390 15443487.0 Cmax of SPP100 following single oral dose of SPP100 600 mg capsule studied in healthy human OUTCOME = Cmax would increase 2.6 fold when doubling the dose of aliskiren, indicating a deviation from true dose-proportionality across the 8-fold range of 75 to 600 mg. Inter-subject variability was high for Cmax (59-117%) FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.0051 ug.mL-1 9.242981677148088e-09 8.034187907887487 CHEMBL3508710 15443504.0 Cmax of aliskiren hemifumarate following single dosing of SPP100B oral solution at 40 mg level studied on day 1 in men FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.011000000000000001 ug.mL-1 1.9935842833064504e-08 7.7003653988271985 CHEMBL3508711 15443505.0 Cmax of aliskiren hemifumarate following single dosing of SPP100B oral solution at 80 mg level studied on day 1 in men FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.0215 ug.mL-1 3.89655109918988e-08 7.409319624069818 CHEMBL3508712 15443506.0 Cmax of aliskiren hemifumarate following single dosing of SPP100B oral solution at 160 mg level studied on day 1 in men FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.1462 ug.mL-1 2.6496547474491187e-07 6.576810711363581 CHEMBL3508713 15443507.0 Cmax of aliskiren hemifumarate following single dosing of SPP100B oral solution at 640 mg level studied on day 1 in men FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.006200000000000001 ug.mL-1 1.1236565960454539e-08 7.9493663944871695 CHEMBL3508763 15443574.0 Cmax of aliskiren hemifumarate following 8 day once-daily dosing of SPP100B oral solution at 40 mg level studied on day 8 in men FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.012700000000000003 ug.mL-1 2.3016836725447205e-08 7.637954363029467 CHEMBL3508764 15443575.0 Cmax of aliskiren hemifumarate following 8 day once-daily dosing of SPP100B oral solution at 80 mg level studied on day 8 in men FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.0391 ug.mL-1 7.086285952480201e-08 7.149581326589557 CHEMBL3508765 15443576.0 Cmax of aliskiren hemifumarate following 8 day once-daily dosing of SPP100B oral solution at 160 mg level studied on day 8 in men FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALISKIREN CHEMBL1639 480746 551.77 Cmax 0.33509999999999995 ug.mL-1 6.07318266669083e-07 6.216583656150152 CHEMBL3508766 15443577.0 Cmax of aliskiren hemifumarate following 8 day once-daily dosing of SPP100B oral solution at 640 mg level studied on day 8 in men FDA Approval Packages FDA drug approval package for Aliskiren hemifumarate ALLOPURINOL ALLOPURINOL CHEMBL1467 395607 136.11 Normal/therapeutic blood-plasma concentration 19.0 mg/L 0.00013959297626919403 3.8551364330328504 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ALMOTRIPTAN ALMOTRIPTAN CHEMBL1505 420985 335.47 Normal/therapeutic blood-plasma concentration 0.07 mg/L 2.0866247354457925e-07 6.680555648672563 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ALPRAZOLAM ALPRAZOLAM CHEMBL661 27648 308.77 Normal/therapeutic blood-plasma concentration 0.08 mg/L 2.5909252841921173e-07 6.586545110800721 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ALPRAZOLAM CHEMBL661 27648 308.77 Cmax 0.007999999999999998 ug.mL-1 2.5909252841921164e-08 7.586545110800721 CHEMBL3889374 17805876.0 Pharmacokinetic parameters for Alprazolam evaluated after oral administration of alprazolam to subjects of different ages and health conditions. Range 8 To 37 Ng/Ml Curated Drug Pharmacokinetic Data DailyMed|setid=2238e083-08f2-0aa8-59b7-16b6d68dbd48 | ALPRAZOLAM - alprazolam tablet|Apotex Corp. AMANTADINE AMANTADINE CHEMBL660 27647 151.25 Normal/therapeutic blood-plasma concentration 1.0 mg/L 6.611570247933885e-06 5.179695383324506 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics 3,4-DIAMINOPYRIDIN AMIFAMPRIDINE CHEMBL354077 282661 109.13 Normal/therapeutic blood-plasma concentration 0.1 mg/L 9.163383121048292e-07 6.037944155203099 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMIKACIN AMIKACIN CHEMBL177 333157 585.61 Normal/therapeutic blood-plasma concentration 30.0 mg/L 5.122863339082324e-05 4.290487229498259 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMIKACIN CHEMBL177 333157 585.61 Cmax 0.19999999999999998 ug.mL-1 3.4152422260548823e-07 6.466578488553941 CHEMBL1279426 3569262.0 Cmax in human neonate at 10 mg/kg, iv by HPLC Scientific Literature 18378715.0 Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates. AMIKACIN CHEMBL177 333157 585.61 Cmax 35.70000000000001 ug.mL-1 6.096207373507968e-05 4.214940268105728 CHEMBL1279424 3569259.0 Cmax in human neonate serum after 25 hrs by fluorescence polarization immunoassay Scientific Literature 18378715.0 Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates. AMINOBENZOIC ACID AMINOBENZOIC ACID CHEMBL542 13372 137.14 Normal/therapeutic blood-plasma concentration 600.0 mg/L 0.004375091147732245 2.3590128947457125 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMINOGLUTETHIMIDE AMINOGLUTETHIMIDE CHEMBL488 6317 232.28 Normal/therapeutic blood-plasma concentration 25.0 mg/L 0.00010762872395384881 3.968071808689249 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMINOPHENAZONE AMINOPYRINE CHEMBL288470 60246 231.3 Normal/therapeutic blood-plasma concentration 20.0 mg/L 8.646779074794638e-05 4.063145637106638 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMIODARONE AMIODARONE CHEMBL633 27185 645.32 Normal/therapeutic blood-plasma concentration 2.5 mg/L 3.8740469844418275e-06 5.411835116461491 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMISULPRIDE AMISULPRIDE CHEMBL243712 389011 369.49 Normal/therapeutic blood-plasma concentration 0.4 mg/L 1.0825732766786653e-06 5.965542697671927 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMITRIPTYLINE AMITRIPTYLINE CHEMBL629 27072 277.41 Normal/therapeutic blood-plasma concentration 0.3 mg/L 1.0814318157240184e-06 5.966000857628784 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMLODIPINE AMLODIPINE CHEMBL1491 418414 408.88 Normal/therapeutic blood-plasma concentration 0.015 mg/L 3.6685580121306983e-08 7.435504608891499 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMMONIA AMMONIA SOLUTION, STRONG CHEMBL1160819 642358 17.03 Normal/therapeutic blood-plasma concentration 1.7 mg/L 9.982384028185554e-05 4.000765726584327 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMOBARBITAL AMOBARBITAL CHEMBL267894 2366 226.28 Normal/therapeutic blood-plasma concentration 5.0 mg/L 2.2096517588828002e-05 4.655676165732353 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMODIAQUINE CHEMBL682 29097 355.87 Cmax 0.235 ug.mL-1 6.603534998735493e-07 6.18022351605633 CHEMBL1220048 3385221.0 Cmax in Ugandan children patient with uncomplicated malaria assessed as desethylamodiaquine level at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day co-administered with artesunate at 4 mg/kg, perorally bid for 3 days From looking at original source this also looks like Cmax of main metabolite Scientific Literature 19841149.0 Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. AMODIAQUINE CHEMBL682 29097 355.87 Cmax 1.185 ug.mL-1 3.329867648298536e-06 5.4775730279819435 CHEMBL1656401 5158104.0 Cmax in children with uncomplicated malaria assessed as desethylamodiaquine at 10 mg/kg, po administered as single dose corrected from ChEMBL Scientific Literature 18779360.0 Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. AMODIAQUINE AMODIAQUINE CHEMBL682 29097 355.87 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.4050074465394667e-07 6.852321373992048 This is the Cmax for the main metabolite 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMODIAQUINE CHEMBL682 29097 355.87 Cmax 0.005199999999999999 ug.mL-1 1.461207744401045e-08 7.835288034693267 CHEMBL1220178 3385217.0 Cmax in Ugandan children patient with uncomplicated malaria at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day co-administered with artesunate at 4 mg/kg, perorally bid for 3 days Scientific Literature 19841149.0 Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. AMOXAPINE AMOXAPINE CHEMBL1113 155045 313.79 Normal/therapeutic blood-plasma concentration 0.6 mg/L 1.9121068230345134e-06 5.718487848797103 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMOXICILLIN CHEMBL1082 143284 365.41 Cmax 19.000000000000004 ug.mL-1 5.1996387619386446e-05 4.284026827354858 CHEMBL855217 1828306.0 Cmax in human at 1 g, po after 0.5 hrs Scientific Literature 17060515.0 Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics. AMOXICILLIN AMOXICILLIN CHEMBL1082 143284 365.41 Normal/therapeutic blood-plasma concentration 15.0 mg/L 4.104977969951561e-05 4.386689169252006 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMPHETAMINE AMPHETAMINE CHEMBL405 543 135.21 Normal/therapeutic blood-plasma concentration 0.1 mg/L 7.395902669920864e-07 6.13100881279064 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMPHOTERICIN B AMPHOTERICIN B CHEMBL267345 8873 924.09 Normal/therapeutic blood-plasma concentration 3.0 mg/L 3.246437035353699e-06 5.488593015851019 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMPHOTERICIN B CHEMBL267345 8873 924.09 Cmax 2.599999999999999 ug.mL-1 2.8135787639732055e-06 5.550740922599864 CHEMBL3889342 17805483.0 Predicted pharmacokinetic parameters of Amphotericin B after administration of multiple intravenous doses of 3 or 4 mg/kg/day AMPHOTEC liquid in 51 bone marrow transplant patients with systemic fungal infections age range 3 to 52 years (median 32) and weight range 14 to 116 kg (median 69.5) or following multiple intravenous administration of 1 mg/kg/day amphoteric B deoxycholate in 15 pateints with aspergillus infection or for empirical therapy of, age range 4 to 66 years (median 21) and weight range 19 to 117 kg (median 60). Curated Drug Pharmacokinetic Data DailyMed|setid=9b8ea543-1de8-472f-9666-34f99ca2f183 | AMPHOTEC- amphotericin b injection, lipid complex|InterMune, Inc. AMPHOTERICIN B CHEMBL267345 8873 924.09 Cmax 2.8999999999999995 ug.mL-1 3.1382224675085753e-06 5.503316272671726 CHEMBL3889342 17805490.0 Predicted pharmacokinetic parameters of Amphotericin B after administration of multiple intravenous doses of 3 or 4 mg/kg/day AMPHOTEC liquid in 51 bone marrow transplant patients with systemic fungal infections age range 3 to 52 years (median 32) and weight range 14 to 116 kg (median 69.5) or following multiple intravenous administration of 1 mg/kg/day amphoteric B deoxycholate in 15 pateints with aspergillus infection or for empirical therapy of, age range 4 to 66 years (median 21) and weight range 19 to 117 kg (median 60). Curated Drug Pharmacokinetic Data DailyMed|setid=9b8ea543-1de8-472f-9666-34f99ca2f183 | AMPHOTEC- amphotericin b injection, lipid complex|InterMune, Inc. AMPHOTERICIN B CHEMBL267345 8873 924.09 Cmax 2.8999999999999995 ug.mL-1 3.1382224675085753e-06 5.503316272671726 CHEMBL3889342 17805495.0 Predicted pharmacokinetic parameters of Amphotericin B after administration of multiple intravenous doses of 3 or 4 mg/kg/day AMPHOTEC liquid in 51 bone marrow transplant patients with systemic fungal infections age range 3 to 52 years (median 32) and weight range 14 to 116 kg (median 69.5) or following multiple intravenous administration of 1 mg/kg/day amphoteric B deoxycholate in 15 pateints with aspergillus infection or for empirical therapy of, age range 4 to 66 years (median 21) and weight range 19 to 117 kg (median 60). Curated Drug Pharmacokinetic Data DailyMed|setid=9b8ea543-1de8-472f-9666-34f99ca2f183 | AMPHOTEC- amphotericin b injection, lipid complex|InterMune, Inc. AMPICILLIN AMPICILLIN CHEMBL174 305519 349.41 Normal/therapeutic blood-plasma concentration 20.0 mg/L 5.723934632666495e-05 4.242305334526925 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMPICILLIN CHEMBL174 305519 349.41 Cmax 3.1999999999999997 ug.mL-1 9.15829541226639e-06 5.038185351871 CHEMBL1032831 2667146.0 Cmax in healthy human at 500 mg administered orally Scientific Literature 18070962.0 Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. AMPRENAVIR CHEMBL116 17347 505.64 Cmax 6.1 ug.mL-1 1.2063918993750494e-05 4.918511587645162 CHEMBL1005847 2301681.0 Cmin in human assessed as amprenavir levels at 700 mg, po bid for 10 days pretreated with paroxetin at 20 mg, po qd for 10 days followed by 16 days washout period then coadministered with paroxetin at 20 mg, po qd and ritonavir at 100 mg, po bid for 10 days Scientific Literature 17846135.0 Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. AMSACRINE AMSACRINE CHEMBL43 2580 393.47 Normal/therapeutic blood-plasma concentration 5.5 mg/L 1.3978194017332959e-05 4.854548935812951 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ANIDULAFUNGIN CHEMBL264241 84251 1140.25 Cmax 3.630000000000001 ug.mL-1 3.1835123876342915e-06 5.497093455876863 CHEMBL1637375 5091279.0 Cmax in human plasma at 100 mg, iv by LC-MS/MS analysis Scientific Literature 19029327.0 In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. ANIDULAFUNGIN CHEMBL264241 84251 1140.25 Cmax 6.599999999999999 ug.mL-1 5.788204341153255e-06 5.237456145371107 CHEMBL1658239 5169807.0 Cmax in healthy human at 200 mg, iv on day 1 as 200 mins infusion followed by maintenance dose of 100 mg every 24 hrs on days 2 and 3 as 100 mins infusions Scientific Literature 19770284.0 Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. ANIDULAFUNGIN CHEMBL264241 84251 1140.25 Cmax 11.0 ug.mL-1 9.647007235255426e-06 5.015607395754751 CHEMBL1058390 2716280.0 Cmax in human at 100 mg/day Scientific Literature 18070979.0 In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. ANILERIDINE ANILERIDINE CHEMBL1201347 675298 352.48 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.418520199727644e-06 5.848164475470673 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENAZONE ANTIPYRINE CHEMBL277474 26820 188.23 Normal/therapeutic blood-plasma concentration 25.0 mg/L 0.00013281623545662223 3.8767488335655207 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AZAPROPAZONE APAZONE CHEMBL1565476 989360 300.36 Normal/therapeutic blood-plasma concentration 90.0 mg/L 0.0002996404314822213 3.5233995862165233 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ARIPIPRAZOLE ARIPIPRAZOLE CHEMBL1112 155006 448.39 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.1151006935926315e-06 5.95268591405336 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ARTEMETHER CHEMBL566534 573926 298.38 Cmax 0.03400000000000001 ug.mL-1 1.1394865607614456e-07 6.943290792573613 CHEMBL1220183 3385211.0 Cmax in Ugandan children patient with uncomplicated malaria administered twice daily for 3 days as 20/120 mg tablets containing artemether-lumefantrine combination Scientific Literature 19841149.0 Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ARTEMETHER CHEMBL566534 573926 298.38 Cmax 0.119 ug.mL-1 3.9882029626650577e-07 6.3992227482233375 CHEMBL1220181 3385214.0 Cmax in Ugandan children patient with uncomplicated malaria assessed as dihydroartemisin administered twice daily for 3 days as 20/120 mg tablets containing artemether-lumefantrine combination Scientific Literature 19841149.0 Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ARTEMISININ CHEMBL567597 575613 282.34 Cmax 1599.9999999999998 nM 1.6e-06 5.795880017344075 CHEMBL3535224 15466271.0 Total Cmax in human Scientific Literature 22679214.0 Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes. ARTEMOTIL CHEMBL301267 88317 312.41 Cmax 0.04979999999999998 ug.mL-1 1.5940590890176364e-07 6.797495584095069 CHEMBL3055342 12464630.0 Cmax in Homo sapiens (human) at 150 mg Scientific Literature PRE-CLINICAL AND CLINICAL PHARMACOKINETICS OF THE DIASTEREOMERS OF ARTEETHER, A POTENT ANTIMALARIAL ARTENIMOL CHEMBL252518 420212 284.35 Cmax 0.698 ug.mL-1 2.4547212941797077e-06 5.609997809965026 CHEMBL1666754 5173249.0 Cmax in Plasmodium falciparum-infected patient at 40 mg/kg, po Scientific Literature 19528277.0 Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. ARTESUNATE CHEMBL361497 316347 384.43 Cmax 0.473 ug.mL-1 1.2303930494498348e-06 5.909956130886361 CHEMBL1220186 3385208.0 Cmax in Ugandan children patient with uncomplicated malaria assessed as dihydroartemisinin level at 4 mg/kg, perorally bid for 3 days co-administered with amodiaquine at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day Scientific Literature 19841149.0 Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ARTESUNATE CHEMBL361497 316347 384.43 Cmax 0.0513 ug.mL-1 1.3344432016231823e-07 6.874699906512356 CHEMBL1220188 3385206.0 Cmax in Ugandan children patient with uncomplicated malaria at 4 mg/kg, perorally bid for 3 days co-administered with amodiaquine at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day Scientific Literature 19841149.0 Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ARTICAINE ARTICAINE CHEMBL1093 150423 284.38 Normal/therapeutic blood-plasma concentration 2.0 mg/L 7.03284337857796e-06 5.152869054217012 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ASCORBIC ACID ASCORBIC ACID CHEMBL196 443348 176.12 Normal/therapeutic blood-plasma concentration 15.0 mg/L 8.516920281626164e-05 4.069717417731807 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ASENAPINE ASENAPINE CHEMBL3187365 1676656 285.77 Normal/therapeutic blood-plasma concentration 0.005 mg/L 1.7496588165307766e-08 7.757046630481726 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ASPIRIN CHEMBL25 1280 180.16 Cmax 2.59 ug.mL-1 1.4376110124333925e-05 4.842358609090001 CHEMBL3509409 15444028.0 Mean Cmax of acetylsalicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human FDA Approval Packages FDA drug approval package for Aspirin (clinical pharmacology review, Ref:ID 3227827) ASPIRIN CHEMBL25 1280 180.16 Cmax 8.799999999999999 ug.mL-1 4.884547069271758e-05 4.311175701021083 CHEMBL3889409 17806029.0 Pharmacokinetic parameters for aspirin and salicylic acid following oral administration of Aspirin,butalbital,caffeine phosphate capsules. Curated Drug Pharmacokinetic Data DailyMed|setid=c8b93fc1-472c-4890-8d02-2ee4f7175c22 | BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE- butalbital, aspirin,caffeine and codeine phosphate capsule|Jerome Stevens Pharmaceuticals ASPIRIN CHEMBL25 1280 180.16 Cmax 5.1000000000000005 ug.mL-1 2.8308170515097692e-05 4.548088197073316 CHEMBL3509415 15444034.0 Mean Cmax of acetylsalicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human FDA Approval Packages FDA drug approval package for Aspirin (clinical pharmacology review, Ref:ID 3227827) ACETYLSALICYLIC ACID ASPIRIN CHEMBL25 1280 180.16 Normal/therapeutic blood-plasma concentration 200.0 mg/L 0.0011101243339253998 2.954628377507271 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ASTEMIZOLE ASTEMIZOLE CHEMBL296419 65605 458.58 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.0903222992716648e-07 6.962445105632598 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ATAZANAVIR CHEMBL1163 188196 704.87 Cmax 3.3999999999999995 ug.mL-1 4.82358449075716e-06 5.316630109894305 CHEMBL1633526 5095532.0 Cmax in HIV-infected patient at 300 mg, qd co-administered with 100 mg minocycline, bid for 15 days Scientific Literature 18573930.0 Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. ATAZANAVIR CHEMBL1163 188196 704.87 Cmax 1.4300000000000006 ug.mL-1 2.0287428887596305e-06 5.692772989471498 CHEMBL981546 2499932.0 Cmax in HIV-negative human at 300 mg, po administered every 12 hrs coadministered with 600 mg of rifampin every 24 hrs Scientific Literature 17576825.0 Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. ATAZANAVIR CHEMBL1163 188196 704.87 Cmax 2.3600000000000003 ug.mL-1 3.3481351171137946e-06 5.475197023966453 CHEMBL981547 2499933.0 Cmax in HIV-negative human at 400 mg, po administered every 12 hrs coadministered with 600 mg of rifampin every 24 hrs Scientific Literature 17576825.0 Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. ATAZANAVIR CHEMBL1163 188196 704.87 Cmax 5.13 ug.mL-1 7.2779377757600695e-06 5.137991661824744 CHEMBL1633525 5094839.0 Cmax in HIV-infected patient at 300 mg, qd Scientific Literature 18573930.0 Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. ATAZANAVIR CHEMBL1163 188196 704.87 Cmax 0.787 ug.mL-1 1.1165179394782018e-06 5.952134294577496 CHEMBL1676388 5230158.0 Cmax in HIV infected patient at 400 mg qd measured after 13.06 hrs by plasma based assay using HPLC Scientific Literature 20660680.0 Clinical evaluation of a dried blood spot assay for atazanavir. ATAZANAVIR CHEMBL1163 188196 704.87 Cmax 2.7449999999999997 ug.mL-1 3.894335125626002e-06 5.4095666781504494 CHEMBL1674618 5223416.0 Cmax in HIV-1 infected patient at 300 mg, po qd coadministered with 100 mg of ritonavir, po qd and NRTI Scientific Literature 18411323.0 Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. ATAZANAVIR CHEMBL1163 188196 704.87 Cmax 2.2570000000000006 ug.mL-1 3.2020088810702694e-06 5.494577467858798 CHEMBL1674623 5223411.0 Cmax in HIV-1 infected patient at 300 mg, po qd coadministered with 400 mg, po bid and 100 mg, po bid of Lopinavir and ritonavir respectively Scientific Literature 18411323.0 Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. ATAZANAVIR CHEMBL1163 188196 704.87 Cmax 3.91 ug.mL-1 5.5471221643707355e-06 5.255932269540693 CHEMBL981545 2499931.0 Cmax in HIV-negative human at 300 mg, po administered every 12 hrs Scientific Literature 17576825.0 Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. ATAZANAVIR CHEMBL1163 188196 704.87 Cmax 7.223 ug.mL-1 1.0247279640217346e-05 4.989391412076269 CHEMBL1676389 5230159.0 Cmax in HIV infected patient at 300 mg qd measured after 16.60 hrs by plasma based assay using HPLC Scientific Literature 20660680.0 Clinical evaluation of a dried blood spot assay for atazanavir. ATAZANAVIR CHEMBL1163 188196 704.87 Cmax 2.599999999999999 ug.mL-1 3.6886234341084162e-06 5.433135678965742 CHEMBL1633527 5095533.0 Cmax in HIV-infected patient at 300 mg, qd co-administered with 100 mg minocycline and 250 mg valporic acid, bid for 15 days Scientific Literature 18573930.0 Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. ATAZANAVIR ATAZANAVIR CHEMBL1163 188196 704.87 Normal/therapeutic blood-plasma concentration 0.15 mg/L 2.1280519812163942e-07 6.672017767880879 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ATENOLOL ATENOLOL CHEMBL24 1279 266.34 Normal/therapeutic blood-plasma concentration 2.0 mg/L 7.5091987684914026e-06 5.124406399745029 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ATOMOXETINE ATOMOXETINE CHEMBL641 27342 255.36 Normal/therapeutic blood-plasma concentration 1.0 mg/L 3.9160401002506265e-06 5.407152869670635 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ATOVAQUONE ATOVAQUONE CHEMBL1450 378315 366.84 Normal/therapeutic blood-plasma concentration 6.9 mg/L 1.8809290153745505e-05 4.7256275940364585 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ATRACURIUM ATRACURIUM CHEMBL1360 306485 929.16 Normal/therapeutic blood-plasma concentration 5.0 mg/L 5.381204528821732e-06 5.269120500975137 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ATROPINE ATROPINE CHEMBL517712 445395 289.37 Normal/therapeutic blood-plasma concentration 0.025 mg/L 8.639458133185887e-08 7.063513495616834 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 0.0169 ug.mL-1 6.095141919428715e-08 7.215016177804876 CHEMBL3790064 16541816.0 Cmax in healthy human subjects (24 subjects) assessed as 6-mercaptopurine at 50 mg, po by HPLC method Scientific Literature 8881811.0 Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 0.022000000000000002 ug.mL-1 7.934504273812531e-08 7.100480201596343 CHEMBL3790079 16541801.0 Cmax in uraemic patient (8 patients) at 100 mg, po Scientific Literature 8881811.0 Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 0.0023500000000000005 ug.mL-1 8.475493201572477e-09 8.071835020146814 CHEMBL3790067 16541813.0 Cmax in healthy human subjects (24 subjects) assessed as 6-mercaptopurine at 50 mg dosed as hydrophilic rectal foam formulation by HPLC method Scientific Literature 8881811.0 Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 0.0024 ug.mL-1 8.655822844159123e-09 8.062691640706944 CHEMBL3790066 16541814.0 Cmax in healthy human subjects (24 subjects) assessed as 6-mercaptopurine at 50 mg dosed as hydrophobic rectal foam formulation by HPLC method Scientific Literature 8881811.0 Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 0.0036999999999999993 ug.mL-1 1.334439355141198e-08 7.874701158351555 CHEMBL3790065 16541815.0 Cmax in healthy human subjects (24 subjects) assessed as 6-mercaptopurine at 50 mg dosed as delayed release oral formulation by HPLC method Scientific Literature 8881811.0 Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 0.0648 ug.mL-1 2.3370721679229633e-07 6.631327876547957 CHEMBL3787901 16541844.0 Cmax in healthy human (29 volunteers) assessed as 6-mercaptopurine at 100 mg, po of standard compound by HPLC analysis Scientific Literature 9048271.0 A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 0.010500000000000002 ug.mL-1 3.786922494319617e-08 7.421713583348612 CHEMBL3787904 16541847.0 Cmax in healthy human (9 volunteers) assessed as 6-mercaptopurine at 200 mg, po of delayed release compound by HPLC analysis Scientific Literature 9048271.0 A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 0.02360000000000001 ug.mL-1 8.511559130089808e-08 7.069990879448443 CHEMBL3788137 16541851.0 Cmax in healthy human (10 volunteers) assessed as 6-mercaptopurine at 400 mg, po of delayed release compound by HPLC analysis Scientific Literature 9048271.0 A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 0.0191 ug.mL-1 6.888592346809969e-08 7.161869515170822 CHEMBL3788141 16541855.0 Cmax in healthy human (10 volunteers) assessed as 6-mercaptopurine at 600 mg, po of delayed release compound by HPLC analysis Scientific Literature 9048271.0 A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 179.99999999999994 nM 1.7999999999999994e-07 6.744727494896694 CHEMBL3790215 16545087.0 Cmax in uremic patient (8 patients) assessed as 6-mercaptopurine at 100 mg, po by gas chromatography-mass spectrometry with multiple detection method Scientific Literature 3957504.0 Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 179.99999999999994 nM 1.7999999999999994e-07 6.744727494896694 CHEMBL3790222 16545090.0 Cmax in uremic patient (8 patients) at 100 mg, po by gas chromatography-mass spectrometry with multiple detection method Scientific Literature 3957504.0 Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 1660.0000000000002 nM 1.6600000000000004e-06 5.779891911959945 CHEMBL3790208 16545102.0 Cmax in uremic patient (15 patients) plasma assessed as 6-mercaptopurine at 100 mg, iv by gas chromatography-mass spectrometry with multiple detection method Scientific Literature 3957504.0 Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 3140.0 nM 3.14e-06 5.503070351926785 CHEMBL3790200 16545109.0 Cmax in uremic patient (15 patients) at 100 mg, iv by gas chromatography-mass spectrometry with multiple detection method Scientific Literature 3957504.0 Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. AZATHIOPRINE AZATHIOPRINE CHEMBL1542 431141 277.27 Normal/therapeutic blood-plasma concentration 2.0 mg/L 7.213185703465936e-06 5.141872886754569 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AZATHIOPRINE CHEMBL1542 431141 277.27 Cmax 0.044999999999999984 ug.mL-1 1.622966783279835e-07 6.789690368643206 CHEMBL3790524 16545074.0 Cmax in renal transplant patient (3 patients) assessed as 6-mercaptopurine at 50 to 100 mg, po measured with in an hour post dose by reversed-phase HPLC method Scientific Literature 3957504.0 Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. AZELASTINE AZELASTINE CHEMBL639 27309 381.91 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.618417951873478e-08 7.581961030166877 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AZITHROMYCIN AZITHROMYCIN CHEMBL529 12428 749.0 Normal/therapeutic blood-plasma concentration 1.0 mg/L 1.335113484646195e-06 5.874481817699467 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AZITHROMYCIN CHEMBL529 12428 749.0 Cmax 0.67 ug.mL-1 8.945260347129507e-07 6.04840701499864 CHEMBL2160354 12067961.0 Cmax in cystic fibrosis patient plasma at 500 mg Scientific Literature 22697905.0 N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. AZITHROMYCIN CHEMBL529 12428 749.0 Cmax 2.01 ug.mL-1 2.6835781041388514e-06 5.571285760278978 CHEMBL2160355 12067951.0 Cmax in cystic fibrosis patient blood at 500 mg Scientific Literature 22697905.0 N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. AZITHROMYCIN CHEMBL529 12428 749.0 Cmax 0.39999999999999997 ug.mL-1 5.34045393858478e-07 6.272421826371504 CHEMBL1032829 2667147.0 Cmax in patient with Crohn's disease at 500 mg administered orally Scientific Literature 18070962.0 Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. AZITHROMYCIN CHEMBL529 12428 749.0 Cmax 0.39999999999999997 ug.mL-1 5.34045393858478e-07 6.272421826371504 CHEMBL1655708 5161038.0 Cmax in healthy human at 500 mg, po administered as single dose Scientific Literature 19223626.0 Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. AZITHROMYCIN CHEMBL529 12428 749.0 Cmax 1100.0 nM 1.1e-06 5.958607314841775 CHEMBL948855 2628570.0 Cmax in human at 1000 mg, po once daily for 3 days Scientific Literature 17698630.0 Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. AZITHROMYCIN CHEMBL529 12428 749.0 Cmax 1.0 ug.mL-1 1.335113484646195e-06 5.874481817699467 CHEMBL1663038 5159738.0 Cmax in human at 1000 mg, po Scientific Literature 19223616.0 Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. AZITHROMYCIN CHEMBL529 12428 749.0 Cmax 0.94 ug.mL-1 1.2550066755674232e-06 5.901353964099767 CHEMBL2160356 12067950.0 Cmax in lung cancer patient serum at 2 gram, po qd Scientific Literature 22697905.0 N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity. AZTREONAM AZTREONAM CHEMBL158 61680 435.44 Normal/therapeutic blood-plasma concentration 250.0 mg/L 0.0005741319125482271 3.2409883126369796 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BACLOFEN CHEMBL701 32869 213.66 Cmax 0.15999999999999998 ug.mL-1 7.488533183562669e-07 6.125603241401972 CHEMBL3889448 17806308.0 Pharmacokinetic parameters for diffferent drugs or their active metabolite, following single oral or intravenous (IV) administration to subjects of different health conditions. Curated Drug Pharmacokinetic Data Goodman and Gilman Ed. 12 | The Pharmaceutical Basis of Therapeutics| Table AII-I: Pharmacokinetic Data BACLOFEN BACLOFEN CHEMBL701 32869 213.66 Normal/therapeutic blood-plasma concentration 0.6 mg/L 2.8081999438360007e-06 5.551571973674254 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BARBITAL BARBITAL CHEMBL444 2256 184.19 Normal/therapeutic blood-plasma concentration 20.0 mg/L 0.00010858352787882079 3.9642360522233964 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BEDAQUILINE CHEMBL376488 373981 555.52 Cmax 8.999999999999996 ug.mL-1 1.620103686635944e-05 4.790457189721055 CHEMBL2169386 12087006.0 Cmax in human at 400 mg, po Scientific Literature 22421275.0 Tuberculosis: the drug development pipeline at a glance. BEDAQUILINE CHEMBL376488 373981 555.52 Cmax 0.07 ug.mL-1 1.2600806451612904e-07 6.899601659146122 CHEMBL2169377 12086987.0 Cmax in human at 10 mg, po Scientific Literature 22421275.0 Tuberculosis: the drug development pipeline at a glance. BEDAQUILINE CHEMBL376488 373981 555.52 Cmax 5.502 ug.mL-1 9.904233870967743e-06 5.004179113106714 CHEMBL1278507 3568885.0 Cmax in pulmonary tuberculosis patient at 400 mg/kg, po once daily for 7 days by liquid chromatography-MS/MS analysis Scientific Literature 18505852.0 Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. BEDAQUILINE CHEMBL376488 373981 555.52 Cmax 1.2080000000000004 ug.mL-1 2.1745391705069133e-06 5.662632764875266 CHEMBL1278506 3568884.0 Cmax in pulmonary tuberculosis patient at 100 mg/kg, po once daily for 7 days by liquid chromatography-MS/MS analysis Scientific Literature 18505852.0 Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. BEDAQUILINE CHEMBL376488 373981 555.52 Cmax 0.3192 ug.mL-1 5.745967741935484e-07 6.240636816481687 CHEMBL1278505 3568883.0 Cmax in pulmonary tuberculosis patient at 25 mg/kg, po once daily for 7 days by liquid chromatography-MS/MS analysis Scientific Literature 18505852.0 Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. BELINOSTAT CHEMBL408513 435188 318.35 Cmax 100908.0 nM 0.000100908 3.9960744014724265 CHEMBL3598924 15656487.0 Cmax in iv dosed human measured under phase 1 trial Scientific Literature 25637120.0 Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). BELINOSTAT CHEMBL408513 435188 318.35 Cmax 2139.0000000000005 nM 2.1390000000000006e-06 5.669789215428472 CHEMBL3598923 15656483.0 Cmax in po dosed human measured under phase 1 trial Scientific Literature 25637120.0 Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). BELINOSTAT CHEMBL408513 435188 318.35 Cmax 182923.99999999997 nM 0.00018292399999999997 3.7377293104679685 CHEMBL3598926 15656490.0 Cmax in iv dosed human measured under phase 1/2 trial Scientific Literature 25637120.0 Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). BENDROFLUAZIDE BENDROFLUMETHIAZIDE CHEMBL1684 515239 421.42 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.3729296189075033e-07 6.62471514276597 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BENOXAPROFEN BENOXAPROFEN CHEMBL340978 219327 301.73 Normal/therapeutic blood-plasma concentration 50.0 mg/L 0.00016571106618499984 3.7806484884267357 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BENPERIDOL BENPERIDOL CHEMBL297302 65455 381.45 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.6215755669157166e-08 7.58143761923139 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BENZBROMARONE BENZBROMARONE CHEMBL388590 374182 424.09 Normal/therapeutic blood-plasma concentration 10.0 mg/L 2.357990049281992e-05 4.627458031959776 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BENZPHETAMINE BENZPHETAMINE CHEMBL3545985 1927831 239.36 Normal/therapeutic blood-plasma concentration 0.5 mg/L 2.088903743315508e-06 5.680081571848349 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BENZTROPINE BENZTROPINE CHEMBL1201203 675154 307.44 Normal/therapeutic blood-plasma concentration 0.18 mg/L 5.854800936768149e-07 6.232487866352987 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BENZYLPENICILLIN CHEMBL29 1615 334.4 Cmax 22.0 ug.mL-1 6.578947368421052e-05 4.181843587944773 CHEMBL935120 2126539.0 Cmax in human term neonates at 15 mg/kg, im administered every 12 hrs after 24 hrs Scientific Literature 17371819.0 Pharmacokinetics of penicillin g in very-low-birth-weight neonates. BENZYLPENICILLIN CHEMBL29 1615 334.4 Cmax 58.9 ug.mL-1 0.00017613636363636366 3.7541509739798773 CHEMBL935119 2126532.0 Cmax in human very low birth weight preterm neonates at 14 mg/kg, iv administered every 12 hrs after 24 hrs Scientific Literature 17371819.0 Pharmacokinetics of penicillin g in very-low-birth-weight neonates. BENZYLPENICILLIN CHEMBL29 1615 334.4 Cmax 145.49999999999997 ug.mL-1 0.0004351076555023923 3.3614032754450527 CHEMBL935118 2126526.0 Cmax in human very low birth weight preterm neonates at 28 mg/kg, iv administered every 12 hrs after 24 hrs Scientific Literature 17371819.0 Pharmacokinetics of penicillin g in very-low-birth-weight neonates. BENZYLPENICILLIN BENZYLPENICILLIN CHEMBL29 1615 334.4 Normal/therapeutic blood-plasma concentration 12.0 mg/L 3.5885167464114834e-05 4.445085022719354 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BENZYLPENICILLIN CHEMBL29 1615 334.4 Cmax 44.999999999999986 ug.mL-1 0.0001345693779904306 3.8710537549916353 CHEMBL935121 2126540.0 Cmax in human adults at 600 mg/kg, iv administered every 12 hrs after 24 hrs Scientific Literature 17371819.0 Pharmacokinetics of penicillin g in very-low-birth-weight neonates. BEPRIDIL BEPRIDIL CHEMBL1008 112651 366.55 Normal/therapeutic blood-plasma concentration 2.5 mg/L 6.820351930159596e-06 5.166193215170067 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BETACAROTENE BETA CAROTENE CHEMBL1293 255373 536.89 Normal/therapeutic blood-plasma concentration 6.0 mg/L 1.1175473560692134e-05 4.951734064577426 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BETAXOLOL BETAXOLOL CHEMBL423 1354 307.43 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.6263864944865498e-07 6.788776240736422 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BETHANIDINE BETHANIDINE CHEMBL1201260 675211 177.25 Normal/therapeutic blood-plasma concentration 0.5 mg/L 2.8208744710860367e-06 5.549616239519086 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BEZAFIBRATE BEZAFIBRATE CHEMBL264374 57488 361.83 Normal/therapeutic blood-plasma concentration 15.0 mg/L 4.1455932343918414e-05 4.382413313126267 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BICALUTAMIDE CHEMBL409 717 430.38 Cmax 0.7679999999999999 ug.mL-1 1.78446953854733e-06 5.748490861187569 CHEMBL3889377 17805884.0 Pharmacokinetic parameters for Bicalutamide following single oral administration of Bicalutamide tablets to 30 healthy male subjects and 40 patients with prostrate cancer. Curated Drug Pharmacokinetic Data DailyMed|setid=020d34eb-9560-4218-9d87-dfdeff705c3a | BICALUTAMIDE - bicalutamide tablet, film coated|Physicians Total Care, Inc. BICALUTAMIDE BICALUTAMIDE CHEMBL409 717 430.38 Normal/therapeutic blood-plasma concentration 25.0 mg/L 5.8088201124587576e-05 4.235912072547043 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BIPERIDEN BIPERIDEN CHEMBL1101 151063 311.47 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.210582078530837e-07 6.4934162228671335 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BISOPROLOL BISOPROLOL CHEMBL645 27417 325.45 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.072668612690122e-07 6.512484275877902 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BRETYLIUM BRETYLIUM CHEMBL1199080 673030 243.17 Normal/therapeutic blood-plasma concentration 2.4 mg/L 9.86963852448904e-06 5.0056987530744905 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BROMAZEPAM BROMAZEPAM CHEMBL277062 16960 316.16 Normal/therapeutic blood-plasma concentration 0.2 mg/L 6.325910931174089e-07 6.198876927243553 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BROMOCRIPTINE BROMOCRIPTINE CHEMBL493 7065 654.61 Normal/therapeutic blood-plasma concentration 0.004 mg/L 6.11050854707383e-09 8.213922644095057 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BROMPERIDOL BROMPERIDOL CHEMBL28218 34949 420.32 Normal/therapeutic blood-plasma concentration 0.02 mg/L 4.7582794061667304e-08 7.322550059778014 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BROMPHENIRAMINE BROMPHENIRAMINE CHEMBL811 54051 319.25 Normal/therapeutic blood-plasma concentration 0.015 mg/L 4.698512137823023e-08 7.3280396468797715 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BUDESONIDE CHEMBL1370 313314 430.54 Cmax 4.999999999999999 nM 4.999999999999999e-09 8.301029995663981 CHEMBL3889346 17805516.0 Evaluation of pharmacokinetic parameters for Budesonide following single oral administration of Budesonide capsules (enteric coated) to healthy subjects and/or patients with Crohn's disease. Curated Drug Pharmacokinetic Data DailyMed|setid=7633c9b3-dfb5-446f-a260-e44b6e48afa2 | BUDESONIDE- budesonide capsule|Carilion Materials Management BUPIVACAINE BUPIVACAINE CHEMBL1098 150882 288.44 Normal/therapeutic blood-plasma concentration 2.0 mg/L 6.933851060879212e-06 5.159025491224905 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BUPRENORPHINE BUPRENORPHINE CHEMBL511142 446784 467.65 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.1383513311237037e-07 6.669920938681443 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BUPROPION CHEMBL894 77128 239.75 Cmax 0.31100000000000005 ug.mL-1 1.2971845672575603e-06 5.886998226815863 CHEMBL1261871 3496215.0 Cmax in healthy human plasma assessed as (R,R)-hydroxybupropion level at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 6 days, 400 mg bid upto 17 day of study measured after 48 hrs by high-performance liquid chromatography-tandem mass spectrometry Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION CHEMBL894 77128 239.75 Cmax 0.345 ug.mL-1 1.4389989572471323e-06 5.841939520769428 CHEMBL1262366 3496254.0 Cmax in healthy human plasma at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 2 days, measured after 48 hrs Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION CHEMBL894 77128 239.75 Cmax 0.26700000000000007 ug.mL-1 1.1136600625651724e-06 5.953247354478126 CHEMBL1262365 3496253.0 Cmax in healthy human plasma at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 6 days, 400 mg bid upto 17 day of study measured after 48 hrs Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION CHEMBL894 77128 239.75 Cmax 0.235 ug.mL-1 9.801876955161627e-07 6.008690753570965 CHEMBL1263993 3496246.0 Cmax in healthy human plasma assessed as R-bupropion at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 2 days measured after 48 hrs by high-performance liquid chromatography-tandem mass spectrometry Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION CHEMBL894 77128 239.75 Cmax 0.188 ug.mL-1 7.841501564129302e-07 6.1056007665790215 CHEMBL1264118 3496245.0 Cmax in healthy human plasma assessed as R-bupropion at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 6 days, 400 mg bid upto 17 day of study measured after 48 hrs by high-performance liquid chromatography-tandem mass spectrometry Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION CHEMBL894 77128 239.75 Cmax 0.11 ug.mL-1 4.588112617309698e-07 6.338365930684476 CHEMBL1264125 3496238.0 Cmax in healthy human plasma assessed as S-bupropion at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 2 days measured after 48 hrs by high-performance liquid chromatography-tandem mass spectrometry Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION CHEMBL894 77128 239.75 Cmax 0.07999999999999999 ug.mL-1 3.336809176225234e-07 6.476668628850757 CHEMBL1264126 3496237.0 Cmax in healthy human plasma assessed as S-bupropion at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 6 days, 400 mg bid upto 17 day of study measured after 48 hrs by high-performance liquid chromatography-tandem mass spectrometry Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION CHEMBL894 77128 239.75 Cmax 0.345 ug.mL-1 1.4389989572471323e-06 5.841939520769428 CHEMBL1261860 3496230.0 Cmax in healthy human plasma assessed as hydroxybupropion level at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 2 days measured after 48 hrs Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION CHEMBL894 77128 239.75 Cmax 0.32999999999999996 ug.mL-1 1.3764337851929091e-06 5.861244675964814 CHEMBL1261861 3496229.0 Cmax in healthy human plasma assessed as hydroxybupropion level at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 6 days, 400 mg bid upto 17 day of study measured after 48 hrs Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION CHEMBL894 77128 239.75 Cmax 0.3249999999999999 ug.mL-1 1.3555787278415012e-06 5.867875254863827 CHEMBL1261870 3496216.0 Cmax in healthy human plasma assessed as (R,R)-hydroxybupropion level at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 2 days measured after 48 hrs by high-performance liquid chromatography-tandem mass spectrometry Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION CHEMBL894 77128 239.75 Cmax 0.022999999999999996 ug.mL-1 9.593326381647548e-08 7.018030779825108 CHEMBL1262011 3496201.0 Cmax in healthy human plasma assessed as (S,S)-hydroxybupropion level at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 6 days, 400 mg bid upto 17 day of study measured after 48 hrs by high-performance liquid chromatography-tandem mass spectrometry Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION CHEMBL894 77128 239.75 Cmax 0.024999999999999998 ug.mL-1 1.0427528675703857e-07 6.981818607170664 CHEMBL1262010 3496202.0 Cmax in healthy human plasma assessed as (S,S)-hydroxybupropion level at 150 mg, po co-treated with ritonavir 200 mg tid for 1 day, 300 mg bid for next 2 days measured after 48 hrs by high-performance liquid chromatography-tandem mass spectrometry Scientific Literature 18285471.0 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. BUPROPION BUPROPION CHEMBL894 77128 239.75 Normal/therapeutic blood-plasma concentration 0.1 mg/L 4.1710114702815434e-07 6.379758615842701 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BUSPIRONE BUSPIRONE CHEMBL49 3599 385.51 Normal/therapeutic blood-plasma concentration 0.004 mg/L 1.0375865736297372e-08 7.983975656658212 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BUSULFAN BUSULFAN CHEMBL820 56644 246.31 Normal/therapeutic blood-plasma concentration 0.9 mg/L 3.6539320368641147e-06 5.437239534785721 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SECBUTABARBITAL BUTABARBITAL CHEMBL449 2393 212.25 Normal/therapeutic blood-plasma concentration 15.0 mg/L 7.06713780918728e-05 4.150756439860309 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BUTALBITAL BUTALBITAL CHEMBL454 2524 224.26 Normal/therapeutic blood-plasma concentration 5.0 mg/L 2.2295549808258274e-05 4.651781813480397 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BUTORPHANOL BUTORPHANOL CHEMBL33986 45838 327.47 Normal/therapeutic blood-plasma concentration 0.002 mg/L 6.107429688215714e-09 8.214141524140969 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics BUTRIPTYLINE BUTRIPTYLINE CHEMBL2110816 1383256 293.45 Normal/therapeutic blood-plasma concentration 0.15 mg/L 5.111603339580849e-07 6.291442854793911 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CABERGOLINE CABERGOLINE CHEMBL1201087 675038 451.62 Normal/therapeutic blood-plasma concentration 144.0 mg/L 0.00031885213232363496 3.496410674322667 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CAFFEINE CAFFEINE CHEMBL113 16485 194.19 Normal/therapeutic blood-plasma concentration 10.0 mg/L 5.1495957567330964e-05 4.288226861737593 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CALCIFEDIOL CALCIFEDIOL CHEMBL1040 125261 400.65 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.2479720454261825e-07 6.903795142741036 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CALCITRIOL CHEMBL846 63252 416.65 Cmax 17999.999999999996 nM 1.7999999999999997e-05 4.7447274948966935 CHEMBL3532320 15445326.0 Cmax in healthy human co-treated with 600 mg ritonavir Scientific Literature 22301272.0 Cytochrome P450 3A-mediated microsomal biotransformation of 1¿,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism. CALCITRIOL CHEMBL846 63252 416.65 Cmax 4499.999999999999 nM 4.499999999999999e-06 5.346787486224656 CHEMBL3532319 15445325.0 Cmax in healthy human co-treated with 200 mg ketoconazile Scientific Literature 22301272.0 Cytochrome P450 3A-mediated microsomal biotransformation of 1¿,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism. CANDESARTAN CANDESARTAN CILEXETIL CHEMBL1014 116349 610.67 Normal/therapeutic blood-plasma concentration 0.18 mg/L 2.9475821638528174e-07 6.53053408010546 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CAPTOPRIL CAPTOPRIL CHEMBL1560 444750 217.29 Normal/therapeutic blood-plasma concentration 0.5 mg/L 2.3010722996916565e-06 5.638069735584359 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CARBACHOL CARBACHOL CHEMBL965 94790 147.2 Normal/therapeutic blood-plasma concentration 0.01 mg/L 6.793478260869566e-08 7.16790781000148 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CARBAMAZEPINE CARBAMAZEPINE CHEMBL108 15086 236.27 Normal/therapeutic blood-plasma concentration 12.0 mg/L 5.078935116603885e-05 4.29422733524797 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CARBENOXOLONE CARBENOXOLONE CHEMBL499915 454298 570.77 Normal/therapeutic blood-plasma concentration 30.0 mg/L 5.256057606391366e-05 4.27933988355467 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PENTOXYVERINE CARBETAPENTANE CHEMBL73234 117805 333.47 Normal/therapeutic blood-plasma concentration 0.18 mg/L 5.397786907367978e-07 6.267784264422135 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CARBIDOPA CARBIDOPA CHEMBL1201236 675187 226.23 Normal/therapeutic blood-plasma concentration 0.2 mg/L 8.840560491535164e-07 6.053520199843901 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CARBIMAZOLE CARBIMAZOLE CHEMBL508102 517099 186.24 Normal/therapeutic blood-plasma concentration 3.4 mg/L 1.8256013745704464e-05 4.738594045927539 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CARBINOXAMINE CARBINOXAMINE CHEMBL864 66273 290.79 Normal/therapeutic blood-plasma concentration 0.04 mg/L 1.375563121152722e-07 6.861519476129007 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CARBOPLATIN CARBOPLATIN CHEMBL1351 300022 371.25 Normal/therapeutic blood-plasma concentration 25.0 mg/L 6.734006734006735e-05 4.171726453653231 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CARFILZOMIB CHEMBL451887 520664 719.92 Cmax 3.707 ug.mL-1 5.149183242582509e-06 5.2882616527782424 CHEMBL3533275 15448813.0 Cmax in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysis Scientific Literature 23118326.0 Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. CARFILZOMIB CHEMBL451887 520664 719.92 Cmax 2.76 ug.mL-1 3.833759306589621e-06 5.416375156742588 CHEMBL3533276 15448812.0 Cmax in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 1 of cycle 1 by LC-MS/MS analysis Scientific Literature 23118326.0 Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. CARISOPRODOL CARISOPRODOL CHEMBL1233 230249 260.33 Normal/therapeutic blood-plasma concentration 30.0 mg/L 0.00011523835132332041 3.938402963653567 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CARTEOLOL CARTEOLOL CHEMBL839 62182 292.38 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.4202065804774613e-07 6.465947661764938 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CARVEDILOL CARVEDILOL CHEMBL723 36662 406.48 Normal/therapeutic blood-plasma concentration 0.3 mg/L 7.380436921865774e-07 6.1319179271825766 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 11.499999999999996 ug.mL-1 1.0518324750990092e-05 4.978053424567844 CHEMBL1003271 2626627.0 Peak plasma concentration in child with invasive aspergillosis at 30 mg/day for 5 days measured on last day of therapy Scientific Literature 17646422.0 Maintenance of therapeutic concentrations of caspofungin after temporary treatment interruption (48 hours) in a child with invasive aspergillosis. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 5.600000000000001 ug.mL-1 5.121966835264744e-06 5.290563237915255 CHEMBL1003273 2626629.0 Peak plasma concentration in child with invasive aspergillosis administered at 30 mg/day schedule for 5 days followed by 48 hrs temporary treatment interruption measured on first day of resumption of therapy Scientific Literature 17646422.0 Maintenance of therapeutic concentrations of caspofungin after temporary treatment interruption (48 hours) in a child with invasive aspergillosis. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 10.04 ug.mL-1 9.182954826081786e-06 5.037017552112455 CHEMBL1697260 5305203.0 Cmax in plasma of adult human at 70 mg, iv dosed once daily measured on day 1 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 17.21 ug.mL-1 1.5740901649090394e-05 4.8029703945938955 CHEMBL1697247 5305190.0 Cmax in plasma of 3-24 months old infants/toddlers at 50 mg/m'2, iv dosed once daily measured on day 4 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 15.17 ug.mL-1 1.3875042301958238e-05 4.857765684134725 CHEMBL1697437 5305246.0 Cmax in plasma of in 10 years old infants/toddlers measured on day 4 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 16.87 ug.mL-1 1.5429925091235038e-05 4.811636182332331 CHEMBL1697445 5305247.0 Cmax in plasma of in 13 years old infants/toddlers measured on day 4 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 16.42 ug.mL-1 1.501833847054412e-05 4.823378112138034 CHEMBL1695418 5305248.0 Cmax in plasma of in 17 years old infants/toddlers measured on day 4 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 12.140000000000002 ug.mL-1 1.1103692389306068e-05 4.954532578182217 CHEMBL1695427 5305249.0 Cmax in plasma of in 20 years old infants/toddlers measured on day 4 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 17.960000000000004 ug.mL-1 1.6426879350241926e-05 4.78444493259017 CHEMBL1697428 5305250.0 Cmax in plasma of in 12 years old infants/toddlers measured on day 4 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 21.299999999999997 ug.mL-1 1.948176671270339e-05 4.710371661482718 CHEMBL1695436 5305251.0 Cmax in plasma of in 22 years old infants/toddlers measured on day 4 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 7.670000000000002 ug.mL-1 7.015265290442961e-06 5.153955900972475 CHEMBL1697251 5305194.0 Cmax in plasma of adult human at 50 mg, iv dosed once daily measured on day 1 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 9.390000000000002 ug.mL-1 8.588440818417132e-06 5.066085672655345 CHEMBL1697256 5305199.0 Cmax in plasma of adult human at 50 mg, iv dosed once daily measured on day 3 to 14 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 17.530000000000005 ug.mL-1 1.6033585468248383e-05 4.794969348827661 CHEMBL1697427 5305239.0 Cmax in plasma of in 12 years old infants/toddlers measured on day 1 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 14.47 ug.mL-1 1.3234796447550146e-05 4.878282733802418 CHEMBL1697436 5305240.0 Cmax in plasma of in 10 years old infants/toddlers measured on day 1 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 13.989999999999997 ug.mL-1 1.2795770718813165e-05 4.892933550429628 CHEMBL1697269 5305212.0 Cmax in plasma of 2-11 years old children at 50 mg/m'2, iv dosed once daily measured on day 1 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 15.750000000000004 ug.mL-1 1.440553172418209e-05 4.841470706795836 CHEMBL1697444 5305241.0 Cmax in plasma of in 13 years old infants/toddlers measured on day 1 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 12.899999999999997 ug.mL-1 1.1798816459806277e-05 4.928161554622207 CHEMBL1697283 5305226.0 Cmax in plasma of 12-17 years old adolescents at 50 mg/m'2, iv dosed once daily measured on day 4 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 13.9 ug.mL-1 1.2713453394674986e-05 4.895736464667361 CHEMBL1695417 5305242.0 Cmax in plasma of in 17 years old infants/toddlers measured on day 1 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 12.999999999999995 ug.mL-1 1.1890280153293145e-05 4.924807912614619 CHEMBL1695426 5305243.0 Cmax in plasma of in 20 years old infants/toddlers measured on day 1 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 21.499999999999996 ug.mL-1 1.966469409967713e-05 4.706312805005851 CHEMBL1695435 5305244.0 Cmax in plasma of in 22 years old infants/toddlers measured on day 1 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 8.949999999999998 ug.mL-1 8.186000567074898e-06 5.086928229605544 CHEMBL1697278 5305221.0 Cmax in plasma of 12-17 years old adolescents at 50 mg/m'2, iv dosed once daily measured on day 1 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 15.610000000000003 ug.mL-1 1.4277482553300472e-05 4.845348361859038 CHEMBL1697274 5305217.0 Cmax in plasma of 2-11 years old children at 50 mg/m'2, iv dosed once daily measured on day 4 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 15.94 ug.mL-1 1.457931274180714e-05 4.836262947861362 CHEMBL1697428 5305245.0 Cmax in plasma of in 12 years old infants/toddlers measured on day 4 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 13.319999999999995 ug.mL-1 1.2182963972451133e-05 4.914247040087174 CHEMBL1697265 5305208.0 Cmax in plasma of adult human at 70 mg, iv dosed once daily measured on day 3 to 14 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CASPOFUNGIN CHEMBL499808 497229 1093.33 Cmax 17.459999999999997 ug.mL-1 1.5969560882807568e-05 4.796707025551905 CHEMBL1697242 5305185.0 Cmax in plasma of 3-24 months old infants/toddlers at 50 mg/m'2, iv dosed once daily measured on day 1 post dose Scientific Literature 19114680.0 Pharmacokinetics and safety of caspofungin in older infants and toddlers. CEFACLOR CEFACLOR CHEMBL680 29005 367.81 Normal/therapeutic blood-plasma concentration 900.0 mg/L 0.0024469155270384164 2.6113810232000385 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFADROXIL CEFADROXIL CHEMBL1644 485902 363.39 Normal/therapeutic blood-plasma concentration 30.0 mg/L 8.25559316436886e-05 4.083251717221604 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFAMANDOLE CEFAMANDOLE CHEMBL1146 180228 462.51 Normal/therapeutic blood-plasma concentration 150.0 mg/L 0.00032431731205811765 3.4890298680688168 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFAZOLIN CEFAZOLIN CHEMBL1435 371631 454.52 Normal/therapeutic blood-plasma concentration 150.0 mg/L 0.00033001848103493797 3.481461738950127 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFDINIR CEFDINIR CHEMBL927 84624 395.42 Normal/therapeutic blood-plasma concentration 4.0 mg/L 1.011582621010571e-05 4.994998640442741 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFDITOREN PIVOXIL CHEMBL454446 506444 620.74 Cmax 3.6999999999999993 ug.mL-1 5.960627637980474e-06 5.224708007816795 CHEMBL1265497 3495180.0 Cmax in human serum at 400 mg/kg, po Scientific Literature 18160517.0 Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil. CEFEPIME CEFEPIME CHEMBL186 372385 480.57 Normal/therapeutic blood-plasma concentration 160.0 mg/L 0.0003329379694945586 3.477636673447585 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFIXIME CHEMBL1541 430642 453.46 Cmax 2.9999999999999996 ug.mL-1 6.615798526882194e-06 5.179417728968753 CHEMBL1282082 3536668.0 Cmax in Neisseria gonorrhoeae infected patient at 400 mg, po Scientific Literature 18663018.0 Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. CEFIXIME CEFIXIME CHEMBL1541 430642 453.46 Normal/therapeutic blood-plasma concentration 7.0 mg/L 1.543686322939179e-05 4.811440943674158 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFMENOXIME CEFMENOXIME CHEMBL1201224 675175 511.57 Normal/therapeutic blood-plasma concentration 200.0 mg/L 0.0003909533397189046 3.4078750725576574 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFODIZIME CEFODIZIME CHEMBL2303613 1503084 584.68 Normal/therapeutic blood-plasma concentration 400.0 mg/L 0.0006841349114045291 3.164858246962555 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFOPERAZONE CEFOPERAZONE CHEMBL507674 508755 645.68 Normal/therapeutic blood-plasma concentration 250.0 mg/L 0.0003871887002849709 3.4120773256288617 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFOTAXIME CHEMBL1730 558106 455.47 Cmax 214.4 ug.mL-1 0.0004707225503326234 3.327234995977579 CHEMBL3889443 17806275.0 Pharmacokinetics parameters for Cefotaxine evaluated after single IV or intramuscular (IM) administration of Cefotaxine to normal volunteers. Curated Drug Pharmacokinetic Data DailyMed|setid=f3c5895f-f54b-43d4-9b38-7bfbdf8335b7 | CEFOTAXIME - cefotaxime injection, powder, for solution|WOCKHARDT USA LLC. CEFOTAXIME CHEMBL1730 558106 455.47 Cmax 38.900000000000006 ug.mL-1 8.540628361911871e-05 4.068510175672603 CHEMBL3889443 17806274.0 Pharmacokinetics parameters for Cefotaxine evaluated after single IV or intramuscular (IM) administration of Cefotaxine to normal volunteers. Curated Drug Pharmacokinetic Data DailyMed|setid=f3c5895f-f54b-43d4-9b38-7bfbdf8335b7 | CEFOTAXIME - cefotaxime injection, powder, for solution|WOCKHARDT USA LLC. CEFOTAXIME CHEMBL1730 558106 455.47 Cmax 11.7 ug.mL-1 2.568775111423365e-05 4.5902739152521495 CHEMBL3889443 17806271.0 Pharmacokinetics parameters for Cefotaxine evaluated after single IV or intramuscular (IM) administration of Cefotaxine to normal volunteers. Mean Curated Drug Pharmacokinetic Data DailyMed|setid=f3c5895f-f54b-43d4-9b38-7bfbdf8335b7 | CEFOTAXIME - cefotaxime injection, powder, for solution|WOCKHARDT USA LLC. CEFOTAXIME CEFOTAXIME CHEMBL1730 558106 455.47 Normal/therapeutic blood-plasma concentration 225.0 mg/L 0.0004939952137352625 3.306277258886949 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFOTAXIME CHEMBL1730 558106 455.47 Cmax 20.500000000000004 ug.mL-1 4.5008452806990586e-05 4.346705915942557 CHEMBL3889443 17806267.0 Pharmacokinetics parameters for Cefotaxine evaluated after single IV or intramuscular (IM) administration of Cefotaxine to normal volunteers. Mean Curated Drug Pharmacokinetic Data DailyMed|setid=f3c5895f-f54b-43d4-9b38-7bfbdf8335b7 | CEFOTAXIME - cefotaxime injection, powder, for solution|WOCKHARDT USA LLC. CEFOTAXIME CHEMBL1730 558106 455.47 Cmax 101.7 ug.mL-1 0.0002232858366083386 3.651138824075567 CHEMBL3889443 17806270.0 Pharmacokinetics parameters for Cefotaxine evaluated after single IV or intramuscular (IM) administration of Cefotaxine to normal volunteers. Curated Drug Pharmacokinetic Data DailyMed|setid=f3c5895f-f54b-43d4-9b38-7bfbdf8335b7 | CEFOTAXIME - cefotaxime injection, powder, for solution|WOCKHARDT USA LLC. CEFOTETAN CEFOTETAN CHEMBL474579 458729 575.63 Normal/therapeutic blood-plasma concentration 90.0 mg/L 0.00015635043343814603 3.8059009104585653 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFOTIAM CEFOTIAM CHEMBL1296 255510 525.64 Normal/therapeutic blood-plasma concentration 150.0 mg/L 0.0002853664104710448 3.5445971475688802 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFOXITIN CEFOXITIN CHEMBL996 109807 427.46 Normal/therapeutic blood-plasma concentration 150.0 mg/L 0.000350910026669162 3.4548042223663074 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFPODOXIME CEFPODOXIME PROXETIL CHEMBL1201016 674967 557.61 Normal/therapeutic blood-plasma concentration 7.0 mg/L 1.2553576872724665e-05 4.901232513644341 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFSULODIN CEFSULODIN CHEMBL3351077 1799684 532.56 Normal/therapeutic blood-plasma concentration 100.0 mg/L 0.00018777226979119725 3.7263685439436145 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFTAROLINE FOSAMIL CHEMBL501122 497230 684.7 Cmax 21.000000000000004 ug.mL-1 3.0670366583905365e-05 4.513281033133399 CHEMBL1667076 5163302.0 Cmax in healthy human at 600 mg/kg, iv administered as 1 hr infusion every 12 hrs for 14 days measured after last dose Scientific Literature 19470504.0 Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge. CEFTAROLINE FOSAMIL CHEMBL501122 497230 684.7 Cmax 19.000000000000004 ug.mL-1 2.774937929020009e-05 4.55674672691449 CHEMBL1667075 5163301.0 Cmax in healthy human at 600 mg/kg, iv administered as 1 hr infusion every 12 hrs for 14 days measured after first dose Scientific Literature 19470504.0 Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge. CEFTAROLINE FOSAMIL CHEMBL501122 497230 684.7 Cmax 18.96 ug.mL-1 2.7690959544325982e-05 4.5576619948652715 CHEMBL986833 2502933.0 Cmax in human at 10 mg/kg infused for 1 hr Scientific Literature 17591849.0 In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. CEFTAZIDIME CEFTAZIDIME CHEMBL44354 61682 546.59 Normal/therapeutic blood-plasma concentration 200.0 mg/L 0.00036590497447812803 3.4366316862397768 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFTAZIDIME CHEMBL44354 61682 546.59 Cmax 445.00000000000006 ug.mL-1 0.000814138568213835 3.089301670922826 CHEMBL1247544 3456218.0 Cmax in cystic fibrosis patient at 2 gram, iv administered in 5 mins infusion Scientific Literature 20065059.0 Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. CEFTAZIDIME CHEMBL44354 61682 546.59 Cmax 210.0 ug.mL-1 0.0003842002232020344 3.4154423871698385 CHEMBL1247549 3456223.0 Cmax in healthy human subjects at 2 gram, iv administered in 5 mins infusion Scientific Literature 20065059.0 Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. CEFTIBUTEN CEFTIBUTEN CHEMBL1605 454578 410.43 Normal/therapeutic blood-plasma concentration 20.0 mg/L 4.872938138050338e-05 4.312209101952157 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFTIBUTEN CHEMBL1605 454578 410.43 Cmax 15.0 ug.mL-1 3.654703603537753e-05 4.437147838560457 CHEMBL1282082 3536665.0 Cmax in Neisseria gonorrhoeae infected patient at 400 mg, po Scientific Literature 18663018.0 Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. CEFTIZOXIME CEFTIZOXIME CHEMBL528 12105 383.41 Normal/therapeutic blood-plasma concentration 160.0 mg/L 0.0004173078427792702 3.3795434531896733 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFTOLOZANE CHEMBL2103872 1376142 666.7 Cmax 33.29999999999999 ug.mL-1 4.9947502624868736e-05 4.301486221619244 CHEMBL1283520 3548796.0 Cmax in healthy human at 500 mg, iv administered as 1 hr infusion every 8 hrs for 10 days measured on day 10 Scientific Literature 20457817.0 Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. CEFTOLOZANE CHEMBL2103872 1376142 666.7 Cmax 16.499999999999996 ug.mL-1 2.47487625618719e-05 4.606446510911658 CHEMBL1283696 3548793.0 Cmax in healthy human at 250 mg, iv administered as single dose as 1 hr iv infusion Scientific Literature 20457817.0 Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. CEFTOLOZANE CHEMBL2103872 1376142 666.7 Cmax 32.2 ug.mL-1 4.8297585120743966e-05 4.316074583429733 CHEMBL1283697 3548794.0 Cmax in healthy human at 500 mg, iv administered as single dose as 1 hr iv infusion Scientific Literature 20457817.0 Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. CEFTOLOZANE CHEMBL2103872 1376142 666.7 Cmax 58.4 ug.mL-1 8.759562021898905e-05 4.057517608013164 CHEMBL1283225 3548795.0 Cmax in healthy human at 1000 mg, iv administered as single dose as 1 hr iv infusion Scientific Literature 20457817.0 Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. CEFTOLOZANE CHEMBL2103872 1376142 666.7 Cmax 52.79999999999999 ug.mL-1 7.919604019799008e-05 4.101296532591752 CHEMBL1283521 3548797.0 Cmax in healthy human at 1000 mg, iv administered as 1 hr infusion every 8 hrs for 10 days measured on day 1 Scientific Literature 20457817.0 Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. CEFTOLOZANE CHEMBL2103872 1376142 666.7 Cmax 127.70000000000003 ug.mL-1 0.0001915404229788511 3.7177395578621484 CHEMBL1283227 3548802.0 Cmax in healthy human at 2000 mg, iv administered as single dose as 1 hr iv infusion Scientific Literature 20457817.0 Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. CEFTOLOZANE CHEMBL2103872 1376142 666.7 Cmax 34.3 ug.mL-1 5.144742762861856e-05 4.288636335082794 CHEMBL1283519 3548810.0 Cmax in healthy human at 500 mg, iv administered as 1 hr infusion every 8 hrs for 10 days measured on day 1 Scientific Literature 20457817.0 Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. CEFTOLOZANE CHEMBL2103872 1376142 666.7 Cmax 87.40000000000002 ug.mL-1 0.00013109344532773363 3.8824190224911606 CHEMBL1283226 3548801.0 Cmax in healthy human at 1500 mg, iv administered as single dose as 1 hr iv infusion Scientific Literature 20457817.0 Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. CEFTOLOZANE CHEMBL2103872 1376142 666.7 Cmax 82.6 ug.mL-1 0.0001238938053097345 3.9069504078051818 CHEMBL1283524 3548800.0 Cmax in healthy human at 1500 mg, iv administered as 1 hr infusion every 12 hrs for 10 days measured on day 10 Scientific Literature 20457817.0 Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. CEFTOLOZANE CHEMBL2103872 1376142 666.7 Cmax 58.0 ug.mL-1 8.699565021748912e-05 4.060502461562627 CHEMBL1283522 3548798.0 Cmax in healthy human at 1000 mg, iv administered as 1 hr infusion every 8 hrs for 10 days measured on day 10 Scientific Literature 20457817.0 Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. CEFTOLOZANE CHEMBL2103872 1376142 666.7 Cmax 85.39999999999999 ug.mL-1 0.00012809359532023397 3.892472584436559 CHEMBL1283523 3548799.0 Cmax in healthy human at 1500 mg, iv administered as 1 hr infusion every 12 hrs for 10 days measured on day 1 Scientific Literature 20457817.0 Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. CEFTRIAXONE CEFTRIAXONE CHEMBL161 83724 554.59 Normal/therapeutic blood-plasma concentration 75.0 mg/L 0.0001352350384969076 3.8689107710099457 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFUROXIME CEFUROXIME CHEMBL1436 371655 424.39 Normal/therapeutic blood-plasma concentration 180.0 mg/L 0.0004241381747920545 3.3724926368649566 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFUROXIME CHEMBL1436 371655 424.39 Cmax 25.99999999999999 ug.mL-1 6.126440302551895e-05 4.212791793997445 CHEMBL1663039 5159734.0 Cmax in human at 1000 mg, im Scientific Literature 19223616.0 Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. CELIPROLOL CELIPROLOL CHEMBL27810 36502 379.5 Normal/therapeutic blood-plasma concentration 1.0 mg/L 2.635046113306983e-06 5.579211780231499 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEFALEXIN CEPHALEXIN CHEMBL1727 555972 347.4 Normal/therapeutic blood-plasma concentration 65.0 mg/L 0.0001871042026482441 3.727916457468224 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEPHALOTHIN CHEMBL617 24991 396.45 Cmax 38.69999999999999 ug.mL-1 9.761634506242904e-05 4.010477457168481 CHEMBL1655143 5165747.0 Cmax in patient with severe burns at 1 g, iv Scientific Literature 19752272.0 Unbound cephalothin pharmacokinetics in adult burn patients are related to the elapsed time after injury. CEPHALOTHIN CEPHALOTHIN CHEMBL617 24991 396.45 Normal/therapeutic blood-plasma concentration 30.0 mg/L 7.567158531971244e-05 4.1210671674677295 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CEPHALOTHIN CHEMBL617 24991 396.45 Cmax 21.299999999999997 ug.mL-1 5.372682557699583e-05 4.269808818748654 CHEMBL1655144 5165748.0 Cmax in healthy human at 1 g, iv Scientific Literature 19752272.0 Unbound cephalothin pharmacokinetics in adult burn patients are related to the elapsed time after injury. CERIVASTATIN CHEMBL1477 403465 459.56 Cmax 24.999999999999996 nM 2.5e-08 7.6020599913279625 CHEMBL944788 2075549.0 Cmax in human Scientific Literature 18155906.0 Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. CERIVASTATIN CERIVASTATIN CHEMBL1477 403465 459.56 Normal/therapeutic blood-plasma concentration 0.04 mg/L 8.703977717817043e-08 7.060282229438346 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CETIRIZINE CETIRIZINE CHEMBL1000 111185 388.9 Normal/therapeutic blood-plasma concentration 0.3 mg/L 7.714065312419645e-07 6.112716688427797 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLORAMBUCIL CHLORAMBUCIL CHEMBL515 11002 304.22 Normal/therapeutic blood-plasma concentration 1.0 mg/L 3.2870948655578196e-06 5.483187761998763 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLORAMPHENICOL CHLORAMPHENICOL CHEMBL130 27340 323.13 Normal/therapeutic blood-plasma concentration 25.0 mg/L 7.736824188407143e-05 4.111437271938078 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLORDIAZEPOXIDE CHLORDIAZEPOXIDE CHEMBL451 2431 299.76 Normal/therapeutic blood-plasma concentration 3.0 mg/L 1.00080064051241e-05 4.9996524253660795 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLORMEZANONE CHLORMEZANONE CHEMBL1200714 674665 273.74 Normal/therapeutic blood-plasma concentration 14.0 mg/L 5.114342076422883e-05 4.291210227241557 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLOROFORM CHLOROFORM CHEMBL44618 67839 119.38 Normal/therapeutic blood-plasma concentration 50.0 mg/L 0.0004188306248952924 3.377961570219637 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROGUANIL CHLOROGUANIDE CHEMBL1377 320522 253.74 Normal/therapeutic blood-plasma concentration 0.15 mg/L 5.911563017261763e-07 6.228297676474863 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLOROQUINE CHLOROQUINE CHEMBL76 6579 319.88 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.5630861573089908e-06 5.806017083009206 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLOROQUINE CHEMBL76 6579 319.88 Cmax 0.3949999999999999 ug.mL-1 1.2348380642741024e-06 5.908389991718765 CHEMBL1264533 3486189.0 Cmax in Papua new Guinean pregnant women at 600 mg/day, po administered as three divided doses by HPLC method Scientific Literature 20086162.0 Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. CHLOROQUINE CHEMBL76 6579 319.88 Cmax 0.18499999999999997 ug.mL-1 5.783418782043265e-07 6.237815358942211 CHEMBL1264685 3486213.0 Cmax in Papua new Guinean pregnant women assessed as monodesethychloroquine at 600 mg/day, po administered as three divided doses by HPLC method Scientific Literature 20086162.0 Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. CHLOROQUINE CHEMBL76 6579 319.88 Cmax 0.186 ug.mL-1 5.814680505189446e-07 6.235474143127309 CHEMBL1264539 3486211.0 Cmax in women assessed as monodesethychloroquine at 450 mg/day, po administered as three divided doses by HPLC method Scientific Literature 20086162.0 Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. CHLOROQUINE CHEMBL76 6579 319.88 Cmax 0.376 ug.mL-1 1.1754407902963613e-06 5.929799242417564 CHEMBL1264531 3486191.0 Cmax in women at 450 mg/day, po administered as three divided doses by HPLC method Scientific Literature 20086162.0 Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. CHLOROQUINE CHEMBL76 6579 319.88 Cmax 0.29599999999999993 ug.mL-1 9.253470051269224e-07 6.033695376286286 CHEMBL1264532 3486190.0 Cmax in Papua new Guinean pregnant women at 450 mg/day, po administered as three divided doses by HPLC method Scientific Literature 20086162.0 Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. CHLOROQUINE CHEMBL76 6579 319.88 Cmax 0.232 ug.mL-1 7.252719769913719e-07 6.139499102454326 CHEMBL1264686 3486214.0 Cmax in Papua new Guinean pregnant women assessed as monodesethychloroquine at 750 mg/day, po administered as three divided doses by HPLC method Scientific Literature 20086162.0 Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. CHLOROQUINE CHEMBL76 6579 319.88 Cmax 0.494 ug.mL-1 1.544329123421283e-06 5.811260138421578 CHEMBL1264534 3486188.0 Cmax in Papua new Guinean pregnant women at 750 mg/day, po administered as three divided doses by HPLC method Scientific Literature 20086162.0 Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. CHLOROQUINE CHEMBL76 6579 319.88 Cmax 0.139 ug.mL-1 4.345379517318995e-07 6.36197228709113 CHEMBL1264540 3486212.0 Cmax in Papua new Guinean pregnant women assessed as monodesethychloroquine at 450 mg/day, po administered as three divided doses by HPLC method Scientific Literature 20086162.0 Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. CHLOROTHIAZIDE CHLOROTHIAZIDE CHEMBL842 62615 295.73 Normal/therapeutic blood-plasma concentration 6.0 mg/L 2.028877692489771e-05 4.692744132896572 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLORPROMAZINE CHLORPROMAZINE CHEMBL71 6216 318.87 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.568037131119265e-06 5.8046436574364835 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLORPROPAMIDE CHLORPROPAMIDE CHEMBL498 8516 276.75 Normal/therapeutic blood-plasma concentration 150.0 mg/L 0.0005420054200542005 3.265996370495079 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLORPROTHIXENE CHLORPROTHIXENE CHEMBL908 80209 315.87 Normal/therapeutic blood-plasma concentration 0.3 mg/L 9.497578117580016e-07 6.022387125686438 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLORTETRACYCLINE CHLORTETRACYCLINE CHEMBL404520 438486 478.89 Normal/therapeutic blood-plasma concentration 10.0 mg/L 2.0881622084403517e-05 4.680235768364048 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLORTALIDONE CHLORTHALIDONE CHEMBL1055 134333 338.77 Normal/therapeutic blood-plasma concentration 1.4 mg/L 4.132597337426573e-06 5.383776908449946 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CHLORTHALIDONE CHEMBL1055 134333 338.77 Cmax 3.6999999999999993 ug.mL-1 1.0921864391770225e-05 4.961703220061189 CHEMBL3889448 17806337.0 Pharmacokinetic parameters for diffferent drugs or their active metabolite, following single oral or intravenous (IV) administration to subjects of different health conditions. Curated Drug Pharmacokinetic Data Goodman and Gilman Ed. 12 | The Pharmaceutical Basis of Therapeutics| Table AII-I: Pharmacokinetic Data VITAMIN D CHOLECALCIFEROL CHEMBL1042 125294 384.65 Normal/therapeutic blood-plasma concentration 0.09 mg/L 2.3397894189522942e-07 6.630823227334441 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CIDOFOVIR CIDOFOVIR CHEMBL152 48701 279.19 Normal/therapeutic blood-plasma concentration 43.0 mg/L 0.0001540169776854472 3.8124314031330138 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CILAZAPRIL CILAZAPRIL CHEMBL515606 453655 417.51 Normal/therapeutic blood-plasma concentration 0.09 mg/L 2.1556369907307608e-07 6.66642437251876 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CIMETIDINE CHEMBL30 1620 252.35 Cmax 11900.0 nM 1.1900000000000001e-05 4.924453038607469 CHEMBL2154113 12064135.0 Cmax in human Scientific Literature 21599003.0 Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. CIMETIDINE CIMETIDINE CHEMBL30 1620 252.35 Normal/therapeutic blood-plasma concentration 4.0 mg/L 1.5851000594412524e-05 4.799943317741742 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CINNARIZINE CINNARIZINE CHEMBL43064 66311 368.52 Normal/therapeutic blood-plasma concentration 0.33 mg/L 8.954737870400521e-07 6.047947122612806 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CINOXACIN CINOXACIN CHEMBL1208 214701 262.22 Normal/therapeutic blood-plasma concentration 15.0 mg/L 5.7203874609106846e-05 4.242574553997795 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CIPROFLOXACIN CIPROFLOXACIN CHEMBL8 241 331.35 Normal/therapeutic blood-plasma concentration 4.0 mg/L 1.2071827372868568e-05 4.918226983599154 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CIPROFLOXACIN CHEMBL8 241 331.35 Cmax 4.0 ug.mL-1 1.2071827372868568e-05 4.918226983599154 CHEMBL1032830 2667148.0 Cmax in patient with Crohn's disease at 400 mg administered intravenously Scientific Literature 18070962.0 Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. CIPROFLOXACIN CHEMBL8 241 331.35 Cmax 7600.000000000002 nM 7.600000000000003e-06 5.119186407719209 CHEMBL948858 2628573.0 Cmax in patient with bronchitis at 500 mg, po twice daily for 3 days Scientific Literature 17698630.0 Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. CIPROFLOXACIN CHEMBL8 241 331.35 Cmax 2.4999999999999996 ug.mL-1 7.544892108042853e-06 5.122346966255079 CHEMBL1284377 3548988.0 Cmax in healthy human at 500 mg administered for every 12 hrs Scientific Literature 20498313.0 Mutant selection window and characterization of allelic diversity for ciprofloxacin-resistant mutants of Rhodococcus equi. CIPROFLOXACIN CHEMBL8 241 331.35 Cmax 4.3999999999999995 ug.mL-1 1.3279010110155422e-05 4.8768342984409285 CHEMBL1284378 3548989.0 Cmax in healthy human at 750 mg administered for every 12 hrs Scientific Literature 20498313.0 Mutant selection window and characterization of allelic diversity for ciprofloxacin-resistant mutants of Rhodococcus equi. CITALOPRAM CITALOPRAM CHEMBL549 14367 324.4 Normal/therapeutic blood-plasma concentration 0.11 mg/L 3.390875462392109e-07 6.469688160380893 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLADRIBINE CLADRIBINE CHEMBL1619 467361 285.69 Normal/therapeutic blood-plasma concentration 0.06 mg/L 2.1001785151737898e-07 6.677743788666141 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 2.9999999999999996 ug.mL-1 4.010909674314133e-06 5.396757118219961 CHEMBL1032831 2667149.0 Cmax in healthy human at 500 mg administered orally Scientific Literature 18070962.0 Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 1.09 ug.mL-1 1.4572971816674688e-06 5.836451874999 CHEMBL1030489 2494923.0 Cmax in fasting human plasma at 250 mg, po Scientific Literature 17606673.0 Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 2.2100000000000004 ug.mL-1 2.9547034600780796e-06 5.5294860992545125 CHEMBL1031327 2494186.0 Cmax in human plasma at 500 mg, po, bid for 3 to 5 days Scientific Literature 17606673.0 Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 0.78 ug.mL-1 1.042836515321675e-06 5.981783770249143 CHEMBL1655707 5161040.0 Cmax in healthy human at 400 mg, po administered as single dose Scientific Literature 19223626.0 Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 3.9570000000000007 ug.mL-1 5.290389860420344e-06 5.276512322673596 CHEMBL3889372 17805847.0 Pharmacokinetic parameters for Clarithromycin evaluated after single oral administration of 1000 or 2 x 500 mg Clarithromycin extended-release tablets to 34 adult volunteers under fasting and feeding conditions. Curated Drug Pharmacokinetic Data DailyMed|setid=f21494ed-c5e8-4ddf-b140-ecd68c5c312b | CLARITHROMYCIN EXTENDED RELEASE - clarithromycin tablet, film coated, extended release|Ranbaxy Pharmaceuticals Inc. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 2.1880000000000006 ug.mL-1 2.925290122466443e-06 5.53383105527823 CHEMBL3889372 17805844.0 Pharmacokinetic parameters for Clarithromycin evaluated after single oral administration of 1000 or 2 x 500 mg Clarithromycin extended-release tablets to 34 adult volunteers under fasting and feeding conditions. Curated Drug Pharmacokinetic Data DailyMed|setid=f21494ed-c5e8-4ddf-b140-ecd68c5c312b | CLARITHROMYCIN EXTENDED RELEASE - clarithromycin tablet, film coated, extended release|Ranbaxy Pharmaceuticals Inc. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 4.999999999999999 ug.mL-1 6.6848494571902225e-06 5.174908368603605 CHEMBL3889368 17805837.0 Evaluation of pharmacokinetic parameters for Clarithromycin following multiple oral doses of Clarithromycin tablets. Range 5 To 10 Ug/Ml Curated Drug Pharmacokinetic Data DailyMed|setid=d9db2fd3-a668-4d37-9082-18f6ceb8c3cb | CLARITHROMYCIN - clarithromycin tablet, film coated, extended release|Dispensing Solutions, Inc. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 2.9999999999999996 ug.mL-1 4.010909674314133e-06 5.396757118219961 CHEMBL3889368 17805836.0 Evaluation of pharmacokinetic parameters for Clarithromycin following multiple oral doses of Clarithromycin tablets. Curated Drug Pharmacokinetic Data DailyMed|setid=d9db2fd3-a668-4d37-9082-18f6ceb8c3cb | CLARITHROMYCIN - clarithromycin tablet, film coated, extended release|Dispensing Solutions, Inc. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 1.0 ug.mL-1 1.3369698914380448e-06 5.873878372939624 CHEMBL3889368 17805835.0 Evaluation of pharmacokinetic parameters for Clarithromycin following multiple oral doses of Clarithromycin tablets. Curated Drug Pharmacokinetic Data DailyMed|setid=d9db2fd3-a668-4d37-9082-18f6ceb8c3cb | CLARITHROMYCIN - clarithromycin tablet, film coated, extended release|Dispensing Solutions, Inc. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 2.9999999999999996 ug.mL-1 4.010909674314133e-06 5.396757118219961 CHEMBL3889368 17805833.0 Evaluation of pharmacokinetic parameters for Clarithromycin following multiple oral doses of Clarithromycin tablets. Curated Drug Pharmacokinetic Data DailyMed|setid=d9db2fd3-a668-4d37-9082-18f6ceb8c3cb | CLARITHROMYCIN - clarithromycin tablet, film coated, extended release|Dispensing Solutions, Inc. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 2.0 ug.mL-1 2.6739397828760896e-06 5.572848377275642 CHEMBL3889368 17805831.0 Evaluation of pharmacokinetic parameters for Clarithromycin following multiple oral doses of Clarithromycin tablets. Range 2 To 4 Ug/Ml Curated Drug Pharmacokinetic Data DailyMed|setid=d9db2fd3-a668-4d37-9082-18f6ceb8c3cb | CLARITHROMYCIN - clarithromycin tablet, film coated, extended release|Dispensing Solutions, Inc. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 1.0 ug.mL-1 1.3369698914380448e-06 5.873878372939624 CHEMBL3889368 17805828.0 Evaluation of pharmacokinetic parameters for Clarithromycin following multiple oral doses of Clarithromycin tablets. Curated Drug Pharmacokinetic Data DailyMed|setid=d9db2fd3-a668-4d37-9082-18f6ceb8c3cb | CLARITHROMYCIN - clarithromycin tablet, film coated, extended release|Dispensing Solutions, Inc. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 2.4099999999999997 ug.mL-1 3.2220974383656877e-06 5.491861330364755 CHEMBL922207 2130385.0 Cmax in human at 500 mg, po administered as single dose Scientific Literature 17936632.0 A new insight into solid-state conformation of macrolide antibiotics. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 3.478 ug.mL-1 4.64998128242152e-06 5.332548795272929 CHEMBL3889372 17805853.0 Pharmacokinetic parameters for Clarithromycin evaluated after single oral administration of 1000 or 2 x 500 mg Clarithromycin extended-release tablets to 34 adult volunteers under fasting and feeding conditions. Curated Drug Pharmacokinetic Data DailyMed|setid=f21494ed-c5e8-4ddf-b140-ecd68c5c312b | CLARITHROMYCIN EXTENDED RELEASE - clarithromycin tablet, film coated, extended release|Ranbaxy Pharmaceuticals Inc. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 2.0 ug.mL-1 2.6739397828760896e-06 5.572848377275642 CHEMBL3889368 17805839.0 Evaluation of pharmacokinetic parameters for Clarithromycin following multiple oral doses of Clarithromycin tablets. Curated Drug Pharmacokinetic Data DailyMed|setid=d9db2fd3-a668-4d37-9082-18f6ceb8c3cb | CLARITHROMYCIN - clarithromycin tablet, film coated, extended release|Dispensing Solutions, Inc. CLARITHROMYCIN CHEMBL1741 570147 747.96 Cmax 2.206 ug.mL-1 2.949355580512327e-06 5.530272864835451 CHEMBL3889372 17805850.0 Pharmacokinetic parameters for Clarithromycin evaluated after single oral administration of 1000 or 2 x 500 mg Clarithromycin extended-release tablets to 34 adult volunteers under fasting and feeding conditions. Curated Drug Pharmacokinetic Data DailyMed|setid=f21494ed-c5e8-4ddf-b140-ecd68c5c312b | CLARITHROMYCIN EXTENDED RELEASE - clarithromycin tablet, film coated, extended release|Ranbaxy Pharmaceuticals Inc. CLARITHROMYCIN CLARITHROMYCIN CHEMBL1741 570147 747.96 Normal/therapeutic blood-plasma concentration 2.0 mg/L 2.6739397828760896e-06 5.572848377275642 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLEMASTINE CLEMASTINE CHEMBL1626 469763 343.9 Normal/therapeutic blood-plasma concentration 0.002 mg/L 5.815644082582146e-09 8.235402180158033 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLENBUTEROL CLENBUTEROL CHEMBL49080 74690 277.2 Normal/therapeutic blood-plasma concentration 0.0006 mg/L 2.1645021645021644e-09 8.664641975556126 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLINDAMYCIN CHEMBL1753 581843 424.99 Cmax 4.0 ug.mL-1 9.411986164380339e-06 5.026318719908436 CHEMBL1696172 5306503.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. CLINDAMYCIN CHEMBL1753 581843 424.99 Cmax 2.4999999999999996 ug.mL-1 5.882491352737711e-06 5.23043870256436 CHEMBL1220037 3385204.0 Cmax po dosed in human co-treated with rifampin Scientific Literature 19841148.0 Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. CLINDAMYCIN CLINDAMYCIN CHEMBL1753 581843 424.99 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.1764982705475424e-06 5.929408706900379 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLOBAZAM CLOBAZAM CHEMBL70418 111390 300.75 Normal/therapeutic blood-plasma concentration 0.3 mg/L 9.97506234413965e-07 6.00108438129222 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLOBUTINOL CLOBUTINOL CHEMBL1474889 898773 255.79 Normal/therapeutic blood-plasma concentration 0.2 mg/L 7.818913952851949e-07 6.106853566254609 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLOFIBRATE CLOFIBRATE CHEMBL565 16415 242.7 Normal/therapeutic blood-plasma concentration 250.0 mg/L 0.0010300782859497322 2.987129767659897 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLOMETHIAZOLE CLOMETHIAZOLE CHEMBL315795 139608 161.66 Normal/therapeutic blood-plasma concentration 5.0 mg/L 3.092911047878263e-05 4.509632570126513 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLOMIPRAMINE CLOMIPRAMINE CHEMBL415 996 314.86 Normal/therapeutic blood-plasma concentration 0.4 mg/L 1.2704058946833514e-06 5.896057499785908 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLONAZEPAM CLONAZEPAM CHEMBL452 2465 315.72 Normal/therapeutic blood-plasma concentration 0.08 mg/L 2.533890789306981e-07 6.596212107141384 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLONIDINE CLONIDINE CHEMBL134 27609 230.1 Normal/therapeutic blood-plasma concentration 0.004 mg/L 1.738374619730552e-08 7.759856627340681 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLOPIDOGREL CLOPIDOGREL CHEMBL1771 598402 321.83 Normal/therapeutic blood-plasma concentration 0.006 mg/L 1.8643383152596092e-08 7.729475274858498 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLOTIAZEPAM CLOTIAZEPAM CHEMBL1697737 1078501 318.83 Normal/therapeutic blood-plasma concentration 0.7 mg/L 2.1955273970454477e-06 5.658461139151067 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLOXACILLIN CLOXACILLIN CHEMBL891 76766 435.89 Normal/therapeutic blood-plasma concentration 85.0 mg/L 0.0001950033265273349 3.7099579800213642 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CLOZAPINE CLOZAPINE CHEMBL42 2261 326.83 Normal/therapeutic blood-plasma concentration 0.35 mg/L 1.0708931248661384e-06 5.970253869594787 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics COCAINE COCAINE CHEMBL370805 333370 303.36 Normal/therapeutic blood-plasma concentration 0.3 mg/L 9.889240506329112e-07 6.00483706093831 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CODEINE CODEINE CHEMBL485 6167 299.37 Normal/therapeutic blood-plasma concentration 0.25 mg/L 8.350870160670742e-07 6.078268268673513 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics COLCHICINE COLCHICINE CHEMBL107 14440 399.44 Normal/therapeutic blood-plasma concentration 0.0025 mg/L 6.258762267174044e-09 8.203511544375015 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics COLISTIN CHEMBL2221249 1451060 2296.97 Cmax 2.9300000000000006 ug.mL-1 1.2755934992620717e-06 5.8942877026948395 CHEMBL1664545 5183932.0 Cmax in patient at 225 mg, iv every 12 hrs for 2 days Scientific Literature 20585134.0 In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. COLISTIN CHEMBL2221249 1451060 2296.97 Cmax 2.9300000000000006 ug.mL-1 1.2755934992620717e-06 5.8942877026948395 CHEMBL1664547 5183930.0 Cmax in patient at 225 mg, iv every 8 hrs for 2 days Scientific Literature 20585134.0 In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. COLISTIN COLISTIN CHEMBL2221249 1451060 2296.97 Normal/therapeutic blood-plasma concentration 5.0 mg/L 2.176780715464286e-06 5.66218531871293 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics COPPER COPPER CHEMBL55643 87251 63.55 Normal/therapeutic blood-plasma concentration 1.5 mg/L 2.3603461841070024e-05 4.627024295834346 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CROMOLYN CROMOLYN CHEMBL428880 7725 468.37 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.1350641586779684e-08 7.670589069893688 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CYCLIZINE CYCLIZINE CHEMBL648 27546 266.39 Normal/therapeutic blood-plasma concentration 0.25 mg/L 9.384736664289201e-07 6.027577909174826 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CYCLOBARBITAL CYCLOBARBITAL CHEMBL268164 2198 236.27 Normal/therapeutic blood-plasma concentration 6.0 mg/L 2.5394675583019426e-05 4.595257330911951 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CYCLOBENZAPRINE CYCLOBENZAPRINE CHEMBL669 28119 275.4 Normal/therapeutic blood-plasma concentration 0.04 mg/L 1.4524328249818448e-07 6.837903944592942 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE CHEMBL88 8417 261.09 Normal/therapeutic blood-plasma concentration 25.0 mg/L 9.575242253629018e-05 4.018850229569951 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 0.044000000000000004 ug.mL-1 3.658648129516144e-08 7.436679356776787 CHEMBL3791220 16541768.0 Cmax in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M17 at 10 mg/kg, po measured at 4 to 14 hrs by HPLC analysis Scientific Literature 8132853.0 Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 0.93 ug.mL-1 7.733051728295486e-07 6.111649084709039 CHEMBL3788823 16534979.0 Cmax in blood of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 6.8 +/- 1.1 hrs during high fat diet phase by HPLC method Scientific Literature 2391396.0 Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 1.5100000000000005 ug.mL-1 1.2555815171748588e-06 5.901155085969805 CHEMBL3788822 16534980.0 Cmax in blood of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 1.8 +/- 0.3 hrs during high fat diet phase by HPLC method Scientific Literature 2391396.0 Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 1.2600000000000005 ug.mL-1 1.0477037825432597e-06 5.979761488145411 CHEMBL3788821 16534981.0 Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 6.8 +/- 1.1 hrs during high fat diet phase by HPLC method Scientific Literature 2391396.0 Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 2.0599999999999996 ug.mL-1 1.712912533364376e-06 5.76626481289382 CHEMBL3788820 16534982.0 Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 1.8 +/- 0.3 hrs during high fat diet phase by HPLC method Scientific Literature 2391396.0 Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 0.42499999999999993 ug.mL-1 3.533921488737183e-07 6.451743103212663 CHEMBL3788568 16534985.0 Cmax in blood of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 8.4 +/- 0.9 hrs during low fat diet phase by HPLC method Scientific Literature 2391396.0 Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 0.9550000000000002 ug.mL-1 7.940929462927086e-07 6.100128661679228 CHEMBL3788567 16534986.0 Cmax in blood of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 2.8 +/- 0.7 hrs during low fat diet phase by HPLC method Scientific Literature 2391396.0 Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 0.36499999999999994 ug.mL-1 3.035014925621346e-07 6.5178391688065 CHEMBL3788566 16534987.0 Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 8.4 +/- 0.9 hrs during low fat diet phase by HPLC method Scientific Literature 2391396.0 Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 0.744 ug.mL-1 6.186441382636388e-07 6.208559097717095 CHEMBL3788565 16534988.0 Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 2.8 +/- 0.7 hrs during low fat diet phase by HPLC method Scientific Literature 2391396.0 Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 0.7339999999999999 ug.mL-1 6.103290288783747e-07 6.2144359733469035 CHEMBL3791203 16541751.0 Cmax in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 10 mg/kg, po administered through solution by HPLC analysis Scientific Literature 8132853.0 Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 0.9950000000000002 ug.mL-1 8.273533838337645e-07 6.0823089525172485 CHEMBL3791205 16541752.0 Cmax in pre-kidney transplant end stage renal disease patient (8 patients) blood at 10 mg/kg, po administered through capsule by HPLC analysis Scientific Literature 8132853.0 Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 0.024999999999999998 ug.mL-1 2.0787773463159903e-08 7.682192024590936 CHEMBL3791219 16541767.0 Cmax in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M17 at 4 mg/kg, iv measured at 2 to 10 hrs by HPLC analysis Scientific Literature 8132853.0 Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 0.963 ug.mL-1 8.007450338009195e-07 6.0965057461384395 CHEMBL3791204 16541753.0 Cmax in pre-kidney transplant end stage renal disease patient (8 patients) blood at 10 mg/kg, po administered through solution by HPLC analysis Scientific Literature 8132853.0 Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 0.82 ug.mL-1 6.818389695916449e-07 6.166318180879258 CHEMBL3791206 16541754.0 Cmax in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 10 mg/kg, po administered through capsule by HPLC analysis Scientific Literature 8132853.0 Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. CYCLOSPORINE CHEMBL160 72873 1202.63 Cmax 1.3330000000000002 ug.mL-1 1.1084040810556864e-06 5.955301883849115 CHEMBL3889330 17805422.0 Pharmacokinetic parameters for Cyclosporine evaluated following oral or intravenous administration of Cyclosporine (NEORAL or SANDIMMUNE). Curated Drug Pharmacokinetic Data Goodman and Gilman Ed. 12 | The Pharmaceutical Basis of Therapeutics| Table AII-I: Pharmacokinetic Data CYPROHEPTADINE CYPROHEPTADINE CHEMBL516 11005 287.41 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.739675028704638e-07 6.759531870350376 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CYSTEAMINE CYSTEAMINE CHEMBL602 21036 77.15 Normal/therapeutic blood-plasma concentration 20.0 umol/L 1.9999999999999998e-05 4.698970004336019 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics CYTARABINE CYTARABINE CHEMBL803 51182 243.22 Normal/therapeutic blood-plasma concentration 0.5 mg/L 2.0557519940794343e-06 5.68702927980295 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics 4-AMINOPYRIDINE DALFAMPRIDINE CHEMBL284348 31289 94.12 Normal/therapeutic blood-plasma concentration 0.075 mg/L 7.968550786230343e-07 6.098620655112284 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DANAZOL DANAZOL CHEMBL1479 405364 337.46 Normal/therapeutic blood-plasma concentration 0.2 mg/L 5.926628341136728e-07 6.227192306514037 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DANTROLENE DANTROLENE CHEMBL1201288 675239 314.26 Normal/therapeutic blood-plasma concentration 3.0 mg/L 9.546235601094635e-06 5.020167851449695 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 56.99999999999999 ug.mL-1 3.517020528293504e-05 4.453825096767342 CHEMBL1696172 5306508.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 67.29999999999998 ug.mL-1 4.152552307967593e-05 4.381684888215856 CHEMBL991837 2573949.0 Cmax in morbidly obese human at 461 mg infused over 30 mins Scientific Literature 17548489.0 Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 42.30000000000001 ug.mL-1 2.6099994446809698e-05 4.58335958506479 CHEMBL991838 2573948.0 Cmax in normal weight human at 236 mg infused over 30 mins Scientific Literature 17548489.0 Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 0.7199999999999998 ug.mL-1 4.4425522462654775e-07 6.352367456008564 CHEMBL991840 2573946.0 Cmax per kg of total body weight in normal weight human at 236 mg infused over 30 mins Scientific Literature 17548489.0 Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 0.61 ug.mL-1 3.7638289864193643e-07 6.424370117429066 CHEMBL991839 2573945.0 Cmax per kg of total body weight in morbidly obese human at 461 mg infused over 30 mins Scientific Literature 17548489.0 Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 42.30000000000001 ug.mL-1 2.6099994446809698e-05 4.58335958506479 CHEMBL990970 2573909.0 Cmax in human at 4 mg/kg of total body weight Scientific Literature 17548489.0 Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 77.50000000000001 ug.mL-1 4.7819138761885375e-05 4.320398249933523 CHEMBL1655779 5162070.0 Cmax in healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 129.7 ug.mL-1 8.002764254731009e-05 4.096759976355753 CHEMBL1661580 5162174.0 Cmax in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 93.90000000000002 ug.mL-1 5.793828554504564e-05 4.2370343601737215 CHEMBL1661578 5162176.0 Cmax in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 123.3 ug.mL-1 7.607870721729633e-05 4.118736875844101 CHEMBL1661577 5162177.0 Cmax in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 141.1 ug.mL-1 8.706168360389711e-05 4.060172938685485 CHEMBL1661576 5162178.0 Cmax in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 183.7 ug.mL-1 0.00011334678439430119 3.9455907961340246 CHEMBL1661575 5162179.0 Cmax in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 139.3 ug.mL-1 8.595104554233073e-05 4.065748836015869 CHEMBL1661574 5162180.0 Cmax in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 181.70000000000002 ug.mL-1 0.0001121127421036719 3.9503450251317984 CHEMBL1661573 5162181.0 Cmax in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 95.7 ug.mL-1 5.9048923606612e-05 4.228788014662989 CHEMBL1661572 5162182.0 Cmax in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on days 1-3 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 48.92 ug.mL-1 3.0184674428792677e-05 4.520213504075585 CHEMBL1655790 5162268.0 Cmax in cancer patient with neutropenic fever at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 95.0 ug.mL-1 5.8617008804891743e-05 4.231976347150985 CHEMBL1660272 5185944.0 Cmax in serum of human infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 6 mg/kg/day, ip for 7 days Scientific Literature 19635963.0 Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 105.99999999999997 ug.mL-1 6.540424140335287e-05 4.184394087175063 CHEMBL1660273 5185943.0 Cmax in serum of human infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 8 mg/kg/day, ip for 7 days Scientific Literature 19635963.0 Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 129.99999999999997 ug.mL-1 8.021274889090447e-05 4.095756600132996 CHEMBL1660274 5185942.0 Cmax in serum of human infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 10 mg/kg/day, ip for 7 days Scientific Literature 19635963.0 Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 164.80000000000004 ug.mL-1 0.00010168508474785432 3.992742745078736 CHEMBL1661579 5162175.0 Cmax in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 95.7 ug.mL-1 5.9048923606612e-05 4.228788014662989 CHEMBL1661582 5162172.0 Cmax in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 42.32 ug.mL-1 2.6112334869715985e-05 4.583154293412703 CHEMBL1655778 5162071.0 Cmax in young healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 106.2 ug.mL-1 6.552764563241583e-05 4.183575435694382 CHEMBL1661581 5162173.0 Cmax in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 86.39999999999999 ug.mL-1 5.331062695518575e-05 4.273186209960939 CHEMBL1661232 5162166.0 Cmax in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 57.8 ug.mL-1 3.5663822199186766e-05 4.447772114019304 CHEMBL1661586 5162168.0 Cmax in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 98.6 ug.mL-1 6.0838284928024475e-05 4.215823037498621 CHEMBL1661585 5162169.0 Cmax in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 133.0 ug.mL-1 8.206381232684844e-05 4.085848311472747 CHEMBL1661584 5162170.0 Cmax in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 64.0 ug.mL-1 3.948935330013759e-05 4.403519978455946 CHEMBL1664953 5146357.0 Cmax in healthy human male at 4 mg/kg, iv every 24 hrs by LC/MS/MS analysis Scientific Literature 19349514.0 Impact of human serum albumin on oritavancin in vitro activity against enterococci. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 129.50000000000003 ug.mL-1 7.990423831824719e-05 4.097430184022562 CHEMBL1661583 5162171.0 Cmax in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 116.3 ug.mL-1 7.175955920009378e-05 4.144120237711385 CHEMBL1661231 5162167.0 Cmax in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 82.00000000000001 ug.mL-1 5.05957339158013e-05 4.295886100056116 CHEMBL1655680 5162081.0 Cmax in healthy adult human at 6 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 54.6 ug.mL-1 3.368935453417989e-05 4.472507309735096 CHEMBL1661233 5162165.0 Cmax in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1 Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 113.71999999999998 ug.mL-1 7.016764464518198e-05 4.153863101421428 CHEMBL1655682 5162079.0 Cmax in adult human with hepatic impairment at 6 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 42.30000000000001 ug.mL-1 2.6099994446809698e-05 4.58335958506479 CHEMBL1655772 5162078.0 Cmax in nonobese human subjects at 4 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 67.29999999999998 ug.mL-1 4.152552307967593e-05 4.381684888215856 CHEMBL1655683 5162077.0 Cmax in morbidly obese human at 4 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 53.21999999999999 ug.mL-1 3.2837865353645665e-05 4.483625082224463 CHEMBL1655773 5162076.0 Cmax in nonobese human at 4 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 67.0 ug.mL-1 4.134041673608154e-05 4.383625149739006 CHEMBL1655774 5162075.0 Cmax in morbidly obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 46.28000000000001 ug.mL-1 2.8555738605162004e-05 4.544306602160121 CHEMBL1655775 5162074.0 Cmax in nonobese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 57.75 ug.mL-1 3.563297114192103e-05 4.448147963875651 CHEMBL1655776 5162073.0 Cmax in moderately obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 43.98 ug.mL-1 2.7136589970938303e-05 4.566444727415061 CHEMBL1655777 5162072.0 Cmax in old healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 118.33 ug.mL-1 7.301211212508253e-05 4.136605087924087 CHEMBL1655681 5162080.0 Cmax in adult human subjects at 6 mg/kg, iv administered as single dose 30 mins infusion Scientific Literature 19015332.0 Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. DAPTOMYCIN CHEMBL387675 374037 1620.69 Cmax 85.99999999999999 ug.mL-1 5.306381849705989e-05 4.275201501196265 CHEMBL1281792 3570020.0 Cmax in human serum at 6 mg/kg, iv administered every 24 hrs Scientific Literature 18426900.0 Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. DARUNAVIR DARUNAVIR CHEMBL1323 267163 547.67 Normal/therapeutic blood-plasma concentration 7.3679999999999986 mg/L 1.3453356948527397e-05 4.8711693348203395 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DASATINIB CHEMBL1421 361469 488.02 Cmax 199.99999999999997 nM 2e-07 6.698970004336019 CHEMBL1221080 3396464.0 Cmax in chronic myeloid leukemia patient Scientific Literature 19219016.0 A pulse at the heart of targeted therapy. DEFEROXAMINE DEFEROXAMINE CHEMBL556 15938 560.69 Normal/therapeutic blood-plasma concentration 15.0 mg/L 2.6752751074568832e-05 4.572631551397107 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DESIPRAMINE DESIPRAMINE CHEMBL72 6243 266.39 Normal/therapeutic blood-plasma concentration 0.25 mg/L 9.384736664289201e-07 6.027577909174826 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DESLORATADINE DESLORATADINE CHEMBL1172 191342 310.83 Normal/therapeutic blood-plasma concentration 0.006 mg/L 1.9303156066016796e-08 7.714371678038968 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DESVENLAFAXINE DESVENLAFAXINE CHEMBL1118 161281 263.38 Normal/therapeutic blood-plasma concentration 0.4 mg/L 1.5187182018376491e-06 5.818522802003136 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DEXAMETHASONE DEXAMETHASONE CHEMBL384467 365281 392.47 Normal/therapeutic blood-plasma concentration 0.265 mg/L 6.752108441409535e-07 6.1705605913931265 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DEXFENFLURAMINE DEXFENFLURAMINE CHEMBL248702 421350 231.26 Normal/therapeutic blood-plasma concentration 0.06 mg/L 2.5944824007610483e-07 6.585949270923297 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DEXKETOPROFEN DEXKETOPROFEN CHEMBL75435 117758 254.29 Normal/therapeutic blood-plasma concentration 3.7 mg/L 1.4550316567698299e-05 4.83712755773588 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DEXMETHYLPHENIDATE DEXMETHYLPHENIDATE CHEMBL827 57397 233.31 Normal/therapeutic blood-plasma concentration 0.023 mg/L 9.858128670009858e-08 7.006205517657194 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DEXTROMETHORPHAN DEXTROMETHORPHAN CHEMBL52440 77456 271.4 Normal/therapeutic blood-plasma concentration 0.04 mg/L 1.4738393515106856e-07 6.831549851995756 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DEXTROMORAMIDE DEXTROMORAMIDE CHEMBL3833389 2096440 392.54 Normal/therapeutic blood-plasma concentration 0.15 mg/L 3.8212666225098074e-07 6.4177926590807495 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIAZEPAM DIAZEPAM CHEMBL12 721 284.75 Normal/therapeutic blood-plasma concentration 2.5 mg/L 8.77963125548727e-06 5.0565237240791 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIAZOXIDE DIAZOXIDE CHEMBL181 364859 230.68 Normal/therapeutic blood-plasma concentration 50.0 mg/L 0.00021675047685104908 3.664039938402841 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIBENZEPINE DIBENZEPIN CHEMBL1442422 866306 295.39 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.692677477233488e-06 5.7714257844790104 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DICLOFENAC CHEMBL139 29890 296.15 Cmax 0.35480000000000006 ug.mL-1 1.1980415330069224e-06 5.921528125817273 CHEMBL3509433 15444064.0 Mean Cmax value of diclofenac following single oral dosing of 35 mg Zorvolex capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 2.0 ug.mL-1 6.753334458889077e-06 5.170481741312981 CHEMBL3790580 16541519.0 Cmax in healthy subject (7 subjects) at 50 mg, po administered as single dose Scientific Literature 527637.0 The pharmacokinetics of diclofenac sodium following intravenous and oral administration. DICLOFENAC CHEMBL139 29890 296.15 Cmax 7.799999999999998 ug.mL-1 2.6338004389667392e-05 4.579417134286482 CHEMBL3790587 16541512.0 Cmax in healthy subject (7 subjects) at 50 mg, iv measured after 5 mins Scientific Literature 527637.0 The pharmacokinetics of diclofenac sodium following intravenous and oral administration. DICLOFENAC DICLOFENAC CHEMBL139 29890 296.15 Normal/therapeutic blood-plasma concentration 3.0 mg/L 1.0130001688333616e-05 4.9943904822573 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DICLOFENAC CHEMBL139 29890 296.15 Cmax 0.4958000000000001 ug.mL-1 1.6741516123586026e-06 5.7762052145451594 CHEMBL3509536 15444040.0 Mean Cmax value of diclofenac following single oral dosing of 18 mg Zorvolex capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 0.8036999999999999 ug.mL-1 2.713827452304575e-06 5.566417768649091 CHEMBL3509422 15444053.0 Geometric mean for Cmax of diclofenac following single oral dosing of 35 mg Zorvolex capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 0.4543 ug.mL-1 1.5340199223366538e-06 5.8141690001623365 CHEMBL3509537 15444041.0 Geometric mean for Cmax of diclofenac following single oral dosing of 18 mg Zorvolex capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 0.5055 ug.mL-1 1.7069052844842142e-06 5.767790577049943 CHEMBL3509522 15444153.0 Mean Cmax of diclofenac potassium following oral dosing of PRO-513 50 mg sachet in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 1.161 ug.mL-1 3.9203106533851094e-06 5.406679517238389 CHEMBL3509514 15444145.0 Mean Cmax of diclofenac potassium following oral dosing of Cataflam 50 mf tablet in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 1.618 ug.mL-1 5.463447577241264e-06 5.262533219700709 CHEMBL3509506 15444137.0 Mean Cmax of diclofenac potassium following oral dosing of PRO-513 50 mg sachet in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 1.1690000000000003 ug.mL-1 3.947323991220666e-06 5.403697225815122 CHEMBL3509490 15444122.0 Mean Cmax of diclofenac following single oral dosing of 50 mg Cataflam in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 1.1249999999999996 ug.mL-1 3.798750633125104e-06 5.420359214529581 CHEMBL3509489 15444121.0 Mean Cmax of diclofenac following single oral dosing of 25 mg diclofenac potassium soft gelatin capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 1.154 ug.mL-1 3.896673982778997e-06 5.4093059281572495 CHEMBL3509471 15444103.0 Mean Cmax of diclofenac following single oral dosing of 50 mg diclofenac potassium softgel capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 2.3649999999999998 ug.mL-1 7.985817997636332e-06 5.097680591903132 CHEMBL3509470 15444102.0 Mean Cmax of diclofenac following single oral dosing of 50 mg diclofenac potassium softgel capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 0.686 ug.mL-1 2.3163937193989535e-06 5.635187621270211 CHEMBL3509469 15444101.0 Mean Cmax of diclofenac following single oral dosing of 25 mg diclofenac potassium softgel capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 1.156 ug.mL-1 3.903427317237886e-06 5.408553902892452 CHEMBL3509468 15444100.0 Mean Cmax of diclofenac following single oral dosing of 25 mg diclofenac potassium softgel capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 0.6207999999999998 ug.mL-1 2.096235016039169e-06 5.678560028726831 CHEMBL3509457 15444089.0 Geometric mean for Cmax of diclofenac following single oral dosing of 50 mg Cataflam tablet in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 0.7125000000000001 ug.mL-1 2.4058754009792343e-06 5.618726868296414 CHEMBL3509456 15444088.0 Mean Cmax value of diclofenac following single oral dosing of 50 mg Cataflam tablet in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 0.8686999999999999 ug.mL-1 2.93331082221847e-06 5.532641915463976 CHEMBL3509548 15444052.0 Mean Cmax value of diclofenac following single oral dosing of 35 mg Zorvolex capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 1.1939999999999997 ug.mL-1 4.0317406719567785e-06 5.394507410183612 CHEMBL3509445 15444076.0 Mean Cmax value of diclofenac following single oral dosing of 50 mg Cataflam tablet in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 0.3210999999999999 ug.mL-1 1.084247847374641e-06 5.96487143141046 CHEMBL3509434 15444065.0 Geometric mean for Cmax of diclofenac following single oral dosing of 35 mg Zorvolex capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 0.8352999999999998 ug.mL-1 2.8205301367550227e-06 5.5496692555711045 CHEMBL3509530 15444161.0 Mean Cmax of diclofenac potassium following oral dosing of Cataflam 50 mf tablet in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 1.0870000000000002 ug.mL-1 3.6704372784062145e-06 5.435282192890668 CHEMBL3509446 15444077.0 Geometric mean for Cmax of diclofenac following single oral dosing of 50 mg Cataflam tablet in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOFENAC CHEMBL139 29890 296.15 Cmax 2.0349999999999997 ug.mL-1 6.871517811919635e-06 5.1629473234157235 CHEMBL3509488 15444120.0 Mean Cmax of diclofenac following single oral dosing of 50 mg diclofenac potassium soft gelatin capsule in healthy human FDA Approval Packages FDA drug approval package for diclofenac acid (NDA 22-202 CP, Ref ID: 3374276) DICLOXACILLIN CHEMBL893 77085 470.33 Cmax 30.0 ug.mL-1 6.37850020198584e-05 4.195281426384329 CHEMBL1663038 5159730.0 Cmax in human at 1000 mg, po Scientific Literature 19223616.0 Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. DICOUMAROL DICUMAROL CHEMBL1466 394231 336.3 Normal/therapeutic blood-plasma concentration 30.0 mg/L 8.920606601248884e-05 4.0496056125949735 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DICYCLOMINE DICYCLOMINE CHEMBL1123 165774 309.49 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.2311221687291995e-07 6.490646620997555 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIDANOSINE DIDANOSINE CHEMBL1460 390877 236.23 Normal/therapeutic blood-plasma concentration 30.0 umol/L 2.9999999999999997e-05 4.522878745280337 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIETHYLCARBAMAZINE DIETHYLCARBAMAZINE CHEMBL684 29569 199.3 Normal/therapeutic blood-plasma concentration 1.0 mg/L 5.017561465127948e-06 5.299507298700488 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIETHYLPROPION DIETHYLPROPION CHEMBL1194666 668616 205.3 Normal/therapeutic blood-plasma concentration 0.2 mg/L 9.74184120798831e-07 6.011358953706611 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIFLUNISAL DIFLUNISAL CHEMBL898 77652 250.2 Normal/therapeutic blood-plasma concentration 200.0 mg/L 0.0007993605115907275 3.0972573096934197 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIGITOXIN DIGITOXIN CHEMBL254219 419508 764.95 Normal/therapeutic blood-plasma concentration 0.025 mg/L 3.268187463232891e-08 7.485693040293661 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIGOXIN DIGOXIN CHEMBL1751 581814 780.95 Normal/therapeutic blood-plasma concentration 0.002 mg/L 2.5609834176323708e-09 8.591593233579237 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIHYDROCODEINE DIHYDROCODEINE CHEMBL1595 454306 301.39 Normal/therapeutic blood-plasma concentration 0.25 mg/L 8.294900295298452e-07 6.081188829827919 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIHYDROERGOTAMINE DIHYDROERGOTAMINE CHEMBL1732 558566 583.69 Normal/therapeutic blood-plasma concentration 0.01 mg/L 1.713238191505765e-08 7.766182252874969 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DILTIAZEM DILTIAZEM CHEMBL23 1278 414.53 Normal/therapeutic blood-plasma concentration 0.25 mg/L 6.030926591561528e-07 6.219615957729309 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIMETHINDENE DIMETHINDENE CHEMBL22108 26443 292.43 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.7098108949150224e-07 6.767051919921517 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIPHENHYDRAMINE DIPHENHYDRAMINE CHEMBL657 27629 255.36 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.9160401002506267e-07 6.407152869670635 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIPHENOXYLATE DIPHENOXYLATE CHEMBL1201294 675245 452.6 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.209456473707468e-08 7.655714549618709 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIPIPANONE DIPIPANONE CHEMBL2111157 1383597 349.52 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.4305333028152896e-07 6.844502027365493 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIPYRIDAMOLE DIPYRIDAMOLE CHEMBL932 86042 504.64 Normal/therapeutic blood-plasma concentration 1.5 mg/L 2.972415979708307e-06 5.5268904125931275 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DIPYRIDAMOLE CHEMBL932 86042 504.64 Cmax 3960.0 nM 3.96e-06 5.402304814074488 CHEMBL2154113 12064130.0 Cmax in human Scientific Literature 21599003.0 Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. METAMIZOLE DIPYRONE CHEMBL461522 453508 311.36 Normal/therapeutic blood-plasma concentration 10.0 mg/L 3.211716341212744e-05 4.493262818588258 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DISOPYRAMIDE DISOPYRAMIDE CHEMBL517 11143 339.48 Normal/therapeutic blood-plasma concentration 7.0 mg/L 2.0619771415105456e-05 4.685716153490358 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DISOPYRAMIDE CHEMBL517 11143 339.48 Cmax 7950.000000000004 nM 7.950000000000004e-06 5.0996328713435295 CHEMBL2154113 12064129.0 Cmax in human Scientific Literature 21599003.0 Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. DISULFIRAM DISULFIRAM CHEMBL964 94571 296.55 Normal/therapeutic blood-plasma concentration 0.4 mg/L 1.3488450514247175e-06 5.870037937041391 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DOLUTEGRAVIR CHEMBL1229211 691562 419.38 Cmax 0.231 ug.mL-1 5.508131050598503e-07 6.258995735467635 CHEMBL1218907 3385959.0 Cmax in healthy human at 2 mg administered as single dose suspension Scientific Literature 19884365.0 Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. DOLUTEGRAVIR CHEMBL1229211 691562 419.38 Cmax 0.6609999999999999 ug.mL-1 1.5761362010587055e-06 5.802406255874139 CHEMBL1217828 3385960.0 Cmax in healthy human at 5 mg administered as single dose suspension Scientific Literature 19884365.0 Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. DOLUTEGRAVIR CHEMBL1229211 691562 419.38 Cmax 6.16 ug.mL-1 1.4688349468262675e-05 4.833027003195354 CHEMBL1217871 3386003.0 Cmax in healthy human at 50 mg, qd for 10 days administered as suspension measured after last dose Scientific Literature 19884365.0 Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. DOLUTEGRAVIR CHEMBL1229211 691562 419.38 Cmax 1.23 ug.mL-1 2.9329009490199818e-06 5.532702603920382 CHEMBL1217829 3385961.0 Cmax in healthy human at 10 mg administered as single dose suspension Scientific Literature 19884365.0 Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. DOLUTEGRAVIR CHEMBL1229211 691562 419.38 Cmax 2.76 ug.mL-1 6.581143592922886e-06 5.181698633294562 CHEMBL1217830 3385962.0 Cmax in healthy human at 25 mg administered as single dose suspension Scientific Literature 19884365.0 Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. DOLUTEGRAVIR CHEMBL1229211 691562 419.38 Cmax 4.56 ug.mL-1 1.087319376222042e-05 4.9636428726953445 CHEMBL1217831 3385963.0 Cmax in healthy human at 50 mg administered as single dose suspension Scientific Literature 19884365.0 Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. DOLUTEGRAVIR CHEMBL1229211 691562 419.38 Cmax 3.0900000000000003 ug.mL-1 7.368019457294102e-06 5.132649235934945 CHEMBL1217870 3386002.0 Cmax in healthy human at 25 mg, qd for 10 days administered as suspension measured after last dose Scientific Literature 19884365.0 Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. DOLUTEGRAVIR CHEMBL1229211 691562 419.38 Cmax 8.139999999999999 ug.mL-1 1.940960465448996e-05 4.711983310470578 CHEMBL1217832 3385964.0 Cmax in healthy human at 100 mg administered as single dose suspension Scientific Literature 19884365.0 Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. DOLUTEGRAVIR CHEMBL1229211 691562 419.38 Cmax 1.4700000000000006 ug.mL-1 3.5051743049263215e-06 5.455290380611603 CHEMBL1217869 3386001.0 Cmax in healthy human at 10 mg, qd for 10 days administered as suspension measured after last dose Scientific Literature 19884365.0 Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. DOMPERIDONE DOMPERIDONE CHEMBL219916 364745 425.92 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.3478587528174306e-07 6.6293280337945815 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DONEPEZIL DONEPEZIL CHEMBL502 9372 379.5 Normal/therapeutic blood-plasma concentration 0.075 mg/L 1.976284584980237e-07 6.704150516839799 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DORIPENEM CHEMBL491571 460466 420.51 Cmax 22.1 ug.mL-1 5.255523055337567e-05 4.279384054375526 CHEMBL1279508 3532772.0 Cmax in healthy man plasma assessed as total compound-derived radioactivity at 500 mg, iv administered as 1 hr infusion by Liquid scintillation counting Scientific Literature 18644951.0 Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. DORIPENEM CHEMBL491571 460466 420.51 Cmax 17.899999999999995 ug.mL-1 4.256735868350336e-05 4.3709232970807435 CHEMBL1693186 5310080.0 Cmax in healthy human at 500 mg, iv Scientific Literature 21199922.0 Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. DORIPENEM CHEMBL491571 460466 420.51 Cmax 21.799999999999997 ug.mL-1 5.1841811134099064e-05 4.285319834456032 CHEMBL1281809 3565372.0 Cmax in healthy human at 500 mg administered as 1 hr infusion Scientific Literature 18458125.0 In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. DORIPENEM CHEMBL491571 460466 420.51 Cmax 7.79 ug.mL-1 1.852512425388219e-05 4.732238870388072 CHEMBL1281811 3565374.0 Cmax in healthy human at 500 mg administered as as 4 hr infusion Scientific Literature 18458125.0 In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. DORIPENEM CHEMBL491571 460466 420.51 Cmax 1.56 ug.mL-1 3.7097809802382827e-06 5.430651729706175 CHEMBL1279503 3532787.0 Cmax in healthy man plasma assessed as doripenem-M-1 at 500 mg, iv administered as 1 hr infusion by LC-MS/MS analysis Scientific Literature 18644951.0 Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. DORIPENEM CHEMBL491571 460466 420.51 Cmax 22.900000000000006 ug.mL-1 5.445768233811326e-05 4.263940845720748 CHEMBL1279496 3532780.0 Cmax in healthy man plasma at 500 mg, iv administered as 1 hr infusion by LC-MS/MS analysis Scientific Literature 18644951.0 Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. DORIPENEM CHEMBL491571 460466 420.51 Cmax 13.199999999999998 ug.mL-1 3.139045444817008e-05 4.503202396854786 CHEMBL1279513 3532777.0 Cmax in healthy man whole blood assessed as total compound-derived radioactivity at 500 mg, iv administered as 1 hr infusion by Liquid scintillation counting Scientific Literature 18644951.0 Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. DORIPENEM CHEMBL491571 460466 420.51 Cmax 24.099999999999998 ug.mL-1 5.7311360015219615e-05 4.2417592854857675 CHEMBL1693170 5310059.0 Cmax in end stage renal disease patient undergoing 12 hours continuous venovenous hemofiltration at 500 mg, iv Scientific Literature 21199922.0 Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. DORIPENEM CHEMBL491571 460466 420.51 Cmax 18.900000000000002 ug.mL-1 4.494542341442535e-05 4.347314523887392 CHEMBL1693178 5310070.0 Cmax in end stage renal disease patient undergoing 12 hours continuous venovenous hemodiafiltration at 500 mg, iv Scientific Literature 21199922.0 Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. DOTHIEPIN DOTHIEPIN CHEMBL1492500 916384 295.45 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.384667456422407e-07 6.4704839943156855 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DOXACURIUM DOXACURIUM CHEMBL1237123 699474 1035.24 Normal/therapeutic blood-plasma concentration 0.3 mg/L 2.8978787527529844e-07 6.5379197893658425 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DOXAPRAM DOXAPRAM CHEMBL1754 581848 378.52 Normal/therapeutic blood-plasma concentration 5.0 mg/L 1.3209341646412345e-05 4.87911882708307 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DOXAZOSIN DOXAZOSIN CHEMBL707 33373 451.48 Normal/therapeutic blood-plasma concentration 0.15 mg/L 3.32240630814211e-07 6.478547257316939 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DOXEPIN DOXEPIN CHEMBL1628227 1051118 279.38 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.579354284487079e-07 6.446195313014636 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DOXORUBICIN DOXORUBICIN CHEMBL53463 78759 543.53 Normal/therapeutic blood-plasma concentration 0.02 mg/L 3.679649697348813e-08 7.434193524193271 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DOXYCYCLINE DOXYCYCLINE CHEMBL1433 371546 444.44 Normal/therapeutic blood-plasma concentration 10.0 mg/L 2.2500225002250025e-05 4.647813138922103 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DOXYCYCLINE CHEMBL1433 371546 444.44 Cmax 6900.000000000002 nM 6.9000000000000025e-06 5.161150909262744 CHEMBL948864 2628576.0 Cmax in patient with tuberculosis at 600 mg, po once daily for 15 to 18 days Scientific Literature 17698630.0 Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. DOXYLAMINE DOXYLAMINE CHEMBL1004 111498 270.38 Normal/therapeutic blood-plasma concentration 0.2 mg/L 7.396996819291368e-07 6.130944568044679 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DRONABINOL DRONABINOL CHEMBL465 4496 314.47 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.5899767863389193e-07 6.798609216332697 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DROPERIDOL DROPERIDOL CHEMBL1108 152751 379.44 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.317731393632722e-07 6.8801731073077965 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DROSPIRENONE CHEMBL1509 421032 366.5 Cmax 0.08750000000000002 ug.mL-1 2.3874488403819924e-07 6.622065925954834 CHEMBL3889388 17805937.0 Evaluation of pharmacokinetic parameters for Drosporine following multiple co-administration of 3 mg Drosporine tablets and 0.02 mg ethinyl estradiol to 12 healthy female subjects. Value For Cycle 1 Curated Drug Pharmacokinetic Data DailyMed|setid=abbf31eb-9966-411a-9c5d-91025ff7a782 | ZARAH- drospirenone and ethinyl estradiol | Watson Pharma, Inc. DROSPIRENONE CHEMBL1509 421032 366.5 Cmax 0.0384 ug.mL-1 1.0477489768076397e-07 6.979742754609616 CHEMBL3889386 17805923.0 Evaluation pharmacokinetic parameters for Drosporine following multiple co-administration of Drosporine tablets and 0.02 mg ethinyl estradiol to 23 healthy females. Value For Cycle 1 Curated Drug Pharmacokinetic Data DailyMed|setid=077bf6ff-afb8-4cb7-9faa-fbb6fd9f037f | YAZ - drospirenone and ethinyl estradiol|Physicians Total Care, Inc. DROSPIRENONE CHEMBL1509 421032 366.5 Cmax 0.08420000000000001 ug.mL-1 2.2974079126875855e-07 6.638761887477497 CHEMBL3889388 17805939.0 Evaluation of pharmacokinetic parameters for Drosporine following multiple co-administration of 3 mg Drosporine tablets and 0.02 mg ethinyl estradiol to 12 healthy female subjects. Value For Cycle 6 Curated Drug Pharmacokinetic Data DailyMed|setid=abbf31eb-9966-411a-9c5d-91025ff7a782 | ZARAH- drospirenone and ethinyl estradiol | Watson Pharma, Inc. DROSPIRENONE CHEMBL1509 421032 366.5 Cmax 0.08129999999999998 ug.mL-1 2.2182810368349245e-07 6.653983433383079 CHEMBL3889388 17805943.0 Evaluation of pharmacokinetic parameters for Drosporine following multiple co-administration of 3 mg Drosporine tablets and 0.02 mg ethinyl estradiol to 12 healthy female subjects. Value For Cycle 9 Curated Drug Pharmacokinetic Data DailyMed|setid=abbf31eb-9966-411a-9c5d-91025ff7a782 | ZARAH- drospirenone and ethinyl estradiol | Watson Pharma, Inc. DROSPIRENONE CHEMBL1509 421032 366.5 Cmax 0.07869999999999998 ug.mL-1 2.1473396998635736e-07 6.668099246618082 CHEMBL3889388 17805950.0 Evaluation of pharmacokinetic parameters for Drosporine following multiple co-administration of 3 mg Drosporine tablets and 0.02 mg ethinyl estradiol to 12 healthy female subjects. Value For Cycle 13 Curated Drug Pharmacokinetic Data DailyMed|setid=abbf31eb-9966-411a-9c5d-91025ff7a782 | ZARAH- drospirenone and ethinyl estradiol | Watson Pharma, Inc. DROSPIRENONE CHEMBL1509 421032 366.5 Cmax 0.0369 ug.mL-1 1.0068212824010915e-07 6.997047612818086 CHEMBL3889388 17805933.0 Evaluation of pharmacokinetic parameters for Drosporine following multiple co-administration of 3 mg Drosporine tablets and 0.02 mg ethinyl estradiol to 12 healthy female subjects. Value For Cycle 1 Curated Drug Pharmacokinetic Data DailyMed|setid=abbf31eb-9966-411a-9c5d-91025ff7a782 | ZARAH- drospirenone and ethinyl estradiol | Watson Pharma, Inc. DROSPIRENONE CHEMBL1509 421032 366.5 Cmax 0.07030000000000002 ug.mL-1 1.9181446111869036e-07 6.717118653957323 CHEMBL3889386 17805927.0 Evaluation pharmacokinetic parameters for Drosporine following multiple co-administration of Drosporine tablets and 0.02 mg ethinyl estradiol to 23 healthy females. Value For Cycle 1 Curated Drug Pharmacokinetic Data DailyMed|setid=077bf6ff-afb8-4cb7-9faa-fbb6fd9f037f | YAZ - drospirenone and ethinyl estradiol|Physicians Total Care, Inc. DROTRECOGIN ALFA DROTRECOGIN ALFA (ACTIVATED) CHEMBL2109065 1381331 Normal/therapeutic blood-plasma concentration 0.07200000000000001 mg/L 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DULOXETINE DULOXETINE CHEMBL1175 192908 297.42 Normal/therapeutic blood-plasma concentration 0.12 mg/L 4.034698406294129e-07 6.3941889232411695 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DYPHYLLINE DYPHYLLINE CHEMBL1752 581819 254.25 Normal/therapeutic blood-plasma concentration 20.0 mg/L 7.866273352999017e-05 4.104230965930801 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics EDARAVONE CHEMBL290916 60371 174.2 Cmax 5999.999999999999 nM 5.999999999999999e-06 5.221848749616356 CHEMBL3532202 15470609.0 Cmax in human at 0.5 mg/kg Scientific Literature 22238289.0 Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform. EDOXABAN CHEMBL1269025 709600 548.07 Cmax 0.332 ug.mL-1 6.057620376959148e-07 6.217697946809992 CHEMBL3538363 15455523.0 Cmax in human plasma at 60 mg, po by LC-MS/MS analysis Scientific Literature 22936313.0 Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. EDOXABAN CHEMBL1269025 709600 548.07 Cmax 0.35200000000000004 ug.mL-1 6.422537267137409e-07 6.192293367035898 CHEMBL3538347 15453958.0 Cmax in human whole blood at 60 mg, po by radio-HPLC chromatogram analysis Scientific Literature 22936313.0 Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. EDOXABAN CHEMBL1269025 709600 548.07 Cmax 0.349 ug.mL-1 6.367799733610669e-07 6.196010603554849 CHEMBL3538346 15453957.0 Cmax in human plasma at 60 mg, po by radio-HPLC chromatogram analysis Scientific Literature 22936313.0 Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. EDROPHONIUM EDROPHONIUM CHEMBL1104 151408 166.24 Normal/therapeutic blood-plasma concentration 0.2 mg/L 1.203079884504331e-06 5.919705534549121 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics EFAVIRENZ CHEMBL223228 374719 315.68 Cmax 3.757999999999999 ug.mL-1 1.1904460212873793e-05 4.924290292143609 CHEMBL1676368 5230150.0 Cmax in healthy human plasma at 400 mg, po qd for 14 days by liquid chromatography-tandem mass spectrometry Scientific Literature 20660679.0 No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. EFAVIRENZ CHEMBL223228 374719 315.68 Cmax 5.52 ug.mL-1 1.7486061834769386e-05 4.7573079901789175 CHEMBL1674676 5223925.0 Cmax in HIV-1 infected children at 10 to 15 mg/kg, po administered once daily by HPLC Scientific Literature 19635964.0 Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? EFAVIRENZ CHEMBL223228 374719 315.68 Cmax 2.7350000000000003 ug.mL-1 8.66383679675621e-06 5.062289737238666 CHEMBL1676367 5230151.0 Cmax in healthy human plasma at 400 mg, po measured on day 1 post dose by liquid chromatography-tandem mass spectrometry Scientific Literature 20660679.0 No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. EFAVIRENZ CHEMBL223228 374719 315.68 Cmax 3.71 ug.mL-1 1.1752407501267107e-05 4.92987315829307 CHEMBL1674677 5223926.0 Cmax in HIV-1 infected children at 14.4 mg/kg, po administered once daily by HPLC Scientific Literature 19635964.0 Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? EFAVIRENZ CHEMBL223228 374719 315.68 Cmax 4.089999999999999 ug.mL-1 1.2956158134820067e-05 4.887523759900774 CHEMBL1674675 5223924.0 Cmax in HIV-1 infected children at 12 mg/kg, po administered once daily by HPLC Scientific Literature 19635964.0 Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? EFAVIRENZ EFAVIRENZ CHEMBL223228 374719 315.68 Normal/therapeutic blood-plasma concentration 2.0 mg/L 6.335529650278763e-06 5.198217072244135 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ELETRIPTAN ELETRIPTAN CHEMBL1510 421034 382.53 Normal/therapeutic blood-plasma concentration 0.23 mg/L 6.012600318929235e-07 6.220937664448643 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ENALAPRIL ENALAPRIL CHEMBL578 16847 376.45 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.656395271616417e-07 6.575707301476683 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ENFUVIRTIDE ENFUVIRTIDE CHEMBL525076 508828 4491.94 Normal/therapeutic blood-plasma concentration 3.4 mg/L 7.569112677373251e-07 6.12095502960261 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ENOXACIN ENOXACIN CHEMBL826 57175 320.32 Normal/therapeutic blood-plasma concentration 4.0 mg/L 1.2487512487512488e-05 4.903524064471262 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ENOXIMONE ENOXIMONE CHEMBL249856 421520 248.31 Normal/therapeutic blood-plasma concentration 4.0 mg/L 1.6108896137892153e-05 4.792934218590548 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ENTACAPONE ENTACAPONE CHEMBL953 92412 305.29 Normal/therapeutic blood-plasma concentration 7.0 mg/L 2.2929018310458906e-05 4.6396145388800605 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ENTACAPONE CHEMBL953 92412 305.29 Cmax 1.1999999999999997 ug.mL-1 3.930688853221526e-06 5.405531332846692 CHEMBL3889411 17806081.0 Pharmacokinetic parameters for Enctacpone after single oral administartion of 200 and 800 mg Entacapone tablets to volunteers. Curated Drug Pharmacokinetic Data DailyMed|setid=ad6a2b73-29d4-4ced-ba42-4c2ad1c5a1af | ENTACAPONE - entacapone tablet, film coated|Sun Pharma Global FZE ENTECAVIR CHEMBL713 33889 277.28 Cmax 30.0 nM 3.0000000000000004e-08 7.522878745280337 CHEMBL1263018 3475802.0 Cmax in human at 1 mg/kg, po Scientific Literature 18316521.0 Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. ENTECAVIR CHEMBL713 33889 277.28 Cmax 30.0 nM 3.0000000000000004e-08 7.522878745280337 CHEMBL1263476 3475979.0 Cmax in human blood Scientific Literature 18316521.0 Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. EPHEDRINE EPHEDRINE CHEMBL211456 351701 165.24 Normal/therapeutic blood-plasma concentration 0.2 mg/L 1.2103606874848706e-06 5.9170851906405675 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics EPIRUBICIN EPIRUBICIN CHEMBL417 1114 543.53 Normal/therapeutic blood-plasma concentration 0.05 mg/L 9.199124243372032e-08 7.036253515521232 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics EPROSARTAN EPROSARTAN CHEMBL813 54211 424.52 Normal/therapeutic blood-plasma concentration 1.85 mg/L 4.357862998209743e-06 5.360726427154649 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ERGOTAMINE ERGOTAMINE CHEMBL442 2203 581.67 Normal/therapeutic blood-plasma concentration 0.00042 mg/L 7.220588993759349e-10 9.141427374964097 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ERIBULIN CHEMBL1683590 1073717 729.91 Cmax 0.44399999999999995 ug.mL-1 6.082941732542368e-07 6.2158863435496565 CHEMBL3537345 15450591.0 Cmax in cancer patient plasma at 2 mg, iv administered as bolus infusion for 2 to 5 mins by LC-MS/MS analysis/liquid scintillation counting Scientific Literature 22041109.0 Mass balance study of [¹¿C]eribulin in patients with advanced solid tumors. LACOSAMIDE ERLOSAMIDE CHEMBL58323 88739 250.3 Normal/therapeutic blood-plasma concentration 10.0 mg/L 3.995205753096284e-05 4.398460849608223 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ERTAPENEM CHEMBL1359 304903 475.52 Cmax 42.99999999999999 ug.mL-1 9.042732166890982e-05 4.043700332164876 CHEMBL1245910 3453230.0 Cmax in patient with bacterial infection at 1 gm/kg, sc administered at 30 mins regimen for 24 hrs by LC/MS/MS analysis Scientific Literature 19933804.0 Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. ERTAPENEM CHEMBL1359 304903 475.52 Cmax 114.99999999999999 ug.mL-1 0.00024184051144010766 3.6164709473908507 CHEMBL1245912 3453229.0 Cmax in patient with bacterial infection at 1 gm/kg, iv administered at 30 mins regimen for 24 hrs by LC/MS/MS analysis Scientific Literature 19933804.0 Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. ERTUGLIFLOZIN CHEMBL1770248 1142547 436.89 Cmax 0.4902 ug.mL-1 1.122021561491451e-06 5.949998797316234 CHEMBL3537478 15444574.0 Cmax in healthy human at 25 mg, po Scientific Literature 23169609.0 Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. ERYTHROMYCIN CHEMBL532 12506 733.94 Cmax 2.0 ug.mL-1 2.7250183938741586e-06 5.564630561889692 CHEMBL1655708 5161037.0 Cmax in healthy human at 500 mg, po administered as single dose Scientific Literature 19223626.0 Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. ERYTHROMYCIN ERYTHROMYCIN CHEMBL532 12506 733.94 Normal/therapeutic blood-plasma concentration 12.0 mg/L 1.6350110363244952e-05 4.786479311506048 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ESCITALOPRAM ESCITALOPRAM CHEMBL1508 421007 324.4 Normal/therapeutic blood-plasma concentration 0.08 mg/L 2.4660912453760796e-07 6.607990858547175 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ESLICARBAZEPINE CHEMBL315985 139782 254.29 Cmax 11000.0 nM 1.1000000000000001e-05 4.958607314841775 CHEMBL3530806 15458467.0 Cmax in human treated with oxcarbazepine at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography Scientific Literature 21389120.0 Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. ESMOLOL ESMOLOL CHEMBL768 43354 295.38 Normal/therapeutic blood-plasma concentration 2.0 mg/L 6.7709391292572285e-06 5.169351090492418 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ESTAZOLAM ESTAZOLAM CHEMBL285674 49847 294.75 Normal/therapeutic blood-plasma concentration 0.2 mg/L 6.785411365564037e-07 6.168423818103146 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ESZOPICLONE ESZOPICLONE CHEMBL1522 421334 388.82 Normal/therapeutic blood-plasma concentration 0.087 mg/L 2.2375392212334757e-07 6.65022934331217 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETHACRYNIC ACID ETHACRYNIC ACID CHEMBL456 2654 303.14 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.298805832288712e-07 6.481643246275584 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETHAMBUTOL ETHAMBUTOL CHEMBL44884 67617 204.31 Normal/therapeutic blood-plasma concentration 6.5 mg/L 3.181439968675053e-05 4.497376267153244 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETHAMBUTOL CHEMBL44884 67617 204.31 Cmax 3.6999999999999993 ug.mL-1 1.810973520630414e-05 4.742087899729104 CHEMBL955457 2498989.0 Cmax in human at 850 mg, po Scientific Literature 17132069.0 OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. ETHAMBUTOL CHEMBL44884 67617 204.31 Cmax 1.9499999999999995 ug.mL-1 9.544319906025155e-06 5.020255012433582 CHEMBL1247266 3454427.0 Cmax in tuberculosis patient at 15 mg/kg, po by HPLC analysis Scientific Literature 20038625.0 Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. ETHAMBUTOL CHEMBL44884 67617 204.31 Cmax 2.1999999999999997 ug.mL-1 1.0767950663207869e-05 4.9678669429738935 CHEMBL1247265 3454426.0 Cmax in diabetic tuberculosis patient at 15 mg/kg, po by HPLC analysis Scientific Literature 20038625.0 Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. ETAMSYLATE ETHAMSYLATE CHEMBL1514715 938599 190.18 Normal/therapeutic blood-plasma concentration 20.0 mg/L 0.0001051635292880429 3.9781348473982896 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETHCHLORVYNOL ETHCHLORVYNOL CHEMBL591 19469 144.6 Normal/therapeutic blood-plasma concentration 8.0 mg/L 5.532503457814662e-05 4.257078305966568 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETHINAMATE ETHINAMATE CHEMBL1576 453538 167.21 Normal/therapeutic blood-plasma concentration 10.0 mg/L 5.980503558399617e-05 4.22326224687663 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETHOSUXIMIDE ETHOSUXIMIDE CHEMBL696 31811 141.17 Normal/therapeutic blood-plasma concentration 60.0 mg/L 0.00042501948005950273 3.3715911643297605 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETIDOCAINE ETIDOCAINE CHEMBL492 6883 276.42 Normal/therapeutic blood-plasma concentration 1.5 mg/L 5.4265248534838285e-06 5.265478203580642 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETILEFRINE ETILEFRINE CHEMBL86882 139072 181.24 Normal/therapeutic blood-plasma concentration 0.06 mg/L 3.310527477378062e-07 6.480102803123504 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETODOLAC ETODOLAC CHEMBL622 26431 287.36 Normal/therapeutic blood-plasma concentration 20.0 mg/L 6.959910913140311e-05 4.1573963193232295 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETOMIDATE ETOMIDATE CHEMBL681 29090 244.29 Normal/therapeutic blood-plasma concentration 0.5 mg/L 2.0467477178762946e-06 5.688935685176481 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETOPOSIDE ETOPOSIDE CHEMBL44657 68607 588.56 Normal/therapeutic blood-plasma concentration 14.0 mg/L 2.3786869647954332e-05 4.623662707356204 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETORICOXIB ETORICOXIB CHEMBL416146 6706 358.85 Normal/therapeutic blood-plasma concentration 3.6 mg/L 1.0032046816218475e-05 4.998610449801047 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ETRAVIRINE CHEMBL308954 113138 435.29 Cmax 1.34 ug.mL-1 3.07840749844931e-06 5.511673891777419 CHEMBL1692700 5308778.0 Cmax in human plasma at 200 mg bid after 8 days Scientific Literature 21189339.0 Interaction potential of etravirine with drug transporters assessed in vitro. ETRAVIRINE CHEMBL308954 113138 435.29 Cmax 0.7660000000000001 ug.mL-1 1.7597463759792326e-06 5.754549920509622 CHEMBL1284945 3543009.0 Cmax in healthy human plasma at 200 mg, po twice a day for 4 days coadministered with 400 mg of raltegravir, po twice a day for 4 days by reverse-phase HPLC-MS method Scientific Literature 18838586.0 Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. ETRAVIRINE CHEMBL308954 113138 435.29 Cmax 0.7339999999999999 ug.mL-1 1.6862321670610393e-06 5.773082630226156 CHEMBL1284944 3543005.0 Cmax in healthy human plasma at 200 mg, po twice a day for 8 days by reverse-phase HPLC-MS method Scientific Literature 18838586.0 Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. ETRAVIRINE ETRAVIRINE CHEMBL308954 113138 435.29 Normal/therapeutic blood-plasma concentration 2.98 mg/L 6.8460107055066735e-06 5.164562426065971 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics EVEROLIMUS EVEROLIMUS CHEMBL1908360 1248731 958.24 Normal/therapeutic blood-plasma concentration 0.014 mg/L 1.4610118550676239e-08 7.835346260061896 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics EZETIMIBE EZETIMIBE CHEMBL1138 175106 409.43 Normal/therapeutic blood-plasma concentration 0.015 mg/L 3.6636299245292235e-08 7.436088402321898 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FAMCICLOVIR CHEMBL880 74284 321.34 Cmax 0.7399999999999999 ug.mL-1 2.302856787203585e-06 5.637733069617687 CHEMBL1265756 3482203.0 Cmax in 2 to <6 months old infant assessed as penciclovir at 6.6 +/- 1.4 mg/kg, po single dose Scientific Literature 20160046.0 Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. FAMCICLOVIR CHEMBL880 74284 321.34 Cmax 0.69 ug.mL-1 2.1472583556357753e-06 5.668115698611407 CHEMBL1265622 3482206.0 Cmax in 1 to <3 months old infant assessed as penciclovir at 6.6 +/- 1.4 mg/kg, po single dose Scientific Literature 20160046.0 Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. FAMCICLOVIR CHEMBL880 74284 321.34 Cmax 3.2399999999999998 ug.mL-1 1.0082778365594075e-05 4.996419779142051 CHEMBL1265759 3482208.0 Cmax in 6 to 12 months old infant assessed as penciclovir at 6.6 +/- 1.4 mg/kg, po single dose Scientific Literature 20160046.0 Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. FAMCICLOVIR CHEMBL880 74284 321.34 Cmax 3.45 ug.mL-1 1.0736291778178879e-05 4.969145694275388 CHEMBL1657662 5156063.0 Cmax in healthy human at 500 mg, po administered as single dose Scientific Literature 19273678.0 Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. FAMOTIDINE FAMOTIDINE CHEMBL902 78303 337.46 Normal/therapeutic blood-plasma concentration 0.2 mg/L 5.926628341136728e-07 6.227192306514037 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FELBAMATE FELBAMATE CHEMBL1094 150451 238.24 Normal/therapeutic blood-plasma concentration 110.0 mg/L 0.00046171927468099396 3.335621995249876 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FELBINAC FELBINAC CHEMBL413965 151923 212.25 Normal/therapeutic blood-plasma concentration 1.0 mg/L 4.711425206124853e-06 5.32684769891599 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FELODIPINE FELODIPINE CHEMBL1480 405365 384.26 Normal/therapeutic blood-plasma concentration 0.012 mg/L 3.1228855462447304e-08 7.505443932370893 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FELODIPINE CHEMBL1480 405365 384.26 Cmax 7.000000000000002 nM 7.000000000000002e-09 8.154901959985743 CHEMBL3889321 17805382.0 Evaluation of pharmacokinetic parameters for Felodipine following single oral administration of Felodipine immediate or extended-release tablets Mean Curated Drug Pharmacokinetic Data DailyMed|setid=dd39c559-5c5d-4d3b-9228-c44085e1699f | FELODIPINE - felodipine tablet, film coated, extended release|Aurobindo Pharma Limited FELODIPINE CHEMBL1480 405365 384.26 Cmax 22.999999999999993 nM 2.2999999999999994e-08 7.638272163982407 CHEMBL3889321 17805385.0 Evaluation of pharmacokinetic parameters for Felodipine following single oral administration of Felodipine immediate or extended-release tablets Mean Curated Drug Pharmacokinetic Data DailyMed|setid=dd39c559-5c5d-4d3b-9228-c44085e1699f | FELODIPINE - felodipine tablet, film coated, extended release|Aurobindo Pharma Limited FELODIPINE CHEMBL1480 405365 384.26 Cmax 19.999999999999996 nM 1.9999999999999997e-08 7.698970004336019 CHEMBL3889322 17805388.0 Evaluation of pharmacokinetic parameters for Felodipine following multiple oral administration of Felodipine immediate-release tablets Mean Curated Drug Pharmacokinetic Data DailyMed|setid=dd39c559-5c5d-4d3b-9228-c44085e1699f | FELODIPINE - felodipine tablet, film coated, extended release|Aurobindo Pharma Limited FENBUFEN FENBUFEN CHEMBL277522 16456 254.28 Normal/therapeutic blood-plasma concentration 60.0 mg/L 0.00023596035865974514 3.627160952374776 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FENFLURAMINE FENFLURAMINE CHEMBL87493 139434 231.26 Normal/therapeutic blood-plasma concentration 0.3 mg/L 1.297241200380524e-06 5.886979266587279 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FENOFIBRATE FENOFIBRATE CHEMBL672 28331 360.84 Normal/therapeutic blood-plasma concentration 30.0 mg/L 8.313934153641504e-05 4.08019341942848 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FENOLDOPAM FENOLDOPAM CHEMBL588 19278 305.76 Normal/therapeutic blood-plasma concentration 0.06 mg/L 1.9623233908948196e-07 6.707229419327294 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FENOPROFEN FENOPROFEN CHEMBL1297 255534 242.27 Normal/therapeutic blood-plasma concentration 60.0 mg/L 0.0002476575721302679 3.606148388924741 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FENOTEROL FENOTEROL CHEMBL32800 49226 303.36 Normal/therapeutic blood-plasma concentration 0.04 mg/L 1.3185654008438818e-07 6.87989832433001 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FENTANYL CHEMBL596 19915 336.48 Cmax 0.0015500000000000002 ug.mL-1 4.606514503090823e-09 8.336627557171955 CHEMBL3889335 17805453.0 The pharmacokinetic parameter of Fentanyl evaluated in adult subjects receiving single doses of 200, 400, 800, and 1600 mcg units of Oral Transmucosal Fentanyl Citrate (OTFC). Mean. Cv = 30 % Curated Drug Pharmacokinetic Data DailyMed|setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f | FENTANYL CITRATE- fentanyl citrate lozenge|Lake Erie Medical DBA Quality Care Products LLC FENTANYL CHEMBL596 19915 336.48 Cmax 0.00251 ug.mL-1 7.459581550166429e-09 8.127285533861208 CHEMBL3889335 17805459.0 The pharmacokinetic parameter of Fentanyl evaluated in adult subjects receiving single doses of 200, 400, 800, and 1600 mcg units of Oral Transmucosal Fentanyl Citrate (OTFC). Mean. Cv = 67 % Curated Drug Pharmacokinetic Data DailyMed|setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f | FENTANYL CITRATE- fentanyl citrate lozenge|Lake Erie Medical DBA Quality Care Products LLC FENTANYL CHEMBL596 19915 336.48 Cmax 0.00085 ug.mL-1 2.526153114598193e-09 8.597540329627954 CHEMBL3889365 17805803.0 Determination of pharmacokinetic pararmeters of Fentanyl following first 72-hour application of Fentanyl Transdermal System to healthy subjects and intravenous (IV) administration to surgical and hepatically impaired patients Curated Drug Pharmacokinetic Data DailyMed|setid=578def77-4959-4392-83a8-0abfcbf1d023 | FENTANYL - fentanyl patch, extended release|Bryant Ranch Prepack FENTANYL CHEMBL596 19915 336.48 Cmax 0.00172 ug.mL-1 5.1117451260104615e-09 8.291430808434697 CHEMBL3889365 17805805.0 Determination of pharmacokinetic pararmeters of Fentanyl following first 72-hour application of Fentanyl Transdermal System to healthy subjects and intravenous (IV) administration to surgical and hepatically impaired patients Curated Drug Pharmacokinetic Data DailyMed|setid=578def77-4959-4392-83a8-0abfcbf1d023 | FENTANYL - fentanyl patch, extended release|Bryant Ranch Prepack FENTANYL CHEMBL596 19915 336.48 Cmax 0.0023199999999999996 ug.mL-1 6.894912030432714e-09 8.161471270451345 CHEMBL3889365 17805806.0 Determination of pharmacokinetic pararmeters of Fentanyl following first 72-hour application of Fentanyl Transdermal System to healthy subjects and intravenous (IV) administration to surgical and hepatically impaired patients Curated Drug Pharmacokinetic Data DailyMed|setid=578def77-4959-4392-83a8-0abfcbf1d023 | FENTANYL - fentanyl patch, extended release|Bryant Ranch Prepack FENTANYL CHEMBL596 19915 336.48 Cmax 0.00336 ug.mL-1 9.985734664764621e-09 8.000619977952402 CHEMBL3889365 17805809.0 Determination of pharmacokinetic pararmeters of Fentanyl following first 72-hour application of Fentanyl Transdermal System to healthy subjects and intravenous (IV) administration to surgical and hepatically impaired patients Curated Drug Pharmacokinetic Data DailyMed|setid=578def77-4959-4392-83a8-0abfcbf1d023 | FENTANYL - fentanyl patch, extended release|Bryant Ranch Prepack FENTANYL FENTANYL CHEMBL596 19915 336.48 Normal/therapeutic blood-plasma concentration 0.3 mg/L 8.915834522111268e-07 6.049838000622583 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FENTANYL CHEMBL596 19915 336.48 Cmax 0.0006 ug.mL-1 1.7831669044222538e-09 8.748808004958603 CHEMBL3889394 17805818.0 Evaluation of pharmacokinetic parameters for Fentanyl following first 72-hour topical application of a Fentanyl transdermal system Curated Drug Pharmacokinetic Data DailyMed|setid=491dd1b2-b91a-4bd9-b022-159b8717699e | FENTANYL - fentanyl patch, extended release|Lake Erie Medical DBA Quality Care Products LLC FENTANYL CHEMBL596 19915 336.48 Cmax 0.0014000000000000002 ug.mL-1 4.16072277698526e-09 8.380831219664008 CHEMBL3889394 17805819.0 Evaluation of pharmacokinetic parameters for Fentanyl following first 72-hour topical application of a Fentanyl transdermal system Curated Drug Pharmacokinetic Data DailyMed|setid=491dd1b2-b91a-4bd9-b022-159b8717699e | FENTANYL - fentanyl patch, extended release|Lake Erie Medical DBA Quality Care Products LLC FENTANYL CHEMBL596 19915 336.48 Cmax 0.0024999999999999996 ug.mL-1 7.42986210175939e-09 8.12901924667021 CHEMBL3889394 17805824.0 Evaluation of pharmacokinetic parameters for Fentanyl following first 72-hour topical application of a Fentanyl transdermal system Curated Drug Pharmacokinetic Data DailyMed|setid=491dd1b2-b91a-4bd9-b022-159b8717699e | FENTANYL - fentanyl patch, extended release|Lake Erie Medical DBA Quality Care Products LLC FENTANYL CHEMBL596 19915 336.48 Cmax 0.0007499999999999999 ug.mL-1 2.228958630527817e-09 8.651897991950547 CHEMBL3889335 17805449.0 The pharmacokinetic parameter of Fentanyl evaluated in adult subjects receiving single doses of 200, 400, 800, and 1600 mcg units of Oral Transmucosal Fentanyl Citrate (OTFC). Mean. Cv = 33 % Curated Drug Pharmacokinetic Data DailyMed|setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f | FENTANYL CITRATE- fentanyl citrate lozenge|Lake Erie Medical DBA Quality Care Products LLC FENTANYL CHEMBL596 19915 336.48 Cmax 0.0017 ug.mL-1 5.052306229196386e-09 8.296510333963973 CHEMBL3889394 17805821.0 Evaluation of pharmacokinetic parameters for Fentanyl following first 72-hour topical application of a Fentanyl transdermal system Curated Drug Pharmacokinetic Data DailyMed|setid=491dd1b2-b91a-4bd9-b022-159b8717699e | FENTANYL - fentanyl patch, extended release|Lake Erie Medical DBA Quality Care Products LLC FEXOFENADINE CHEMBL914 81683 501.67 Cmax 0.494 ug.mL-1 9.84711065042757e-07 6.0066911819545865 CHEMBL3889437 17806361.0 Mean pharmacokinetic parameters for Fexofenadine hydrochloride following single oral administration in healthy male subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=286343b7-96a9-49db-80de-adeaa15647fe | FEXOFENADINE HYDROCHLORIDE - fexofenadine hydrochloride tablet, film coated|NCS HealthCare of KY, Inc dba Vangard Labs FEXOFENADINE CHEMBL914 81683 501.67 Cmax 0.08800000000000001 ug.mL-1 1.7541411684972194e-07 6.7559354587280644 CHEMBL3889453 17806367.0 Mean pharmacokinetic parameters for fexofenadine hydrochloride following single oral administration of 30 mg fexofenadine hydrochloride in the form of oral Disintegrating Tablets (ODT) and oral suspension. Curated Drug Pharmacokinetic Data DailyMed|setid=ac0c0247-3b20-445a-84c0-cb7f3939c823 | ALLEGRA - fexofenadine hydrochloride tablet, film coated|Sanofi-Synthelabo Limited FEXOFENADINE CHEMBL914 81683 501.67 Cmax 0.191 ug.mL-1 3.8072836725337376e-07 6.4193847636305055 CHEMBL3889378 17806355.0 Evaluation of pharmacokinetic parameters for Fexofenadine following single oral co-administration of 60 mg Fexofenadine tablets with 120 mg pseudoephedrine hydrochloride. Curated Drug Pharmacokinetic Data DailyMed|setid=14710a71-e2e9-4e4e-bd65-1c296f70c166 | ALLEGRA D-12 HOUR - fexofenadine hydrochloride and pseudoephedrine hydrochloride tablet, etended release|sanofi-aventis U.S. LLC. FEXOFENADINE CHEMBL914 81683 501.67 Cmax 0.131 ug.mL-1 2.6112783303765425e-07 6.583146835222469 CHEMBL3889437 17806360.0 Mean pharmacokinetic parameters for Fexofenadine hydrochloride following single oral administration in healthy male subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=286343b7-96a9-49db-80de-adeaa15647fe | FEXOFENADINE HYDROCHLORIDE - fexofenadine hydrochloride tablet, film coated|NCS HealthCare of KY, Inc dba Vangard Labs FEXOFENADINE CHEMBL914 81683 501.67 Cmax 0.142 ug.mL-1 2.8305459764386943e-07 6.548129786495177 CHEMBL3889437 17806359.0 Mean pharmacokinetic parameters for Fexofenadine hydrochloride following single oral administration in healthy male subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=286343b7-96a9-49db-80de-adeaa15647fe | FEXOFENADINE HYDROCHLORIDE - fexofenadine hydrochloride tablet, film coated|NCS HealthCare of KY, Inc dba Vangard Labs FEXOFENADINE FEXOFENADINE CHEMBL914 81683 501.67 Normal/therapeutic blood-plasma concentration 0.3 mg/L 5.980026710785974e-07 6.223296876158571 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FEXOFENADINE CHEMBL914 81683 501.67 Cmax 0.255 ug.mL-1 5.083022704168079e-07 6.293877950444278 CHEMBL3889379 17806357.0 Evaluation of pharmacokinetic parameters for Fexofenadine following multiple oral co-administration of Fexofenadine tablets with 120 mg pseudoephedrine hydrochloride Curated Drug Pharmacokinetic Data DailyMed|setid=14710a71-e2e9-4e4e-bd65-1c296f70c166 | ALLEGRA D-12 HOUR - fexofenadine hydrochloride and pseudoephedrine hydrochloride tablet, etended release|sanofi-aventis U.S. LLC. FINASTERIDE FINASTERIDE CHEMBL710 33679 372.55 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.684203462622467e-08 7.571184567733605 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLECAINIDE FLECAINIDE CHEMBL652 27588 414.35 Normal/therapeutic blood-plasma concentration 0.8 mg/L 1.9307348859659706e-06 5.714277356187775 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLUCLOXACILLIN FLOXACILLIN CHEMBL222645 371745 453.88 Normal/therapeutic blood-plasma concentration 40.0 mg/L 8.812902088657796e-05 4.054881054862772 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLUCONAZOLE FLUCONAZOLE CHEMBL106 13758 306.28 Normal/therapeutic blood-plasma concentration 15.0 mg/L 4.897479430586392e-05 4.310027379366219 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLUCYTOSINE FLUCYTOSINE CHEMBL1463 393942 129.09 Normal/therapeutic blood-plasma concentration 50.0 mg/L 0.0003873266713145867 3.411922596466199 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLUMAZENIL FLUMAZENIL CHEMBL407 635 303.29 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.2971743216063834e-07 6.481858091100589 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLUNARIZINE FLUNARIZINE CHEMBL30008 38764 404.5 Normal/therapeutic blood-plasma concentration 0.2 mg/L 4.944375772558714e-07 6.30588853028431 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLUNITRAZEPAM FLUNITRAZEPAM CHEMBL13280 11715 313.29 Normal/therapeutic blood-plasma concentration 0.015 mg/L 4.7878961984104185e-08 7.319855273667932 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics 5-FLUOROURACIL FLUOROURACIL CHEMBL185 368538 130.08 Normal/therapeutic blood-plasma concentration 0.3 mg/L 2.306273062730627e-06 5.63708927353033 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLUOXETINE FLUOXETINE CHEMBL41 2223 309.33 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.6163967284130218e-06 5.791452037240531 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLUPHENAZINE FLUPHENAZINE CHEMBL726 36842 437.53 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.2855575617671933e-08 7.641007836530388 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLURAZEPAM FLURAZEPAM CHEMBL968 95929 387.89 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.578050478228364e-07 6.58870858341341 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLURBIPROFEN FLURBIPROFEN CHEMBL563 16308 244.26 Normal/therapeutic blood-plasma concentration 15.0 mg/L 6.140997297961189e-05 4.211761093707362 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLUTAMIDE CHEMBL806 52087 276.21 Cmax 0.8690000000000002 ug.mL-1 3.146156909597771e-06 5.502219621422481 CHEMBL3788494 16534791.0 Cmax in patient (6 patients) with renal insufficiency assessed as hydroxy flutamide at 250 mg, po administered as single dose 4 hrs prior to hemodialysis treatment measured at starting time of dialysis and post dialysis treatment by gas chromatography Scientific Literature 10073738.0 Pharmacokinetics of flutamide in patients with renal insufficiency. FLUTAMIDE CHEMBL806 52087 276.21 Cmax 0.08100000000000002 ug.mL-1 2.932551319648095e-07 6.532754378992498 CHEMBL3788485 16534782.0 Cmax in patient (6 patients) with renal insufficiency at 250 mg, po administered as single dose 4 hrs prior to hemodialysis treatment measured at starting time of dialysis and post dialysis treatment by gas chromatography Scientific Literature 10073738.0 Pharmacokinetics of flutamide in patients with renal insufficiency. FLUTAMIDE CHEMBL806 52087 276.21 Cmax 0.8739999999999999 ug.mL-1 3.1642590782375728e-06 5.499727965236745 CHEMBL3788232 16534772.0 Cmax in patient (4 patients) with renal insufficiency assessed as hydroxy flutamide at 250 mg, po administered as single dose by gas chromatography Scientific Literature 10073738.0 Pharmacokinetics of flutamide in patients with renal insufficiency. FLUTAMIDE CHEMBL806 52087 276.21 Cmax 0.044000000000000004 ug.mL-1 1.5929908403026686e-07 6.79778672138496 CHEMBL3788224 16534764.0 Cmax in patient (4 patients) with renal insufficiency at 250 mg, po administered as single dose by gas chromatography Scientific Literature 10073738.0 Pharmacokinetics of flutamide in patients with renal insufficiency. FLUTAMIDE CHEMBL806 52087 276.21 Cmax 0.05340000000000001 ug.mL-1 1.9333116107309661e-07 6.713698140842591 CHEMBL3790459 16534135.0 Cmax in patient (6 patients) with renal insufficiency at 250 mg, po administered as single dose by gas chromatography Scientific Literature 10073738.0 Pharmacokinetics of flutamide in patients with renal insufficiency. FLUTAMIDE CHEMBL806 52087 276.21 Cmax 0.04100000000000001 ug.mL-1 1.4843778284638505e-07 6.828455541151412 CHEMBL3790762 16534171.0 Cmax in patient (3 patients) with renal insufficiency at 250 mg, po administered as single dose by gas chromatography Scientific Literature 10073738.0 Pharmacokinetics of flutamide in patients with renal insufficiency. FLUTAMIDE CHEMBL806 52087 276.21 Cmax 1.0700000000000005 ug.mL-1 3.873864088917854e-06 5.411855620185937 CHEMBL3790464 16534143.0 Cmax in patient (6 patients) with renal insufficiency assessed as hydroxy flutamide at 250 mg, po administered as single dose by gas chromatography Scientific Literature 10073738.0 Pharmacokinetics of flutamide in patients with renal insufficiency. FLUTAMIDE CHEMBL806 52087 276.21 Cmax 0.0209 ug.mL-1 7.566706491437674e-08 7.121093111760094 CHEMBL3790477 16534153.0 Cmax in patient (7 patients) with renal insufficiency at 250 mg, po administered as single dose by gas chromatography Scientific Literature 10073738.0 Pharmacokinetics of flutamide in patients with renal insufficiency. FLUTAMIDE CHEMBL806 52087 276.21 Cmax 0.9670000000000002 ug.mL-1 3.5009594149379107e-06 5.455812923788145 CHEMBL3790752 16534161.0 Cmax in patient (7 patients) with renal insufficiency assessed as hydroxy flutamide at 250 mg, po administered as single dose by gas chromatography Scientific Literature 10073738.0 Pharmacokinetics of flutamide in patients with renal insufficiency. FLUTAMIDE CHEMBL806 52087 276.21 Cmax 0.9019999999999998 ug.mL-1 3.2656312226204695e-06 5.486032860329206 CHEMBL3790770 16534179.0 Cmax in patient (3 patients) with renal insufficiency assessed as hydroxy flutamide at 250 mg, po administered as single dose by gas chromatography Scientific Literature 10073738.0 Pharmacokinetics of flutamide in patients with renal insufficiency. FLUVASTATIN FLUVASTATIN CHEMBL2220442 1450253 411.47 Normal/therapeutic blood-plasma concentration 0.4 mg/L 9.721243347024084e-07 6.012278185257004 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FLUVOXAMINE FLUVOXAMINE CHEMBL814 54722 318.34 Normal/therapeutic blood-plasma concentration 0.23 mg/L 7.224979581579444e-07 6.141163375923651 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FOSAMPRENAVIR FOSAMPRENAVIR CHEMBL1664 499624 585.62 Normal/therapeutic blood-plasma concentration 0.4 mg/L 6.830367815306855e-07 6.165555908930906 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FOSINOPRIL CHEMBL3039598 1592409 563.67 Cmax 0.09999999999999999 ug.mL-1 1.7740876754129188e-07 6.751024921140632 CHEMBL2155975 12049441.0 Cmax in healthy human at 10 mg dosed as single daily dose Scientific Literature 21780776.0 Remarkable potential of the ¿-aminophosphonate/phosphinate structural motif in medicinal chemistry. FROVATRIPTAN FROVATRIPTAN CHEMBL1279 250328 243.31 Normal/therapeutic blood-plasma concentration 0.008 mg/L 3.287986519255271e-08 7.483069971735713 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FUROSEMIDE FUROSEMIDE CHEMBL35 2046 330.75 Normal/therapeutic blood-plasma concentration 10.0 mg/L 3.0234315948601665e-05 4.519499852859538 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics FUSIDIC ACID CHEMBL374975 372428 516.72 Cmax 30.0 ug.mL-1 5.80585229911751e-05 4.236134016815431 CHEMBL1696172 5306502.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. GABAPENTIN GABAPENTIN CHEMBL940 88316 171.24 Normal/therapeutic blood-plasma concentration 30.0 mg/L 0.0001751927119831815 3.7564839644426096 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GALANTAMINE GALANTAMINE CHEMBL659 27639 287.36 Normal/therapeutic blood-plasma concentration 0.06 mg/L 2.0879732739420935e-07 6.680275064603567 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GANCICLOVIR GANCICLOVIR CHEMBL182 365284 255.23 Normal/therapeutic blood-plasma concentration 5.0 mg/L 1.959017356893782e-05 4.707961716139108 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GATIFLOXACIN CHEMBL31 1712 375.4 Cmax 3.3999999999999995 ug.mL-1 9.057005860415556e-06 5.043015351243072 CHEMBL1695971 5303995.0 Cmax in patients with pulmonary tuberculosis at 400 mg/kg, po Scientific Literature 19075046.0 New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. GATIFLOXACIN CHEMBL31 1712 375.4 Cmax 4.0 ug.mL-1 1.0655301012253598e-05 4.972434276957365 CHEMBL1279833 3566362.0 Cmax in tuberculosis patient at 400 mg/day, po administered for 7 days by HPLC Scientific Literature 18070980.0 Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. GATIFLOXACIN CHEMBL31 1712 375.4 Cmax 3.3999999999999995 ug.mL-1 9.057005860415556e-06 5.043015351243072 CHEMBL2169386 12087008.0 Cmax in human at 400 mg, po Scientific Literature 22421275.0 Tuberculosis: the drug development pipeline at a glance. GEMCITABINE GEMCITABINE CHEMBL888 75901 263.2 Normal/therapeutic blood-plasma concentration 20.0 umol/L 1.9999999999999998e-05 4.698970004336019 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GEMFIBROZIL GEMFIBROZIL CHEMBL457 2994 250.34 Normal/therapeutic blood-plasma concentration 25.0 mg/L 9.986418470879605e-05 4.00059023922363 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GENTAMICIN CHEMBL3039597 1592408 1390.73 Cmax 4.0 ug.mL-1 2.876187326080548e-06 5.541182831768388 CHEMBL1283206 3541976.0 Cmax in war-wounded patient infected with Acinetobacter baumannii-calcoacetius at 5 to 7 mg/kg/day Scientific Literature 20404121.0 In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center. GENTAMICIN CHEMBL3039597 1592408 1390.73 Cmax 17.999999999999993 ug.mL-1 1.2942842967362459e-05 4.8879703179930445 CHEMBL1032836 2667119.0 Cmax in human Scientific Literature 18070962.0 Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. GENTAMICIN CHEMBL3039597 1592408 1390.73 Cmax 9.999999999999998 ug.mL-1 7.190468315201368e-06 5.143242823096351 CHEMBL1663040 5159742.0 Cmax in human at 240 mg, im Scientific Literature 19223616.0 Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. GENTAMICIN CHEMBL3039597 1592408 1390.73 Cmax 17.999999999999993 ug.mL-1 1.2942842967362459e-05 4.8879703179930445 CHEMBL1696172 5306504.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. GENTAMICIN GENTAMICIN CHEMBL3039597 1592408 1390.73 Normal/therapeutic blood-plasma concentration 10.0 mg/L 7.190468315201369e-06 5.14324282309635 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GLIMEPIRIDE CHEMBL1481 405366 490.63 Cmax 0.591 ug.mL-1 1.2045737113507122e-06 5.919166619116546 CHEMBL3889381 17805907.0 Evalaution of pharmacokinetic parameters for Glimepiride following single oral co-administration of Glimepiride tablets with 37.5 mg Tramadol to healthy subjects and to patients with type 2 diabetes. Curated Drug Pharmacokinetic Data DailyMed|setid=5eda246b-ac51-46e7-b473-35937f84ed05 | GLIMEPIRIDE - glimepiride tablet|Perrigo New York Inc GLIMEPIRIDE CHEMBL1481 405366 490.63 Cmax 0.5510000000000002 ug.mL-1 1.1230458797872127e-06 5.949602501146016 CHEMBL3889381 17805902.0 Evalaution of pharmacokinetic parameters for Glimepiride following single oral co-administration of Glimepiride tablets with 37.5 mg Tramadol to healthy subjects and to patients with type 2 diabetes. Curated Drug Pharmacokinetic Data DailyMed|setid=5eda246b-ac51-46e7-b473-35937f84ed05 | GLIMEPIRIDE - glimepiride tablet|Perrigo New York Inc GLIMEPIRIDE CHEMBL1481 405366 490.63 Cmax 0.309 ug.mL-1 6.298024988280374e-07 6.200795620572967 CHEMBL3889382 17805913.0 Evalaution of pharmacokinetic parameters for Glimepiride following multiple doses of Glimepiride with 37.5 mg Tramadol to healthy subjects and to patients with type 2 diabetes Curated Drug Pharmacokinetic Data DailyMed|setid=5eda246b-ac51-46e7-b473-35937f84ed05 | GLIMEPIRIDE - glimepiride tablet|Perrigo New York Inc GLIMEPIRIDE CHEMBL1481 405366 490.63 Cmax 0.177 ug.mL-1 3.6076065466848745e-07 6.442780833635995 CHEMBL3889381 17805901.0 Evalaution of pharmacokinetic parameters for Glimepiride following single oral co-administration of Glimepiride tablets with 37.5 mg Tramadol to healthy subjects and to patients with type 2 diabetes. Curated Drug Pharmacokinetic Data DailyMed|setid=5eda246b-ac51-46e7-b473-35937f84ed05 | GLIMEPIRIDE - glimepiride tablet|Perrigo New York Inc GLIMEPIRIDE CHEMBL1481 405366 490.63 Cmax 0.308 ug.mL-1 6.277643030389499e-07 6.202203383497357 CHEMBL3889381 17805900.0 Evalaution of pharmacokinetic parameters for Glimepiride following single oral co-administration of Glimepiride tablets with 37.5 mg Tramadol to healthy subjects and to patients with type 2 diabetes. Curated Drug Pharmacokinetic Data DailyMed|setid=5eda246b-ac51-46e7-b473-35937f84ed05 | GLIMEPIRIDE - glimepiride tablet|Perrigo New York Inc GLIMEPIRIDE CHEMBL1481 405366 490.63 Cmax 0.35200000000000004 ug.mL-1 7.174449177588001e-07 6.1442114365196705 CHEMBL3889381 17805899.0 Evalaution of pharmacokinetic parameters for Glimepiride following single oral co-administration of Glimepiride tablets with 37.5 mg Tramadol to healthy subjects and to patients with type 2 diabetes. Curated Drug Pharmacokinetic Data DailyMed|setid=5eda246b-ac51-46e7-b473-35937f84ed05 | GLIMEPIRIDE - glimepiride tablet|Perrigo New York Inc GLIMEPIRIDE CHEMBL1481 405366 490.63 Cmax 0.578 ug.mL-1 1.1780771660925747e-06 5.928826261577272 CHEMBL3889382 17805912.0 Evalaution of pharmacokinetic parameters for Glimepiride following multiple doses of Glimepiride with 37.5 mg Tramadol to healthy subjects and to patients with type 2 diabetes Curated Drug Pharmacokinetic Data DailyMed|setid=5eda246b-ac51-46e7-b473-35937f84ed05 | GLIMEPIRIDE - glimepiride tablet|Perrigo New York Inc GLIMEPIRIDE CHEMBL1481 405366 490.63 Cmax 0.10319999999999997 ug.mL-1 2.1034180543382992e-07 6.677074402706609 CHEMBL3889381 17805897.0 Evalaution of pharmacokinetic parameters for Glimepiride following single oral co-administration of Glimepiride tablets with 37.5 mg Tramadol to healthy subjects and to patients with type 2 diabetes. Curated Drug Pharmacokinetic Data DailyMed|setid=5eda246b-ac51-46e7-b473-35937f84ed05 | GLIMEPIRIDE - glimepiride tablet|Perrigo New York Inc GLIMEPIRIDE GLIMEPIRIDE CHEMBL1481 405366 490.63 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.01909789454375e-06 5.9917840956617825 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GLIMEPIRIDE CHEMBL1481 405366 490.63 Cmax 0.10239999999999999 ug.mL-1 2.0871124880255995e-07 6.68045414335799 CHEMBL3889381 17805895.0 Evalaution of pharmacokinetic parameters for Glimepiride following single oral co-administration of Glimepiride tablets with 37.5 mg Tramadol to healthy subjects and to patients with type 2 diabetes. Curated Drug Pharmacokinetic Data DailyMed|setid=5eda246b-ac51-46e7-b473-35937f84ed05 | GLIMEPIRIDE - glimepiride tablet|Perrigo New York Inc GLIMEPIRIDE CHEMBL1481 405366 490.63 Cmax 0.10300000000000001 ug.mL-1 2.099341662760125e-07 6.677916875292629 CHEMBL3889381 17805892.0 Evalaution of pharmacokinetic parameters for Glimepiride following single oral co-administration of Glimepiride tablets with 37.5 mg Tramadol to healthy subjects and to patients with type 2 diabetes. Curated Drug Pharmacokinetic Data DailyMed|setid=5eda246b-ac51-46e7-b473-35937f84ed05 | GLIMEPIRIDE - glimepiride tablet|Perrigo New York Inc GLIPIZIDE GLIPIZIDE CHEMBL1073 139286 445.55 Normal/therapeutic blood-plasma concentration 1.5 mg/L 3.366625519021434e-06 5.47280518894825 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GLUTETHIMIDE GLUTETHIMIDE CHEMBL1102 151300 217.27 Normal/therapeutic blood-plasma concentration 5.0 mg/L 2.3012841165370277e-05 4.6380297600245095 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GLIBENCLAMIDE GLYBURIDE CHEMBL472 5582 494.01 Normal/therapeutic blood-plasma concentration 0.2 mg/L 4.048501042489019e-07 6.392705744556959 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GOLD GOLD SODIUM THIOMALATE CHEMBL306043 113247 346.11 Normal/therapeutic blood-plasma concentration 8.0 mg/L 2.3114038889370432e-05 4.6361241603578875 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GRANISETRON GRANISETRON CHEMBL289469 54547 312.42 Normal/therapeutic blood-plasma concentration 0.017 mg/L 5.441392996607132e-08 7.2642899066810624 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GRISEOFULVIN CHEMBL562 16303 352.77 Cmax 0.6006 ug.mL-1 1.7025257249766139e-06 5.768906317223703 CHEMBL3889405 17806004.0 Mean pharmacokinetic parameters for Griseofulvin following single dose administration of unaltered 250 mg ultramicrocrystalline Griseofulvin tablets, with or without applesauce, to 24 healthy volunteers Curated Drug Pharmacokinetic Data DailyMed|setid=9ddd37f9-299e-4c98-91ed-deeb72c63b00 | GRIS-PEG - griseofulvin tablet, film coated|State of Florida DOH Central Pharmacy GRISEOFULVIN CHEMBL562 16303 352.77 Cmax 0.6726000000000003 ug.mL-1 1.9066247129857991e-06 5.719734782108048 CHEMBL3889405 17806009.0 Mean pharmacokinetic parameters for Griseofulvin following single dose administration of unaltered 250 mg ultramicrocrystalline Griseofulvin tablets, with or without applesauce, to 24 healthy volunteers Curated Drug Pharmacokinetic Data DailyMed|setid=9ddd37f9-299e-4c98-91ed-deeb72c63b00 | GRIS-PEG - griseofulvin tablet, film coated|State of Florida DOH Central Pharmacy GRISEOFULVIN GRISEOFULVIN CHEMBL562 16303 352.77 Normal/therapeutic blood-plasma concentration 1.3 mg/L 3.6851206168324978e-06 5.433548292779829 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GUAIFENESIN GUAIFENESIN CHEMBL980 100157 198.22 Normal/therapeutic blood-plasma concentration 1.4 mg/L 7.062859449096963e-06 5.151019436123031 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics GUANETHIDINE GUANETHIDINE CHEMBL765 43086 198.31 Normal/therapeutic blood-plasma concentration 0.01 mg/L 5.04261005496445e-08 7.297344614534694 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics HALOPERIDOL HALOPERIDOL CHEMBL54 3859 375.87 Normal/therapeutic blood-plasma concentration 0.02 mg/L 5.320988639689255e-08 7.274007668293007 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics HEXACHLOROPHENE HEXACHLOROPHENE CHEMBL496 8167 406.91 Normal/therapeutic blood-plasma concentration 0.65 mg/L 1.5974048315352291e-06 5.796585006327789 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics HYDRALAZINE HYDRALAZINE CHEMBL276832 8788 160.18 Normal/therapeutic blood-plasma concentration 1.5 mg/L 9.364464976900985e-06 5.028517030271354 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE CHEMBL435 2045 297.75 Normal/therapeutic blood-plasma concentration 2.0 mg/L 6.717044500419815e-06 5.172821774490834 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics HYDROCODONE HYDROCODONE CHEMBL1457 388373 299.37 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.6701740321341485e-07 6.777238273009532 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics HYDROMORPHONE HYDROMORPHONE CHEMBL398707 419580 285.34 Normal/therapeutic blood-plasma concentration 0.015 mg/L 5.25688652134296e-08 7.279271397850605 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics HYDROXYCHLOROQUINE CHEMBL1535 429737 335.88 Cmax 1220.0 nM 1.2200000000000002e-06 5.913640169325252 CHEMBL1661721 5155767.0 Cmax in healthy human plasma at 400 mg, po administered as single dose Scientific Literature 19188392.0 Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. HYDROXYCHLOROQUINE CHEMBL1535 429737 335.88 Cmax 60.0 nM 6.000000000000001e-08 7.221848749616356 CHEMBL1661728 5155774.0 Cmax in healthy human plasma assessed as desethylchloroquine level at 400 mg, po administered as single dose Scientific Literature 19188392.0 Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. HYDROXYCHLOROQUINE CHEMBL1535 429737 335.88 Cmax 7000.000000000002 nM 7.0000000000000024e-06 5.154901959985743 CHEMBL3424545 15234217.0 Cmax in human at 1200 mg Scientific Literature 25699157.0 Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells. HYDROXYCHLOROQUINE CHEMBL1535 429737 335.88 Cmax 359.9999999999999 nM 3.599999999999999e-07 6.443697499232713 CHEMBL1661844 5155781.0 Cmax in healthy human plasma assessed as bisdesethylchloroquine level at 400 mg, po administered as single dose Scientific Literature 19188392.0 Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. HYDROXYCHLOROQUINE HYDROXYCHLOROQUINE CHEMBL1535 429737 335.88 Normal/therapeutic blood-plasma concentration 0.4 mg/L 1.1909015124449209e-06 5.924124153185825 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics HYDROXYPROGESTERONE CAPROATE CHEMBL1200848 674799 428.61 Cmax 19.999999999999996 nM 1.9999999999999997e-08 7.698970004336019 CHEMBL3540500 15469692.0 Cmax in adult human cold blood Scientific Literature 23129211.0 Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes. HYDROXYPROGESTERONE CAPROATE CHEMBL1200848 674799 428.61 Cmax 70.00000000000003 nM 7.000000000000003e-08 7.154901959985743 CHEMBL3540499 15469693.0 Cmax in adult human plasma Scientific Literature 23129211.0 Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes. HYDROXYZINE HYDROXYZINE CHEMBL896 77459 374.91 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.6673068203035395e-07 6.573927024542379 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics IBUPROFEN IBUPROFEN CHEMBL521 11674 206.28 Normal/therapeutic blood-plasma concentration 30.0 mg/L 0.00014543339150668993 3.837335868015015 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics IDEBENONE IDEBENONE CHEMBL252556 418736 338.44 Normal/therapeutic blood-plasma concentration 0.2 mg/L 5.90946696607966e-07 6.2284516907144 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ILOPERIDONE ILOPERIDONE CHEMBL14376 13949 426.49 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.3447208609815003e-08 7.629908852629606 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ILOPROST ILOPROST CHEMBL494 7494 360.49 Normal/therapeutic blood-plasma concentration 0.0001 mg/L 2.774002052761519e-10 9.556893221884698 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics IMATINIB CHEMBL941 88797 493.62 Cmax 2000.0 nM 2.0000000000000003e-06 5.698970004336019 CHEMBL1221080 3396462.0 Cmax in chronic myeloid leukemia patient Scientific Literature 19219016.0 A pulse at the heart of targeted therapy. IMATINIB IMATINIB CHEMBL941 88797 493.62 Normal/therapeutic blood-plasma concentration 2.3 mg/L 4.659454641221992e-06 5.331664911672245 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics IMATINIB CHEMBL941 88797 493.62 Cmax 3650.0 nM 3.65e-06 5.437707135543525 CHEMBL2320296 12636119.0 Cmax in po dosed human Scientific Literature 23241029.0 Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. IMATINIB CHEMBL941 88797 493.62 Cmax 2.1999999999999997 ug.mL-1 4.4568696568210355e-06 5.350970066867632 CHEMBL3536743 15461317.0 Cmax in chronic myeloid leukemia patient at 400 mg, qd by multiple dose study Scientific Literature 23028140.0 Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. IMIPENEM IMIPENEM CHEMBL148 43934 299.35 Normal/therapeutic blood-plasma concentration 75.0 mg/L 0.00025054284282612327 3.6011179990900035 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics IMIPENEM CHEMBL148 43934 299.35 Cmax 6.599999999999999 ug.mL-1 2.2047770168698843e-05 4.656635326939835 CHEMBL1634391 5092147.0 Cmax in febrile neutropenic patient with hematological malignancies at 500 mg administered as 30 mins infusion every 6 hrs Scientific Literature 19047655.0 Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. IMIPRAMINE CHEMBL11 605 280.42 Cmax 0.19999999999999998 ug.mL-1 7.132158904500391e-07 6.146778989307833 CHEMBL3889451 17806347.0 Pharmacokinetic parameters for different drugs following multiple oral or intravenous administration in healthy subjects. Curated Drug Pharmacokinetic Data Goodman and Gilman Ed. 10 | The Pharmaceutical Basis of Therapeutics| Table A-II-I: Pharmacokinetic Data IMIPRAMINE CHEMBL11 605 280.42 Cmax 709.9999999999999 nM 7.1e-07 6.1487416512809245 CHEMBL2154113 12064131.0 Cmax in human Scientific Literature 21599003.0 Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. IMIPRAMINE IMIPRAMINE CHEMBL11 605 280.42 Normal/therapeutic blood-plasma concentration 0.35 mg/L 1.2481278082875686e-06 5.903740940621539 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics AMRINONE INAMRINONE CHEMBL12856 11066 187.2 Normal/therapeutic blood-plasma concentration 4.0 mg/L 2.136752136752137e-05 4.670245853074124 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics INDINAVIR INDINAVIR CHEMBL115 17170 613.8 Normal/therapeutic blood-plasma concentration 0.1 mg/L 1.6291951775822745e-07 6.788026884095804 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics INDINAVIR CHEMBL115 17170 613.8 Cmax 9.27 ug.mL-1 1.5102639296187686e-05 4.820947149951307 CHEMBL920825 1833980.0 Cmax in HIV1 infected pregnant woman during postpartum period at 800 mg three times/day Scientific Literature 17158945.0 Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. INDINAVIR CHEMBL115 17170 613.8 Cmax 4.369999999999999 ug.mL-1 7.1195829260345374e-06 5.147545447125382 CHEMBL920824 1833979.0 Cmax in HIV1 infected pregnant woman during antepartum period at 800 mg three times/day Scientific Literature 17158945.0 Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. INDOMETACIN INDOMETHACIN CHEMBL6 173 357.79 Normal/therapeutic blood-plasma concentration 3.0 mg/L 8.384806730204869e-06 5.076506943430334 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics INDOMETHACIN CHEMBL6 173 357.79 Cmax 1.0 ug.mL-1 2.794935576734956e-06 5.553628198149997 CHEMBL3889440 17806251.0 Pharmacokinetic parameters for Indomethacin evaluated after single oral administration of 25 or 50 mg Indomethacin capsules. Curated Drug Pharmacokinetic Data DailyMed|setid=b463cd5f-299a-45f8-a1b3-c9e7fe271955 | INDOMETHACIN- indomethacin capsule|PD-Rx Pharmaceuticals, Inc. INDOMETHACIN CHEMBL6 173 357.79 Cmax 2.0 ug.mL-1 5.589871153469912e-06 5.252598202486015 CHEMBL3889440 17806253.0 Pharmacokinetic parameters for Indomethacin evaluated after single oral administration of 25 or 50 mg Indomethacin capsules. Curated Drug Pharmacokinetic Data DailyMed|setid=b463cd5f-299a-45f8-a1b3-c9e7fe271955 | INDOMETHACIN- indomethacin capsule|PD-Rx Pharmaceuticals, Inc. INDORAMIN INDORAMIN CHEMBL279516 33466 347.46 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.8780291256547517e-07 6.540904815317018 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ADIPIODONE IODIPAMIDE CHEMBL1165268 646449 1139.76 Normal/therapeutic blood-plasma concentration 1200.0 mg/L 0.001052853232259423 2.977632165246 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics IPRONIAZID IPRONIAZID CHEMBL92401 150743 179.22 Normal/therapeutic blood-plasma concentration 5.0 mg/L 2.7898672023211696e-05 4.554416468651753 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics IRBESARTAN IRBESARTAN CHEMBL1513 421066 428.54 Normal/therapeutic blood-plasma concentration 3.3 mg/L 7.700564708078592e-06 5.113477425397686 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics IRBESARTAN CHEMBL1513 421066 428.54 Cmax 1.2999999999999996 ug.mL-1 3.033555794091566e-06 5.518048012968736 CHEMBL3889448 17806354.0 Pharmacokinetic parameters for diffferent drugs or their active metabolite, following single oral or intravenous (IV) administration to subjects of different health conditions. Curated Drug Pharmacokinetic Data Goodman and Gilman Ed. 12 | The Pharmaceutical Basis of Therapeutics| Table AII-I: Pharmacokinetic Data ISAVUCONAZONIUM CHEMBL1183349 657299 717.78 Cmax 1.09 ug.mL-1 1.5185711499345204e-06 5.818564855178014 CHEMBL1694974 5312391.0 Cmax in healthy human plasma assessed as isavuconazole level at 180.5 mg, iv administered as single dose over 2 hrs following overnight fasting by high-pressure liquid chromatography coupled with tandem mass spectrometry by HPLC-tandem mass spectrometry Scientific Literature 19667286.0 Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. ISAVUCONAZONIUM CHEMBL1183349 657299 717.78 Cmax 0.8400000000000001 ug.mL-1 1.170275014628438e-06 5.931712067056756 CHEMBL1694977 5312389.0 Cmax in healthy human plasma assessed as isavuconazole level at 180.5 mg, po administered as single dose over 2 hrs following overnight fasting by high-pressure liquid chromatography coupled with tandem mass spectrometry by HPLC-tandem mass spectrometry Scientific Literature 19667286.0 Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. ISONIAZID CHEMBL64 4941 137.14 Cmax 5.720000000000002 ug.mL-1 4.170920227504742e-05 4.379768116336331 CHEMBL3790554 16534950.0 Cmax in healthy Chinese subject (8 subjects) with heterozygous mutant of NAT2 genotype at 300 mg, po administered after overnight fast by HPLC method Scientific Literature 21980963.0 Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. ISONIAZID ISONIAZID CHEMBL64 4941 137.14 Normal/therapeutic blood-plasma concentration 10.0 mg/L 7.291818579553741e-05 4.137164145129356 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ISONIAZID CHEMBL64 4941 137.14 Cmax 4.499999999999998 ug.mL-1 3.281318360799182e-05 4.483951631354013 CHEMBL955455 2498864.0 Cmax in human at 300 mg, po Scientific Literature 17132069.0 OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. ISONIAZID CHEMBL64 4941 137.14 Cmax 3.99 ug.mL-1 2.9094356132419432e-05 4.5361912494426075 CHEMBL3790814 16534946.0 Cmax in healthy Chinese subject (8 subjects) with heterozygous mutant of NAT2 genotype assessed as N-acetylisoniazid at 300 mg, po administered after overnight fast by HPLC method Scientific Literature 21980963.0 Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. ISONIAZID CHEMBL64 4941 137.14 Cmax 4.93 ug.mL-1 3.5948665597199944e-05 4.444317225852126 CHEMBL3790819 16534941.0 Cmax in healthy Chinese subject (8 subjects) with homozygous wild type NAT2 genotype at 300 mg, po administered after overnight fast by HPLC method Scientific Literature 21980963.0 Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. ISONIAZID CHEMBL64 4941 137.14 Cmax 8.279999999999998 ug.mL-1 6.037625783870496e-05 4.219133808344476 CHEMBL3790828 16534932.0 Cmax in healthy Chinese subject (8 subjects) with homozygous mutant of NAT2 genotype at 300 mg, po administered after overnight fast by HPLC method Scientific Literature 21980963.0 Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. ISONIAZID CHEMBL64 4941 137.14 Cmax 1.38 ug.mL-1 1.0062709639784162e-05 4.99728505872812 CHEMBL3790832 16534928.0 Cmax in healthy Chinese subject (8 subjects) with homozygous mutant of NAT2 genotype assessed as N-acetylisoniazid at 300 mg, po administered after overnight fast by HPLC method Scientific Literature 21980963.0 Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. ISONIAZID CHEMBL64 4941 137.14 Cmax 5.59 ug.mL-1 4.076126585970542e-05 4.389752337242933 CHEMBL3790823 16534937.0 Cmax in healthy Chinese subject (8 subjects) with homozygous wild type NAT2 genotype assessed as N-acetylisoniazid at 300 mg, po administered after overnight fast by HPLC method Scientific Literature 21980963.0 Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. ISOSORBIDE MONONITRATE CHEMBL1311 263453 191.14 Cmax 1.1509999999999998 ug.mL-1 6.021764151930522e-06 5.220276258042945 CHEMBL3889348 17805690.0 Pharmacokinetic parameters for Isosorbide mononitrate after multiple oral dose administrations of 60 and 120 mg Isosorbide mononitrate tablets to subjects Range 1151 To 1180 Curated Drug Pharmacokinetic Data DailyMed|setid=891194e8-7083-4438-8d27-c72f2372e40f | ISOSORBIDE MONONITRATE - isosorbide mononitrate tablet, extended release|Mckesson Contract Packaging ISOSORBIDE MONONITRATE CHEMBL1311 263453 191.14 Cmax 0.424 ug.mL-1 2.2182693313801406e-06 5.6539857250800045 CHEMBL3889347 17805675.0 Pharmacokinetic parameters for Isosorbide mononitrate after single oral dose administration of 60 mg Isosorbide mononitrate solution or table to subjects. Ranges From 424 To 541 Curated Drug Pharmacokinetic Data DailyMed|setid=891194e8-7083-4438-8d27-c72f2372e40f | ISOSORBIDE MONONITRATE - isosorbide mononitrate tablet, extended release|Mckesson Contract Packaging ISOSORBIDE MONONITRATE CHEMBL1311 263453 191.14 Cmax 1.242 ug.mL-1 6.497854975410695e-06 5.187229985832176 CHEMBL3889347 17805680.0 Pharmacokinetic parameters for Isosorbide mononitrate after single oral dose administration of 60 mg Isosorbide mononitrate solution or table to subjects. Ranges From 1242 To 1534 Curated Drug Pharmacokinetic Data DailyMed|setid=891194e8-7083-4438-8d27-c72f2372e40f | ISOSORBIDE MONONITRATE - isosorbide mononitrate tablet, extended release|Mckesson Contract Packaging ISOSORBIDE MONONITRATE CHEMBL1311 263453 191.14 Cmax 0.557 ug.mL-1 2.91409438108193e-06 5.535496386499009 CHEMBL3889348 17805685.0 Pharmacokinetic parameters for Isosorbide mononitrate after multiple oral dose administrations of 60 and 120 mg Isosorbide mononitrate tablets to subjects Range 557 To 572 Curated Drug Pharmacokinetic Data DailyMed|setid=891194e8-7083-4438-8d27-c72f2372e40f | ISOSORBIDE MONONITRATE - isosorbide mononitrate tablet, extended release|Mckesson Contract Packaging ISOTRETINOIN CHEMBL547 13928 300.44 Cmax 0.862 ug.mL-1 2.8691252829183864e-06 5.542250487483457 CHEMBL3889357 17805715.0 Mean pharmacokinetics parameters for Isotretinoin following single oral administration of Isotretinoin to healthy subjects. %Cv = 22% Curated Drug Pharmacokinetic Data DailyMed|setid=517810a4-76bb-4739-893f-1f2ba94a5d0c | ZENATANE -isotretinoin capsule, gelatine coated ISOTRETINOIN CHEMBL547 13928 300.44 Cmax 0.301 ug.mL-1 1.0018639328984156e-06 5.999191257714327 CHEMBL3889357 17805720.0 Mean pharmacokinetics parameters for Isotretinoin following single oral administration of Isotretinoin to healthy subjects. %Cv = 63% Curated Drug Pharmacokinetic Data DailyMed|setid=517810a4-76bb-4739-893f-1f2ba94a5d0c | ZENATANE -isotretinoin capsule, gelatine coated ISOTRETINOIN CHEMBL547 13928 300.44 Cmax 0.5732999999999999 ug.mL-1 1.9082013047530287e-06 5.719375811533495 CHEMBL3889357 17805724.0 Mean pharmacokinetics parameters for Isotretinoin following single oral administration of Isotretinoin to healthy subjects. Dose-Normalised Curated Drug Pharmacokinetic Data DailyMed|setid=517810a4-76bb-4739-893f-1f2ba94a5d0c | ZENATANE -isotretinoin capsule, gelatine coated ISOTRETINOIN CHEMBL547 13928 300.44 Cmax 0.7320000000000001 ug.mL-1 2.4364265743576094e-06 5.613246672249779 CHEMBL3889358 17805729.0 Steady-state pharmacokinetic parameters of Isotretinoin following multiple oral administration of Isotretinoin to 38 pediatric patients, age ramge (0 to 12 years), after a non-standardised meal. Dose-Normalised Curated Drug Pharmacokinetic Data DailyMed|setid=517810a4-76bb-4739-893f-1f2ba94a5d0c | ZENATANE -isotretinoin capsule, gelatine coated ISOTRETINOIN ISOTRETINOIN CHEMBL547 13928 300.44 Normal/therapeutic blood-plasma concentration 0.002 mg/L 6.656903208627346e-09 8.176727757644189 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ISOXICAM ISOXICAM CHEMBL53292 78364 335.34 Normal/therapeutic blood-plasma concentration 15.0 mg/L 4.473072105922348e-05 4.349394100943868 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ISRADIPINE ISRADIPINE CHEMBL1648 486789 371.39 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.6925873071434343e-08 7.569830205803096 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.4599999999999999 ug.mL-1 6.518812442428965e-07 6.185831514187599 CHEMBL1636027 5086141.0 Cmax in human at 15 mg, po pretreated with itraconazole at 200 mg, po qd for 4 days Scientific Literature 19015346.0 Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.21299999999999994 ug.mL-1 3.0184935874725423e-07 6.520209742430435 CHEMBL3889333 17805431.0 The pharmacokinetic parameters of Itraconazole after single oral administration of 200 mg Itraconzole to 9 male and 9 female healthy subjects in fasting and in fed conditions Mean Value. Drug Given After Fda Standard High-Fat Breakfast Curated Drug Pharmacokinetic Data DailyMed|setid=fb8a2e5b-fd23-4977-81de-a95f4af168e2 | ONMEL- itraconazole tablet|Merz Pharmaceuticals, LLC ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.16200000000000003 ug.mL-1 2.2957556862467233e-07 6.639074331326541 CHEMBL3889333 17805434.0 The pharmacokinetic parameters of Itraconazole after single oral administration of 200 mg Itraconzole to 9 male and 9 female healthy subjects in fasting and in fed conditions Curated Drug Pharmacokinetic Data DailyMed|setid=fb8a2e5b-fd23-4977-81de-a95f4af168e2 | ONMEL- itraconazole tablet|Merz Pharmaceuticals, LLC ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.11679999999999997 ug.mL-1 1.655211507121094e-07 6.781146503092792 CHEMBL3889334 17805438.0 The steady-state pharmacokinetics of itraconazole analyzed after multiple oral dosing of 16 healthy volunteers with 200 mg Itraconazole following a moderate-fat breakfast once daily for 14 days in an open-label study Mean Curated Drug Pharmacokinetic Data DailyMed|setid=fb8a2e5b-fd23-4977-81de-a95f4af168e2 | ONMEL- itraconazole tablet|Merz Pharmaceuticals, LLC ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.32099999999999995 ug.mL-1 4.548997378303691e-07 6.342084313464301 CHEMBL993624 2556255.0 Cmax in adolescents of >12-16 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose Scientific Literature 17517842.0 Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.277 ug.mL-1 3.925458796853965e-07 6.406109576804724 CHEMBL993620 2556251.0 Cmax in children of >6-12 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose Scientific Literature 17517842.0 Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.299 ug.mL-1 4.2372280875788284e-07 6.372918157544743 CHEMBL990881 2556247.0 Cmax in children of >2-6 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose Scientific Literature 17517842.0 Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.26499999999999996 ug.mL-1 3.7554028200949477e-07 6.425343471932364 CHEMBL990044 2556243.0 Cmax in infants of 0.6-2 yrs age at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose Scientific Literature 17517842.0 Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.293 ug.mL-1 4.1522000991993195e-07 6.381721725515063 CHEMBL990048 2556239.0 Cmax in human at risk for fungal infection assessed as hydroxyitraconazole level at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose Scientific Literature 17517842.0 Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.8059999999999998 ug.mL-1 1.1422093105647274e-06 5.942254304064082 CHEMBL990031 2556226.0 Cmax in adolescents of >12-16 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose Scientific Literature 17517842.0 Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 1.5530000000000002 ug.mL-1 2.2008077658896055e-06 5.657417890140613 CHEMBL990023 2556225.0 Cmax in children of >2-6 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose Scientific Literature 17517842.0 Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.8270000000000002 ug.mL-1 1.1719691064975557e-06 5.931083836316626 CHEMBL987345 2556224.0 Cmax in infants of 0.6-2 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose Scientific Literature 17517842.0 Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.785 ug.mL-1 1.1124495146318997e-06 5.95371968912392 CHEMBL990027 2556223.0 Cmax in children of >6-12 yrs age at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose Scientific Literature 17517842.0 Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 1.0150000000000003 ug.mL-1 1.4383901367533484e-06 5.842123303619941 CHEMBL990035 2556214.0 Cmax in human at risk for fungal infection at 2.5 mg/kg, iv in 0.1 g/kg hydroxypropyl-beta-cyclodextrin administered as single dose Scientific Literature 17517842.0 Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 0.6581 ug.mL-1 9.326153192092398e-07 6.030297455069176 CHEMBL3889334 17805443.0 The steady-state pharmacokinetics of itraconazole analyzed after multiple oral dosing of 16 healthy volunteers with 200 mg Itraconazole following a moderate-fat breakfast once daily for 14 days in an open-label study Mean Curated Drug Pharmacokinetic Data DailyMed|setid=fb8a2e5b-fd23-4977-81de-a95f4af168e2 | ONMEL- itraconazole tablet|Merz Pharmaceuticals, LLC ITRACONAZOLE CHEMBL22587 27986 705.65 Cmax 2.1 ug.mL-1 2.9759795932827895e-06 5.526370051135253 CHEMBL1633993 5088978.0 Cmax in healthy human plasma at 200 mg, po every 12 hrs for 5 days Scientific Literature 19029316.0 Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. ITRACONAZOLE ITRACONAZOLE CHEMBL22587 27986 705.65 Normal/therapeutic blood-plasma concentration 2.0 mg/L 2.834266279316942e-06 5.547559350205191 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics IVERMECTIN IVERMECTIN CHEMBL1200633 674584 1736.18 Normal/therapeutic blood-plasma concentration 0.05 mg/L 2.879885726134387e-08 7.540624744703921 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics KANAMYCIN KANAMYCIN CHEMBL1384 325239 484.5 Normal/therapeutic blood-plasma concentration 25.0 mg/L 5.159958720330238e-05 4.287353772714747 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics KETAMINE KETAMINE CHEMBL742 38833 237.73 Normal/therapeutic blood-plasma concentration 6.0 mg/L 2.5238716190636437e-05 4.5979327399787175 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics KETANSERIN KETANSERIN CHEMBL51 3683 395.43 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.264446298965683e-06 5.898099610414565 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics KETAZOLAM KETAZOLAM CHEMBL2104356 1376626 368.82 Normal/therapeutic blood-plasma concentration 0.02 mg/L 5.422699419771163e-08 7.26578446784052 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics KETOCONAZOLE KETOCONAZOLE CHEMBL157101 255904 531.44 Normal/therapeutic blood-plasma concentration 6.0 mg/L 1.1290079783230468e-05 4.94730298904985 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics KETOPROFEN KETOPROFEN CHEMBL571 16591 254.29 Normal/therapeutic blood-plasma concentration 20.0 mg/L 7.86503598253962e-05 4.104299286138895 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics KETOROLAC KETOROLAC CHEMBL469 5080 255.27 Normal/therapeutic blood-plasma concentration 3.0 mg/L 1.175226231049477e-05 4.929878523656783 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics KETOTIFEN KETOTIFEN CHEMBL534 12957 309.43 Normal/therapeutic blood-plasma concentration 0.004 mg/L 1.2926994796884594e-08 7.888502425995464 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LABETALOL LABETALOL CHEMBL429 1785 328.41 Normal/therapeutic blood-plasma concentration 0.65 mg/L 1.9792332754788224e-06 5.703503016161117 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LACIDIPINE LACIDIPINE CHEMBL460291 453548 455.55 Normal/therapeutic blood-plasma concentration 0.006 mg/L 1.3170892327955219e-08 7.880384800590303 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LAMIVUDINE CHEMBL141 33986 229.26 Cmax 0.9799999999999996 ug.mL-1 4.274622699118903e-06 5.369102212379557 CHEMBL1677107 5216106.0 Cmax in HIV-1 infected children aged 2.5 to 4.8 years at 4 mg/kg, po every 12 hrs by HPLC Scientific Literature 20516271.0 Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? LAMIVUDINE CHEMBL141 33986 229.26 Cmax 3.810000000000001 ug.mL-1 1.661868620779901e-05 4.779403312396433 CHEMBL991930 2574934.0 Cmax in healthy human at 300 mg, po once daily coadministered with 600 mg, po apricitabine twice daily for 4 days Scientific Literature 17242147.0 Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. LAMIVUDINE CHEMBL141 33986 229.26 Cmax 3.980000000000001 ug.mL-1 1.736020239029923e-05 4.760445215998365 CHEMBL991923 2574927.0 Cmax in healthy human at 300 mg, po administered once daily for 4 days Scientific Literature 17242147.0 Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. LAMIVUDINE CHEMBL141 33986 229.26 Cmax 1.6999999999999997 ug.mL-1 7.41516182500218e-06 5.129879366693778 CHEMBL1677100 5216099.0 Cmax in HIV-1 infected children aged 2.5 to 14 years at 8 mg/kg, po every 24 hrs coadministered with 240 mg/m2 of didanosine and efavirenz by HPLC Scientific Literature 20516271.0 Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? LAMIVUDINE CHEMBL141 33986 229.26 Cmax 1.3299999999999998 ug.mL-1 5.801273663089941e-06 5.236476647104967 CHEMBL1677104 5216103.0 Cmax in HIV-1 infected children aged 6.9 years at 4 mg/kg, po every 12 hrs coadministered with nevirapine and stavudine by HPLC Scientific Literature 20516271.0 Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? LAMIVUDINE CHEMBL141 33986 229.26 Cmax 1.1099999999999999 ug.mL-1 4.8416644857367175e-06 5.315005309285395 CHEMBL1677115 5216114.0 Cmax in HIV-1 infected children aged 2.1 to 12.8 years at 4 mg/kg, po every 12 hrs coadministered with 8 mg/kg abacavir by HPLC Scientific Literature 20516271.0 Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? LAMIVUDINE CHEMBL141 33986 229.26 Cmax 1.8399999999999996 ug.mL-1 8.025822210590594e-06 5.0955104650625165 CHEMBL1677111 5216110.0 Cmax in HIV-1 infected children aged 8.5 to 12.3 years at 4 mg/kg, po every 12 hrs by HPLC Scientific Literature 20516271.0 Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? LAMIVUDINE CHEMBL141 33986 229.26 Cmax 2.0900000000000003 ug.mL-1 9.116287184855624e-06 5.040182001960998 CHEMBL1677119 5216118.0 Cmax in HIV-1 infected children aged 2.1 to 12.8 years at 4 mg/kg, po every 24 hrs coadministered with 8 mg/kg abacavir by HPLC Scientific Literature 20516271.0 Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? LAMOTRIGINE LAMOTRIGINE CHEMBL741 38727 256.1 Normal/therapeutic blood-plasma concentration 14.0 mg/L 5.466614603670441e-05 4.262281542790191 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LAPATINIB CHEMBL554 14805 581.07 Cmax 0.32999999999999996 ug.mL-1 5.679178068046878e-07 6.245714513996984 CHEMBL3539976 15450545.0 Cmax in healthy human at 250 mg, po administered as single dose Scientific Literature 21965624.0 Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. LAPATINIB CHEMBL554 14805 581.07 Cmax 0.7199999999999998 ug.mL-1 1.239093396664773e-06 5.906895957443603 CHEMBL3539976 15450546.0 Cmax in healthy human at 250 mg, po administered as single dose Scientific Literature 21965624.0 Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. LEDIPASVIR CHEMBL2374220 1548671 889.02 Cmax 21.299999999999997 nM 2.13e-08 7.671620396561262 CHEMBL3122340 13926765.0 Cmax in fasted healthy human at 10 mg/kg, po Scientific Literature 24320933.0 Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. LEDIPASVIR CHEMBL2374220 1548671 889.02 Cmax 6.75 nM 6.75e-09 8.170696227168975 CHEMBL3122346 13926771.0 Cmax in fasted healthy human at 3 mg/kg, po Scientific Literature 24320933.0 Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. LEDIPASVIR CHEMBL2374220 1548671 889.02 Cmax 133.0 nM 1.33e-07 6.876148359032914 CHEMBL3122328 13926753.0 Cmax in fasted healthy human at 60 mg/kg, po Scientific Literature 24320933.0 Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. LEDIPASVIR CHEMBL2374220 1548671 889.02 Cmax 82.19999999999999 nM 8.22e-08 7.0851281824599495 CHEMBL3122335 13926759.0 Cmax in fasted healthy human at 30 mg/kg, po Scientific Literature 24320933.0 Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. LEDIPASVIR CHEMBL2374220 1548671 889.02 Cmax 242.0 nM 2.42e-07 6.616184634019569 CHEMBL3122322 13926747.0 Cmax in fasted healthy human at 100 mg/kg, po Scientific Literature 24320933.0 Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. LEFLUNOMIDE LEFLUNOMIDE CHEMBL960 93895 270.21 Normal/therapeutic blood-plasma concentration 63.0 mg/L 0.00023315199289441547 3.632360868009838 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LETROZOLE CHEMBL1444 374548 285.31 Cmax 114.99999999999999 nM 1.15e-07 6.939302159646388 CHEMBL3889332 17805430.0 Pharmacokinetic parameters for Letrozole evaluated following single oral administration of Letrozole tablets Curated Drug Pharmacokinetic Data Goodman and Gilman Ed. 12 | The Pharmaceutical Basis of Therapeutics| Table AII-I: Pharmacokinetic Data LEVAMISOLE CHEMBL1454 384948 204.3 Cmax 0.82 ug.mL-1 4.013705335291238e-06 5.396454514248731 CHEMBL3539352 15469748.0 Cmax in female human at 150 mg, po Scientific Literature 22393119.0 Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: a case for reactive metabolite(s) involvement. LEVAMISOLE LEVAMISOLE CHEMBL1454 384948 204.3 Normal/therapeutic blood-plasma concentration 0.7 mg/L 3.4263338228095935e-06 5.465170326618191 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LEVAMISOLE CHEMBL1454 384948 204.3 Cmax 0.7169999999999999 ug.mL-1 3.5095447870778258e-06 5.454749210964647 CHEMBL3539350 15469750.0 Cmax in human at 150 mg, po Scientific Literature 22393119.0 Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: a case for reactive metabolite(s) involvement. LEVAMISOLE CHEMBL1454 384948 204.3 Cmax 0.6720000000000002 ug.mL-1 3.2892804698972105e-06 5.482899093578622 CHEMBL3539351 15469749.0 Cmax in male human at 150 mg, po Scientific Literature 22393119.0 Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: a case for reactive metabolite(s) involvement. LEVETIRACETAM LEVETIRACETAM CHEMBL1286 252155 170.21 Normal/therapeutic blood-plasma concentration 40.0 mg/L 0.0002350038188120557 3.6289250803855917 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LEVOCABASTINE LEVOCABASTINE CHEMBL1615438 1038389 420.53 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.377951632463796e-08 7.623796983177253 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LEVODOPA LEVODOPA CHEMBL1009 112655 197.19 Normal/therapeutic blood-plasma concentration 2.0 mg/L 1.0142502155281709e-05 4.993854891336049 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 8.7 ug.mL-1 2.407504773500844e-05 4.618432843101446 CHEMBL3889351 17805674.0 Pharmacokinetic parameters for Levofloxacin evaluated after multiple oral or IV administration of 250, 500 or 750 mg Levofloxacin, to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 7.5 ug.mL-1 2.075435149569693e-05 4.682890832328365 CHEMBL3889349 17805597.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 7.000000000000002 ug.mL-1 1.9370728062650474e-05 4.712854055705808 CHEMBL3889349 17805584.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 5.5 ug.mL-1 1.5219857763511081e-05 4.817589406225821 CHEMBL3889349 17805581.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 7.000000000000002 ug.mL-1 1.9370728062650474e-05 4.712854055705808 CHEMBL3889349 17805576.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 5.700000000000001 ug.mL-1 1.577330713672967e-05 4.8020772400475735 CHEMBL3889349 17805612.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 6.9 ug.mL-1 1.9094003376041177e-05 4.719103004982809 CHEMBL3889349 17805619.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 8.999999999999996 ug.mL-1 2.4905221794836305e-05 4.60370958628074 CHEMBL1279705 3566360.0 Cmax in tuberculosis patient at 1000 mg/day, po administered for 7 days by HPLC Scientific Literature 18070980.0 Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 5.700000000000001 ug.mL-1 1.577330713672967e-05 4.8020772400475735 CHEMBL3889351 17805626.0 Pharmacokinetic parameters for Levofloxacin evaluated after multiple oral or IV administration of 250, 500 or 750 mg Levofloxacin, to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 5.5 ug.mL-1 1.5219857763511081e-05 4.817589406225821 CHEMBL3889349 17805567.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 8.7 ug.mL-1 2.407504773500844e-05 4.618432843101446 CHEMBL3889351 17805633.0 Pharmacokinetic parameters for Levofloxacin evaluated after multiple oral or IV administration of 250, 500 or 750 mg Levofloxacin, to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 2.8000000000000007 ug.mL-1 7.74829122506019e-06 5.110794064377846 CHEMBL3889349 17805521.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 8.200000000000001 ug.mL-1 2.269142430196198e-05 4.644138243336348 CHEMBL3889349 17805605.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 5.1000000000000005 ug.mL-1 1.4112959017073914e-05 4.850381919622128 CHEMBL3889349 17805529.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 5.799999999999999 ug.mL-1 1.6050031823338958e-05 4.794524102157127 CHEMBL3889349 17805543.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 5.700000000000001 ug.mL-1 1.577330713672967e-05 4.8020772400475735 CHEMBL1678030 5228610.0 Cmax in human at 500 mg, po QD measured on day 10 by LS/MS/MS analysis Scientific Literature 20625157.0 Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus). LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 8.5 ug.mL-1 2.3521598361789855e-05 4.628533170005772 CHEMBL1678046 5228614.0 Cmax in human at 500 mg, po by LS/MS/MS analysis Scientific Literature 20625157.0 Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus). LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 8.7 ug.mL-1 2.407504773500844e-05 4.618432843101446 CHEMBL3889351 17805644.0 Pharmacokinetic parameters for Levofloxacin evaluated after multiple oral or IV administration of 250, 500 or 750 mg Levofloxacin, to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 9.3 ug.mL-1 2.5735395854664196e-05 4.589469147166129 CHEMBL3889349 17805554.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 11.499999999999996 ug.mL-1 3.1823338960068615e-05 4.497254255366453 CHEMBL3889349 17805558.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 8.6 ug.mL-1 2.3798323048399146e-05 4.6234536444764975 CHEMBL3889351 17805653.0 Pharmacokinetic parameters for Levofloxacin evaluated after multiple oral or IV administration of 250, 500 or 750 mg Levofloxacin, to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 12.1 ug.mL-1 3.348368707972438e-05 4.475166725403615 CHEMBL3889351 17805658.0 Pharmacokinetic parameters for Levofloxacin evaluated after multiple oral or IV administration of 250, 500 or 750 mg Levofloxacin, to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 6.3999999999999995 ug.mL-1 1.7710379942994714e-05 4.7517721217361775 CHEMBL3889351 17805665.0 Pharmacokinetic parameters for Levofloxacin evaluated after multiple oral or IV administration of 250, 500 or 750 mg Levofloxacin, to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 6.200000000000003 ug.mL-1 1.715693056977614e-05 4.765560406221811 CHEMBL3889349 17805536.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOFLOXACIN CHEMBL33 1795 361.37 Cmax 7.099999999999999 ug.mL-1 1.9647452749259758e-05 4.7066937470009895 CHEMBL3889349 17805601.0 Pharmacokinetic parameters for Levofloxacin evaluated after oral or IV single dose administration of 250, 500 or 750 mg Levofloxacin to male and/or female subjects of variable age ranges and health status. Curated Drug Pharmacokinetic Data DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc. LEVOMEPROMAZINE LEVOMEPROMAZINE CHEMBL1764 583530 328.48 Normal/therapeutic blood-plasma concentration 0.2 mg/L 6.088650754992693e-07 6.215478936362535 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LEVACETYLMETHADOL LEVOMETHADYL ACETATE CHEMBL1514 421070 353.51 Normal/therapeutic blood-plasma concentration 0.06 mg/L 1.69726457525954e-07 6.770250453133694 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LEVORPHANOL LEVORPHANOL CHEMBL592 19572 257.38 Normal/therapeutic blood-plasma concentration 0.02 mg/L 7.77061154712876e-08 7.109544800878346 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LEVOTHYROXINE LEVOTHYROXINE CHEMBL1624 469690 776.87 Normal/therapeutic blood-plasma concentration 0.14 mg/L 1.8021033120084444e-07 6.744220315161033 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LIDOCAINE LIDOCAINE CHEMBL79 6723 234.34 Normal/therapeutic blood-plasma concentration 5.0 mg/L 2.1336519586924982e-05 4.670876421250182 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LIDOCAINE CHEMBL79 6723 234.34 Cmax 0.03150000000000001 ug.mL-1 1.344200733976274e-07 6.871535871796601 CHEMBL3889432 17806185.0 Pharmacokinetic parameters for Lidocaine obtained following application of 46.1 mg Lidocaine patch system (DentiPatch) to female and other subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=1b5826d4-5177-42b9-8ac2-d35071b4bccb | DENTIPATCH- lidocaine patch|Noven Parmaceuticals, Inc. LIDOCAINE CHEMBL79 6723 234.34 Cmax 0.11999999999999998 ug.mL-1 5.120764700861995e-07 6.290665179538577 CHEMBL3889430 17806170.0 Pharmacokinetic parameters for Lidocaine, and Prilocaine after topical administration of EMLA cream intact skin on the lateral thighs, vaginal fornices and penile skin of subjects Curated Drug Pharmacokinetic Data DailyMed|setid=823c2d42-d00d-401d-4081-fc1d434455e0 | EMLA- lidocaine cream|APP Pharmaceuticals, LLC LIDOCAINE CHEMBL79 6723 234.34 Cmax 0.0272 ug.mL-1 1.1607066655287189e-07 6.935277521552003 CHEMBL3889432 17806184.0 Pharmacokinetic parameters for Lidocaine obtained following application of 46.1 mg Lidocaine patch system (DentiPatch) to female and other subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=1b5826d4-5177-42b9-8ac2-d35071b4bccb | DENTIPATCH- lidocaine patch|Noven Parmaceuticals, Inc. LIDOCAINE CHEMBL79 6723 234.34 Cmax 0.022199999999999998 ug.mL-1 9.47341469659469e-08 7.023493451135563 CHEMBL3889432 17806186.0 Pharmacokinetic parameters for Lidocaine obtained following application of 46.1 mg Lidocaine patch system (DentiPatch) to female and other subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=1b5826d4-5177-42b9-8ac2-d35071b4bccb | DENTIPATCH- lidocaine patch|Noven Parmaceuticals, Inc. LIDOCAINE CHEMBL79 6723 234.34 Cmax 0.0165 ug.mL-1 7.041051463685245e-08 7.152362481372295 CHEMBL3889432 17806190.0 Pharmacokinetic parameters for Lidocaine obtained following application of 46.1 mg Lidocaine patch system (DentiPatch) to female and other subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=1b5826d4-5177-42b9-8ac2-d35071b4bccb | DENTIPATCH- lidocaine patch|Noven Parmaceuticals, Inc. LIDOCAINE CHEMBL79 6723 234.34 Cmax 0.28 ug.mL-1 1.194845096867799e-06 5.922688394243981 CHEMBL3889430 17806172.0 Pharmacokinetic parameters for Lidocaine, and Prilocaine after topical administration of EMLA cream intact skin on the lateral thighs, vaginal fornices and penile skin of subjects Curated Drug Pharmacokinetic Data DailyMed|setid=823c2d42-d00d-401d-4081-fc1d434455e0 | EMLA- lidocaine cream|APP Pharmaceuticals, LLC LINEZOLID CHEMBL126 26280 337.35 Cmax 14.700000000000003 ug.mL-1 4.3574922187638955e-05 4.360763379743137 CHEMBL1676936 5213562.0 Cmax in patient plasma at 600 mg, iv or 600 mg, po administered every 12 hrs by HPLC Scientific Literature 20733043.0 Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. LINEZOLID CHEMBL126 26280 337.35 Cmax 13.4 ug.mL-1 3.9721357640432787e-05 4.400975916126506 CHEMBL1665706 5178791.0 Cmax in human adults with pulmonary tuberculosis at 600 mg administered twice daily for 5 days Scientific Literature 19564361.0 Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. LINEZOLIDE LINEZOLID CHEMBL126 26280 337.35 Normal/therapeutic blood-plasma concentration 4.0 mg/L 1.185712168371128e-05 4.926020723163351 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LINEZOLID CHEMBL126 26280 337.35 Cmax 16.0 ug.mL-1 4.742848673484512e-05 4.323960731835388 CHEMBL1696172 5306507.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. LINEZOLID CHEMBL126 26280 337.35 Cmax 14.899999999999997 ug.mL-1 4.41677782718245e-05 4.354894446079039 CHEMBL1665684 5178769.0 Cmax in human adults with pulmonary tuberculosis at 600 mg administered daily for 7 days Scientific Literature 19564361.0 Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. LINEZOLID CHEMBL126 26280 337.35 Cmax 19.399999999999995 ug.mL-1 5.7507040165999694e-05 4.240278984561088 CHEMBL1665694 5178779.0 Cmax in human adults with pulmonary tuberculosis at 600 mg administered twice daily for 7 days Scientific Literature 19564361.0 Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. LINEZOLID CHEMBL126 26280 337.35 Cmax 10.300000000000002 ug.mL-1 3.0532088335556546e-05 4.515243489786141 CHEMBL1665699 5178784.0 Cmax in human adults with pulmonary tuberculosis at 600 mg administered once daily for 5 days Scientific Literature 19564361.0 Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. LINEZOLID CHEMBL126 26280 337.35 Cmax 16.0 ug.mL-1 4.742848673484512e-05 4.323960731835388 CHEMBL1664954 5146390.0 Cmax in healthy human male at 600 mg, po every 12 hrs by LC/MS/MS analysis Scientific Literature 19349514.0 Impact of human serum albumin on oritavancin in vitro activity against enterococci. LINEZOLID CHEMBL126 26280 337.35 Cmax 14.100000000000003 ug.mL-1 4.179635393508226e-05 4.378861601835934 CHEMBL1677745 5231071.0 Cmax in healthy human at 600 mg, iv, bid administered as 0.5 hr infusion Scientific Literature 20100878.0 Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype. LISINOPRIL LISINOPRIL CHEMBL1237 230659 405.5 Normal/therapeutic blood-plasma concentration 0.07 mg/L 1.7262638717632555e-07 6.762892818532918 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LOFEPRAMINE LOFEPRAMINE CHEMBL87708 139311 418.97 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.386805737880994e-08 7.622182926782751 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LOPINAVIR LOPINAVIR CHEMBL729 37316 628.81 Normal/therapeutic blood-plasma concentration 1.0 mg/L 1.5903054976861058e-06 5.798519439695292 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LOPINAVIR CHEMBL729 37316 628.81 Cmax 99.99999999999999 ug.mL-1 0.00015903054976861055 3.798519439695292 CHEMBL3539971 15467709.0 Maximum plasma concentration in healthy human at 400 mg Scientific Literature 21953914.0 CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir. LOPINAVIR CHEMBL729 37316 628.81 Cmax 11.169999999999998 ug.mL-1 1.7763712409153797e-05 4.750466266579683 CHEMBL1661866 5149029.0 Cmax in HIV-infected Thai pregnant women at 400 mg, po bid initiated intrapartum in combination with 100 mg, po bid ritonavir measured within 72 hrs postpartum Scientific Literature 19237646.0 Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women. LOPINAVIR CHEMBL729 37316 628.81 Cmax 6.847 ug.mL-1 1.0888821742656766e-05 4.963019111827973 CHEMBL1674630 5223421.0 Cmax in HIV-1 infected patient at 400 mg, po bid coadministered with 100 mg, po bid of ritonavir and NRTI Scientific Literature 18411323.0 Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. LOPINAVIR CHEMBL729 37316 628.81 Cmax 16.05 ug.mL-1 2.5524403237861997e-05 4.593044402954401 CHEMBL1696353 5294720.0 Cmax in HIV-infected patient at 400 mg/m2, po administered every 12 hrs for 2 weeks co-administered with ritonavir and NNRTI Scientific Literature 18625762.0 Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. LOPINAVIR CHEMBL729 37316 628.81 Cmax 17.2 ug.mL-1 2.7353254560201017e-05 4.562990992787743 CHEMBL1696348 5294715.0 Cmax in HIV-infected patient at 400 mg/m2, po administered every 12 hrs for 2 weeks co-administered with 120 mg/m2 of ritonavir Scientific Literature 18625762.0 Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. LOPINAVIR CHEMBL729 37316 628.81 Cmax 5.252 ug.mL-1 8.352284473847426e-06 5.07819472227785 CHEMBL1674635 5223426.0 Cmax in HIV-1 infected patient at 400 mg, po bid coadministered with 100 mg, po bid of ritonavir and 300 mg, po qd of atazanavir Scientific Literature 18411323.0 Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. LORATADINE LORATADINE CHEMBL998 110803 382.89 Normal/therapeutic blood-plasma concentration 0.02 mg/L 5.2234323173757484e-08 7.2820440282926615 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LORAZEPAM LORAZEPAM CHEMBL580 16959 321.16 Normal/therapeutic blood-plasma concentration 0.25 mg/L 7.784281977830365e-07 6.108781440571449 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LORMETAZEPAM LORMETAZEPAM CHEMBL22097 27028 335.19 Normal/therapeutic blood-plasma concentration 0.025 mg/L 7.458456397863899e-08 7.127351044813643 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LORNOXICAM LORNOXICAM CHEMBL1569487 993371 371.83 Normal/therapeutic blood-plasma concentration 0.8 mg/L 2.151520856305301e-06 5.667254439618887 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LOSARTAN LOSARTAN CHEMBL191 408842 422.92 Normal/therapeutic blood-plasma concentration 0.65 mg/L 1.5369336990447367e-06 5.813344866891975 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics LOSARTAN CHEMBL191 408842 422.92 Cmax 0.31209999999999993 ug.mL-1 7.37964626879788e-07 6.1319644548694985 CHEMBL3531498 15444439.0 Cmax in human plasma expressing CYP2C9*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. LOSARTAN CHEMBL191 408842 422.92 Cmax 0.21029999999999996 ug.mL-1 4.972571644755508e-07 6.30341895084851 CHEMBL3531124 15444434.0 Cmax in human plasma expressing CYP2C9*2 allele carrier polymorphism at 50 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. LOSARTAN CHEMBL191 408842 422.92 Cmax 0.2576 ug.mL-1 6.090986474983448e-07 6.2153123648470565 CHEMBL3531119 15444429.0 Cmax in human plasma expressing CYP2C9*1/*1 polymorphism at 50 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. LOSARTAN CHEMBL191 408842 422.92 Cmax 0.3452 ug.mL-1 8.162300198619123e-07 6.088187436491659 CHEMBL3531114 15444424.0 Cmax in human plasma expressing CYP2C8*4 allele carrier polymorphism at 50 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. LOSARTAN CHEMBL191 408842 422.92 Cmax 0.2341 ug.mL-1 5.535325829944198e-07 6.256856809838206 CHEMBL3536746 15461383.0 Cmax in men plasma at 50 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. LOSARTAN CHEMBL191 408842 422.92 Cmax 0.231 ug.mL-1 5.462025915066679e-07 6.262646243642687 CHEMBL3531109 15469817.0 Cmax in human plasma expressing CYP2C8*3 allele carrier polymorphism at 50 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. LOSARTAN CHEMBL191 408842 422.92 Cmax 0.2865 ug.mL-1 6.774330842712569e-07 6.169133597231422 CHEMBL3536747 15461384.0 Cmax in women plasma at 50 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. LOSARTAN CHEMBL191 408842 422.92 Cmax 0.26270000000000004 ug.mL-1 6.211576657523883e-07 6.20679815074876 CHEMBL3531104 15469812.0 Cmax in human plasma expressing CYP2C8*1/*1 polymorphism at 50 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. LOXAPINE LOXAPINE CHEMBL831 59519 327.81 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.050547573289406e-07 6.515622197796337 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MAPROTILINE MAPROTILINE CHEMBL21731 27713 277.41 Normal/therapeutic blood-plasma concentration 0.13 mg/L 4.6862045348040805e-07 6.32917876004161 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MARAVIROC MARAVIROC CHEMBL1201187 675138 513.68 Normal/therapeutic blood-plasma concentration 0.05 mg/L 9.733686341691327e-08 7.011722652572419 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MEBENDAZOLE MEBENDAZOLE CHEMBL685 29637 295.3 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.3863867253640365e-07 6.470263446965078 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MEDAZEPAM MEDAZEPAM CHEMBL28333 34350 270.76 Normal/therapeutic blood-plasma concentration 1.0 mg/L 3.6933077263997637e-06 5.432584505425221 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MEFENAMIC ACID MEFENAMIC ACID CHEMBL686 29989 241.29 Normal/therapeutic blood-plasma concentration 20.0 mg/L 8.288781134734138e-05 4.081509327758223 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MEFLOQUINE MEFLOQUINE CHEMBL416956 51162 378.32 Normal/therapeutic blood-plasma concentration 1.0 mg/L 2.6432649608796786e-06 5.57785930100737 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MELATONIN MELATONIN CHEMBL45 3012 232.28 Normal/therapeutic blood-plasma concentration 0.1 mg/L 4.3051489581539524e-07 6.3660118173612865 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MELOXICAM CHEMBL599 20496 351.41 Cmax 1.2499999999999998 ug.mL-1 3.5570985458581137e-06 5.448904102953227 CHEMBL1636022 5086131.0 Cmax in human at 15 mg, po Scientific Literature 19015346.0 Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. MELOXICAM MELOXICAM CHEMBL599 20496 351.41 Normal/therapeutic blood-plasma concentration 2.0 mg/L 5.691357673372983e-06 5.244784120297302 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MELPHALAN MELPHALAN CHEMBL852 65415 305.21 Normal/therapeutic blood-plasma concentration 1.5 mg/L 4.91464893024475e-06 5.308507499826347 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MEMANTINE MEMANTINE CHEMBL807 52523 179.31 Normal/therapeutic blood-plasma concentration 0.15 mg/L 8.365400702693658e-07 6.077513251497662 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PETHIDINE MEPERIDINE CHEMBL607 22528 247.34 Normal/therapeutic blood-plasma concentration 0.8 mg/L 3.2344141667340504e-06 5.490204369460385 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MEPHENESIN MEPHENESIN CHEMBL229128 380430 182.22 Normal/therapeutic blood-plasma concentration 10.0 mg/L 5.487871803314675e-05 4.260596042301909 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MEPIVACAINE MEPIVACAINE CHEMBL1087 147981 246.35 Normal/therapeutic blood-plasma concentration 4.0 mg/L 1.6237061091942358e-05 4.789492575282965 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MEPROBAMATE MEPROBAMATE CHEMBL979 99389 218.25 Normal/therapeutic blood-plasma concentration 10.0 mg/L 4.581901489117984e-05 4.338954252377607 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MEPTAZINOL MEPTAZINOL CHEMBL314437 139237 233.35 Normal/therapeutic blood-plasma concentration 0.25 mg/L 1.0713520462824085e-06 5.970067796549137 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MERCAPTOPURINE CHEMBL1425 364693 152.18 Cmax 0.019999999999999997 ug.mL-1 1.3142331449599158e-07 6.881327584100552 CHEMBL3889449 17806306.0 Pharmacokinetic parameters for different drugs, or their active metabolite following multiple oral or intravenous administration to subjects of varying health conditions. Range 20 To 90 Ng/Ml. Mercaptopurine Is An Active Metabolite Of Azathioprine Curated Drug Pharmacokinetic Data Goodman and Gilman Ed. 12 | The Pharmaceutical Basis of Therapeutics| Table AII-I: Pharmacokinetic Data MERCAPTOPURINE MERCAPTOPURINE CHEMBL1425 364693 152.18 Normal/therapeutic blood-plasma concentration 0.08 mg/L 5.256932579839664e-07 6.279267592772589 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MEROPENEM CHEMBL127 26386 383.47 Cmax 56.599999999999994 ug.mL-1 0.00014759955146426056 3.8309149622751217 CHEMBL1283390 3548919.0 Cmax in critically ill patient with sepsis at 1000 mg/kg, iv administered every 8 hrs by HPLC method Scientific Literature 20479205.0 Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. MESALAZINE MESALAMINE CHEMBL704 33202 153.14 Normal/therapeutic blood-plasma concentration 1.0 mg/L 6.52997257411519e-06 5.185088642757919 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MESORIDAZINE MESORIDAZINE CHEMBL1088 148004 386.59 Normal/therapeutic blood-plasma concentration 1.0 mg/L 2.586719780646163e-06 5.587250615856558 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METFORMIN METFORMIN CHEMBL1431 369464 129.17 Normal/therapeutic blood-plasma concentration 1.3 mg/L 1.0064256406286291e-05 4.997218307270751 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHADONE METHADONE CHEMBL651 27576 309.45 Normal/therapeutic blood-plasma concentration 0.75 mg/L 2.423654871546292e-06 5.615529223637132 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHAMPHETAMINE METHAMPHETAMINE CHEMBL1201201 675152 149.24 Normal/therapeutic blood-plasma concentration 0.1 mg/L 6.700616456714018e-07 6.173885240368792 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHAPYRILENE METHAPYRILENE CHEMBL1411979 835863 261.39 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.825701059719194e-07 6.417288968753737 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHAQUALONE METHAQUALONE CHEMBL282052 22572 250.3 Normal/therapeutic blood-plasma concentration 3.0 mg/L 1.1985617259288853e-05 4.921339594888561 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHIMAZOLE METHIMAZOLE CHEMBL1515 421089 114.17 Normal/therapeutic blood-plasma concentration 2.5 mg/L 2.189717088552159e-05 4.659611992382495 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHOCARBAMOL METHOCARBAMOL CHEMBL1201117 675068 241.24 Normal/therapeutic blood-plasma concentration 50.0 mg/L 0.0002072624772011275 3.6834793154628964 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHOHEXITAL METHOHEXITAL CHEMBL7413 2216 262.31 Normal/therapeutic blood-plasma concentration 11.0 mg/L 4.193511494033776e-05 4.377422162283197 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHOTREXATE METHOTREXATE CHEMBL34259 49931 454.45 Normal/therapeutic blood-plasma concentration 0.04 mg/L 8.801848388161515e-08 7.055426116431097 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHOTREXATE CHEMBL34259 49931 454.45 Cmax 999999.9999999998 nM 0.0009999999999999998 3.0 CHEMBL3869049 16801937.0 Cmax in human Scientific Literature 27571379.0 Quambalarine B, a Secondary Metabolite from Quambalaria cyanescens with Potential Anticancer Properties. METHOXSALEN METHOXSALEN CHEMBL416 1063 216.19 Normal/therapeutic blood-plasma concentration 0.2 mg/L 9.251121698505944e-07 6.033805605862375 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHSUXIMIDE METHSUXIMIDE CHEMBL697 31857 203.24 Normal/therapeutic blood-plasma concentration 40.0 mg/L 0.000196811651249754 3.705949194910296 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHYLDOPA METHYLDOPA CHEMBL459 3730 211.22 Normal/therapeutic blood-plasma concentration 5.0 mg/L 2.3672000757504024e-05 4.62576503395 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHYLPHENIDATE METHYLPHENIDATE CHEMBL796 49842 233.31 Normal/therapeutic blood-plasma concentration 0.06 mg/L 2.5716857400025716e-07 6.589782103291143 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ALIMEMAZINE METHYLPROMAZINE CHEMBL829 57833 298.45 Normal/therapeutic blood-plasma concentration 0.4 mg/L 1.3402579996649356e-06 5.872811591899731 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METHYPRYLON METHYPRYLON CHEMBL1200790 674741 183.25 Normal/therapeutic blood-plasma concentration 20.0 mg/L 0.00010914051841746248 3.9620139876491844 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METILDIGOXIN METILDIGOXIN CHEMBL1697843 1078592 794.98 Normal/therapeutic blood-plasma concentration 0.0008 mg/L 1.0063146242672772e-09 8.997266215879751 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METIPRANOLOL METIPRANOLOL CHEMBL1291 255221 309.41 Normal/therapeutic blood-plasma concentration 0.08 mg/L 2.585566077373065e-07 6.587444358811732 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METOCLOPRAMIDE METOCLOPRAMIDE CHEMBL86 7736 299.8 Normal/therapeutic blood-plasma concentration 0.15 mg/L 5.003335557038025e-07 6.300740369456579 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METOCURINE METOCURINE CHEMBL1259 239465 652.83 Normal/therapeutic blood-plasma concentration 0.4 mg/L 6.127169400916011e-07 6.2127401123453705 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METOPROLOL METOPROLOL CHEMBL13 789 267.37 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.8700676964506116e-06 5.7281426717186905 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METRONIDAZOLE CHEMBL137 27912 171.16 Cmax 0.031999999999999994 ug.mL-1 1.8695956999298898e-07 6.728252299491989 CHEMBL3889398 17805977.0 Evaluation of pharmacokinetic parameters for metronidazole following topical administration of metronidazole gel USP, 1% to the face of 13 patients with moderate to severe rosacea. Curated Drug Pharmacokinetic Data DailyMed|setid=caaf1b7f-eaab-4fb6-a955-b7d881038fef | METRONIDAZOLE - metronidazole gel|Sandoz Inc METRONIDAZOLE CHEMBL137 27912 171.16 Cmax 11.999999999999998 ug.mL-1 7.010983874737088e-05 4.15422103176427 CHEMBL3889393 17805973.0 Evaluation of pharmacokinetic parameters for Metronidazole following oral administration of Metronidazole tablets Curated Drug Pharmacokinetic Data DailyMed|setid=dc3d3905-2f08-4b71-b949-53f49fb3ea10 | METRONIDAZOLE- metronidazole tablet|Lake Erie Medical DBA Quality Care Products LLC METRONIDAZOLE METRONIDAZOLE CHEMBL137 27912 171.16 Normal/therapeutic blood-plasma concentration 20.0 mg/L 0.00011684973124561814 3.932372282147914 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METRONIDAZOLE CHEMBL137 27912 171.16 Cmax 0.09599999999999999 ug.mL-1 5.60878709978967e-07 6.251131044772327 CHEMBL3889399 17805979.0 Evaluation of pharmacokinetic parameters for metronidazole following topical administration of 7.5 mg of metronidazole (1 g metronidazole topical lotion) for 4 days to the faces of 8 patients. Curated Drug Pharmacokinetic Data DailyMed|setid=970a767a-7a65-4cdf-84fe-4dbe0a77b80a | METRONIDAZOLE - metronidazole lotion|Physicians Total Care, Inc. METRONIDAZOLE CHEMBL137 27912 171.16 Cmax 5.999999999999999 ug.mL-1 3.505491937368544e-05 4.455251027428251 CHEMBL3889393 17805974.0 Evaluation of pharmacokinetic parameters for Metronidazole following oral administration of Metronidazole tablets Curated Drug Pharmacokinetic Data DailyMed|setid=dc3d3905-2f08-4b71-b949-53f49fb3ea10 | METRONIDAZOLE- metronidazole tablet|Lake Erie Medical DBA Quality Care Products LLC METRONIDAZOLE CHEMBL137 27912 171.16 Cmax 39.99999999999999 ug.mL-1 0.00023369946249123623 3.6313422864839326 CHEMBL3889393 17805972.0 Evaluation of pharmacokinetic parameters for Metronidazole following oral administration of Metronidazole tablets Curated Drug Pharmacokinetic Data DailyMed|setid=dc3d3905-2f08-4b71-b949-53f49fb3ea10 | METRONIDAZOLE- metronidazole tablet|Lake Erie Medical DBA Quality Care Products LLC MEXILETINE MEXILETINE CHEMBL558 15958 179.26 Normal/therapeutic blood-plasma concentration 2.0 mg/L 1.1156978690170702e-05 4.952453396423033 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MIANSERIN MIANSERIN CHEMBL6437 573 264.37 Normal/therapeutic blood-plasma concentration 0.07 mg/L 2.647804213791278e-07 6.577114131019967 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MIBEFRADIL MIBEFRADIL CHEMBL45816 72035 495.64 Normal/therapeutic blood-plasma concentration 0.3 mg/L 6.052780243725284e-07 6.218045093586206 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MICAFUNGIN CHEMBL457547 500520 1270.29 Cmax 6.3999999999999995 ug.mL-1 5.038219619142085e-06 5.297722905257383 CHEMBL1654695 5174954.0 Cmax in patient with acute lymphoblastic leukemia infected with Candida albicans FP633 at 1.2 mg/kg administered once daily after 15 days by HPLC Scientific Literature 19687246.0 Antifungal activity of micafungin in serum. MICAFUNGIN CHEMBL457547 500520 1270.29 Cmax 33.6 ug.mL-1 2.6450653000495954e-05 4.577563601851426 CHEMBL1654686 5174964.0 Cmax in patient with malignant lymphoma infected with Candida albicans FP633 at 5.8 mg/kg administered once daily after 8 days by HPLC Scientific Literature 19687246.0 Antifungal activity of micafungin in serum. MICAFUNGIN CHEMBL457547 500520 1270.29 Cmax 6.499999999999997 ug.mL-1 5.116941800691179e-06 5.290989522598415 CHEMBL1654697 5174955.0 Cmax in patient with acute lymphoblastic leukemia infected with Candida albicans FP633 at 1.2 mg/kg administered once daily after 17 days by HPLC Scientific Literature 19687246.0 Antifungal activity of micafungin in serum. MICAFUNGIN CHEMBL457547 500520 1270.29 Cmax 34.20000000000001 ug.mL-1 2.692298608979053e-05 4.569876773185134 CHEMBL1654685 5174965.0 Cmax in patient with malignant lymphoma infected with Candida albicans FP633 at 3.9 mg/kg administered once daily after 10 days by HPLC Scientific Literature 19687246.0 Antifungal activity of micafungin in serum. MICAFUNGIN CHEMBL457547 500520 1270.29 Cmax 16.400000000000002 ug.mL-1 1.2910437774051596e-05 4.889059031193572 CHEMBL1654689 5174961.0 Cmax in patient with malignant lymphoma infected with Candida albicans FP633 at 2.6 mg/kg administered once daily after 12 days by HPLC Scientific Literature 19687246.0 Antifungal activity of micafungin in serum. MICAFUNGIN CHEMBL457547 500520 1270.29 Cmax 19.100000000000005 ug.mL-1 1.5035936675877167e-05 4.8228695119935425 CHEMBL1636165 5099414.0 Cmax in healthy human plasma at 150 mg, iv TID Scientific Literature 19114675.0 Bronchopulmonary disposition of micafungin in healthy adult volunteers. MICAFUNGIN CHEMBL457547 500520 1270.29 Cmax 8.4 ug.mL-1 6.612663250123988e-06 5.179623593179389 CHEMBL1654691 5174959.0 Cmax in patient with acute myeloid leukemia infected with Candida albicans FP633 at 1.1 mg/kg administered once daily after 8 days by HPLC Scientific Literature 19687246.0 Antifungal activity of micafungin in serum. MICAFUNGIN CHEMBL457547 500520 1270.29 Cmax 6.7 ug.mL-1 5.274386163789371e-06 5.277828076540444 CHEMBL1654687 5174956.0 Cmax in patient with myelodysplastic syndrome infected with Candida albicans FP633 at 1.4 mg/kg administered once daily after 45 days by HPLC Scientific Literature 19687246.0 Antifungal activity of micafungin in serum. MICAFUNGIN CHEMBL457547 500520 1270.29 Cmax 5.600000000000001 ug.mL-1 4.408442166749327e-06 5.355714852235069 CHEMBL1654693 5174951.0 Cmax in patient with acute myeloid leukemia infected with Candida albicans FP633 at 1.1 mg/kg administered once daily after 15 days by HPLC Scientific Literature 19687246.0 Antifungal activity of micafungin in serum. MICAFUNGIN CHEMBL457547 500520 1270.29 Cmax 37.10000000000001 ug.mL-1 2.9205929354714285e-05 4.534528969626224 CHEMBL1654688 5174968.0 Cmax in patient with malignant lymphoma infected with Candida albicans FP633 at 4.8 mg/kg administered once daily after 43 days by HPLC Scientific Literature 19687246.0 Antifungal activity of micafungin in serum. MICONAZOLE MICONAZOLE CHEMBL91 8917 416.14 Normal/therapeutic blood-plasma concentration 1.0 mg/L 2.403037439323305e-06 5.6192394628353615 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MIDAZOLAM CHEMBL655 27611 325.77 Cmax 0.0163 ug.mL-1 5.003530097921847e-08 7.300723483443462 CHEMBL3534791 15448877.0 Cmax in solid tumor patient at 2 mg, po administered as single dose measured on day 7 Scientific Literature 23118326.0 Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. MIDAZOLAM CHEMBL655 27611 325.77 Cmax 0.0157 ug.mL-1 4.819351075912454e-08 7.317011435438186 CHEMBL3534797 15448883.0 Cmax in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 1 Scientific Literature 23118326.0 Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. MIDAZOLAM CHEMBL655 27611 325.77 Cmax 0.015999999999999997 ug.mL-1 4.911440586917149e-08 7.308791105191495 CHEMBL3534803 15448889.0 Cmax in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 16 Scientific Literature 23118326.0 Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. MIDAZOLAM MIDAZOLAM CHEMBL655 27611 325.77 Normal/therapeutic blood-plasma concentration 0.25 mg/L 7.674125917058048e-07 6.1149710791753815 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MIFEPRISTONE CHEMBL1276308 712273 429.6 Cmax 2.4999999999999996 ug.mL-1 5.819366852886405e-06 5.235124264019461 CHEMBL1279099 3568463.0 Cmax in pregnant women at 800 mg, po Scientific Literature 18347111.0 Chlamydia pneumoniae growth inhibition in cells by the steroid receptor antagonist RU486 (mifepristone). MILNACIPRAN MILNACIPRAN CHEMBL259209 427379 246.35 Normal/therapeutic blood-plasma concentration 0.11 mg/L 4.465191800284149e-07 6.3501598814527025 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MILNACIPRAN CHEMBL259209 427379 246.35 Cmax 0.23960000000000006 ug.mL-1 9.725999594073476e-07 6.012065752893654 CHEMBL3535550 15445680.0 Cmax in human at 100 mg, po by LC-MS/MS analysis Scientific Literature 22653299.0 Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride. MILRINONE MILRINONE CHEMBL189 380567 211.22 Normal/therapeutic blood-plasma concentration 0.25 mg/L 1.1836000378752013e-06 5.926795029613981 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MILTEFOSINE CHEMBL125 25047 407.58 Cmax 70.00000000000003 ug.mL-1 0.00017174542421119788 3.7651148249601136 CHEMBL1282011 3571647.0 Cmax in serum of patient with cutaneous leishmaniasis at 2.5 mg/kg, po once a day for 23 days by LC-MS/MS assay Scientific Literature 18519729.0 Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. MINAPRINE MINAPRINE CHEMBL278819 33583 298.39 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.351318743925735e-07 6.474784264452135 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MINOCYCLINE CHEMBL1434 371561 457.48 Cmax 0.5999999999999999 ug.mL-1 1.3115327446008564e-06 5.882220862052705 CHEMBL1657569 5156839.0 Cmax in simulated human serum in in vitro hollow-fiber PK model at 100 mg administered every 12 hrs Scientific Literature 18519719.0 Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. MINOXIDIL MINOXIDIL CHEMBL802 51042 209.25 Normal/therapeutic blood-plasma concentration 0.2 mg/L 9.55794504181601e-07 6.019635471001316 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MIRABEGRON CHEMBL2095212 1369608 396.52 Cmax 0.8789999999999999 ug.mL-1 2.2167860385352567e-06 5.654276222432515 CHEMBL3531776 15461859.0 Cmax as total radioactivity in healthy human plasma at 160 mg, po as single dose Scientific Literature 22269146.0 Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective ß(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. MIRABEGRON CHEMBL2095212 1369608 396.52 Cmax 0.37100000000000005 ug.mL-1 9.356400685967923e-07 6.028891187891241 CHEMBL3528336 15451870.0 Cmax in healthy human plasma at 160 mg, po as single dose Scientific Literature 22269146.0 Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective ß(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. MIRABEGRON CHEMBL2095212 1369608 396.52 Cmax 0.7769999999999999 ug.mL-1 1.9595480681932814e-06 5.707844078705373 CHEMBL3528348 15451863.0 Cmax as total radioactivity in healthy human whole blood at 160 mg, po as single dose Scientific Literature 22269146.0 Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective ß(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. MIRTAZAPINE MIRTAZAPINE CHEMBL654 27610 265.36 Normal/therapeutic blood-plasma concentration 0.3 mg/L 1.1305396442568585e-06 5.946714203791763 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MITOTANE MITOTANE CHEMBL1670 504310 320.05 Normal/therapeutic blood-plasma concentration 20.0 mg/L 6.249023590064053e-05 4.2041878358678275 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MIZOLASTINE MIZOLASTINE CHEMBL94454 152819 432.5 Normal/therapeutic blood-plasma concentration 0.8 mg/L 1.8497109826589595e-06 5.73289612480889 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MOCLOBEMIDE MOCLOBEMIDE CHEMBL86304 139099 268.74 Normal/therapeutic blood-plasma concentration 3.0 mg/L 1.1163206072784103e-05 4.952211058108669 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MODAFINIL MODAFINIL CHEMBL1373 317124 273.36 Normal/therapeutic blood-plasma concentration 3.0 mg/L 1.0974539069359086e-05 4.959613711071044 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MOLINDONE MOLINDONE CHEMBL460 3799 276.38 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.8091034083508214e-06 5.742536608158096 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MOLSIDOMINE MOLSIDOMINE CHEMBL1329455 753339 242.24 Normal/therapeutic blood-plasma concentration 0.01 mg/L 4.128137384412154e-08 7.3842458578199786 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MONTELUKAST MONTELUKAST CHEMBL787 47447 586.2 Normal/therapeutic blood-plasma concentration 0.3 mg/L 5.117707267144319e-07 6.290924559382754 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MONTELUKAST CHEMBL787 47447 586.2 Cmax 0.5 ug.mL-1 8.529512111907198e-07 6.069075809766398 CHEMBL3542036 15467878.0 Cmax in human at 10 mg, po Scientific Literature 21289076.0 Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. MORPHINE MORPHINE CHEMBL70 6005 285.34 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.50459101422864e-07 6.455362656906286 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.700000000000001 ug.mL-1 1.1707851733758472e-05 4.931522786034818 CHEMBL3889325 17805365.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.1000000000000005 ug.mL-1 1.0213232363491431e-05 4.9908367872507995 CHEMBL3889325 17805369.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Mean Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.1000000000000005 ug.mL-1 1.0213232363491431e-05 4.9908367872507995 CHEMBL3889325 17805366.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Mean Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 1.0599999999999998 ug.mL-1 2.6404942208051016e-06 5.578314778705765 CHEMBL1266685 3477211.0 Cmax in plasma of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3 Scientific Literature 18362186.0 Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.6 ug.mL-1 1.145874850538063e-05 4.9408628122889615 CHEMBL3889325 17805363.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.0 ug.mL-1 9.964129135113591e-06 5.001560652642573 CHEMBL1696172 5306510.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 1.63 ug.mL-1 4.0603826225587885e-06 5.391433039566578 CHEMBL1063299 2680127.0 Cmax in human at 400 mg, po administered once a day Scientific Literature 17664314.0 Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 2.4999999999999996 ug.mL-1 6.227580709445994e-06 5.2056806352984974 CHEMBL1033599 2675217.0 Cmax in human at 400 mg, po Scientific Literature 17938193.0 In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.1000000000000005 ug.mL-1 1.0213232363491431e-05 4.9908367872507995 CHEMBL3889325 17805364.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.469999999999999 ug.mL-1 1.1134914308489436e-05 4.953313120838599 CHEMBL1279833 3566371.0 Cmax in tuberculosis patient at 400 mg/day, po administered for 7 days by HPLC Scientific Literature 18070980.0 Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.3 ug.mL-1 1.071143882024711e-05 4.970152188390949 CHEMBL2169386 12087007.0 Cmax in human at 400 mg, po Scientific Literature 22421275.0 Tuberculosis: the drug development pipeline at a glance. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 2.4999999999999996 ug.mL-1 6.227580709445994e-06 5.2056806352984974 CHEMBL1029672 2502730.0 Cmax in human serum at 400 mg, po administered as single dose after 1 hr Scientific Literature 17576849.0 In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 3.1000000000000014 ug.mL-1 7.722200079713038e-06 5.112258950136263 CHEMBL3889323 17805337.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following single oral or intravenous administration of 400 mg Moxifloxacin to healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 2.4999999999999996 ug.mL-1 6.227580709445994e-06 5.2056806352984974 CHEMBL1695971 5303990.0 Cmax in patients with pulmonary tuberculosis at 400 mg/kg, po Scientific Literature 19075046.0 New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 3.899999999999999 ug.mL-1 9.715025906735749e-06 5.012556036944036 CHEMBL3889323 17805340.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following single oral or intravenous administration of 400 mg Moxifloxacin to healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.3999999999999995 ug.mL-1 1.0960542048624949e-05 4.960167967484348 CHEMBL3889323 17805343.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following single oral or intravenous administration of 400 mg Moxifloxacin to healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 2.3999999999999995 ug.mL-1 5.978477481068153e-06 5.2234094022589295 CHEMBL1063303 2680131.0 Cmax in human at 200 mg, po administered twice a day Scientific Literature 17664314.0 Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.499999999999998 ug.mL-1 1.1209645277002784e-05 4.950408130195192 CHEMBL3889323 17805344.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following single oral or intravenous administration of 400 mg Moxifloxacin to healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 3.3299999999999987 ug.mL-1 8.295137504982062e-06 5.081176410464216 CHEMBL1680356 5226675.0 Cmax in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose by HPLC Scientific Literature 18765687.0 Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 40.29999999999999 ug.mL-1 0.00010038860103626941 3.998315597829426 CHEMBL1680350 5226674.0 Cmax in healthy human at 400 mg, po qd measured on day 4 by HPLC Scientific Literature 18765687.0 Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 2.4499999999999997 ug.mL-1 6.1030290952570745e-06 5.214454559606003 CHEMBL1266686 3477212.0 Cmax in plasma of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3 Scientific Literature 18362186.0 Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.3 ug.mL-1 1.071143882024711e-05 4.970152188390949 CHEMBL3889323 17805346.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following single oral or intravenous administration of 400 mg Moxifloxacin to healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.999999999999999 ug.mL-1 1.2455161418891988e-05 4.904650639634516 CHEMBL1662922 5155436.0 Cmax in healthy human at 400 mg/kg Scientific Literature 19188390.0 P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.499999999999998 ug.mL-1 1.1209645277002784e-05 4.950408130195192 CHEMBL3889325 17805347.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 3.8 ug.mL-1 9.465922678357912e-06 5.023837047353725 CHEMBL3889325 17805350.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 3.599999999999999 ug.mL-1 8.967716221602231e-06 5.047318143203248 CHEMBL3889325 17805352.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.2 ug.mL-1 1.0462335591869272e-05 4.980371353572635 CHEMBL3889325 17805355.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.2 ug.mL-1 1.0462335591869272e-05 4.980371353572635 CHEMBL3889325 17805356.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 6.1 ug.mL-1 1.5195296931048225e-05 4.818290808959769 CHEMBL3889325 17805359.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.2 ug.mL-1 1.0462335591869272e-05 4.980371353572635 CHEMBL3889325 17805362.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following multiple oral administration of 400 mg Moxifloxacin to male Japanese or Caucasian healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 4.499999999999998 ug.mL-1 1.1209645277002784e-05 4.950408130195192 CHEMBL3889323 17805345.0 Pharmacokinetic parameters for Moxifloxacin hydrochloride following single oral or intravenous administration of 400 mg Moxifloxacin to healthy or patient male and/or female Curated Drug Pharmacokinetic Data DailyMed|setid=be8e0025-5726-4965-9510-e7e657687d23 | AVELOX - moxifloxacin hydrochloride tablet, coated|Lake Erie Medical Supply DBA Quality Care Products LLC MOXIFLOXACIN CHEMBL32 1788 401.44 Cmax 0.32999999999999996 ug.mL-1 8.220406536468711e-07 6.085106704092648 CHEMBL1063301 2680129.0 Cmax in human at 80 mg, po administered once a day Scientific Literature 17664314.0 Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. MOXONIDINE MOXONIDINE CHEMBL19236 21698 241.68 Normal/therapeutic blood-plasma concentration 0.004 mg/L 1.6550810989738497e-08 7.781180720937262 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MUROMONAB-CD3 MUROMONAB-CD3 CHEMBL1201608 675588 Normal/therapeutic blood-plasma concentration 1.3 mg/L 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 13.199999999999998 ug.mL-1 4.120621839295748e-05 4.385037240035703 CHEMBL3889390 17806461.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 13.1 ug.mL-1 4.0894050071798716e-05 4.388339875585788 CHEMBL3889390 17806463.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 11.7 ug.mL-1 3.6523693575575955e-05 4.43742530949539 CHEMBL3889390 17806465.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 10.300000000000002 ug.mL-1 3.2153337079353195e-05 4.4927739465363805 CHEMBL3889390 17806453.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 27.8 ug.mL-1 8.678279328213774e-05 4.061566375323476 CHEMBL3889390 17806448.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 29.2 ug.mL-1 9.11531497783605e-05 4.040228319793134 CHEMBL3889390 17806445.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 30.4 ug.mL-1 9.489916963226573e-05 4.022737587632799 CHEMBL3889390 17806441.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 11.499999999999996 ug.mL-1 3.5899356933258404e-05 4.444913330887941 CHEMBL3889390 17806431.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 25.599999999999998 ug.mL-1 7.991509021664482e-05 4.0973712059297025 CHEMBL3889390 17806438.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 23.800000000000004 ug.mL-1 7.4296060435787e-05 4.12903421418504 CHEMBL3889390 17806435.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 17.899999999999995 ug.mL-1 5.587812948741961e-05 4.252758140261659 CHEMBL3889390 17806456.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 19.999999999999996 ug.mL-1 6.243366423175375e-05 4.204581175577571 CHEMBL3889390 17806429.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 24.3 ug.mL-1 7.585690204158083e-05 4.12000489764324 CHEMBL3889389 17806392.0 Pharmacokinetic parameters for Mycophenolic acid following single oral administration of Mycophenolate Mofetil to subjects with different health status. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 13.5 ug.mL-1 4.214272335643379e-05 4.375277402746546 CHEMBL3889390 17806425.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 18.900000000000002 ug.mL-1 5.899981269900732e-05 4.229149367068308 CHEMBL3889455 17806492.0 Mean pharmacokinetic parameters of Mycophenolic acid following multiple dose administration of 720 mg Mycophenolic acid delayed-release tablets to adult renal transplant patients on Cyclosporine, USP MODIFIED based immunosuppression Curated Drug Pharmacokinetic Data DailyMed|setid=d7fbf301-0b08-4b19-bfa0-e0c0067cb5ab | MYCOPHENOLIC ACID - mycophenolic acid tablet, delayed release|Mylan Instituinal Inc. MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 24.099999999999998 ug.mL-1 7.523256539926328e-05 4.123594128666684 CHEMBL3889455 17806489.0 Mean pharmacokinetic parameters of Mycophenolic acid following multiple dose administration of 720 mg Mycophenolic acid delayed-release tablets to adult renal transplant patients on Cyclosporine, USP MODIFIED based immunosuppression Curated Drug Pharmacokinetic Data DailyMed|setid=d7fbf301-0b08-4b19-bfa0-e0c0067cb5ab | MYCOPHENOLIC ACID - mycophenolic acid tablet, delayed release|Mylan Instituinal Inc. MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 26.2 ug.mL-1 8.178810014359743e-05 4.087309879921807 CHEMBL3889455 17806486.0 Mean pharmacokinetic parameters of Mycophenolic acid following multiple dose administration of 720 mg Mycophenolic acid delayed-release tablets to adult renal transplant patients on Cyclosporine, USP MODIFIED based immunosuppression Curated Drug Pharmacokinetic Data DailyMed|setid=d7fbf301-0b08-4b19-bfa0-e0c0067cb5ab | MYCOPHENOLIC ACID - mycophenolic acid tablet, delayed release|Mylan Instituinal Inc. MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 37.0 ug.mL-1 0.00011550227882874446 3.9374094471745575 CHEMBL3889455 17806482.0 Mean pharmacokinetic parameters of Mycophenolic acid following multiple dose administration of 720 mg Mycophenolic acid delayed-release tablets to adult renal transplant patients on Cyclosporine, USP MODIFIED based immunosuppression Curated Drug Pharmacokinetic Data DailyMed|setid=d7fbf301-0b08-4b19-bfa0-e0c0067cb5ab | MYCOPHENOLIC ACID - mycophenolic acid tablet, delayed release|Mylan Instituinal Inc. MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 26.100000000000005 ug.mL-1 8.147593182243868e-05 4.088970663903272 CHEMBL3889454 17806476.0 Mean pharmacokinetic parameters of Mycophenolic acid following single oral administration of Mycophenolic acid delayed-release tablets to adult or pediatric (age range 5 to 16 years) renal transplant patients on Cyclosporine, USP MODIFIED based immunosuppression Curated Drug Pharmacokinetic Data DailyMed|setid=d7fbf301-0b08-4b19-bfa0-e0c0067cb5ab | MYCOPHENOLIC ACID - mycophenolic acid tablet, delayed release|Mylan Instituinal Inc. MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 36.300000000000004 ug.mL-1 0.00011331710058063311 3.9457045462054396 CHEMBL3889454 17806474.0 Mean pharmacokinetic parameters of Mycophenolic acid following single oral administration of Mycophenolic acid delayed-release tablets to adult or pediatric (age range 5 to 16 years) renal transplant patients on Cyclosporine, USP MODIFIED based immunosuppression Curated Drug Pharmacokinetic Data DailyMed|setid=d7fbf301-0b08-4b19-bfa0-e0c0067cb5ab | MYCOPHENOLIC ACID - mycophenolic acid tablet, delayed release|Mylan Instituinal Inc. MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 22.700000000000003 ug.mL-1 7.086220890304054e-05 4.14958531404843 CHEMBL3889390 17806470.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 24.49999999999999 ug.mL-1 7.648123868389833e-05 4.11644508687702 CHEMBL3889389 17806385.0 Pharmacokinetic parameters for Mycophenolic acid following single oral administration of Mycophenolate Mofetil to subjects with different health status. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 24.099999999999998 ug.mL-1 7.523256539926328e-05 4.123594128666684 CHEMBL3889390 17806426.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 25.299999999999994 ug.mL-1 7.89785852531685e-05 4.102490650065735 CHEMBL3889389 17806389.0 Pharmacokinetic parameters for Mycophenolic acid following single oral administration of Mycophenolate Mofetil to subjects with different health status. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 16.3 ug.mL-1 5.0883436348879325e-05 4.293423566837594 CHEMBL3889389 17806400.0 Pharmacokinetic parameters for Mycophenolic acid following single oral administration of Mycophenolate Mofetil to subjects with different health status. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 22.400000000000006 ug.mL-1 6.992570393956424e-05 4.155363152907389 CHEMBL3889389 17806403.0 Pharmacokinetic parameters for Mycophenolic acid following single oral administration of Mycophenolate Mofetil to subjects with different health status. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 11.999999999999998 ug.mL-1 3.7460198539052254e-05 4.426429925193927 CHEMBL3889390 17806405.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 10.700000000000005 ug.mL-1 3.340201036398828e-05 4.476227393556343 CHEMBL3889390 17806408.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 8.16 ug.mL-1 2.5472935006555537e-05 4.593921012487692 CHEMBL3889390 17806411.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 17.0 ug.mL-1 5.3068614596990705e-05 4.275162249863278 CHEMBL3889390 17806415.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 13.1 ug.mL-1 4.0894050071798716e-05 4.388339875585788 CHEMBL3889390 17806419.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 19.300000000000004 ug.mL-1 6.02484859836424e-05 4.220053862233779 CHEMBL3889390 17806420.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 25.99999999999999 ug.mL-1 8.116376350127985e-05 4.090637823270734 CHEMBL3889389 17806398.0 Pharmacokinetic parameters for Mycophenolic acid following single oral administration of Mycophenolate Mofetil to subjects with different health status. Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 18.099999999999994 ug.mL-1 5.650246612973714e-05 4.247932596372368 CHEMBL3889390 17806452.0 Pharmacokinetic parameters for Mycophenolic acid following multiple administration of Mycophenolate Mofetil to hepatic, cardiac and renal transplant patients, at least 5 days after transplant. Dose Adjusted To 600 Mg/M2 Curated Drug Pharmacokinetic Data DailyMed|setid=56428c8f-8a4b-4cbf-93f1-28d8b5cfb51a | MYCOPHENOLATE MOFETIL- mycophenolate mofetil capsule|MYCOPHENOLATE MOFETIL- mycophenolate mofetil tablet, film coated | Cadila Healthcare Limited MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 15.0 ug.mL-1 4.6825248173815326e-05 4.329519912185871 CHEMBL3889455 17806499.0 Mean pharmacokinetic parameters of Mycophenolic acid following multiple dose administration of 720 mg Mycophenolic acid delayed-release tablets to adult renal transplant patients on Cyclosporine, USP MODIFIED based immunosuppression Two Weeks Post-Transplant Administration. Curated Drug Pharmacokinetic Data DailyMed|setid=d7fbf301-0b08-4b19-bfa0-e0c0067cb5ab | MYCOPHENOLIC ACID - mycophenolic acid tablet, delayed release|Mylan Instituinal Inc. MYCOPHENOLIC ACID CHEMBL866 68396 320.34 Cmax 31.199999999999992 ug.mL-1 9.739651620153585e-05 4.01145657722311 CHEMBL3889455 17806495.0 Mean pharmacokinetic parameters of Mycophenolic acid following multiple dose administration of 720 mg Mycophenolic acid delayed-release tablets to adult renal transplant patients on Cyclosporine, USP MODIFIED based immunosuppression Curated Drug Pharmacokinetic Data DailyMed|setid=d7fbf301-0b08-4b19-bfa0-e0c0067cb5ab | MYCOPHENOLIC ACID - mycophenolic acid tablet, delayed release|Mylan Instituinal Inc. NADOLOL NADOLOL CHEMBL649 27570 309.41 Normal/therapeutic blood-plasma concentration 0.25 mg/L 8.079893991790827e-07 6.092594337131638 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NALBUPHINE NALBUPHINE CHEMBL895 77207 357.45 Normal/therapeutic blood-plasma concentration 0.2 mg/L 5.595188138201147e-07 6.2521853057381565 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NALIDIXIC ACID NALIDIXIC ACID CHEMBL5 147 232.24 Normal/therapeutic blood-plasma concentration 30.0 mg/L 0.00012917671374440234 3.888815768103955 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NALMEFENE NALMEFENE CHEMBL982 100696 339.44 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.9460287532406316e-07 6.5307630187585595 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NALOXONE NALOXONE CHEMBL80 6902 327.38 Normal/therapeutic blood-plasma concentration 0.03 mg/L 9.163663021565154e-08 7.037930889644752 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NALTREXONE NALTREXONE CHEMBL19019 21459 341.41 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.464514806244691e-07 6.834306233242975 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NAPROXEN NAPROXEN CHEMBL154 51056 230.26 Normal/therapeutic blood-plasma concentration 100.0 mg/L 0.00043429167028576397 3.3622185003260525 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NARATRIPTAN NARATRIPTAN CHEMBL1278 250297 335.47 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.4904462396041374e-07 6.826683684350801 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NEBIVOLOL NEBIVOLOL CHEMBL434394 27569 405.44 Normal/therapeutic blood-plasma concentration 0.2 mg/L 4.932912391475927e-07 6.3068965975393665 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NEDOCROMIL NEDOCROMIL CHEMBL746 39540 371.35 Normal/therapeutic blood-plasma concentration 0.025 mg/L 6.732193348592972e-08 7.171843419579579 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NEFAZODONE NEFAZODONE CHEMBL623 26465 470.02 Normal/therapeutic blood-plasma concentration 0.3 mg/L 6.382707118846006e-07 6.194995083439113 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NEFOPAM NEFOPAM CHEMBL465026 458338 253.35 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.9471087428458657e-07 6.40372090862669 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NELFINAVIR CHEMBL584 17224 567.8 Cmax 1577.0000000000005 ug.mL-1 0.0027773864036632627 2.556363694860935 CHEMBL623118 765250.0 The maximum plasma concentration (400 mg/kg) administered orally in human Scientific Literature 9397180.0 Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. NELFINAVIR CHEMBL584 17224 567.8 Cmax 312.99999999999994 ug.mL-1 0.0005512504402958787 3.25865105064339 CHEMBL626235 765248.0 The maximum plasma concentration (100 mg/kg) administered orally in human Scientific Literature 9397180.0 Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. NELFINAVIR CHEMBL584 17224 567.8 Cmax 439.00000000000006 ug.mL-1 0.0007731595632264884 3.111730867947717 CHEMBL622412 765249.0 The maximum plasma concentration (200 mg/kg) administered orally in human Scientific Literature 9397180.0 Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. NELFINAVIR CHEMBL584 17224 567.8 Cmax 3163.0 ug.mL-1 0.005570623458964425 2.2540961962741153 CHEMBL623286 765251.0 The maximum plasma concentration (800 mg/kg) administered orally in human Scientific Literature 9397180.0 Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. NELFINAVIR NELFINAVIR CHEMBL584 17224 567.8 Normal/therapeutic blood-plasma concentration 0.8 mg/L 1.4089468122578374e-06 5.851105401197895 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NEOSTIGMINE NEOSTIGMINE CHEMBL278020 14126 223.3 Normal/therapeutic blood-plasma concentration 0.01 mg/L 4.478280340349306e-08 7.348888723071438 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NETILMICIN NETILMICIN CHEMBL1572 453520 475.59 Normal/therapeutic blood-plasma concentration 12.0 mg/L 2.5231817321642592e-05 4.598051468295839 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NEVIRAPINE NEVIRAPINE CHEMBL57 4345 266.3 Normal/therapeutic blood-plasma concentration 3.0 mg/L 1.1265490048817123e-05 4.948249911719278 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NICOTINIC ACID NIACIN CHEMBL573 16656 123.11 Normal/therapeutic blood-plasma concentration 18.0 mg/L 0.0001462107058727967 3.835020826206804 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NICARDIPINE NICARDIPINE CHEMBL1484 407549 479.53 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.0853752632786272e-07 6.680815782365699 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NICOTINE NICOTINE CHEMBL3 115 162.24 Normal/therapeutic blood-plasma concentration 0.03 mg/L 1.849112426035503e-07 6.733036682933579 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NIFEDIPINE NIFEDIPINE CHEMBL193 419596 346.34 Normal/therapeutic blood-plasma concentration 0.15 mg/L 4.3310042155107696e-07 6.363411393556656 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NIMESULIDE NIMESULIDE CHEMBL56367 85553 308.31 Normal/therapeutic blood-plasma concentration 6.5 mg/L 2.1082676526872306e-05 4.676074254604531 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NIMODIPINE NIMODIPINE CHEMBL1428 365248 418.45 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.194885888397658e-07 6.9226735678585545 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NIRAPARIB CHEMBL1094636 624225 320.4 Cmax 2000.0 nM 2.0000000000000003e-06 5.698970004336019 CHEMBL3374524 15005653.0 Cmax in BRCA mutation carrying cancer patient with sporadic cancer Scientific Literature 24893124.0 Development of synthetic lethality anticancer therapeutics. NISOLDIPINE NISOLDIPINE CHEMBL1726 554892 388.42 Normal/therapeutic blood-plasma concentration 0.001 mg/L 2.5745327223109e-09 8.589301583918802 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NITRAZEPAM NITRAZEPAM CHEMBL13209 11745 281.27 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.555302734027803e-07 6.4491234131845605 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NITRENDIPINE NITRENDIPINE CHEMBL475534 453570 360.37 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.3874628853678164e-07 6.857778625427297 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NITROFURANTOIN NITROFURANTOIN CHEMBL572 16592 238.16 Normal/therapeutic blood-plasma concentration 5.0 mg/L 2.0994289553241517e-05 4.6778988173026494 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NITROGLYCERIN NITROGLYCERIN CHEMBL730 37493 227.09 Normal/therapeutic blood-plasma concentration 0.015 mg/L 6.605310669778502e-08 7.180106751251948 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NIZATIDINE NIZATIDINE CHEMBL3183075 1672366 331.47 Normal/therapeutic blood-plasma concentration 1.0 mg/L 3.016864271276435e-06 5.520444228294238 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NOMIFENSINE NOMIFENSINE CHEMBL273575 16225 238.33 Normal/therapeutic blood-plasma concentration 0.1 mg/L 4.1958628792011076e-07 6.377178712990244 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NORFLOXACIN NORFLOXACIN CHEMBL9 246 319.34 Normal/therapeutic blood-plasma concentration 5.0 mg/L 1.5657293167157264e-05 4.805283316618867 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NORTRIPTYLINE NORTRIPTYLINE CHEMBL445 2262 263.38 Normal/therapeutic blood-plasma concentration 0.15 mg/L 5.695193256891184e-07 6.244491534275417 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics NOSCAPINE NOSCAPINE CHEMBL364713 320260 413.43 Normal/therapeutic blood-plasma concentration 0.4 mg/L 9.675156616597732e-07 6.0143419961102245 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics OFLOXACIN CHEMBL4 146 361.37 Cmax 2.1999999999999997 ug.mL-1 6.0879431054044326e-06 5.215529414897858 CHEMBL3889401 17805997.0 Steady-state pharmacokinetic parameters for Ofloxacin following multiple oral and intravenous (IV) doses of Ofloxacin to healthy 70 to 80 kg male volunteers. Predicted Curated Drug Pharmacokinetic Data DailyMed|setid=d3417226-1f42-40cd-82ac-bc31ddf79b97 | OFLOXACIN - ofloxacin tablet, film coated|PD-Rx Pharmaceuticals, Inc. OFLOXACIN CHEMBL4 146 361.37 Cmax 3.599999999999999 ug.mL-1 9.962088717934526e-06 5.001649594952777 CHEMBL3889401 17805998.0 Steady-state pharmacokinetic parameters for Ofloxacin following multiple oral and intravenous (IV) doses of Ofloxacin to healthy 70 to 80 kg male volunteers. Predicted Curated Drug Pharmacokinetic Data DailyMed|setid=d3417226-1f42-40cd-82ac-bc31ddf79b97 | OFLOXACIN - ofloxacin tablet, film coated|PD-Rx Pharmaceuticals, Inc. OFLOXACIN CHEMBL4 146 361.37 Cmax 1.4999999999999998 ug.mL-1 4.1508702991393855e-06 5.381860836664384 CHEMBL3889400 17805989.0 Pharmcokinetic parameters for Ofloxacin following single oral dose administration of Ofloxacin to healthy male volunteers, body mass 70 to 80 kg. Curated Drug Pharmacokinetic Data DailyMed|setid=d3417226-1f42-40cd-82ac-bc31ddf79b97 | OFLOXACIN - ofloxacin tablet, film coated|PD-Rx Pharmaceuticals, Inc. OFLOXACIN CHEMBL4 146 361.37 Cmax 2.3999999999999995 ug.mL-1 6.641392478623016e-06 5.177740854008459 CHEMBL3889400 17805991.0 Pharmcokinetic parameters for Ofloxacin following single oral dose administration of Ofloxacin to healthy male volunteers, body mass 70 to 80 kg. Curated Drug Pharmacokinetic Data DailyMed|setid=d3417226-1f42-40cd-82ac-bc31ddf79b97 | OFLOXACIN - ofloxacin tablet, film coated|PD-Rx Pharmaceuticals, Inc. OFLOXACIN CHEMBL4 146 361.37 Cmax 2.8999999999999995 ug.mL-1 8.025015911669479e-06 5.0955540978211085 CHEMBL3889400 17805993.0 Pharmcokinetic parameters for Ofloxacin following single oral dose administration of Ofloxacin to healthy male volunteers, body mass 70 to 80 kg. Curated Drug Pharmacokinetic Data DailyMed|setid=d3417226-1f42-40cd-82ac-bc31ddf79b97 | OFLOXACIN - ofloxacin tablet, film coated|PD-Rx Pharmaceuticals, Inc. OFLOXACIN OFLOXACIN CHEMBL4 146 361.37 Normal/therapeutic blood-plasma concentration 5.5 mg/L 1.5219857763511081e-05 4.817589406225821 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics OFLOXACIN CHEMBL4 146 361.37 Cmax 4.6 ug.mL-1 1.2729335584027451e-05 4.895194264038491 CHEMBL3889401 17805999.0 Steady-state pharmacokinetic parameters for Ofloxacin following multiple oral and intravenous (IV) doses of Ofloxacin to healthy 70 to 80 kg male volunteers. Curated Drug Pharmacokinetic Data DailyMed|setid=d3417226-1f42-40cd-82ac-bc31ddf79b97 | OFLOXACIN - ofloxacin tablet, film coated|PD-Rx Pharmaceuticals, Inc. OLANZAPINE OLANZAPINE CHEMBL715 34197 312.44 Normal/therapeutic blood-plasma concentration 0.08 mg/L 2.560491614389963e-07 6.591676642141684 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics OLAPARIB CHEMBL521686 469866 434.47 Cmax 2.599999999999999 ug.mL-1 5.984302713651114e-06 5.222986445968608 CHEMBL3373930 15005666.0 Cmax in advanced breast cancer patient with BRCA1/2 mutations at 400 mg dosed twice daily Scientific Literature 24893124.0 Development of synthetic lethality anticancer therapeutics. OMBITASVIR CHEMBL3127326 1623950 894.13 Cmax 0.0057 ug.mL-1 6.374911925558924e-09 8.195525810973692 CHEMBL3132172 13950149.0 Cmax in HCV1 infected patient at 5 to 200 mg qd for 3 days Scientific Literature 24400777.0 Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. OMEPRAZOLE CHEMBL1503 419601 345.42 Cmax 0.6680000000000001 ug.mL-1 1.9338775982861447e-06 5.713571017363232 CHEMBL3889418 17806284.0 Pharmacokinetic parameters of Omeprazole following single oral administration in pediatric population compared with adult subjects. Plasma Concentration Adjusted To An Oral Dose Of 1Mg/Kg Curated Drug Pharmacokinetic Data DailyMed|setid=93ec1327-22b1-4a5d-a793-e014f6dffd33 | OMEPRAZOLE - omeprazole capsule, delayed release|STAT Rx USA LLC OMEPRAZOLE CHEMBL1503 419601 345.42 Cmax 0.2879999999999999 ug.mL-1 8.337675872850441e-07 6.078954992079547 CHEMBL3889418 17806280.0 Pharmacokinetic parameters of Omeprazole following single oral administration in pediatric population compared with adult subjects. Plasma Concentration Adjusted To An Oral Dose Of 1Mg/Kg Curated Drug Pharmacokinetic Data DailyMed|setid=93ec1327-22b1-4a5d-a793-e014f6dffd33 | OMEPRAZOLE - omeprazole capsule, delayed release|STAT Rx USA LLC OMEPRAZOLE CHEMBL1503 419601 345.42 Cmax 0.495 ug.mL-1 1.4330380406461699e-06 5.843742280905209 CHEMBL3889418 17806282.0 Pharmacokinetic parameters of Omeprazole following single oral administration in pediatric population compared with adult subjects. Plasma Concentration Adjusted To An Oral Dose Of 1Mg/Kg Curated Drug Pharmacokinetic Data DailyMed|setid=93ec1327-22b1-4a5d-a793-e014f6dffd33 | OMEPRAZOLE - omeprazole capsule, delayed release|STAT Rx USA LLC OMEPRAZOLE CHEMBL1503 419601 345.42 Cmax 1.4580000000000004 ug.mL-1 4.220948410630538e-06 5.3745899558568215 CHEMBL3889420 17806285.0 Pharmacokinetic parameters for Omeprazole measured after repeated dose administration of 20 mg of Omeprazole to adults of mean body weight 76 kg and children > 20 kg. Plasma Concentration Adjusted To An Oral Dose Of 1Mg/Kg Curated Drug Pharmacokinetic Data DailyMed|setid=93ec1327-22b1-4a5d-a793-e014f6dffd33 | OMEPRAZOLE - omeprazole capsule, delayed release|STAT Rx USA LLC OMEPRAZOLE CHEMBL1503 419601 345.42 Cmax 0.5390000000000001 ug.mL-1 1.5604191998147189e-06 5.806758714652039 CHEMBL3889420 17806287.0 Pharmacokinetic parameters for Omeprazole measured after repeated dose administration of 20 mg of Omeprazole to adults of mean body weight 76 kg and children > 20 kg. Plasma Concentration Adjusted To An Oral Dose Of 1Mg/Kg Curated Drug Pharmacokinetic Data DailyMed|setid=93ec1327-22b1-4a5d-a793-e014f6dffd33 | OMEPRAZOLE - omeprazole capsule, delayed release|STAT Rx USA LLC OMEPRAZOLE OMEPRAZOLE CHEMBL1503 419601 345.42 Normal/therapeutic blood-plasma concentration 4.0 mg/L 1.1580105378958949e-05 4.936287488510815 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics OMEPRAZOLE CHEMBL1503 419601 345.42 Cmax 0.8509999999999999 ug.mL-1 2.463667419373516e-06 5.6084179197541895 CHEMBL3889420 17806290.0 Pharmacokinetic parameters for Omeprazole measured after repeated dose administration of 20 mg of Omeprazole to adults of mean body weight 76 kg and children > 20 kg. Plasma Concentration Adjusted To An Oral Dose Of 1Mg/Kg Curated Drug Pharmacokinetic Data DailyMed|setid=93ec1327-22b1-4a5d-a793-e014f6dffd33 | OMEPRAZOLE - omeprazole capsule, delayed release|STAT Rx USA LLC ONDANSETRON ONDANSETRON CHEMBL46 3183 293.37 Normal/therapeutic blood-plasma concentration 0.3 mg/L 1.0225994477962982e-06 5.990294446128439 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ONDANSETRON CHEMBL46 3183 293.37 Cmax 129.99999999999997 nM 1.2999999999999997e-07 6.886056647693163 CHEMBL2154113 12064134.0 Cmax in human Scientific Literature 21599003.0 Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. ORITAVANCIN CHEMBL1688530 1076140 1793.12 Cmax 32.0 ug.mL-1 1.784598911394664e-05 4.748459376269575 CHEMBL1664951 5146298.0 Cmax in healthy human male at 200 mg, iv every 24 hrs by LC/MS/MS analysis Scientific Literature 19349514.0 Impact of human serum albumin on oritavancin in vitro activity against enterococci. ORITAVANCIN CHEMBL1688530 1076140 1793.12 Cmax 24.999999999999996 ug.mL-1 1.3942178995270813e-05 4.855669345917444 CHEMBL1696172 5306512.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. ORPHENADRINE ORPHENADRINE CHEMBL900 77779 269.39 Normal/therapeutic blood-plasma concentration 0.6 mg/L 2.227254166821337e-06 5.6522302198992955 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ORPHENADRINE CHEMBL900 77779 269.39 Cmax 310.00000000000006 nM 3.100000000000001e-07 6.508638306165727 CHEMBL2154113 12064133.0 Cmax in human Scientific Literature 21599003.0 Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. OSELTAMIVIR CHEMBL1229 228121 312.41 Cmax 0.11499999999999998 ug.mL-1 3.6810601453218516e-07 6.434027086501175 CHEMBL1281221 3538355.0 Cmax in healthy adult plasma at 150 mg, po administered as single dose by LC/MS analysis Scientific Literature 18676886.0 Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. OSELTAMIVIR CHEMBL1229 228121 312.41 Cmax 0.5440000000000002 ug.mL-1 1.7413014948305117e-06 5.759126027156606 CHEMBL1281239 3538373.0 Cmax in healthy adult plasma assessed as oseltamivir carboxylate at 150 mg, po administered as single dose by LC/MS analysis Scientific Literature 18676886.0 Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. OSELTAMIVIR CHEMBL1229 228121 312.41 Cmax 0.12400000000000003 ug.mL-1 3.969143113216607e-07 6.401303241692551 CHEMBL3536303 15460268.0 Cmax in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fasting conditions Scientific Literature 22584254.0 Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. OSELTAMIVIR CHEMBL1229 228121 312.41 Cmax 0.101 ug.mL-1 3.232931084152236e-07 6.490403553072143 CHEMBL3538252 15460252.0 Cmax in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fed conditions Scientific Literature 22584254.0 Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. OXACILLIN CHEMBL819 56432 401.44 Cmax 64.0 ug.mL-1 0.00015942606616181745 3.7974406699866483 CHEMBL1696172 5306501.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. OXATOMIDE OXATOMIDE CHEMBL13828 12890 426.56 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.3443360840210054e-07 6.6299801277337655 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics OXAZEPAM OXAZEPAM CHEMBL568 16506 286.72 Normal/therapeutic blood-plasma concentration 1.5 mg/L 5.231584821428571e-06 5.28136672892635 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics OXCARBAZEPINE OXCARBAZEPINE CHEMBL1068 139014 252.27 Normal/therapeutic blood-plasma concentration 35.0 mg/L 0.00013874023863321046 3.8577975628493353 This is the Cmax for the main metabolite 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics OXCARBAZEPINE CHEMBL1068 139014 252.27 Cmax 2000.0 nM 2.0000000000000003e-06 5.698970004336019 CHEMBL3530803 15458474.0 Cmax in human at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography Scientific Literature 21389120.0 Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. OXCARBAZEPINE CHEMBL1068 139014 252.27 Cmax 79.99999999999999 nM 7.999999999999999e-08 7.096910013008056 CHEMBL3541464 15458500.0 Cmax in human treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography Scientific Literature 21389120.0 Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. OXPRENOLOL OXPRENOLOL CHEMBL546 13756 265.35 Normal/therapeutic blood-plasma concentration 1.0 mg/L 3.768607499528924e-06 5.423819091965404 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics 4-HYDROXYBUTYRATE OXYBATE CHEMBL1342 286065 104.11 Normal/therapeutic blood-plasma concentration 120.0 mg/L 0.0011526270291038324 2.9383112004296503 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics OXYCODONE OXYCODONE CHEMBL656 27624 315.37 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.1708786504740465e-07 6.49882037810471 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics OXYPHENBUTAZONE OXYPHENBUTAZONE CHEMBL1228 227917 324.38 Normal/therapeutic blood-plasma concentration 100.0 mg/L 0.0003082804118626303 3.5110540694682135 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics OXYPURINOL OXYPURINOL CHEMBL859 65935 152.11 Normal/therapeutic blood-plasma concentration 15.0 mg/L 9.861284596673458e-05 4.0060665072791 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics OXYTOCIN OXYTOCIN CHEMBL395429 392195 1007.21 Normal/therapeutic blood-plasma concentration 0.0002 mg/L 1.9856832239552824e-10 9.702090033313565 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PACLITAXEL PACLITAXEL CHEMBL428647 8062 853.92 Normal/therapeutic blood-plasma concentration 6.8 mg/L 7.963275248266816e-06 5.098908272753276 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PALIPERIDONE PALIPERIDONE CHEMBL1621 468656 426.49 Normal/therapeutic blood-plasma concentration 0.06 mg/L 1.4068325165889002e-07 6.8517576022459625 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PAMIDRONIC ACID CHEMBL834 60401 235.07 Cmax 0.7299999999999999 ug.mL-1 3.1054579486961324e-06 5.507874347201839 CHEMBL3889452 17806370.0 Mean pharmacokinetic parameters for Pamidronate after intravenous infusion of 30, 60 and 90 mg of Pamidronate disodium for 4 hours and 90 mg for 24 hours in cancer patients, 6 in each group. Cv = 19.1 % Curated Drug Pharmacokinetic Data DailyMed|setid=da574350-be6b-49f3-b2ef-64da06af9b9d | PAMDRONATE DISODIUM - pamodronate disodium injection, solution|GENERAMEDIX, INC. PAMIDRONIC ACID CHEMBL834 60401 235.07 Cmax 1.38 ug.mL-1 5.870591738631046e-06 5.231318120921058 CHEMBL3889452 17806378.0 Mean pharmacokinetic parameters for Pamidronate after intravenous infusion of 30, 60 and 90 mg of Pamidronate disodium for 4 hours and 90 mg for 24 hours in cancer patients, 6 in each group. Cv = 142.7 % Curated Drug Pharmacokinetic Data DailyMed|setid=da574350-be6b-49f3-b2ef-64da06af9b9d | PAMDRONATE DISODIUM - pamodronate disodium injection, solution|GENERAMEDIX, INC. PAMIDRONIC ACID CHEMBL834 60401 235.07 Cmax 1.4399999999999995 ug.mL-1 6.125834857701959e-06 5.212834715227045 CHEMBL3889452 17806373.0 Mean pharmacokinetic parameters for Pamidronate after intravenous infusion of 30, 60 and 90 mg of Pamidronate disodium for 4 hours and 90 mg for 24 hours in cancer patients, 6 in each group. Cv = 39.6 % Curated Drug Pharmacokinetic Data DailyMed|setid=da574350-be6b-49f3-b2ef-64da06af9b9d | PAMDRONATE DISODIUM - pamodronate disodium injection, solution|GENERAMEDIX, INC. PAMIDRONATE PAMIDRONIC ACID CHEMBL834 60401 235.07 Normal/therapeutic blood-plasma concentration 0.25 mg/L 1.0635129961288127e-06 5.9732571986502565 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PAMIDRONIC ACID CHEMBL834 60401 235.07 Cmax 2.6100000000000008 ug.mL-1 1.1103075679584809e-05 4.954556699984013 CHEMBL3889452 17806376.0 Mean pharmacokinetic parameters for Pamidronate after intravenous infusion of 30, 60 and 90 mg of Pamidronate disodium for 4 hours and 90 mg for 24 hours in cancer patients, 6 in each group. Cv = 28.3 % Curated Drug Pharmacokinetic Data DailyMed|setid=da574350-be6b-49f3-b2ef-64da06af9b9d | PAMDRONATE DISODIUM - pamodronate disodium injection, solution|GENERAMEDIX, INC. PANCURONIUM PANCURONIUM CHEMBL185073 306486 572.88 Normal/therapeutic blood-plasma concentration 0.6 mg/L 1.0473397570171764e-06 5.979912410334717 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PANOBINOSTAT CHEMBL483254 499179 349.43 Cmax 191.00000000000006 nM 1.9100000000000006e-07 6.718966632752272 CHEMBL3598925 15656489.0 Cmax in po dosed human measured under phase 2 trial Scientific Literature 25637120.0 Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). PANOBINOSTAT CHEMBL483254 499179 349.43 Cmax 31.000000000000007 nM 3.1000000000000006e-08 7.508638306165727 CHEMBL3598923 15656482.0 Cmax in po dosed human measured under phase 1 trial Scientific Literature 25637120.0 Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). PANOBINOSTAT CHEMBL483254 499179 349.43 Cmax 1410.0000000000002 nM 1.4100000000000003e-06 5.85078088734462 CHEMBL3598924 15656486.0 Cmax in iv dosed human measured under phase 1 trial Scientific Literature 25637120.0 Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). PANTOPRAZOLE PANTOPRAZOLE CHEMBL1502 419598 383.38 Normal/therapeutic blood-plasma concentration 6.0 mg/L 1.565026866294538e-05 4.805478202664934 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PANTOPRAZOLE CHEMBL1502 419598 383.38 Cmax 5450.0 nM 5.45e-06 5.2636034977233574 CHEMBL2320289 12636090.0 Cmax in human at 40 mg, po after 7 days Scientific Literature 23241029.0 Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. PAPAVERINE PAPAVERINE CHEMBL19224 21716 339.39 Normal/therapeutic blood-plasma concentration 2.0 mg/L 5.892925542885766e-06 5.229669046180964 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PARALDEHYDE PARALDEHYDE CHEMBL1410743 834627 132.16 Normal/therapeutic blood-plasma concentration 100.0 mg/L 0.0007566585956416466 3.121100029976307 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PAROXETINE PAROXETINE CHEMBL490 6643 329.37 Normal/therapeutic blood-plasma concentration 0.12 mg/L 3.6433190636670006e-07 6.438502793753349 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PAROXETINE CHEMBL490 6643 329.37 Cmax 0.03400000000000001 ug.mL-1 1.0322737347056506e-07 6.986205122758719 CHEMBL1002563 2301674.0 Cmax in human at 20 mg, po qd for 10 days Scientific Literature 17846135.0 Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. PAROXETINE CHEMBL490 6643 329.37 Cmax 0.017000000000000005 ug.mL-1 5.161368673528253e-08 7.2872351184227 CHEMBL1005060 2301675.0 Cmax in human at 20 mg, po qd for 10 days followed by 16 days washout period and treated with 20 mg, po qd for 10 days coadministered with fosamprenavir at 700 mg, po bid and ritonavir at 100 mg, po bid Scientific Literature 17846135.0 Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. PEFLOXACIN PEFLOXACIN CHEMBL267648 11474 333.36 Normal/therapeutic blood-plasma concentration 6.0 mg/L 1.7998560115190783e-05 4.7447622370655775 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PEMOLINE PEMOLINE CHEMBL1177 193096 176.18 Normal/therapeutic blood-plasma concentration 7.0 mg/L 3.9732092178453853e-05 4.40085856563594 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PENBUTOLOL PENBUTOLOL CHEMBL1290 254975 291.44 Normal/therapeutic blood-plasma concentration 1.0 mg/L 3.4312379906670328e-06 5.46454915823386 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PENCICLOVIR CHEMBL1540 430597 253.26 Cmax 6.599999999999999 ug.mL-1 2.6060175313906656e-05 4.584022666996183 CHEMBL3889387 17806075.0 Mean pharmacokinetic parameters for Penciclovir following single dose oral or IV administration of Femciclovir to healthy adult subjects and patients with different degrees of renal impairment. Curated Drug Pharmacokinetic Data DailyMed|setid=5c133dfe-3cb5-426b-ac30-daf814e12c47 | FAMCICLOVIR - famciclovir tablet, film coated|Golden State Medical Supply, Inc PENCICLOVIR CHEMBL1540 430597 253.26 Cmax 3.4100000000000006 ug.mL-1 1.346442391218511e-05 4.8708122235455535 CHEMBL1657661 5156077.0 Cmax in 6 to <=12 years aged pediatric patient administered as single dose Scientific Literature 19273678.0 Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. PENCICLOVIR CHEMBL1540 430597 253.26 Cmax 3.0599999999999996 ug.mL-1 1.2082444918265813e-05 4.917845176056471 CHEMBL1657659 5156079.0 Cmax in 1 to <2 years aged pediatric patient administered as single dose Scientific Literature 19273678.0 Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. PENCICLOVIR CHEMBL1540 430597 253.26 Cmax 1.5999999999999999 ug.mL-1 6.317618257916765e-06 5.199446619882127 CHEMBL3889387 17806069.0 Mean pharmacokinetic parameters for Penciclovir following single dose oral or IV administration of Femciclovir to healthy adult subjects and patients with different degrees of renal impairment. Curated Drug Pharmacokinetic Data DailyMed|setid=5c133dfe-3cb5-426b-ac30-daf814e12c47 | FAMCICLOVIR - famciclovir tablet, film coated|Golden State Medical Supply, Inc PENCICLOVIR CHEMBL1540 430597 253.26 Cmax 3.2999999999999994 ug.mL-1 1.3030087656953328e-05 4.885052662660164 CHEMBL3889387 17806057.0 Mean pharmacokinetic parameters for Penciclovir following single dose oral or IV administration of Femciclovir to healthy adult subjects and patients with different degrees of renal impairment. Curated Drug Pharmacokinetic Data DailyMed|setid=5c133dfe-3cb5-426b-ac30-daf814e12c47 | FAMCICLOVIR - famciclovir tablet, film coated|Golden State Medical Supply, Inc PENCICLOVIR CHEMBL1540 430597 253.26 Cmax 0.7999999999999999 ug.mL-1 3.1588091289583824e-06 5.500476615546108 CHEMBL3889387 17806070.0 Mean pharmacokinetic parameters for Penciclovir following single dose oral or IV administration of Femciclovir to healthy adult subjects and patients with different degrees of renal impairment. Curated Drug Pharmacokinetic Data DailyMed|setid=5c133dfe-3cb5-426b-ac30-daf814e12c47 | FAMCICLOVIR - famciclovir tablet, film coated|Golden State Medical Supply, Inc PENCICLOVIR CHEMBL1540 430597 253.26 Cmax 2.78 ug.mL-1 1.097686172313038e-05 4.959521806619976 CHEMBL1657660 5156078.0 Cmax in 2 to <6 years aged pediatric patient administered as single dose Scientific Literature 19273678.0 Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. PENTAMIDINE PENTAMIDINE CHEMBL55 3965 340.43 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.4687307229092618e-06 5.833057820461857 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PENTAMIDINE CHEMBL55 3965 340.43 Cmax 899.9999999999998 nM 8.999999999999999e-07 6.045757490560675 CHEMBL3598943 15656524.0 Cmax in human Scientific Literature 25637120.0 Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). PENTAZOCINE PENTAZOCINE CHEMBL100116 165474 285.43 Normal/therapeutic blood-plasma concentration 0.2 mg/L 7.006971937077392e-07 6.154469621852342 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PENTOBARBITAL PENTOBARBITAL CHEMBL448 2327 226.28 Normal/therapeutic blood-plasma concentration 10.0 mg/L 4.4193035177656004e-05 4.354646170068372 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PENTOXIFYLLINE PENTOXIFYLLINE CHEMBL628 27029 278.31 Normal/therapeutic blood-plasma concentration 2.0 mg/L 7.1862311810570945e-06 5.143498815653154 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PERAMIVIR CHEMBL139367 228354 328.41 Cmax 9.999999999999998 ug.mL-1 3.044974269967418e-05 4.516416372803973 CHEMBL1658169 5170778.0 Cmax in healthy human at 300 mg/kg parenteral dose Scientific Literature 19651908.0 In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. PERHEXILINE PERHEXILINE CHEMBL75880 119288 277.5 Normal/therapeutic blood-plasma concentration 0.6 mg/L 2.162162162162162e-06 5.665111737075051 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PERICIAZINE PERICIAZINE CHEMBL251940 418410 365.5 Normal/therapeutic blood-plasma concentration 0.03 mg/L 8.207934336525308e-08 7.0857661265742165 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PERINDOPRIL PERINDOPRIL CHEMBL1581 453579 368.47 Normal/therapeutic blood-plasma concentration 0.15 mg/L 4.0708877249165463e-07 6.39031087529724 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PERPHENAZINE PERPHENAZINE CHEMBL567 16505 403.98 Normal/therapeutic blood-plasma concentration 0.0024 mg/L 5.940888162780335e-09 8.226148623139983 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENACETIN PHENACETIN CHEMBL16073 16498 179.22 Normal/therapeutic blood-plasma concentration 20.0 mg/L 0.00011159468809284678 3.9523564773237907 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENDIMETRAZINE PHENDIMETRAZINE CHEMBL1615439 1038390 191.27 Normal/therapeutic blood-plasma concentration 0.1 mg/L 5.228211428870183e-07 6.281646857867514 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENELZINE PHENELZINE CHEMBL1089 148018 136.2 Normal/therapeutic blood-plasma concentration 0.04 mg/L 2.9368575624082236e-07 6.532117116248804 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENFORMIN PHENFORMIN CHEMBL170988 282509 205.26 Normal/therapeutic blood-plasma concentration 0.1 mg/L 4.871869823638313e-07 6.312304324568706 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENIRAMINE PHENIRAMINE CHEMBL1193 208661 240.35 Normal/therapeutic blood-plasma concentration 0.27 mg/L 1.1233617640940297e-06 5.949480362305678 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENMETRAZINE PHENMETRAZINE CHEMBL1201208 675159 177.25 Normal/therapeutic blood-plasma concentration 0.25 mg/L 1.4104372355430184e-06 5.850646235183066 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENOBARBITAL CHEMBL40 2217 232.24 Cmax 5.5 ug.mL-1 2.3682397519807095e-05 4.625574333329373 CHEMBL3788620 16541666.0 Cmax in healthy human subjects (6 subjects) at 2.9 mg/kg, po by HPLC method Scientific Literature 7068937.0 Phenobarbital pharmacokinetics and bioavailability in adults. PHENOBARBITAL PHENOBARBITAL CHEMBL40 2217 232.24 Normal/therapeutic blood-plasma concentration 40.0 mg/L 0.00017223561832586977 3.763877031495655 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENPROCOUMON PHENPROCOUMON CHEMBL1465 394229 280.32 Normal/therapeutic blood-plasma concentration 5.0 mg/L 1.7836757990867582e-05 4.748684080151968 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENSUXIMIDE PHENSUXIMIDE CHEMBL797 49869 189.21 Normal/therapeutic blood-plasma concentration 20.0 mg/L 0.00010570265842185931 3.975914090049001 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENTERMINE PHENTERMINE CHEMBL1574 453532 149.24 Normal/therapeutic blood-plasma concentration 0.1 mg/L 6.700616456714018e-07 6.173885240368792 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENYLBUTAZONE PHENYLBUTAZONE CHEMBL101 12417 308.38 Normal/therapeutic blood-plasma concentration 100.0 mg/L 0.0003242752448278099 3.4890862041023505 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENYLEPHRINE PHENYLEPHRINE CHEMBL1215 219334 167.21 Normal/therapeutic blood-plasma concentration 0.1 mg/L 5.980503558399618e-07 6.22326224687663 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENYLPROPANOLAMINE PHENYLPROPANOLAMINE CHEMBL61006 94091 151.21 Normal/therapeutic blood-plasma concentration 0.5 mg/L 3.3066596124594934e-06 5.480610509059391 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENYTOIN PHENYTOIN CHEMBL16 921 252.27 Normal/therapeutic blood-plasma concentration 20.0 mg/L 7.928013636183454e-05 4.10083561153563 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHENYTOIN CHEMBL16 921 252.27 Cmax 4.31 ug.mL-1 1.708486938597534e-05 4.767388337038879 CHEMBL3790792 16534821.0 Cmax in healthy adult human subjects at 300 mg, po dosed 30 minutes after ingestion of soup (melahu rasam) with black pepper by HPLC method Scientific Literature 11808866.0 Piperine in food: interference in the pharmacokinetics of phenytoin. PHENYTOIN CHEMBL16 921 252.27 Cmax 3.8200000000000007 ug.mL-1 1.51425060451104e-05 4.819802244287902 CHEMBL3790519 16534832.0 Cmax in healthy adult human subjects at 300 mg, po by HPLC method Scientific Literature 11808866.0 Piperine in food: interference in the pharmacokinetics of phenytoin. PHENYTOIN CHEMBL16 921 252.27 Cmax 2.599999999999999 ug.mL-1 1.0306417727038487e-05 4.986892259228793 CHEMBL3788303 16545227.0 Cmax in healthy human volunteer (5 volunteers) at 5 mg/kg, po administered as single dose by gas chromatographic method Scientific Literature 4853604.0 Pharmacokinetics of single and multiple doses of phenytoin in man. PHOLCODINE PHOLCODINE CHEMBL2105224 1377494 398.5 Normal/therapeutic blood-plasma concentration 0.2 mg/L 5.018820577164367e-07 6.29939833006815 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PHYSOSTIGMINE PHYSOSTIGMINE CHEMBL94 9277 275.35 Normal/therapeutic blood-plasma concentration 0.005 mg/L 1.8158707100054476e-08 7.740915076481283 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PIMOZIDE PIMOZIDE CHEMBL1423 364141 461.56 Normal/therapeutic blood-plasma concentration 0.02 mg/L 4.333131120547708e-08 7.363198169015764 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PINDOLOL PINDOLOL CHEMBL500 8543 248.33 Normal/therapeutic blood-plasma concentration 0.15 mg/L 6.040349534893085e-07 6.218937929477692 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PIPERACILLINE PIPERACILLIN CHEMBL702 33055 517.56 Normal/therapeutic blood-plasma concentration 70.0 mg/L 0.00013525001932143137 3.8688626641793196 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PIPERAZINE PIPERAZINE CHEMBL1412 352917 86.14 Normal/therapeutic blood-plasma concentration 0.1 mg/L 1.1609008590666357e-06 5.935204867426581 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PIPOTIAZINE PIPOTIAZINE PALMITATE CHEMBL2106439 1378709 714.09 Normal/therapeutic blood-plasma concentration 0.06 mg/L 8.402302230811241e-08 7.075601700944552 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PIRACETAM PIRACETAM CHEMBL36715 53623 142.16 Normal/therapeutic blood-plasma concentration 50.0 mg/L 0.0003517163759144626 3.453807410461226 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PIRENZEPINE PIRENZEPINE CHEMBL9967 6772 351.41 Normal/therapeutic blood-plasma concentration 0.45 mg/L 1.2805554765089212e-06 5.892601602185939 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PIROXICAM PIROXICAM CHEMBL527 11968 331.35 Normal/therapeutic blood-plasma concentration 6.0 mg/L 1.8107741059302852e-05 4.7421357245434725 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.5549999999999999 ug.mL-1 7.919633556414903e-07 6.101294912868677 CHEMBL1681510 5230732.0 Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.23299999999999996 ug.mL-1 3.3248191326931034e-07 6.478231974965334 CHEMBL1653630 5164219.0 Cmax in healthy human at 400 mg/kg administered via nasogastric tube by ITT analysis Scientific Literature 19433558.0 Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 2.399 ug.mL-1 3.4232794417728568e-06 5.465557648023522 CHEMBL912756 1833317.0 Cmax in black racial/ethnic human plasma at 400 mg, po twice daily after 8 days Scientific Literature 17101682.0 Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 2.857 ug.mL-1 4.076827580302231e-06 5.38967765560861 CHEMBL912751 1833312.0 Cmax in white racial/ethnic human plasma at 400 mg, po twice daily after 8 days Scientific Literature 17101682.0 Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 3.4979999999999998 ug.mL-1 4.991509582043123e-06 5.301768090848695 CHEMBL912746 1833305.0 Cmax in >=65 yr old woman plasma at 400 mg, po twice daily after 8 days Scientific Literature 17101682.0 Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 3.2499999999999987 ug.mL-1 4.637623253756473e-06 5.333704535012479 CHEMBL912741 1833294.0 Cmax in >=65 yr old man plasma at 400 mg, po twice daily after 8 days Scientific Literature 17101682.0 Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 2.517 ug.mL-1 3.5916608399092456e-06 5.44470468044299 CHEMBL913289 1833285.0 Cmax in 18-45 yr old woman plasma at 400 mg, po twice daily after 8 days Scientific Literature 17101682.0 Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 2.681999999999999 ug.mL-1 3.827109405099958e-06 5.417129122475773 CHEMBL913284 1833276.0 Cmax in 18-45 yr old man plasma at 400 mg, po twice daily after 8 days Scientific Literature 17101682.0 Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.4530000000000001 ug.mL-1 6.46413333523595e-07 6.189489693978521 CHEMBL1268718 3509310.0 Cmax in high fat fed healthy human plasma at 400 mg, po bid after 1 day Scientific Literature 20194702.0 Skin concentrations and pharmacokinetics of posaconazole after oral administration. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 3.374 ug.mL-1 4.8145664178998e-06 5.317442817738247 CHEMBL913279 1833265.0 Cmax in >=65 yr old human plasma at 400 mg, po twice daily after 8 days Scientific Literature 17101682.0 Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.6540000000000002 ug.mL-1 9.332324947559188e-07 6.0300101476670855 CHEMBL1220246 3385330.0 Cmax in patient undergoing allogenic hematopoietic stem cell transplantation Scientific Literature 19858252.0 Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.5440000000000002 ug.mL-1 7.762667846287765e-07 6.109988996293173 CHEMBL1681511 5230733.0 Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension after consumption of high fat meal Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.303 ug.mL-1 4.3236918335021906e-07 6.3641452674890475 CHEMBL1681512 5230734.0 Cmax in healthy human plasma at 400 mg administered as single dose suspension coadministered with nutritional supplement Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.232 ug.mL-1 3.3105495226815454e-07 6.480099911100453 CHEMBL1681513 5230735.0 Cmax in healthy human plasma at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.29400000000000004 ug.mL-1 4.1952653433981657e-07 6.3772405655791955 CHEMBL1681514 5230736.0 Cmax in healthy human plasma at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.623 ug.mL-1 8.889967037200874e-07 6.051099849332183 CHEMBL1675107 5230847.0 Cmax in plasma in hematopoietic stem cell transplant recipient human with GVHD and diarrhea Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 1.4599999999999997 ug.mL-1 2.083363061687524e-06 5.681235040206916 CHEMBL1675108 5230848.0 Cmax in plasma in hematopoietic stem cell transplant recipient human with GVHD Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 2.607 ug.mL-1 3.7200873300132715e-06 5.429446864823024 CHEMBL913274 1833259.0 Cmax in 18-45 yr old human plasma at 400 mg, po twice daily after 8 days Scientific Literature 17101682.0 Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 1.7399999999999998 ug.mL-1 2.4829121420111586e-06 5.605038647708753 CHEMBL1268719 3509311.0 Cmax in high fat fed healthy human plasma at 400 mg, po bid after 8 days Scientific Literature 20194702.0 Skin concentrations and pharmacokinetics of posaconazole after oral administration. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.2860000000000001 ug.mL-1 4.081108463305699e-07 6.38922186286231 CHEMBL1681353 5230723.0 Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.18099999999999997 ug.mL-1 2.582799412092067e-07 6.587909321122169 CHEMBL1681360 5230730.0 Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 2.0799999999999996 ug.mL-1 2.968078882404144e-06 5.527524561028591 CHEMBL1678136 5216126.0 Cmax in healthy human plasma at 400 mg, po BID by LS/MS analysis Scientific Literature 20516276.0 Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.32400000000000007 ug.mL-1 4.6233536437449176e-07 6.33504288578474 CHEMBL1654422 5164204.0 Cmax in healthy human at 400 mg/kg, po Scientific Literature 19433558.0 Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.266 ug.mL-1 3.795716263074531e-07 6.420706259360286 CHEMBL1653639 5164211.0 Cmax in healthy human at 400 mg/kg administered via nasogastric tube Scientific Literature 19433558.0 Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 2.0799999999999996 ug.mL-1 2.968078882404144e-06 5.527524561028591 CHEMBL1634008 5088989.0 Cmax in healthy human plasma at 400 mg, po every 12 hrs for 7 days Scientific Literature 19029316.0 Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.15100000000000005 ug.mL-1 2.154711111745317e-07 6.6666109486981835 CHEMBL1681352 5230722.0 Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.274 ug.mL-1 3.9098731431669983e-07 6.407837333170964 CHEMBL1681509 5230731.0 Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.0767 ug.mL-1 1.0944790878865283e-07 6.960792532042372 CHEMBL1681354 5230724.0 Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension coadministered with proton pump inhibitor Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.09330000000000001 ug.mL-1 1.3313546140783973e-07 6.875706252244853 CHEMBL1681355 5230725.0 Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.289 ug.mL-1 4.1239172933403726e-07 6.384690053234805 CHEMBL1653632 5164218.0 Cmax in healthy human at 400 mg/kg, po by ITT analysis Scientific Literature 19433558.0 Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 1.5900000000000003 ug.mL-1 2.2688679918377834e-06 5.644190771670901 CHEMBL1681357 5230727.0 Cmax in healthy human plasma at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 2.3 ug.mL-1 3.2820103026584283e-06 5.48386005997376 CHEMBL1681358 5230728.0 Cmax in fasted healthy human plasma at 200 mg QID, po administered as suspension for 7 days Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 2.16 ug.mL-1 3.082235762496611e-06 5.511134144840422 CHEMBL1681359 5230729.0 Cmax in healthy human plasma at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. POSACONAZOLE CHEMBL1397 334337 700.79 Cmax 0.9820000000000002 ug.mL-1 1.4012757031350337e-06 5.853476408204403 CHEMBL1681356 5230726.0 Cmax in fasted healthy human plasma at 400 mg BID, po administered as suspension for 7 days Scientific Literature 19075045.0 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. PRACTOLOL PRACTOLOL CHEMBL6995 1380 266.34 Normal/therapeutic blood-plasma concentration 5.0 mg/L 1.8772996921228507e-05 4.726466391072991 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PRAJMALIUM PRAJMALIUM CHEMBL3833412 2096463 369.53 Normal/therapeutic blood-plasma concentration 0.44 mg/L 1.190701702162206e-06 5.924197025529028 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PRAMIPEXOLE PRAMIPEXOLE CHEMBL301265 88815 211.33 Normal/therapeutic blood-plasma concentration 0.006999999999999999 mg/L 3.312355084465054e-08 7.4798631130230975 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PRAVASTATIN CHEMBL1144 178796 424.53 Cmax 99.99999999999999 nM 1e-07 7.0 CHEMBL944788 2075550.0 Cmax in human Scientific Literature 18155906.0 Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. PRAZEPAM PRAZEPAM CHEMBL969 95969 324.81 Normal/therapeutic blood-plasma concentration 0.7 mg/L 2.15510606200548e-06 5.666531351484576 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PRAZIQUANTEL PRAZIQUANTEL CHEMBL976 99024 312.41 Normal/therapeutic blood-plasma concentration 0.2 mg/L 6.401843730994527e-07 6.193694931190805 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PRAZOSIN PRAZOSIN CHEMBL2 97 383.41 Normal/therapeutic blood-plasma concentration 0.02 mg/L 5.216348034740878e-08 7.282633440181617 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PREDNISOLONE PREDNISOLONE CHEMBL131 27370 360.45 Normal/therapeutic blood-plasma concentration 1.0 mg/L 2.7743098904147594e-06 5.5568450298595815 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PREDNISOLONE CHEMBL131 27370 360.45 Cmax 0.458 ug.mL-1 1.27063392980996e-06 5.895979551855712 CHEMBL3889449 17806319.0 Pharmacokinetic parameters for different drugs, or their active metabolite following multiple oral or intravenous administration to subjects of varying health conditions. Curated Drug Pharmacokinetic Data Goodman and Gilman Ed. 12 | The Pharmaceutical Basis of Therapeutics| Table AII-I: Pharmacokinetic Data PREGABALIN PREGABALIN CHEMBL1059 136161 159.23 Normal/therapeutic blood-plasma concentration 8.0 mg/L 5.024178860767444e-05 4.298934908112094 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PRILOCAINE CHEMBL1194 208749 220.32 Cmax 0.07 ug.mL-1 3.1771968046477854e-07 6.497955882898592 CHEMBL3889430 17806210.0 Pharmacokinetic parameters for Lidocaine, and Prilocaine after topical administration of EMLA cream intact skin on the lateral thighs, vaginal fornices and penile skin of subjects Curated Drug Pharmacokinetic Data DailyMed|setid=823c2d42-d00d-401d-4081-fc1d434455e0 | EMLA- lidocaine cream|APP Pharmaceuticals, LLC PRILOCAINE CHEMBL1194 208749 220.32 Cmax 0.14 ug.mL-1 6.354393609295571e-07 6.1969258872346105 CHEMBL3889430 17806212.0 Pharmacokinetic parameters for Lidocaine, and Prilocaine after topical administration of EMLA cream intact skin on the lateral thighs, vaginal fornices and penile skin of subjects Curated Drug Pharmacokinetic Data DailyMed|setid=823c2d42-d00d-401d-4081-fc1d434455e0 | EMLA- lidocaine cream|APP Pharmaceuticals, LLC PRILOCAINE PRILOCAINE CHEMBL1194 208749 220.32 Normal/therapeutic blood-plasma concentration 2.0 mg/L 9.077705156136529e-06 5.042023927248867 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PRIMAQUINE PRIMAQUINE CHEMBL506 10389 259.35 Normal/therapeutic blood-plasma concentration 0.2 mg/L 7.71158665895508e-07 6.112856256665623 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PRIMIDONE PRIMIDONE CHEMBL856 65728 218.26 Normal/therapeutic blood-plasma concentration 15.0 mg/L 6.872537340786218e-05 4.162882891811399 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROBENECID CHEMBL897 77474 285.37 Cmax 123700.0 nM 0.0001237 3.9076303003708794 CHEMBL3784396 16519819.0 Cmax in po dosed human plasma at 500 mg measured after 48 hrs by HPLC analysis Scientific Literature 26422006.0 Inhibiting the Inflammasome: A Chemical Perspective. PROBENECID PROBENECID CHEMBL897 77474 285.37 Normal/therapeutic blood-plasma concentration 150.0 mg/L 0.0005256333882328205 3.2793170561866045 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROCAINAMIDE PROCAINAMIDE CHEMBL640 27341 235.33 Normal/therapeutic blood-plasma concentration 12.0 mg/L 5.09922236858879e-05 4.292496048761037 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROCAINE PROCAINE CHEMBL569 16581 236.31 Normal/therapeutic blood-plasma concentration 15.0 mg/L 6.347594261774787e-05 4.197390841133298 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROCHLORPERAZINE PROCHLORPERAZINE CHEMBL728 37266 373.95 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.3370771493515176e-07 6.873843533223436 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROCYCLIDINE PROCYCLIDINE CHEMBL86715 139241 287.45 Normal/therapeutic blood-plasma concentration 0.63 mg/L 2.1916855105235696e-06 5.659221763528412 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROMAZINE PROMAZINE CHEMBL564 16391 284.43 Normal/therapeutic blood-plasma concentration 0.4 mg/L 1.4063214147593432e-06 5.851915409967919 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROMETHAZINE PROMETHAZINE CHEMBL643 27368 284.43 Normal/therapeutic blood-plasma concentration 0.4 mg/L 1.4063214147593432e-06 5.851915409967919 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROPAFENONE PROPAFENONE CHEMBL631 27112 341.45 Normal/therapeutic blood-plasma concentration 2.0 mg/L 5.857372968223752e-06 5.232297121390443 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROPANTHELINE PROPANTHELINE CHEMBL1180725 654675 368.5 Normal/therapeutic blood-plasma concentration 0.02 mg/L 5.4274084124830396e-08 7.265407496531089 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROPIOMAZINE PROPIOMAZINE CHEMBL1201210 675161 340.49 Normal/therapeutic blood-plasma concentration 0.3 mg/L 8.810831448794384e-07 6.054983106731511 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROPOFOL PROPOFOL CHEMBL526 11819 178.27 Normal/therapeutic blood-plasma concentration 8.0 mg/L 4.487575026644976e-05 4.347988277492059 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics DEXTROPROPOXYPHENE PROPOXYPHENE CHEMBL1213351 685193 339.48 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.4728408153646753e-06 5.831844189168597 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROPRANOLOL PROPRANOLOL CHEMBL27 1370 259.35 Normal/therapeutic blood-plasma concentration 0.3 mg/L 1.1567379988432618e-06 5.9367649976099415 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROTHIPENDYL PROTHIPENDYL CHEMBL2111030 1383470 285.42 Normal/therapeutic blood-plasma concentration 0.01 mg/L 3.503608716978488e-08 7.455484401803545 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PROTRIPTYLINE PROTRIPTYLINE CHEMBL668 28112 263.38 Normal/therapeutic blood-plasma concentration 0.3 mg/L 1.1390386513782368e-06 5.943461538611436 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PSEUDOEPHEDRINE PSEUDOEPHEDRINE CHEMBL1590 454076 165.24 Normal/therapeutic blood-plasma concentration 0.8 mg/L 4.841442749939482e-06 5.315025199312605 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PYRAZINAMIDE CHEMBL614 23522 123.11 Cmax 59.329999999999984 ug.mL-1 0.0004819267321907236 3.3170189829726566 CHEMBL955459 2498991.0 Cmax in human at 1 to 2 mg, po Scientific Literature 17132069.0 OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PYRAZINAMIDE PYRAZINAMIDE CHEMBL614 23522 123.11 Normal/therapeutic blood-plasma concentration 75.0 mg/L 0.0006092112744699861 3.2152320679184103 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PYRAZINAMIDE CHEMBL614 23522 123.11 Cmax 45.999999999999986 ug.mL-1 0.00037364958167492474 3.427535499628536 CHEMBL958922 2345633.0 Cmax in tuberculosis patient at 1500 mg, po coadministered with 600 mg, po rifampin Scientific Literature 17452486.0 Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. PYRAZINAMIDE CHEMBL614 23522 123.11 Cmax 43.8 ug.mL-1 0.0003557793842904719 3.4488192208060107 CHEMBL958923 2345634.0 Cmax in tuberculosis patient at 1500 mg, po coadministered with 450 mg, po rifampin Scientific Literature 17452486.0 Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. PYRAZINAMIDE CHEMBL614 23522 123.11 Cmax 20.200000000000003 ug.mL-1 0.00016408090325724964 3.7849419618634865 CHEMBL1283291 3547650.0 Cmax in TB patient serum at 500 mg/kg TID Scientific Literature 20439617.0 Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. PYRAZINAMIDE CHEMBL614 23522 123.11 Cmax 45.49999999999999 ug.mL-1 0.00036958817317845824 3.432281934652998 CHEMBL1247257 3454418.0 Cmax in diabetic tuberculosis patient at 30 mg/kg, po by HPLC analysis Scientific Literature 20038625.0 Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. PYRAZINAMIDE CHEMBL614 23522 123.11 Cmax 47.0 ug.mL-1 0.000381772398667858 3.418195473374393 CHEMBL1247258 3454419.0 Cmax in tuberculosis patient at 30 mg/kg, po by HPLC analysis Scientific Literature 20038625.0 Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. PYRAZINAMIDE CHEMBL614 23522 123.11 Cmax 33.800000000000004 ug.mL-1 0.0002745512143611405 3.5613766310324553 CHEMBL1283292 3547651.0 Cmax in TB patient serum at 1500 mg/kg daily Scientific Literature 20439617.0 Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. PYRAZINAMIDE CHEMBL614 23522 123.11 Cmax 67.5 ug.mL-1 0.0005482901470229876 3.260989558479085 CHEMBL1283289 3547652.0 Cmax in TB patient serum at 3000 mg/kg administered alternate day Scientific Literature 20439617.0 Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. PYRIDOSTIGMINE PYRIDOSTIGMINE CHEMBL1115 157330 181.22 Normal/therapeutic blood-plasma concentration 0.2 mg/L 1.1036309458117206e-06 5.9571761304048465 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PYRIDOXINE PYRIDOXINE CHEMBL1364 308201 169.18 Normal/therapeutic blood-plasma concentration 0.018000000000000002 mg/L 1.0639555503014542e-07 6.973076515520331 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics PYRIMETHAMINE PYRIMETHAMINE CHEMBL36 2080 248.72 Normal/therapeutic blood-plasma concentration 1.5 mg/L 6.030878095850756e-06 5.219619449979454 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics QUAZEPAM QUAZEPAM CHEMBL1200472 674423 386.8 Normal/therapeutic blood-plasma concentration 0.15 mg/L 3.8779731127197514e-07 6.411395206355283 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics QUETIAPINE QUETIAPINE CHEMBL716 34234 383.52 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.3037129745515228e-06 5.88481801235356 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics QUINIDINE QUINIDINE CHEMBL1294 255477 324.42 Normal/therapeutic blood-plasma concentration 5.0 mg/L 1.5412120091239752e-05 4.812137615623249 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics QUININE QUININE CHEMBL170 255947 324.42 Normal/therapeutic blood-plasma concentration 7.0 mg/L 2.157696812773565e-05 4.666009579945012 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics RABEPRAZOLE RABEPRAZOLE CHEMBL1219 222203 359.45 Normal/therapeutic blood-plasma concentration 0.6 mg/L 1.6692168590902767e-06 5.777487237563911 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 7230.0 nM 7.23e-06 5.140861702705469 CHEMBL1285096 3543019.0 Cmax in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by ritonavir dosing at 100 mg, po bid for 16 days coadministered with compound at 400 mg, po on day 14 Scientific Literature 18838589.0 Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 1.4019999999999997 ug.mL-1 3.1546735070428867e-06 5.501045581404599 CHEMBL1677084 5216343.0 Cmax in healthy human plasma at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis Scientific Literature 20823282.0 Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 0.799 ug.mL-1 1.7978488816884929e-06 5.745246815721247 CHEMBL1677222 5216362.0 Cmax in healthy human plasma assessed as raltegravir-glucoronide at 400 mg, po Bid for 1 week by LC-MS/MS analysis Scientific Literature 20823282.0 Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 9570.0 nM 9.57e-06 5.019088062223156 CHEMBL1282946 3543013.0 Cmax in HIV-negative human at 400 mg, po administered as single dose Scientific Literature 18838589.0 Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 1540.0 nM 1.54e-06 5.8124792791635365 CHEMBL1284937 3543000.0 Cmax in healthy human plasma at 400 mg, po twice a day for 4 days coadministered with 200mg of etravirine twice a day for 4 days by reverse-phase HPLC-MS method Scientific Literature 18838586.0 Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 1740.0000000000002 nM 1.7400000000000003e-06 5.7594507517174005 CHEMBL1284936 3542999.0 Cmax in healthy human plasma at 400 mg, po twice a day for 4 days by reverse-phase HPLC-MS method Scientific Literature 18838586.0 Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 5340.000000000002 nM 5.340000000000002e-06 5.272458742971444 CHEMBL1654428 5164228.0 Cmax in healthy human at 400 mg/kg, po administered as single dose in presence of 600 mg/kg, po rifampin Scientific Literature 19433563.0 Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 8609.999999999996 nM 8.609999999999997e-06 5.064996848546345 CHEMBL1654434 5164234.0 Cmax in healthy human at 400 mg/kg, po administered as single dose Scientific Literature 19433563.0 Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 1950.0 nM 1.95e-06 5.709965388637482 CHEMBL1654440 5164240.0 Cmax in healthy human at 800 mg/kg, po BID for 14 days in presence of 600 mg/kg, po rifampin Scientific Literature 19433563.0 Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 1210.0000000000005 nM 1.2100000000000005e-06 5.91721462968355 CHEMBL1654444 5164244.0 Cmax in healthy human at 400 mg/kg, po BID for 4 days Scientific Literature 19433563.0 Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 1.016 ug.mL-1 2.28612573691553e-06 5.640899887087338 CHEMBL1676673 5216335.0 Cmax in healthy human plasma at 400 mg, po Bid for 1 week by LC-MS/MS analysis Scientific Literature 20823282.0 Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 6449.999999999997 nM 6.4499999999999975e-06 5.1904402853647325 CHEMBL1285090 3543025.0 Cmax in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by efavirenz dosing at 600 mg, po bid for 14 days coadministered with compound at 400 mg, po on day 12 Scientific Literature 18838589.0 Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 1.445 ug.mL-1 3.2514288285855724e-06 5.487925747942672 CHEMBL1691470 5298748.0 Cmax in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose by LC-MS/MS in presence of albuminium, magnesium and simethicone-containg antacid Scientific Literature 20921313.0 Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 3850.0 nM 3.85e-06 5.414539270491499 CHEMBL1661636 5148777.0 Cmax in patient with severe renal insufficiency at 400 mg, po administered as single dose Scientific Literature 19223645.0 Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 2.6399999999999997 ug.mL-1 5.940326717969487e-06 5.226189668165407 CHEMBL1696104 5300804.0 Cmax in HIV-infected human plasma at 800 mg qd for 10 days administered in fasted condition on day 10 by HPLC with fluorescence detector Scientific Literature 20937791.0 Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients. RALTEGRAVIR RALTEGRAVIR CHEMBL254316 422253 444.42 Normal/therapeutic blood-plasma concentration 0.118 mg/L 2.6551460330318165e-07 6.575911587729113 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 4409.999999999999 nM 4.409999999999999e-06 5.355561410532162 CHEMBL1661492 5148765.0 Cmax in patient with hepatic insufficiency at 400 mg, po administered as single dose Scientific Literature 19223645.0 Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 5679.999999999999 nM 5.68e-06 5.245651664288981 CHEMBL1661498 5148771.0 Cmax in healthy human at 400 mg, po administered as single dose Scientific Literature 19223645.0 Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 0.458 ug.mL-1 1.030556680617434e-06 5.986928117031369 CHEMBL1677228 5216368.0 Cmax in healthy human plasma assessed as raltegravir-glucoronide at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis Scientific Literature 20823282.0 Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. RALTEGRAVIR CHEMBL254316 422253 444.42 Cmax 0.9450000000000002 ug.mL-1 2.1263669501822606e-06 5.6723617865259754 CHEMBL1691472 5298751.0 Cmax in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose by LC-MS/MS Scientific Literature 20921313.0 Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. RAMIPRIL RAMIPRIL CHEMBL1168 189203 416.52 Normal/therapeutic blood-plasma concentration 0.04 mg/L 9.603380389897245e-08 7.0175758683910745 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics RANITIDINE RANITIDINE CHEMBL1790041 1153672 314.41 Normal/therapeutic blood-plasma concentration 1.0 mg/L 3.180560414745078e-06 5.497496350585415 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics REBOXETINE REBOXETINE CHEMBL14370 14263 313.4 Normal/therapeutic blood-plasma concentration 0.35 mg/L 1.116783663050415e-06 5.952030947782296 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics REMIFENTANIL REMIFENTANIL CHEMBL1005 111871 376.45 Normal/therapeutic blood-plasma concentration 0.02 mg/L 5.312790543232833e-08 7.274677305812702 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics REMOXIPRIDE REMOXIPRIDE CHEMBL22242 27616 371.28 Normal/therapeutic blood-plasma concentration 2.15 mg/L 5.790777849601379e-06 5.2372630954953685 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.0366 ug.mL-1 8.086610693769332e-08 7.092233464224299 CHEMBL3538936 15467729.0 Cmax in healthy white human with SLCO1B1 521TT/CYP2C8*3/*3 combined genotype at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.05279999999999999 ug.mL-1 1.166593018117543e-07 6.933080627084897 CHEMBL3541217 15467792.0 Cmax in healthy white human at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.0603 ug.mL-1 1.332302253645603e-07 6.875397237478558 CHEMBL3541218 15467791.0 Cmax in healthy white human with CYP2C8*1/*1 genotype at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.05030000000000002 ug.mL-1 1.1113566062748567e-07 6.954146564562782 CHEMBL3541219 15467790.0 Cmax in healthy white human with CYP2C8*1/*3 genotype at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.0385 ug.mL-1 8.506407423773751e-08 7.070253820110209 CHEMBL3541220 15467789.0 Cmax in healthy white human with CYP2C8*3/*3 genotype at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.052500000000000005 ug.mL-1 1.1599646486964209e-07 6.935555246212753 CHEMBL3538911 15467755.0 Cmax in healthy white human with SLCO1B1 521TT/CYP2C8*1/*1 combined genotype at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.08370000000000001 ug.mL-1 1.849315068493151e-07 6.732989091625449 CHEMBL3538916 15467750.0 Cmax in healthy white human with SLCO1B1 521TC/CYP2C8*1/*1 combined genotype at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.057000000000000016 ug.mL-1 1.259390190013257e-07 6.899839693946218 CHEMBL3538921 15467745.0 Cmax in healthy white human with SLCO1B1 521TT/CYP2C8*1/*3 combined genotype at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.044999999999999984 ug.mL-1 9.942554131683602e-08 7.002502035843366 CHEMBL3538926 15467740.0 Cmax in healthy white human with SLCO1B1 521TC/CYP2C8*1/*3 combined genotype at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.0177 ug.mL-1 3.910737958462218e-08 7.407741283256903 CHEMBL3538931 15467735.0 Cmax in healthy white human with SLCO1B1 521CC/CYP2C8*1/*3 combined genotype at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.015299999999999998 ug.mL-1 3.3804684047724254e-08 7.471023118801111 CHEMBL3541856 15459105.0 Cmax in healthy white human with SLCO1B1 521TC/CYP2C8*3/*3 combined genotype at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. REPAGLINIDE CHEMBL1272 248669 452.6 Cmax 0.06790000000000002 ug.mL-1 1.5002209456473708e-07 6.823844775338208 CHEMBL3541861 15459100.0 Cmax in healthy white human with SLCO1B1 521CC/CYP2C8*3/*3 combined genotype at 2 mg, po Scientific Literature 21270106.0 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. RETINOL RETINOL CHEMBL986 104574 286.46 Normal/therapeutic blood-plasma concentration 0.8 mg/L 2.7927110242267686e-06 5.553974000595658 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics RIFABUTIN RIFABUTIN CHEMBL444633 397074 847.02 Normal/therapeutic blood-plasma concentration 0.15 mg/L 1.7709145002479279e-07 6.751802406041366 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics RIFABUTIN CHEMBL444633 397074 847.02 Cmax 7.290000000000002 ug.mL-1 8.606644471204934e-06 5.065166136779073 CHEMBL1026295 2679082.0 Cmax in human at 150 mg, po QOD co-treated with 700 mg, po fosamprenavir BID and 100 mg ritonavir po BID Scientific Literature 18056271.0 Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. RIFABUTIN CHEMBL444633 397074 847.02 Cmax 0.023999999999999997 ug.mL-1 2.8334632003966844e-08 7.547682423385442 CHEMBL1026298 2679085.0 Cmax in human assessed as dAc-RFB level at 300 mg, po QD Scientific Literature 18056271.0 Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. RIFABUTIN CHEMBL444633 397074 847.02 Cmax 0.139 ug.mL-1 1.6410474368964135e-07 6.784878864842953 CHEMBL1026302 2679089.0 Cmax in human assessed as dAc-RFB level at 150 mg, po QD po QD coadministered with 700 mg fosamprenavir and 100 mg ritonavir po BID Scientific Literature 18056271.0 Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. RIFABUTIN CHEMBL444633 397074 847.02 Cmax 0.3129999999999999 ug.mL-1 3.6953082571840086e-07 6.432349327550599 CHEMBL1026289 2679077.0 Cmax in human at 300 mg, po QD Scientific Literature 18056271.0 Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. RIFABUTIN CHEMBL444633 397074 847.02 Cmax 0.26799999999999996 ug.mL-1 3.164033907109631e-07 6.499758871068259 CHEMBL1026292 2679079.0 Cmax in human at 150 mg, po QD po QD coadministered with 700 mg fosamprenavir and 100 mg ritonavir po BID Scientific Literature 18056271.0 Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 10.11 ug.mL-1 1.2285071997083661e-05 4.910622293978811 CHEMBL992319 2499967.0 Cmax in HIV-negative human at 600 mg, po administered every 24 hrs coadministered with 400 mg of atazanavir every 12 hrs Scientific Literature 17576825.0 Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 17.999999999999993 ug.mL-1 2.1872531745549536e-05 4.660100944466506 CHEMBL1696172 5306505.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 10.500000000000002 ug.mL-1 1.2758976851570571e-05 4.894184150499874 CHEMBL1247238 3454388.0 Cmax in diabetic tuberculosis patient at 10 mg/kg, po and 10 mg/kg, iv by HPLC analysis Scientific Literature 20038625.0 Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 9.599999999999998 ug.mL-1 1.1665350264293089e-05 4.933102216530243 CHEMBL1247239 3454389.0 Cmax in tuberculosis patient at 10 mg/kg, po by HPLC analysis Scientific Literature 20038625.0 Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 15.0 ug.mL-1 1.8227109787957954e-05 4.739282190514131 CHEMBL1697240 5305182.0 Cmax in serum of human patient undergoing fibre-optic bronchoscopy at 600 mg, po administered as single dose Scientific Literature 19114679.0 Roles of NF-kappaB activation and peroxisome proliferator-activated receptor gamma inhibition in the effect of rifampin on inducible nitric oxide synthase transcription in human lung epithelial cells. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 2.5299999999999994 ug.mL-1 3.074305850902241e-06 5.512252928393994 CHEMBL990070 2556288.0 Cmax in Mycobacterium tuberculosis infected patient at 3 mg/kg Scientific Literature 17517849.0 Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 8.0 ug.mL-1 9.721125220244242e-06 5.0122834625778685 CHEMBL1695954 5303979.0 Cmax in healthy human at 10 mg/kg, po Scientific Literature 19075046.0 New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 14.000000000000004 ug.mL-1 1.701196913542743e-05 4.769245413891574 CHEMBL990073 2556291.0 Cmax in Mycobacterium tuberculosis infected patient at 20 mg/kg, po administered daily for 5 days Scientific Literature 17517849.0 Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 9.489999999999998 ug.mL-1 1.1531684792514732e-05 4.938107237142519 CHEMBL992312 2499953.0 Cmax in HIV-negative human at 600 mg, po administered every 24 hrs coadministered with 300 mg of atazanavir every 12 hrs Scientific Literature 17576825.0 Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 7.000000000000002 ug.mL-1 8.505984567713715e-06 5.0702754095555544 CHEMBL3889406 17806010.0 Evaluation of pharmacokinetic parameters for Rifampin in serum following single oral administration of 10 mg/kg Rifampin to pediatric patients. Range 4 To 32 Mcg/Ml Curated Drug Pharmacokinetic Data DailyMed|setid=d7131853-8850-45bd-9227-c4b1916dd28d | RIFAMPIN- rifampin capsule|Rebel Distributors Corp RIFAMPIN CHEMBL374478 365189 822.95 Cmax 11.499999999999996 ug.mL-1 1.3974117504101095e-05 4.8546756092162004 CHEMBL3889406 17806015.0 Evaluation of pharmacokinetic parameters for Rifampin in serum following single oral administration of 10 mg/kg Rifampin to pediatric patients. Curated Drug Pharmacokinetic Data DailyMed|setid=d7131853-8850-45bd-9227-c4b1916dd28d | RIFAMPIN- rifampin capsule|Rebel Distributors Corp RIFAMPIN CHEMBL374478 365189 822.95 Cmax 10.700000000000005 ug.mL-1 1.300200498207668e-05 4.885989671884602 CHEMBL3889406 17806013.0 Evaluation of pharmacokinetic parameters for Rifampin in serum following single oral administration of 10 mg/kg Rifampin to pediatric patients. Curated Drug Pharmacokinetic Data DailyMed|setid=d7131853-8850-45bd-9227-c4b1916dd28d | RIFAMPIN- rifampin capsule|Rebel Distributors Corp RIFAMPICIN RIFAMPIN CHEMBL374478 365189 822.95 Normal/therapeutic blood-plasma concentration 10.0 mg/L 1.2151406525305304e-05 4.915373449569812 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics RIFAMPIN CHEMBL374478 365189 822.95 Cmax 9.999999999999998 ug.mL-1 1.2151406525305302e-05 4.915373449569812 CHEMBL1663041 5159746.0 Cmax in human at 600 mg, po Scientific Literature 19223616.0 Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 2.0 ug.mL-1 2.4302813050610606e-06 5.614343453905831 CHEMBL1657570 5156842.0 Cmax in simulated human serum in in vitro hollow-fiber PK model at 600 mg administered every 24 hrs by HPLC Scientific Literature 18519719.0 Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 12.999999999999995 ug.mL-1 1.5796828482896886e-05 4.801430097262975 CHEMBL990072 2556290.0 Cmax in Mycobacterium tuberculosis infected patient at 12 mg/kg Scientific Literature 17517849.0 Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 8000.0 nM 8.000000000000001e-06 5.096910013008056 CHEMBL948861 2628579.0 Cmax in patient with severe malaria at 200 mg, perorally Scientific Literature 17698630.0 Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 10.500000000000002 ug.mL-1 1.2758976851570571e-05 4.894184150499874 CHEMBL1032832 2667150.0 Cmax in fasted healthy human serum at 600 mg, po by high-pressure liquid chromatography Scientific Literature 18070962.0 Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 3.500000000000001 ug.mL-1 4.2529922838568575e-06 5.371305405219536 CHEMBL3889406 17806018.0 Evaluation of pharmacokinetic parameters for Rifampin in serum following single oral administration of 10 mg/kg Rifampin to pediatric patients. Curated Drug Pharmacokinetic Data DailyMed|setid=d7131853-8850-45bd-9227-c4b1916dd28d | RIFAMPIN- rifampin capsule|Rebel Distributors Corp RIFAMPIN CHEMBL374478 365189 822.95 Cmax 3.1899999999999995 ug.mL-1 3.876298681572391e-06 5.41158276651263 CHEMBL990071 2556289.0 Cmax in Mycobacterium tuberculosis infected patient at 6 mg/kg Scientific Literature 17517849.0 Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 10.500000000000002 ug.mL-1 1.2758976851570571e-05 4.894184150499874 CHEMBL958905 2345615.0 Cmax in tuberculosis patient at 450 mg, po Scientific Literature 17452486.0 Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 1.1999999999999997 ug.mL-1 1.458168783036636e-06 5.836192203522187 CHEMBL958916 2345638.0 Cmax in tuberculosis patient assessed as desacetylrifampin level at 450 mg, po Scientific Literature 17452486.0 Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 2.1999999999999997 ug.mL-1 2.6733094355671664e-06 5.572950768747606 CHEMBL958915 2345640.0 Cmax in tuberculosis patient assessed as desacetylrifampin level at 600 mg, po Scientific Literature 17452486.0 Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 5.5 ug.mL-1 6.683273588917916e-06 5.175010760075568 CHEMBL955453 2498866.0 Cmax in human at 450 mg, po Scientific Literature 17132069.0 OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. RIFAMPIN CHEMBL374478 365189 822.95 Cmax 15.599999999999996 ug.mL-1 1.895619417947627e-05 4.72224885121535 CHEMBL958906 2345614.0 Cmax in human tuberculosis patient at 600 mg, po Scientific Literature 17452486.0 Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. RIFAPENTINE CHEMBL1660 497291 877.04 Cmax 9.999999999999998 ug.mL-1 1.1401988506795583e-05 4.943019401100504 CHEMBL1695961 5303984.0 Cmax in healthy human at 600 mg/kg, po Scientific Literature 19075046.0 New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. RIFAPENTINE CHEMBL1660 497291 877.04 Cmax 21.9 ug.mL-1 2.497035482988233e-05 4.602575286260386 CHEMBL1680485 5227733.0 Cmax in healthy human at 900 mg, po administered as a single dose measured on day 5 post compound dose by HPLC Scientific Literature 18765687.0 Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. RIFAPENTINE CHEMBL1660 497291 877.04 Cmax 21.2 ug.mL-1 2.417221563440664e-05 4.616683540171753 CHEMBL1680491 5227739.0 Cmax in healthy human at 900 mg, po thrice weekly measured on day 19 post compound dose by HPLC Scientific Literature 18765687.0 Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. RIFAXIMIN CHEMBL1617 466768 785.89 Cmax 0.0012300000000000002 ug.mL-1 1.5651045311684845e-09 8.805456651220654 CHEMBL1266514 3493975.0 Cmax in Shigella flexneri challenged human at 200 mg/kg, po administered every 8 hrs for three days measured after last dose Scientific Literature 18086855.0 Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. RIFAXIMIN CHEMBL1617 466768 785.89 Cmax 0.00163 ug.mL-1 2.0740816144753084e-09 8.683174158256096 CHEMBL1264469 3493972.0 Cmax in Shigella flexneri challenged human at 200 mg/kg, po administered every 8 hrs for three days measured after third dose Scientific Literature 18086855.0 Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. RILUZOLE RILUZOLE CHEMBL744 38898 234.2 Normal/therapeutic blood-plasma concentration 0.5 mg/L 2.1349274124679764e-06 5.6706168864003255 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics RIMONABANT CHEMBL111 16088 463.8 Cmax 399.99999999999994 nM 4e-07 6.3979400086720375 CHEMBL3532640 15455069.0 Cmax in male human subjects Scientific Literature 21511945.0 Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4. RISPERIDONE RISPERIDONE CHEMBL85 7714 410.49 Normal/therapeutic blood-plasma concentration 0.02 mg/L 4.87222587639163e-08 7.312272586016282 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics RITONAVIR RITONAVIR CHEMBL163 88100 720.96 Normal/therapeutic blood-plasma concentration 20.0 mg/L 2.7740790057700843e-05 4.556881174379756 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics RITONAVIR CHEMBL163 88100 720.96 Cmax 0.8795000000000002 ug.mL-1 1.2199012427873949e-06 5.913675326250257 CHEMBL981606 2500918.0 Cmax in HIV1 infected human at 100 mg, po administered twice daily Scientific Literature 17576836.0 Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. RITONAVIR CHEMBL163 88100 720.96 Cmax 10.500000000000002 ug.mL-1 1.4563914780292946e-05 4.836721870973799 CHEMBL955383 2626602.0 Cmax in human at 400 mg, po bid from day 11 to day 20 pretreated with placebo from day 1 to day 3 followed by washout from day 4 to day 10 Scientific Literature 17646413.0 Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. RITONAVIR CHEMBL163 88100 720.96 Cmax 10.700000000000005 ug.mL-1 1.4841322680869957e-05 4.828527392358527 CHEMBL955379 2626580.0 Cmax in human at 400 mg, po bid from day 11 to day 20 pretreated with voriconazole 400 mg, po bid on day 1 and 200 mg, po bid on day 2 and 3 followed by washout from day 4 to day 10 Scientific Literature 17646413.0 Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. RITONAVIR CHEMBL163 88100 720.96 Cmax 10.399999999999997 ug.mL-1 1.4425210830004435e-05 4.840877830744956 CHEMBL955390 2626609.0 Cmax in human at 400 mg, po bid from day 11 to day 20 pretreated with voriconazole 400 mg, po bid on day 1 and 200 mg, po bid on day 2 and 3 followed by washout from day 4 to day 10 followed by 400 mg, po of drug coadministered with voriconazole 200 mg, po from day 21 to day 30 Scientific Literature 17646413.0 Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. RITONAVIR CHEMBL163 88100 720.96 Cmax 1.4100000000000004 ug.mL-1 1.95572569906791e-06 5.708692057388356 CHEMBL955386 2626605.0 Cmax in human at 100 mg, po bid from day 11 to day 20 pretreated with voriconazole 400 mg, po bid on day 1 and 200 mg, po bid on day 2 and 3 followed by washout from day 4 to day 10 Scientific Literature 17646413.0 Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. RITONAVIR CHEMBL163 88100 720.96 Cmax 0.5999999999999999 ug.mL-1 8.322237017310251e-07 6.079759919660093 CHEMBL1661872 5149042.0 Cmax in HIV-infected Thai pregnant women at 100 mg, po bid initiated intrapartum in combination with 400 mg, po bid Lopinavir measured within 72 hrs postpartum Scientific Literature 19237646.0 Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women. RITONAVIR CHEMBL163 88100 720.96 Cmax 0.884 ug.mL-1 1.2261429205503773e-06 5.911458905030663 CHEMBL1633644 5095536.0 Cmax in HIV-infected patient at 100 mg, qd co-administered with 100 mg minocycline and 250 mg valporic acid, bid for 15 days Scientific Literature 18573930.0 Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. RITONAVIR CHEMBL163 88100 720.96 Cmax 0.99 ug.mL-1 1.3731691078561916e-06 5.862275975446187 CHEMBL1633643 5095535.0 Cmax in HIV-infected patient at 100 mg, qd co-administered with 100 mg minocycline, bid for 15 days Scientific Literature 18573930.0 Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. RITONAVIR CHEMBL163 88100 720.96 Cmax 0.525 ug.mL-1 7.281957390146472e-07 6.13775186663778 CHEMBL1674645 5223441.0 Cmax in HIV-1 infected patient at 100 mg, po bid coadministered with 400 mg, po bid of Lopinavir and NRTI Scientific Literature 18411323.0 Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. RITONAVIR CHEMBL163 88100 720.96 Cmax 0.8690000000000002 ug.mL-1 1.2053373280071017e-06 5.918891393595071 CHEMBL1674640 5223436.0 Cmax in HIV-1 infected patient at 100 mg, po bid coadministered with 300 mg, po qd of atazanavir and NRTI Scientific Literature 18411323.0 Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. RITONAVIR CHEMBL163 88100 720.96 Cmax 0.957 ug.mL-1 1.3273968042609853e-06 5.876999232266893 CHEMBL1633642 5095534.0 Cmax in HIV-infected patient at 100 mg, qd Scientific Literature 18573930.0 Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. RITONAVIR CHEMBL163 88100 720.96 Cmax 0.4680000000000001 ug.mL-1 6.491344873501999e-07 6.187665316969612 CHEMBL1674628 5223431.0 Cmax in HIV-1 infected patient at 100 mg, po bid coadministered with 400 mg, po bid of Lopinavir and 300 mg, po qd of atazanavir Scientific Literature 18411323.0 Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. RITONAVIR CHEMBL163 88100 720.96 Cmax 10.200000000000001 ug.mL-1 1.4147802929427431e-05 4.849310998281819 CHEMBL1003252 2626621.0 Cmax in human at 400 mg, po bid from day 11 to day 20 pretreated with placebo from day 1 to day 3 followed by washout from day 4 to day 10 followed by 400 mg, po of drug coadministered with placebo from day 21 to day 30 Scientific Literature 17646413.0 Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. RITONAVIR CHEMBL163 88100 720.96 Cmax 0.9920000000000002 ug.mL-1 1.375943186861962e-06 5.861399497889558 CHEMBL1000560 2626613.0 Cmax in human at 100 mg, po bid from day 11 to day 20 pretreated with voriconazole 400 mg, po bid on day 1 and 200 mg, po bid on day 2 and 3 followed by washout from day 4 to day 10 followed by 100 mg, po of drug coadministered with voriconazole 200 mg, po from day 21 to day 30 Scientific Literature 17646413.0 Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. RIVASTIGMINE RIVASTIGMINE CHEMBL636 27251 250.34 Normal/therapeutic blood-plasma concentration 0.02 mg/L 7.989134776703684e-08 7.097500252231686 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics RIZATRIPTAN RIZATRIPTAN CHEMBL905 79047 269.35 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.7126415444588824e-07 6.430316979881974 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ROCURONIUM ROCURONIUM CHEMBL1201244 675195 529.79 Normal/therapeutic blood-plasma concentration 17.0 mg/L 3.2088185884973296e-05 4.493654835176735 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ROPINIROLE ROPINIROLE CHEMBL589 19316 260.38 Normal/therapeutic blood-plasma concentration 0.006 mg/L 2.304324448882403e-08 7.637456372280504 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ROSIGLITAZONE CHEMBL121 20027 357.44 Cmax 0.07600000000000003 ug.mL-1 2.126230975828112e-07 6.672389559154723 CHEMBL3889402 17806193.0 Mean pharmacokinetic parameters for Rosiglitazone following single oral doses to 32 healthy fasted or fed subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | ROSIGLITAZONE MALEATE - rosiglitazone maleate tablet|West-ward Pharmaceutical Corp ROSIGLITAZONE CHEMBL121 20027 357.44 Cmax 0.156 ug.mL-1 4.364368845120859e-07 6.3600785530810535 CHEMBL3889402 17806196.0 Mean pharmacokinetic parameters for Rosiglitazone following single oral doses to 32 healthy fasted or fed subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | ROSIGLITAZONE MALEATE - rosiglitazone maleate tablet|West-ward Pharmaceutical Corp ROSIGLITAZONE CHEMBL121 20027 357.44 Cmax 0.43199999999999994 ug.mL-1 1.2085944494180839e-06 5.917719404620603 CHEMBL3889402 17806206.0 Mean pharmacokinetic parameters for Rosiglitazone following single oral doses to 32 healthy fasted or fed subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | ROSIGLITAZONE MALEATE - rosiglitazone maleate tablet|West-ward Pharmaceutical Corp ROSIGLITAZONE ROSIGLITAZONE CHEMBL121 20027 357.44 Normal/therapeutic blood-plasma concentration 0.3 mg/L 8.393017009847806e-07 6.076081896715853 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ROSIGLITAZONE CHEMBL121 20027 357.44 Cmax 0.598 ug.mL-1 1.6730080572963294e-06 5.776501967447104 CHEMBL3889402 17806201.0 Mean pharmacokinetic parameters for Rosiglitazone following single oral doses to 32 healthy fasted or fed subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | ROSIGLITAZONE MALEATE - rosiglitazone maleate tablet|West-ward Pharmaceutical Corp ROSUVASTATIN CHEMBL1496 418845 481.55 Cmax 74.99999999999999 nM 7.5e-08 7.1249387366083 CHEMBL944788 2075551.0 Cmax in human Scientific Literature 18155906.0 Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. ROSUVASTATIN CHEMBL1496 418845 481.55 Cmax 0.004579999999999999 ug.mL-1 9.51095421036237e-09 8.021775909192346 CHEMBL1786157 6212668.0 Cmax in human plasma at 10 mg administered qd for 14 days Scientific Literature 21183342.0 Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution. ROSUVASTATIN CHEMBL1496 418845 481.55 Cmax 5.999999999999999 nM 5.999999999999999e-09 8.221848749616356 CHEMBL3540628 15444800.0 Cmax in healthy human at 20 mg, po Scientific Literature 22855735.0 The role of a basolateral transporter in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell monolayer systems. ROXITHROMYCIN CHEMBL1214185 686036 837.06 Cmax 7.9 ug.mL-1 9.437794184407333e-06 5.025129497807947 CHEMBL921223 2130389.0 Cmax in human at 150 mg, po administered as single dose Scientific Literature 17936632.0 A new insight into solid-state conformation of macrolide antibiotics. ROXITHROMYCIN ROXITHROMYCIN CHEMBL1214185 686036 837.06 Normal/therapeutic blood-plasma concentration 12.0 mg/L 1.4335889900365566e-05 4.843575343050763 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SALICYLIC ACID CHEMBL424 1362 138.12 Cmax 34.10000000000001 ug.mL-1 0.00024688676513176955 3.6075021906849187 CHEMBL3509403 15444022.0 Mean Cmax of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human FDA Approval Packages FDA drug approval package for Aspirin (clinical pharmacology review, Ref:ID 3227827) SALICYLIC ACID CHEMBL424 1362 138.12 Cmax 16.8 ug.mL-1 0.0001216333622936577 3.914947287951554 CHEMBL3509397 15444016.0 Mean Cmax of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human FDA Approval Packages FDA drug approval package for Aspirin (clinical pharmacology review, Ref:ID 3227827) SALICYLIC ACID SALICYLIC ACID CHEMBL424 1362 138.12 Normal/therapeutic blood-plasma concentration 200.0 mg/L 0.0014480162177816392 2.8392265740134355 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SAQUINAVIR CHEMBL114 17169 670.86 Cmax 0.332 ug.mL-1 4.948871597650778e-07 6.30549381415311 CHEMBL3509581 15444198.0 Mean exposure of saquinavir mesylate estimated by Cmax following oral repeat dosing of 1000 mg Invirase Film-coated tablet in healthy human FDA Approval Packages FDA drug approval package for saquinavir mesylate (NDA: 21-785) SAQUINAVIR CHEMBL114 17169 670.86 Cmax 0.285 ug.mL-1 4.2482783293086485e-07 6.371787037848636 CHEMBL3509580 15444197.0 Mean exposure of saquinavir mesylate estimated by Cmax following oral repeat dosing of 1000 mg Invirase Hard Gel Capsules capsules in healthy human FDA Approval Packages FDA drug approval package for saquinavir mesylate (NDA: 21-785) SAQUINAVIR CHEMBL114 17169 670.86 Cmax 3.6720000000000006 ug.mL-1 5.473571236919776e-06 5.261729225327941 CHEMBL951340 2126227.0 Cmax in HIV infected patient plasma after 24 hrs Scientific Literature 17371813.0 Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients. SAQUINAVIR CHEMBL114 17169 670.86 Cmax 0.26499999999999996 ug.mL-1 3.950153534269445e-07 6.403386023920338 CHEMBL3509578 15444195.0 Mean exposure of saquinavir mesylate estimated by Cmax following oral repeat dosing of 1000 mg Invirase Hard Gel Capsules capsules in healthy men FDA Approval Packages FDA drug approval package for saquinavir mesylate (NDA: 21-785) SAQUINAVIR CHEMBL114 17169 670.86 Cmax 0.3949999999999999 ug.mL-1 5.887964702024266e-07 6.230034802230685 CHEMBL3509577 15444194.0 Mean exposure of saquinavir mesylate estimated by Cmax following oral repeat dosing of 1000 mg Invirase Film-coated tablet in healthy woman FDA Approval Packages FDA drug approval package for saquinavir mesylate (NDA: 21-785) SAQUINAVIR CHEMBL114 17169 670.86 Cmax 0.30599999999999994 ug.mL-1 4.5613093640998115e-07 6.340910471375566 CHEMBL3509576 15444193.0 Mean exposure of saquinavir mesylate estimated by Cmax following oral repeat dosing of 1000 mg Invirase Hard Gel Capsules capsules in healthy woman FDA Approval Packages FDA drug approval package for saquinavir mesylate (NDA: 21-785) SAQUINAVIR CHEMBL114 17169 670.86 Cmax 0.332 ug.mL-1 4.948871597650778e-07 6.30549381415311 CHEMBL3509564 15444181.0 Geometric mean of Cmax of saquinavir mesylate following oral repeat dosing of 1000 mg Invirase Film-coated tablet in healthy human FDA Approval Packages FDA drug approval package for saquinavir mesylate (NDA: 21-785) SAQUINAVIR CHEMBL114 17169 670.86 Cmax 0.404 ug.mL-1 6.022120859791909e-07 6.220250532746541 CHEMBL3509563 15444180.0 Arithmetic mean of Cmax of saquinavir mesylate following oral repeat dosing of 1000 mg Invirase Film-coated tablet in healthy human FDA Approval Packages FDA drug approval package for saquinavir mesylate (NDA: 21-785) SAQUINAVIR CHEMBL114 17169 670.86 Cmax 0.285 ug.mL-1 4.2482783293086485e-07 6.371787037848636 CHEMBL3509553 15444170.0 Geometric mean of Cmax of saquinavir mesylate following oral repeat dosing of 1000 mg Invirase Hard Gel Capsules capsules in healthy human FDA Approval Packages FDA drug approval package for saquinavir mesylate (NDA: 21-785) SAQUINAVIR CHEMBL114 17169 670.86 Cmax 0.348 ug.mL-1 5.18737143368214e-07 6.285052653910565 CHEMBL3509552 15444169.0 Arithmetic mean of Cmax of saquinavir mesylate following oral repeat dosing of 1000 mg Invirase Hard Gel Capsules capsules in healthy human FDA Approval Packages FDA drug approval package for saquinavir mesylate (NDA: 21-785) SAQUINAVIR CHEMBL114 17169 670.86 Cmax 3.3200000000000003 ug.mL-1 4.9488715976507775e-06 5.30549381415311 CHEMBL951352 2126239.0 Cmax in HIV infected virological failure patient plasma after 24 hrs Scientific Literature 17371813.0 Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients. SAQUINAVIR CHEMBL114 17169 670.86 Cmax 2.6150000000000007 ug.mL-1 3.897981695137585e-06 5.409160204653853 CHEMBL993203 2500911.0 Cmax in HIV1 infected human at 1000 mg, po administered twice daily Scientific Literature 17576836.0 Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. SAQUINAVIR CHEMBL114 17169 670.86 Cmax 3.599999999999999 ug.mL-1 5.366246310705661e-06 5.270329397089858 CHEMBL1696358 5294725.0 Cmax in HIV-infected patient at 480 mg/m2, po administered every 12 hrs for 6 weeks co-administered with 120 mg/m2 of ritonavir and saquinavir Scientific Literature 18625762.0 Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. SAQUINAVIR CHEMBL114 17169 670.86 Cmax 149.99999999999997 nM 1.5e-07 6.823908740944319 CHEMBL3414246 15189977.0 Maximum concentration at steady state in HIV infected patient Scientific Literature 25707014.0 Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir. SAQUINAVIR CHEMBL114 17169 670.86 Cmax 0.278 ug.mL-1 4.143934651044928e-07 6.38258710193907 CHEMBL3509579 15444196.0 Mean exposure of saquinavir mesylate estimated by Cmax following oral repeat dosing of 1000 mg Invirase Film-coated tablet in healthy men FDA Approval Packages FDA drug approval package for saquinavir mesylate (NDA: 21-785) SAQUINAVIR SAQUINAVIR CHEMBL114 17169 670.86 Normal/therapeutic blood-plasma concentration 0.25 mg/L 3.7265599379900425e-07 6.428691889185108 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SAXAGLIPTIN CHEMBL385517 360723 315.42 Cmax 0.7790000000000001 ug.mL-1 2.469722909137024e-06 5.6073517697295046 CHEMBL3536335 15465636.0 Cmax in human at 50 mg, po by LC-MS/MS analysis Scientific Literature 22496391.0 Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human. SAXAGLIPTIN CHEMBL385517 360723 315.42 Cmax 0.279 ug.mL-1 8.845349058398326e-07 6.0532850241284715 CHEMBL3536335 15465643.0 Cmax in human at 50 mg, po by LC-MS/MS analysis Scientific Literature 22496391.0 Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human. SCOPOLAMINE SCOPOLAMINE CHEMBL1187846 661796 303.36 Normal/therapeutic blood-plasma concentration 0.001 mg/L 3.2964135021097044e-09 8.481958315657971 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SECOBARBITAL SECOBARBITAL CHEMBL447 2326 238.29 Normal/therapeutic blood-plasma concentration 5.0 mg/L 2.0982836040119184e-05 4.678135812933035 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SERTINDOLE SERTINDOLE CHEMBL12713 10813 440.95 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.2678308198208415e-07 6.644389346939082 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SERTRALINE SERTRALINE CHEMBL809 53616 306.24 Normal/therapeutic blood-plasma concentration 0.25 mg/L 8.163531870428422e-07 6.088121907424712 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SEVOFLURANE SEVOFLURANE CHEMBL1200694 674645 200.05 Normal/therapeutic blood-plasma concentration 134.0 mg/L 0.0006698325418645339 3.1740337573502084 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SIBUTRAMINE SIBUTRAMINE CHEMBL1419 358192 279.86 Normal/therapeutic blood-plasma concentration 0.01 mg/L 3.573215179018081e-08 7.446940829796355 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SILDENAFIL SILDENAFIL CHEMBL192 410802 474.59 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.0535409511367708e-06 5.977348578701278 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SIMVASTATIN CHEMBL1064 138562 418.57 Cmax 0.028500000000000008 ug.mL-1 6.808896958692695e-08 7.1669232380950865 CHEMBL3788515 16534884.0 Cmax in healthy human subjects at 40 mg with 200 ml grape fruit juice drug administered as single dose on day 3 of grape fruit juice challenge measured upto 24 hrs by LC-MS analysis Scientific Literature 15206993.0 Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. SIMVASTATIN CHEMBL1064 138562 418.57 Cmax 0.011099999999999999 ug.mL-1 2.6518861839118903e-08 7.576445119316939 CHEMBL3788519 16534888.0 Cmax in healthy human subjects assessed as simvastatin acid at 40 mg with 200 ml grape fruit juice drug administered as single dose on day 3 of grape fruit juice challenge measured upto 24 hrs by LC-MS analysis Scientific Literature 15206993.0 Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. SIMVASTATIN CHEMBL1064 138562 418.57 Cmax 120.0 nM 1.2000000000000002e-07 6.920818753952375 CHEMBL944788 2075552.0 Cmax in human Scientific Literature 18155906.0 Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. SIMVASTATIN CHEMBL1064 138562 418.57 Cmax 0.0025999999999999994 ug.mL-1 6.211625295649473e-09 8.20679475013278 CHEMBL3788511 16534880.0 Cmax in healthy human subjects assessed as simvastatin acid at 40 mg with water administered as single dose measured upto 24 hrs by LC-MS analysis Scientific Literature 15206993.0 Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. SIMVASTATIN CHEMBL1064 138562 418.57 Cmax 0.01944 ug.mL-1 4.6443844518240676e-08 7.333071837513341 CHEMBL3508673 15443318.0 Mean Cmax of simvastatin following administration of reference product Zocor 80 mg tablet in healthy human FDA Approval Packages FDA drug approval package for Simvastatin SIMVASTATIN CHEMBL1064 138562 418.57 Cmax 0.007299999999999998 ug.mL-1 1.744033256086198e-08 7.758445237983141 CHEMBL3788507 16534876.0 Cmax in healthy human subjects at 40 mg with water administered as single dose measured upto 24 hrs by LC-MS analysis Scientific Literature 15206993.0 Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. SIMVASTATIN SIMVASTATIN CHEMBL1064 138562 418.57 Normal/therapeutic blood-plasma concentration 0.0056 mg/L 1.3378885252168096e-08 7.873580071097396 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SIMVASTATIN CHEMBL1064 138562 418.57 Cmax 0.018270000000000005 ug.mL-1 4.364861313519843e-08 7.360029550751059 CHEMBL3508672 15443317.0 Mean Cmax of simvastatin following administration of simvastatin 80 mg orally disintegrating tablet in healthy human FDA Approval Packages FDA drug approval package for Simvastatin SIROLIMUS SIROLIMUS CHEMBL413 923 914.19 Normal/therapeutic blood-plasma concentration 0.03 mg/L 3.28159354182391e-08 7.4839152116664085 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SITAGLIPTIN SITAGLIPTIN CHEMBL1422 363589 407.32 Normal/therapeutic blood-plasma concentration 0.38 mg/L 9.329274280663852e-07 6.030152138478737 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics THIOCYANATE FROM NITROPRUSSIDE SODIUM NITROPRUSSIDE CHEMBL136478 226851 261.92 Normal/therapeutic blood-plasma concentration 30.0 mg/L 0.00011453879047037262 3.941047407348204 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SOTALOL SOTALOL CHEMBL471 5528 272.37 Normal/therapeutic blood-plasma concentration 4.0 mg/L 1.4685905202481918e-05 4.833099279490037 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SPARTEINE SPARTEINE CHEMBL412873 11265 234.39 Normal/therapeutic blood-plasma concentration 1.0 mg/L 4.266393617475149e-06 5.369939079029239 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SPIRAMYCIN SPIRAMYCIN CHEMBL453514 497011 843.06 Normal/therapeutic blood-plasma concentration 3.0 mg/L 3.5584655896377484e-06 5.448737229444391 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SPIRONOLACTONE SPIRONOLACTONE CHEMBL1393 328201 416.58 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.200249651927601e-06 5.920728411304178 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics STIRIPENTOL STIRIPENTOL CHEMBL1983350 1304641 234.29 Normal/therapeutic blood-plasma concentration 10.0 mg/L 4.2682146058303814e-05 4.369753752372034 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics STREPTOMYCIN STREPTOMYCIN CHEMBL372795 334866 581.58 Normal/therapeutic blood-plasma concentration 40.0 mg/L 6.877815605763609e-05 4.162549471792988 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SUFENTANIL SUFENTANIL CHEMBL658 27638 386.56 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.5869205298013247e-08 7.587216912605019 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SULBACTAM SULBACTAM CHEMBL403 194 233.24 Normal/therapeutic blood-plasma concentration 80.0 mg/L 0.0003429943405933802 3.464713045757063 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SULFAMETHOXAZOLE CHEMBL443 2247 253.28 Cmax 39.99999999999999 ug.mL-1 0.00015792798483891342 3.8015409061903185 CHEMBL1032833 2667151.0 Cmax in immunodeficiency virus-infected patient at 800 mg, po by high-pressure liquid chromatography Scientific Literature 18070962.0 Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. SULFAMETHOXAZOLE SULFAMETHOXAZOLE CHEMBL443 2247 253.28 Normal/therapeutic blood-plasma concentration 200.0 mg/L 0.0007896399241945673 3.1025709018542993 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SULFASALAZINE SULFASALAZINE CHEMBL421 1223 398.4 Normal/therapeutic blood-plasma concentration 70.0 mg/L 0.00017570281124497996 3.7552212897374044 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SULFINPYRAZONE SULFINPYRAZONE CHEMBL832 60232 404.49 Normal/therapeutic blood-plasma concentration 17.0 mg/L 4.2028233083636184e-05 4.376458867861729 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SULFISOXAZOLE SULFISOXAZOLE CHEMBL453 2484 267.31 Normal/therapeutic blood-plasma concentration 100.0 mg/L 0.00037409748980584345 3.4270152059079915 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SULINDAC SULINDAC CHEMBL15770 16510 356.42 Normal/therapeutic blood-plasma concentration 5.0 mg/L 1.402839346838e-05 4.8529920615280755 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SULPIRIDE SULPIRIDE CHEMBL26 1333 341.43 Normal/therapeutic blood-plasma concentration 1.0 mg/L 2.928858038250886e-06 5.533301678061803 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SULTIAM SULTHIAME CHEMBL328560 151273 290.37 Normal/therapeutic blood-plasma concentration 8.0 mg/L 2.7551055549815752e-05 4.559861757586111 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SUMATRIPTAN SUMATRIPTAN CHEMBL128 27111 295.41 Normal/therapeutic blood-plasma concentration 0.06 mg/L 2.031075454453133e-07 6.692273942255493 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics SUNITINIB CHEMBL535 13048 398.48 Cmax 0.024399999999999998 ug.mL-1 6.123268419995984e-08 7.213016702385597 CHEMBL3536432 15456863.0 Cmax in human plasma at 50 mg, po administered as single dose by LC/MS/MS analysis Scientific Literature 22180047.0 Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. TACRINE CHEMBL95 9333 198.27 Cmax 169.99999999999997 nM 1.7e-07 6.769551078621726 CHEMBL2154113 12064132.0 Cmax in human Scientific Literature 21599003.0 Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. TACRINE TACRINE CHEMBL95 9333 198.27 Normal/therapeutic blood-plasma concentration 0.01 mg/L 5.0436273768094016e-08 7.297257006590092 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TACROLIMUS TACROLIMUS CHEMBL269732 924 804.03 Normal/therapeutic blood-plasma concentration 0.02 mg/L 2.4874693730333447e-08 7.604242257800126 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TADALAFIL TADALAFIL CHEMBL779 44920 389.41 Normal/therapeutic blood-plasma concentration 0.48 mg/L 1.2326339847461544e-06 5.909165862579497 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TAMOXIFEN TAMOXIFEN CHEMBL83 6968 371.52 Normal/therapeutic blood-plasma concentration 0.5 mg/L 1.3458225667527995e-06 5.871012193722461 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TAPENTADOL TAPENTADOL CHEMBL1201776 675727 221.34 Normal/therapeutic blood-plasma concentration 0.13 mg/L 5.87331706876299e-07 6.23111655330361 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TEICOPLANIN TEICOPLANIN CHEMBL2367892 1542343 1767.46 Normal/therapeutic blood-plasma concentration 40.0 mg/L 2.2631346678284093e-05 4.645289602583211 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TELAVANCIN CHEMBL507870 497165 1755.66 Cmax 5.199999999999998 ug.mL-1 2.9618491051798178e-06 5.528437070884711 CHEMBL1029782 2501342.0 Cmax in human at 10 mg/kg once daily Scientific Literature 17620377.0 Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. TELAVANCIN CHEMBL507870 497165 1755.66 Cmax 89.99999999999997 ug.mL-1 5.126277297426607e-05 4.290197905080186 CHEMBL1696172 5306511.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. TELAVANCIN CHEMBL507870 497165 1755.66 Cmax 60.0 ug.mL-1 3.4175181982844054e-05 4.466289164135866 CHEMBL1009786 2501312.0 Cmax in human serum at 7.5 mg/kg Scientific Literature 17620377.0 Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. TELAVANCIN CHEMBL507870 497165 1755.66 Cmax 89.00000000000001 ug.mL-1 5.069318660788536e-05 4.295050407874597 CHEMBL953899 2351424.0 Cmax in human at 7.5 mg/kg, iv administered every 24 hrs Scientific Literature 17485502.0 Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. TELAVANCIN CHEMBL507870 497165 1755.66 Cmax 116.0 ug.mL-1 6.607201850016519e-05 4.179982425292591 CHEMBL1063648 2723052.0 Cmax in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion Scientific Literature 17923490.0 Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. TELBIVUDINE CHEMBL374731 366271 242.23 Cmax 13199.999999999996 nM 1.3199999999999997e-05 4.87942606879415 CHEMBL1259437 3497053.0 Cmax in human at 600 mg Scientific Literature 20308377.0 Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. TELBIVUDINE CHEMBL374731 366271 242.23 Cmax 3.3999999999999995 ug.mL-1 1.403624654254221e-05 4.852749012134796 CHEMBL1061000 2722936.0 Cmax in human with normal renal function at 600 mg, po administered as single dose Scientific Literature 17875994.0 Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. TELBIVUDINE CHEMBL374731 366271 242.23 Cmax 2.1 ug.mL-1 8.669446393923133e-06 5.062008634443131 CHEMBL1058377 2722886.0 Cmax in patient with end-stage renal disease at 200 mg, po administered as two single doses within 2 hrs of after completion of dialysis separated by 1 week washout period Scientific Literature 17875994.0 Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. TELBIVUDINE CHEMBL374731 366271 242.23 Cmax 1.1999999999999997 ug.mL-1 4.953969367956074e-06 5.305046683129426 CHEMBL1058376 2722885.0 Cmax in patient with end-stage renal disease at 200 mg, po administered as two single doses 2 hrs before dialysis separated by 1 week washout period Scientific Literature 17875994.0 Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. TELBIVUDINE CHEMBL374731 366271 242.23 Cmax 1.5999999999999999 ug.mL-1 6.605292490608099e-06 5.180107946521126 CHEMBL1055959 2722884.0 Cmax in patient with severe renal impairment at 200 mg, po administered as single dose Scientific Literature 17875994.0 Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. TELBIVUDINE CHEMBL374731 366271 242.23 Cmax 2.8000000000000007 ug.mL-1 1.1559261858564179e-05 4.9370698978348315 CHEMBL1055958 2722883.0 Cmax in patient with moderate renal impairment at 400 mg, po administered as single dose Scientific Literature 17875994.0 Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. TELBIVUDINE CHEMBL374731 366271 242.23 Cmax 3.1999999999999997 ug.mL-1 1.3210584981216198e-05 4.879077950857145 CHEMBL1055957 2722882.0 Cmax in patient with mild renal impairment at 600 mg, po administered as single dose Scientific Literature 17875994.0 Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. TELITHROMYCIN CHEMBL1136 171587 812.02 Cmax 1.9 ug.mL-1 2.3398438462106847e-06 5.630813125065035 CHEMBL3889337 17805462.0 The pharmacokinetics of Telithromycin evaluated after administration of single 800-mg doses to healthy adult subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=ba1cca98-f350-4655-88e3-6ef990779fb9 | KETEK - telithromycin tablet, film coated|Physicians Total Care, Inc. TELITHROMYCIN CHEMBL1136 171587 812.02 Cmax 1.9 ug.mL-1 2.3398438462106847e-06 5.630813125065035 CHEMBL1051728 2711850.0 Cmax in human at 12 mg/kg administered as single oral dose Scientific Literature 18056275.0 Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum. TELITHROMYCIN CHEMBL1136 171587 812.02 Cmax 2.27 ug.mL-1 2.795497647841186e-06 5.553540868824741 CHEMBL3889338 17805468.0 The pharmacokinetics of Telithromycin evaluated after administration of multiple 800-mg doses to healthy adult subjects. Curated Drug Pharmacokinetic Data DailyMed|setid=ba1cca98-f350-4655-88e3-6ef990779fb9 | KETEK - telithromycin tablet, film coated|Physicians Total Care, Inc. TELITHROMYCIN CHEMBL1136 171587 812.02 Cmax 0.7999999999999999 ug.mL-1 9.851974089308145e-07 6.00647673902592 CHEMBL1655707 5161039.0 Cmax in healthy human at 400 mg, po administered as single dose Scientific Literature 19223626.0 Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. TELMISARTAN CHEMBL1017 116949 514.63 Cmax 0.5105 ug.mL-1 9.91974816858714e-07 6.003499353085865 CHEMBL3540009 15444558.0 Cmax in human plasma expressing CYP2C9*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. TELMISARTAN CHEMBL1017 116949 514.63 Cmax 0.4456999999999999 ug.mL-1 8.660591104288516e-07 6.062452465422617 CHEMBL3540004 15444553.0 Cmax in human plasma expressing CYP2C9*1/*1 polymorphism at 80 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. TELMISARTAN CHEMBL1017 116949 514.63 Cmax 0.2821 ug.mL-1 5.481608145658046e-07 6.261092013353427 CHEMBL3531095 15469803.0 Cmax in men plasma at 80 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. TELMISARTAN CHEMBL1017 116949 514.63 Cmax 0.4938 ug.mL-1 9.595243184423763e-07 6.017944013912881 CHEMBL3539701 15444548.0 Cmax in human plasma expressing CYP2C8*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. TELMISARTAN CHEMBL1017 116949 514.63 Cmax 0.5904999999999999 ug.mL-1 1.1474263062782968e-06 5.94027519755926 CHEMBL3531096 15469804.0 Cmax in women plasma at 80 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. TELMISARTAN CHEMBL1017 116949 514.63 Cmax 0.4374 ug.mL-1 8.4993101840157e-07 6.070616320807176 CHEMBL3539691 15444538.0 Cmax in human plasma expressing CYP2C8*1/*1 polymorphism at 80 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. TELMISARTAN CHEMBL1017 116949 514.63 Cmax 0.4979000000000001 ug.mL-1 9.674912072751299e-07 6.0143529732333345 CHEMBL3539696 15444543.0 Cmax in human plasma expressing CYP2C8*2 allele carrier polymorphism at 80 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. TEMAZEPAM TEMAZEPAM CHEMBL967 95909 300.75 Normal/therapeutic blood-plasma concentration 0.9 mg/L 2.9925187032418956e-06 5.523963126572557 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TENOXICAM TENOXICAM CHEMBL302795 112102 337.38 Normal/therapeutic blood-plasma concentration 10.0 mg/L 2.9640168356156264e-05 4.528119333893047 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TERAZOSIN TERAZOSIN CHEMBL611 23093 387.44 Normal/therapeutic blood-plasma concentration 0.08 mg/L 2.064835845550279e-07 6.685114469046539 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TERBINAFINE TERBINAFINE CHEMBL822 56831 291.44 Normal/therapeutic blood-plasma concentration 3.0 mg/L 1.0293713972001098e-05 4.987427903514197 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TERBUTALINE TERBUTALINE CHEMBL1760 583322 225.29 Normal/therapeutic blood-plasma concentration 0.01 mg/L 4.4387234231435045e-08 7.352741915020753 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TERFENADINE TERFENADINE CHEMBL17157 19569 471.69 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.120036464627192e-08 7.673656669141918 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TESTOSTERONE CHEMBL386630 364520 288.43 Cmax 0.005379999999999999 ug.mL-1 1.865270602919252e-08 7.729258154295219 CHEMBL3889396 17805980.0 Mean steady-state pharmacokinetic parammeters for Testosterone evaluated on day 30 following multiple topical administration of Testosterone gel to adult male subjetcs with testosterone levels <= 300ng/dL. Curated Drug Pharmacokinetic Data DailyMed|setid=e42c6a90-37f6-44f5-8112-126c2c4a4b2c | TESTIM- testosterone gel | A-S Medication Solutions LLC TESTOSTERONE CHEMBL386630 364520 288.43 Cmax 0.00897 ug.mL-1 3.1099400201088654e-08 7.507247986917516 CHEMBL3889396 17805984.0 Mean steady-state pharmacokinetic parammeters for Testosterone evaluated on day 30 following multiple topical administration of Testosterone gel to adult male subjetcs with testosterone levels <= 300ng/dL. Curated Drug Pharmacokinetic Data DailyMed|setid=e42c6a90-37f6-44f5-8112-126c2c4a4b2c | TESTIM- testosterone gel | A-S Medication Solutions LLC TETRACYCLINE CHEMBL1440 373985 444.44 Cmax 1.6999999999999997 ug.mL-1 3.825038250382503e-06 5.417364217543829 CHEMBL1032834 2667152.0 Cmax in patient with Billroth-II gastrectomy at 250 mg, po Scientific Literature 18070962.0 Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. TETRACYCLINE TETRACYCLINE CHEMBL1440 373985 444.44 Normal/therapeutic blood-plasma concentration 10.0 mg/L 2.2500225002250025e-05 4.647813138922103 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TETRAZEPAM TETRAZEPAM CHEMBL2105527 1377797 288.78 Normal/therapeutic blood-plasma concentration 1.0 mg/L 3.4628436872359587e-06 5.460567112061002 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics THALIDOMIDE THALIDOMIDE CHEMBL468 5028 258.23 Normal/therapeutic blood-plasma concentration 8.0 mg/L 3.09801339890795e-05 4.508916708249116 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics THEOPHYLLINE THEOPHYLLINE CHEMBL190 381693 180.17 Normal/therapeutic blood-plasma concentration 20.0 mg/L 0.00011100627185435978 3.9546524828819005 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics THIAMYLAL THIAMYLAL CHEMBL440 2132 254.35 Normal/therapeutic blood-plasma concentration 5.0 mg/L 1.9657951641438962e-05 4.706461737631355 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics THIOPENTAL THIOPENTAL CHEMBL441 2166 242.34 Normal/therapeutic blood-plasma concentration 5.0 mg/L 2.063216967896344e-05 4.685455099217613 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics THIORIDAZINE THIORIDAZINE CHEMBL479 5970 370.59 Normal/therapeutic blood-plasma concentration 1.25 mg/L 3.3729998111120108e-06 5.471983683131289 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TIOTIXENE THIOTHIXENE CHEMBL1201 209829 443.64 Normal/therapeutic blood-plasma concentration 0.014 mg/L 3.155711838427554e-08 7.500902660942494 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TIAGABINE TIAGABINE CHEMBL1027 122170 375.56 Normal/therapeutic blood-plasma concentration 0.2 mg/L 5.325380764724678e-07 6.273649334723604 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TIAPROFENIC ACID TIAPROFENIC ACID CHEMBL365795 317367 260.31 Normal/therapeutic blood-plasma concentration 40.0 mg/L 0.0001536629403403634 3.8134308608435066 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TICLOPIDINE TICLOPIDINE CHEMBL833 60319 263.79 Normal/therapeutic blood-plasma concentration 2.0 mg/L 7.58178854391751e-06 5.120228332213779 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TIGECYCLINE CHEMBL376140 373970 585.66 Cmax 0.6300000000000002 ug.mL-1 1.0757094559983613e-06 5.968305013702771 CHEMBL1638228 5094359.0 Cmax in human serum at 100 mg/kg, iv bolus dose followed by dose regimen of 50 mg/kg every 12 hrs Scientific Literature 19075049.0 In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. TIGECYCLINE CHEMBL376140 373970 585.66 Cmax 0.6300000000000002 ug.mL-1 1.0757094559983613e-06 5.968305013702771 CHEMBL1661102 5145652.0 Cmax in human serum at 100 mg/kg, iv followed by regimen of 50 mg/kg for every 12 hrs Scientific Literature 19139287.0 Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. TIGECYCLINE CHEMBL376140 373970 585.66 Cmax 0.8699999999999999 ug.mL-1 1.4855035344739267e-06 5.828126310537734 CHEMBL3868729 16801130.0 Cmax in human at 50 mg, iv q12h Scientific Literature 27469981.0 Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. TIGECYCLINE CHEMBL376140 373970 585.66 Cmax 1.0 ug.mL-1 1.7074753269815253e-06 5.767645563156353 CHEMBL1696172 5306509.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. TIGECYCLINE CHEMBL376140 373970 585.66 Cmax 0.42000000000000004 ug.mL-1 7.171396373322407e-07 6.144396272758453 CHEMBL1676006 5215064.0 Cmax in plasma of diabetic patient with chronic wound infection at 100 mg/kg, iv loading dose followed by 50 mg/kg, iv BID for 2 to 3 doses by microdialysis Scientific Literature 20921312.0 Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. TILUDRONATE TILUDRONIC ACID CHEMBL1350 299299 318.61 Normal/therapeutic blood-plasma concentration 1.5 mg/L 4.707950158500989e-06 5.3271681435351805 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TIMOLOL TIMOLOL CHEMBL499 8531 316.43 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.1602566128369626e-07 6.500277651237841 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TIOPRONIN TIOPRONIN CHEMBL1314 264400 163.2 Normal/therapeutic blood-plasma concentration 5.0 mg/L 3.0637254901960784e-05 4.513750150081823 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TIOTROPIUM TIOTROPIUM CHEMBL1900528 1241099 392.52 Normal/therapeutic blood-plasma concentration 1.6e-05 mg/L 4.076225415265465e-11 10.389741807516682 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TIPRANAVIR TIPRANAVIR CHEMBL222559 372438 602.68 Normal/therapeutic blood-plasma concentration 20.5 mg/L 3.401473418729674e-05 4.468332918542641 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TIPRANAVIR CHEMBL222559 372438 602.68 Cmax 49449.99999999999 nM 4.9449999999999996e-05 4.305833704066802 CHEMBL956341 2349515.0 Cmax ( 0 to 12 hrs) in healthy human blood at 500 mg, po twice daily coadministered with ritonavir 200 mg, po twice daily for 21 days with additional single dose of 551 mg, po on day 7 Scientific Literature 17485497.0 Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir. TIPRANAVIR CHEMBL222559 372438 602.68 Cmax 99389.99999999999 nM 9.939e-05 4.002657309398377 CHEMBL956334 2349509.0 Cmax in healthy human at 500 mg, po twice daily coadministered with ritonavir 200 mg, po twice daily for 21 days with additional single dose of 551 mg, po on day 7 Scientific Literature 17485497.0 Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir. TIZANIDINE TIZANIDINE CHEMBL1079 140117 253.72 Normal/therapeutic blood-plasma concentration 0.015 mg/L 5.912029008355668e-08 7.228263443669745 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TOBRAMYCIN CHEMBL1747 577488 467.52 Cmax 4.6 ug.mL-1 9.83915126625599e-06 5.007042362572629 CHEMBL3889450 17806322.0 Pharmacokinetic parameters for different drugs following single oral or intravenous administration in healthy subjects. Curated Drug Pharmacokinetic Data Goodman and Gilman Ed. 10 | The Pharmaceutical Basis of Therapeutics| Table A-II-I: Pharmacokinetic Data TOBRAMYCIN TOBRAMYCIN CHEMBL1747 577488 467.52 Normal/therapeutic blood-plasma concentration 10.0 mg/L 2.138945927446954e-05 4.6698001942542025 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TOBRAMYCIN CHEMBL1747 577488 467.52 Cmax 5.199999999999998 ug.mL-1 1.112251882272416e-05 4.953796850619404 CHEMBL3889450 17806323.0 Pharmacokinetic parameters for different drugs following single oral or intravenous administration in healthy subjects. Curated Drug Pharmacokinetic Data Goodman and Gilman Ed. 10 | The Pharmaceutical Basis of Therapeutics| Table A-II-I: Pharmacokinetic Data TOCAINIDE TOCAINIDE CHEMBL1762 583520 192.26 Normal/therapeutic blood-plasma concentration 10.0 mg/L 5.2012899199001353e-05 4.283888937976056 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TOLBUTAMIDE TOLBUTAMIDE CHEMBL782 46726 270.35 Normal/therapeutic blood-plasma concentration 100.0 mg/L 0.000369890882189754 3.4319263739116432 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TOLCAPONE TOLCAPONE CHEMBL1324 267825 273.24 Normal/therapeutic blood-plasma concentration 6.0 mg/L 2.1958717610891522e-05 4.658393026279124 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TOLMETIN TOLMETIN CHEMBL1020 118617 257.29 Normal/therapeutic blood-plasma concentration 80.0 mg/L 0.0003109331882311788 3.5073329199754344 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TOPIRAMATE TOPIRAMATE CHEMBL220492 366279 339.37 Normal/therapeutic blood-plasma concentration 29.0 mg/L 8.545245602145151e-05 4.068275450541426 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TOPOTECAN TOPOTECAN CHEMBL84 7501 421.45 Normal/therapeutic blood-plasma concentration 0.01 mg/L 2.372760707082691e-08 7.624746058172765 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRAMADOL TRAMADOL CHEMBL1237044 699395 263.38 Normal/therapeutic blood-plasma concentration 2.0 mg/L 7.593591009188246e-06 5.119552797667117 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRANEXAMIC ACID TRANEXAMIC ACID CHEMBL877 73547 157.21 Normal/therapeutic blood-plasma concentration 50.0 mg/L 0.0003180459258316901 3.4975101633641295 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRANYLCYPROMINE TRANYLCYPROMINE CHEMBL3989843 2197714 266.39 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.8769473328578402e-07 6.726547913510845 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRAZODONE TRAZODONE CHEMBL621 26401 371.87 Normal/therapeutic blood-plasma concentration 1.0 mg/L 2.6891117863769597e-06 5.570391143779831 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRIAMCINOLONE ACETONIDE CHEMBL1504 419622 434.5 Cmax 0.0004999999999999999 ug.mL-1 1.1507479861910239e-09 8.939019776448667 CHEMBL3889425 17806153.0 Pharmacokinetic parameters for triamcinolone acetonide evaluated after intranasal administration of triamcinolone acetonide nasal spray. Range 0.1 To 1 Ng/Ml Curated Drug Pharmacokinetic Data DailyMed|setid=14ed9edd-bfd3-4fa4-9293-66666f779ba3 | TRIAMCINOLONE ACETONIDE - triamcinolone acetonide spray, metered|Physicians Total Care, Inc. TRIAMCINOLONE ACETONIDE CHEMBL1504 419622 434.5 Cmax 0.0004999999999999999 ug.mL-1 1.1507479861910239e-09 8.939019776448667 CHEMBL3889425 17806158.0 Pharmacokinetic parameters for triamcinolone acetonide evaluated after intranasal administration of triamcinolone acetonide nasal spray. Range 0.1 To 1.0 Ng/Ml Curated Drug Pharmacokinetic Data DailyMed|setid=14ed9edd-bfd3-4fa4-9293-66666f779ba3 | TRIAMCINOLONE ACETONIDE - triamcinolone acetonide spray, metered|Physicians Total Care, Inc. TRIAMTERENE TRIAMTERENE CHEMBL585 17411 253.27 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.948355509930114e-07 6.403583750366688 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRIAZOLAM TRIAZOLAM CHEMBL646 27419 343.22 Normal/therapeutic blood-plasma concentration 0.02 mg/L 5.8271662490530854e-08 7.234542591311529 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics METRIFONATE TRICHLORFON CHEMBL167150 277372 257.44 Normal/therapeutic blood-plasma concentration 3.6 mg/L 1.398384089496582e-05 4.854373525987667 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRIFLUOPERAZINE TRIFLUOPERAZINE CHEMBL422 1325 407.51 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.2269637554906628e-07 6.91116826614251 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRIFLUPROMAZINE TRIFLUPROMAZINE CHEMBL570 16584 352.43 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.8374428964617086e-07 6.547072869887322 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRIHEXYPHENIDYL TRIHEXYPHENIDYL CHEMBL1490 418411 301.47 Normal/therapeutic blood-plasma concentration 0.2 mg/L 6.634159286164461e-07 6.178214105280843 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRIMETHADIONE TRIMETHADIONE CHEMBL695 31804 143.14 Normal/therapeutic blood-plasma concentration 40.0 mg/L 0.00027944669554282525 3.553701021549961 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRIMETHOBENZAMIDE TRIMETHOBENZAMIDE CHEMBL1201256 675207 388.46 Normal/therapeutic blood-plasma concentration 2.0 mg/L 5.14853524172373e-06 5.288316310166291 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRIMETHOPRIM TRIMETHOPRIM CHEMBL22 1216 290.32 Normal/therapeutic blood-plasma concentration 10.0 mg/L 3.4444750620005514e-05 4.4628769551925 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRIMETHOPRIM CHEMBL22 1216 290.32 Cmax 2.3 ug.mL-1 7.922292642601268e-06 5.101149119174908 CHEMBL1032835 2667153.0 Cmax in healthy human at 160 mg administered orally Scientific Literature 18070962.0 Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. TRIMIPRAMINE TRIMIPRAMINE CHEMBL644 27385 294.44 Normal/therapeutic blood-plasma concentration 0.3 mg/L 1.0188833038989266e-06 5.99187555433994 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TRIPROLIDINE TRIPROLIDINE CHEMBL855 65539 278.4 Normal/therapeutic blood-plasma concentration 0.045 mg/L 1.6163793103448276e-07 6.791456717163181 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TROGLITAZONE CHEMBL408 666 441.55 Cmax 6300.000000000001 nM 6.3000000000000015e-06 5.200659450546418 CHEMBL1960576 8051596.0 Cmax in human at 600 mg/day Scientific Literature 22409968.0 Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study. TROPISETRON TROPISETRON CHEMBL56564 88800 284.36 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.758334505556337e-07 6.754898501220181 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics TUBOCURARINE TUBOCURARINE CHEMBL339427 203627 609.74 Normal/therapeutic blood-plasma concentration 6.0 mg/L 9.840259782858268e-06 5.006993436042991 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VABORBACTAM CHEMBL3317857 1782496 297.14 Cmax 22.0 ug.mL-1 7.40391734535909e-05 4.130538438197742 CHEMBL3579018 15604604.0 Cmax in human at 1 g administered as 3 hrs of infusion Scientific Literature 25782055.0 Discovery of a Cyclic Boronic Acid ß-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. VALPROIC ACID CHEMBL109 15217 144.21 Cmax 107.49999999999997 ug.mL-1 0.0007454406767907909 3.1275869125966853 CHEMBL3788252 16545047.0 Cmax in healthy human (6 volunteers) at 1 g, po administered as single dose by gas liquid chromatography Scientific Literature 3921078.0 Pharmacokinetics of valproic acid in volunteers after a single dose study. VALPROIC ACID CHEMBL109 15217 144.21 Cmax 71.8 ug.mL-1 0.0004978850287774772 3.302870932606009 CHEMBL3790182 16544981.0 Cmax in epileptic patient (6 patients) at 800 mg, po administered as single dose by gas liquid chromatographic method Scientific Literature 350251.0 Disposition of sodium valproate in epileptic patients. VALPROIC ACID VALPROIC ACID CHEMBL109 15217 144.21 Normal/therapeutic blood-plasma concentration 150.0 mg/L 0.0010401497815685458 2.982904117792628 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VALSARTAN CHEMBL1069 139045 435.53 Cmax 4.857000000000001 ug.mL-1 1.1151929832617734e-05 4.952649971796531 CHEMBL3537473 15444518.0 Cmax in human plasma expressing CYP2C8*4 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. VALSARTAN CHEMBL1069 139045 435.53 Cmax 4.838000000000001 ug.mL-1 1.1108304824007535e-05 4.954352211243707 CHEMBL3539765 15444528.0 Cmax in human plasma expressing CYP2C9*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. VALSARTAN CHEMBL1069 139045 435.53 Cmax 4.711 ug.mL-1 1.0816706082244625e-05 4.9659049710313345 CHEMBL3537468 15444513.0 Cmax in human plasma expressing CYP2C8*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. VALSARTAN CHEMBL1069 139045 435.53 Cmax 4.884999999999999 ug.mL-1 1.1216219318990653e-05 4.950153507214776 CHEMBL3539760 15444523.0 Cmax in human plasma expressing CYP2C9*1/*1 polymorphism at 25 to 320 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. VALSARTAN CHEMBL1069 139045 435.53 Cmax 4.01 ug.mL-1 9.20717286983675e-06 5.035873702649385 CHEMBL3539686 15444533.0 Cmax in human plasma expressing CYP2C9*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. VALSARTAN VALSARTAN CHEMBL1069 139045 435.53 Normal/therapeutic blood-plasma concentration 6.0 mg/L 1.3776318508483917e-05 4.860866824885925 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VALSARTAN CHEMBL1069 139045 435.53 Cmax 6.143999999999999 ug.mL-1 1.410695015268753e-05 4.850566868246112 CHEMBL3540792 15444508.0 Cmax in human plasma expressing CYP2C8*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. VALSARTAN CHEMBL1069 139045 435.53 Cmax 4.5889999999999995 ug.mL-1 1.0536587605905448e-05 4.977300017574908 CHEMBL3531085 15469793.0 Cmax in men plasma at 25 to 320 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. VALSARTAN CHEMBL1069 139045 435.53 Cmax 4.9110000000000005 ug.mL-1 1.1275916699194087e-05 4.947848141137964 CHEMBL3531086 15469794.0 Cmax in women plasma at 25 to 320 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. VALSARTAN CHEMBL1069 139045 435.53 Cmax 4.546 ug.mL-1 1.0437857323261316e-05 4.981388643880616 CHEMBL3540787 15444503.0 Cmax in human plasma expressing CYP2C8*1/*1 polymorphism at 25 to 320 mg by LC/MS/MS analysis Scientific Literature 23118328.0 Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. VANCOMYCIN VANCOMYCIN CHEMBL262777 70140 1449.27 Normal/therapeutic blood-plasma concentration 40.0 mg/L 2.7600102120377845e-05 4.559089311042227 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VANCOMYCIN CHEMBL262777 70140 1449.27 Cmax 51.99999999999998 ug.mL-1 3.5880132756491186e-05 4.44514595873539 CHEMBL953893 2351410.0 Cmax in human at 1 g, iv administered every 12 hrs Scientific Literature 17485502.0 Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. VANCOMYCIN CHEMBL262777 70140 1449.27 Cmax 49.99999999999999 ug.mL-1 3.4500127650472303e-05 4.462179298034171 CHEMBL1696172 5306506.0 Cmax in human plasma Scientific Literature 19188393.0 Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. VANCOMYCIN CHEMBL262777 70140 1449.27 Cmax 51.99999999999998 ug.mL-1 3.5880132756491186e-05 4.44514595873539 CHEMBL1281788 3570012.0 Cmax in human serum at 1 g, iv administered every 12 hrs Scientific Literature 18426900.0 Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. VANCOMYCIN CHEMBL262777 70140 1449.27 Cmax 15.0 ug.mL-1 1.0350038295141691e-05 4.985058043314508 CHEMBL1657730 5156845.0 Cmax in simulated human serum in in vitro hollow-fiber PK model at 1 g administered every 12 hrs by fluorescence polarization immunoassay method Scientific Literature 18519719.0 Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. VANCOMYCIN CHEMBL262777 70140 1449.27 Cmax 64.0 ug.mL-1 4.416016339260455e-05 4.354969328386302 CHEMBL1664952 5146330.0 Cmax in healthy human male at 1000 mg, iv every 12 hrs by LC/MS/MS analysis Scientific Literature 19349514.0 Impact of human serum albumin on oritavancin in vitro activity against enterococci. VARENICLINE VARENICLINE CHEMBL1396 330452 211.27 Normal/therapeutic blood-plasma concentration 0.005 mg/L 2.3666398447484263e-08 7.625867827976824 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VECURONIUM VECURONIUM CHEMBL1201219 675170 557.84 Normal/therapeutic blood-plasma concentration 0.5 mg/L 8.963143553707156e-07 6.047539647860843 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VENLAFAXINE VENLAFAXINE CHEMBL637 27278 277.41 Normal/therapeutic blood-plasma concentration 0.4 mg/L 1.4419090876320248e-06 5.841062121020484 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VERAPAMIL VERAPAMIL CHEMBL6966 1219 454.61 Normal/therapeutic blood-plasma concentration 0.4 mg/L 8.798750577418007e-07 6.055578993288119 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VIGABATRIN VIGABATRIN CHEMBL89598 141484 129.16 Normal/therapeutic blood-plasma concentration 45.0 mg/L 0.0003484050789718179 3.45791552256978 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VILOXAZINE VILOXAZINE CHEMBL306700 114406 237.3 Normal/therapeutic blood-plasma concentration 8.0 mg/L 3.37126000842815e-05 4.472207751225396 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VINCAMINE VINCAMINE CHEMBL1165342 644928 354.45 Normal/therapeutic blood-plasma concentration 0.25 mg/L 7.053180984624066e-07 6.151614972016013 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VORICONAZOLE CHEMBL638 27308 349.32 Cmax 1.9 ug.mL-1 5.439138898431238e-06 5.264469850533606 CHEMBL908107 1832571.0 Cmax in leukemic patient with pulmonary aspergillosis at 200 mg twice daily, po on day 7 Scientific Literature 17088483.0 Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 0.29999999999999993 ug.mL-1 8.588114050154584e-07 6.066102196766773 CHEMBL908110 1832578.0 Cmax in leukemic patient with pulmonary aspergillosis at 200 mg twice daily, po on day 14 Scientific Literature 17088483.0 Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 4.3 ug.mL-1 1.2309630138554907e-05 4.909754995906849 CHEMBL908685 1832583.0 Cmax in leukemic neutropenic patient with pulmonary aspergillosis at 300 mg twice daily, po Scientific Literature 17088483.0 Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 3.9199999999999986 ug.mL-1 1.1221802358868656e-05 4.949937384465978 CHEMBL1028003 2494174.0 Cmax in bacterial infection patient at 400 mg, po administered daily Scientific Literature 17606672.0 Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 5.999999999999999 ug.mL-1 1.7176228100309172e-05 4.765072201102792 CHEMBL908116 1832554.0 Cmax in patient with invasive mycoses on day 1 Scientific Literature 17088483.0 Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 5.3 ug.mL-1 1.5172334821939769e-05 4.818947581885647 CHEMBL1658117 5169801.0 Cmax in healthy human at 6 mg/kg, iv for every 12 hrs on day 1 as 120 mins infusions followed by maintenance dose of 4 mg/kg every 12 hrs on day 2 and single 4 mg/kg dose on day 3 as 100 mins infusions Scientific Literature 19770284.0 Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 2.81 ug.mL-1 8.044200160311463e-06 5.094517131581355 CHEMBL955377 2626590.0 Cmax in human at 400 mg, po bid on day 1 and 200 mg, po bid on day 2 and 3 followed by 7 days of washout period then treated with ritonavir 100 mg, po for 10 days followed by 200 mg, po of drug coadministered with 100 mg, po ritonavir till day 30 Scientific Literature 17646413.0 Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 3.3600000000000003 ug.mL-1 9.618687736173139e-06 5.0168841740965915 CHEMBL955375 2626597.0 Cmax in human at 400 mg, po bid on day 1 and 200 mg, po bid on day 2 and 3 measured after 3 days Scientific Literature 17646413.0 Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 1.2899999999999996 ug.mL-1 3.6928890415664713e-06 5.432633741187186 CHEMBL1636016 5086136.0 Cmax in human at 15 mg, po pretreated with voriconazole at 400 mg, po every 12 hrs for 1 day and 200, po mg every 12 hrs for one additional day Scientific Literature 19015346.0 Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 1.7999999999999996 ug.mL-1 5.152868430092751e-06 5.28795094638313 CHEMBL1640346 5111193.0 Cmax in patient with end-stage renal failure undergoing genius system-mediated dialysis at 4 mg/kg, iv after 2 hrs by LC/MS/MS analysis Scientific Literature 20368400.0 Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 1.6999999999999997 ug.mL-1 4.866597961754265e-06 5.312774530108162 CHEMBL1640347 5111194.0 Cmax in patient with end-stage renal failure undergoing hemodialysis at 4 mg/kg, iv after 2 hrs by LC/MS/MS analysis Scientific Literature 20368400.0 Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 1.9 ug.mL-1 5.439138898431238e-06 5.264469850533606 CHEMBL1640348 5111195.0 Cmax in patient with end-stage renal failure undergoing hemodiafiltration at 4 mg/kg, iv after 2 hrs by LC/MS/MS analysis Scientific Literature 20368400.0 Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. VORICONAZOLE CHEMBL638 27308 349.32 Cmax 0.03800000000000001 ug.mL-1 1.087827779686248e-07 6.963439854869625 CHEMBL1030471 2494176.0 Cmax in bacterial infection patient at 400 mg, po administered daily after 36 days of drug therapy and 30 days of rifampin coadministration Scientific Literature 17606672.0 Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. VORICONAZOLE VORICONAZOLE CHEMBL638 27308 349.32 Normal/therapeutic blood-plasma concentration 6.0 mg/L 1.7176228100309172e-05 4.765072201102792 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics VORICONAZOLE CHEMBL638 27308 349.32 Cmax 1.22 ug.mL-1 3.4924997137295314e-06 5.456863620811688 CHEMBL952711 2626593.0 Cmax in human at 400 mg, po bid on day 1 and 200 mg, po bid on day 2 and 3 followed by 7 days of washout period then treated with ritonavir 400 mg, po for 10 days followed by 200 mg, po of drug coadministered with 400 mg, po ritonavir till day 30 Scientific Literature 17646413.0 Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. WARFARIN WARFARIN CHEMBL1464 394165 308.33 Normal/therapeutic blood-plasma concentration 7.0 mg/L 2.2702948139979893e-05 4.643917742904255 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics XAMOTEROL XAMOTEROL CHEMBL75753 122859 339.39 Normal/therapeutic blood-plasma concentration 0.1 mg/L 2.946462771442883e-07 6.530699041844945 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics XIPAMIDE XIPAMIDE CHEMBL517199 452689 354.82 Normal/therapeutic blood-plasma concentration 20.0 mg/L 5.63666084211713e-05 4.248978095892653 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics YOHIMBINE YOHIMBINE CHEMBL15245 15191 354.45 Normal/therapeutic blood-plasma concentration 0.3 mg/L 8.463817181548878e-07 6.072433725968388 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ZAFIRLUKAST CHEMBL603 21523 575.69 Cmax 0.6009999999999998 ug.mL-1 1.0439646337438546e-06 5.981314213623077 CHEMBL3889421 17806131.0 Evaluation of pharmacokinetic parameters for Zafirlukast following single oral administration to healthy boys and girls. Curated Drug Pharmacokinetic Data DailyMed|setid=a60f39f6-d590-4b00-8751-7f12b7ec5385 | ZAFIRLUKAST- zafirlukast tablet, film coated|American Health Packaging ZAFIRLUKAST CHEMBL603 21523 575.69 Cmax 0.326 ug.mL-1 5.662769893519081e-07 6.2469710855578775 CHEMBL3889421 17806138.0 Evaluation of pharmacokinetic parameters for Zafirlukast following single oral administration to healthy boys and girls. Curated Drug Pharmacokinetic Data DailyMed|setid=a60f39f6-d590-4b00-8751-7f12b7ec5385 | ZAFIRLUKAST- zafirlukast tablet, film coated|American Health Packaging ZAFIRLUKAST ZAFIRLUKAST CHEMBL603 21523 575.69 Normal/therapeutic blood-plasma concentration 0.03 mg/L 5.21113793882124e-08 7.283067430906153 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ZAFIRLUKAST CHEMBL603 21523 575.69 Cmax 0.756 ug.mL-1 1.3132067605829526e-06 5.88166689012461 CHEMBL3889421 17806130.0 Evaluation of pharmacokinetic parameters for Zafirlukast following single oral administration to healthy boys and girls. Curated Drug Pharmacokinetic Data DailyMed|setid=a60f39f6-d590-4b00-8751-7f12b7ec5385 | ZAFIRLUKAST- zafirlukast tablet, film coated|American Health Packaging ZALCITABINE ZALCITABINE CHEMBL853 65494 211.22 Normal/therapeutic blood-plasma concentration 0.1 mg/L 4.734400151500805e-07 6.324735038286018 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ZALEPLON ZALEPLON CHEMBL1521 421332 305.34 Normal/therapeutic blood-plasma concentration 0.1 mg/L 3.275037662933124e-07 6.484783701256938 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ZIDOVUDINE ZIDOVUDINE CHEMBL129 27307 267.25 Normal/therapeutic blood-plasma concentration 1.0 mg/L 3.741814780168382e-06 5.426917713880815 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ZIDOVUDINE CHEMBL129 27307 267.25 Cmax 2.0220000000000002 ug.mL-1 7.565949485500469e-06 5.121136562625833 CHEMBL1681307 5228342.0 Cmax in HIV-1 infected patient at 300 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis corrected from ChEMBL Scientific Literature 20038617.0 Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals. ZIDOVUDINE CHEMBL129 27307 267.25 Cmax 0.8679999999999999 ug.mL-1 3.2478952291861548e-06 5.488397988704324 CHEMBL1681301 5228336.0 Cmax in HIV-1 infected patient at 200 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis corrected from ChEMBL Scientific Literature 20038617.0 Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals. ZIDOVUDINE CHEMBL129 27307 267.25 Cmax 2.2739999999999996 ug.mL-1 8.508886810102898e-06 5.070127253529099 CHEMBL1681295 5228330.0 Cmax in HIV-1 infected patient on day 10 by LC-MS/MS analysis corrected from ChEMBL Scientific Literature 20038617.0 Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals. ZIPRASIDONE ZIPRASIDONE CHEMBL708 33664 412.95 Normal/therapeutic blood-plasma concentration 0.2 mg/L 4.84320135609638e-07 6.31486747478503 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ZOLMITRIPTAN ZOLMITRIPTAN CHEMBL1185 196215 287.36 Normal/therapeutic blood-plasma concentration 0.01 mg/L 3.479955456570156e-08 7.458426314987211 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ZOLPIDEM ZOLPIDEM CHEMBL911 80965 307.4 Normal/therapeutic blood-plasma concentration 0.15 mg/L 4.879635653871178e-07 6.311612604108045 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ZOMEPIRAC ZOMEPIRAC CHEMBL19490 23001 291.73 Normal/therapeutic blood-plasma concentration 4.0 mg/L 1.3711308401604223e-05 4.862921100682098 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ZONISAMIDE ZONISAMIDE CHEMBL750 39857 212.23 Normal/therapeutic blood-plasma concentration 40.0 mg/L 0.00018847476794044198 3.7247467827404757 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ZOPICLONE ZOPICLONE CHEMBL135400 224263 388.82 Normal/therapeutic blood-plasma concentration 0.05 mg/L 1.285942081168664e-07 6.89077859159477 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics ZOTEPINE ZOTEPINE CHEMBL285802 34266 331.87 Normal/therapeutic blood-plasma concentration 0.15 mg/L 4.519842106849067e-07 6.3448767362775325 22835221.0 Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics